<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1310222733
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        YASMIN TAB.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DROSPINENONE,ETHINYLESTRADIOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3,0.03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03AA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Yasmin is a contraceptive pill and is used to prevent pregnancy.</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Each film-coated tablet contains a small amount of two different female hormones, namely drospirenone and ethinylestradiol.</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Contraceptive pills that contain two hormones are called &ldquo;combination&rdquo; pills.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--><strong><em>General notes</em></strong></p><p>Before you start using Yasmin, you should read the information on blood clots in section 2. It is particularly important to read the symptoms of a blood clot &ndash; see section 2 &ldquo;Blood clots&rdquo;.</p><p>Before you can begin taking Yasmin, your doctor will ask you some questions about your personal health history and that of your close relatives. The doctor will also measure your blood pressure, and depending upon your personal situation, may also carry out some other tests<strong><em>.</em></strong></p><p>In this leaflet, several situations are described where you should stop using Yasmin, or where the reliability of Yasmin may be decreased. In such situations you should either not have sex or you should take extra non-hormonal contraceptive precautions, e.g., use a condom or another barrier method. Do not use rhythm or temperature methods. These methods can be unreliable because Yasmin alters the monthly changes of body temperature and of the cervical mucus.</p><p><strong>Yasmin, like other hormonal contraceptives, does not protect against HIV infection (AIDS) or any other sexually transmitted disease.</strong></p><p><strong>When you should not use Yasmin</strong></p><p>You should not use Yasmin if you have any of the conditions listed below. If you do have any of the conditions listed below, you must tell your doctor. Your doctor will discuss with you what other form of birth control would be more appropriate.</p><p><strong>Do not use Yasmin</strong>:</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) a blood clot in a blood vessel of your leg (deep vein thrombosis, DVT), your lungs (pulmonary embolus, PE) or other organs;</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you know you have a disorder affecting your blood clotting &ndash; for instance, protein C deficiency, protein S deficiency, antithrombin-III deficiency, Factor V Leiden or antiphospholipid antibodies;</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you need an operation or if you are off your feet for a long time (see section &lsquo;Blood clots&rsquo;);</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have ever had a heart attack or stroke;</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) angina pectoris (a condition that causes severe chest pain and may be a first sign of a heart attack) or transient ischaemic attack (TIA &ndash; temporary stroke symptoms);</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have any of the following diseases that may increase your risk of a clot in the arteries.</p><ul><li>severe diabetes with blood vessel damage</li><li>very high blood pressure</li><li>a very high level of fat in the blood (cholesterol or triglycerides)</li><li>a condition known as hyperhomocysteinaemia</li></ul><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) a type of migraine called &lsquo;migraine with aura&rsquo;;</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) a liver disease and your liver function is still not normal</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if your kidneys are not working well (renal failure)</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) a tumour in the liver</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have (or have ever had) or if you are suspected of having breast cancer or cancer of the genital organs</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have any unexplained bleeding from the vagina</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic to ethinylestradiol or drospirenone, or any of the other ingredients of this medicine (listed in section 6). This may cause itching, rash or swelling.</p><p>Do not use Yasmin if you have hepatitis C and are taking the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir or glecaprevir/pibrentasvir (see also in section &ldquo;Other medicines and Yasmin&rdquo;).</p><p>Yasmin is different from other birth-control pills because it contains the progestin drospirenone. Drospirenone may increase potassium. Therefore, patients with kidney, liver or adrenal disease should not take Yasmin because this could cause serious heart and health problems.</p><p><strong>Additional information on special populations</strong></p><p><em>Use in children and adolescents</em></p><p>Yasmin is not intended for use in females whose periods have not yet started.</p><p><em>Use in elderly women</em></p><p>Yasmin is not intended for use after the menopause.</p><p><em>Women with impaired liver function</em></p><p>Do not take Yasmin if you have a liver disorder. See also the sections &ldquo;When you should not use Yasmin&rdquo; and &ldquo;Warnings and precautions&rdquo;.</p><p><em>Women with impaired kidney function</em></p><p>Do not take Yasmin if you have poorly functioning kidneys or acute kidney failure. See also the sections &ldquo;When you should not use Yasmin&rdquo; and &ldquo;Warnings and precautions&rdquo;.</p><p><strong>Warnings and precautions</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:444.25pt"><p>When should you contact your doctor?</p><p><u>Seek urgent medical attention </u></p><p style="margin-left:.5in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you notice possible signs of a blood clot that may mean you are suffering from a blood clot in the leg (i.e. deep vein thrombosis), a blood clot in the lung (i.e. pulmonary embolism), a heart attack or a stroke (see &lsquo;Blood clots` section below).</p><p>For a description of the symptoms of these serious side effects please go to &ldquo;How to recognise a blood clot&rdquo;.</p></td></tr></tbody></table><p><strong>Tell your doctor if any of the following conditions apply to you</strong></p><p>Talk to your doctor before taking Yasmin. In some situations you need to take special care while using Yasmin or any other combination pill, and your doctor may need to examine you regularly. If the condition develops, or gets worse while you are using Yasmin, you should also tell your doctor.</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if a close relative has or has ever had breast cancer</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a disease of the liver or the gallbladder</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have diabetes</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have depression</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have Crohn&rsquo;s disease or ulcerative colitis (chronic inflammatory bowel disease;)</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have haemolytic uraemic syndrome (HUS &ndash; a disorder of blood clotting causing failure of the kidneys)</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have sickle cell anaemia (an inherited disease of the red blood cells);</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have elevated levels of fat in the blood (hypertriglyceridaemia) or a positive family history for this condition. Hypertriglyceridaemia has been associated with an increased risk of developing pancreatitis (inflammation of the pancreas)</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you need an operation, or you are off your feet for a long time (see in section 2 &lsquo;Blood clots&rsquo;)</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have just given birth you are at an increased risk of blood clots. You should ask your doctor how soon after delivery you can start taking Yasmin</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have an inflammation in the veins under the skin (superficial thrombophlebitis)</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have varicose veins</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have epilepsy (see &ldquo;Other medicines and Yasmin&rdquo;);</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have systemic lupus erythematosus (SLE &ndash; a disease affecting your natural defence system);</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a disease that first appeared during pregnancy or earlier use of sex hormones (for example, hearing loss, a blood disease called porphyria, skin rash with blisters during pregnancy (gestational herpes), a disease of the nerves in which sudden movements of the body occur (Sydenham&rsquo;s chorea))</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have or have ever had chloasma (a discolouration of the skin especially of the face or neck known as &ldquo;pregnancy patches&rdquo;). If so, avoid direct sunlight or ultraviolet light.</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have hereditary angioedema, products containing oestrogens may cause or worsen the symptoms. You should see your doctor immediately if you experience symptoms of angioedema such as swollen face, tongue and/or throat and/or difficulty swallowing, or hives together with difficulty breathing.</p><p><strong>BLOOD CLOTS</strong></p><p>Using a combined hormonal contraceptive such as Yasmin increases your risk of developing a<strong> blood clot</strong> compared with not using one. In rare cases a blood clot can block vessels and cause serious problems.</p><p>Blood clots can develop</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->in veins (referred to as a &lsquo;venous thrombosis&rsquo;, &lsquo;venous thromboembolism&rsquo; or VTE);</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:-14.2pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->in the arteries (referred to as an &lsquo;arterial thrombosis&rsquo;, &lsquo;arterial thromboembolism&rsquo; or ATE);</p><p style="margin-left:0in; margin-right:0in">Recovery from blood clots is not always complete. Rarely, there may be serious lasting effects or, very rarely, they may be fatal;</p><p><strong>It is important to remember that the overall risk of a harmful blood clot due to Yasmin is small.</strong></p><p><strong>HOW TO RECOGNISE A BLOOD CLOT</strong></p><p>Seek urgent medical attention if you notice any of the following signs or symptoms.</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="background-color:#cccccc; width:293.4pt"><p><strong>Are you experiencing any of these signs?</strong></p></td><td style="background-color:#cccccc; width:139.3pt"><p><strong>What are you possibly suffering from?</strong></p></td></tr><tr><td style="vertical-align:top; width:293.4pt"><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling of one leg or along a vein in the leg or foot especially when accompanied by:</p><p style="margin-left:.5in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain or tenderness in the leg which may be felt only when standing or walking</p><p style="margin-left:.5in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increased warmth in the affected leg</p><p style="margin-left:.5in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->change in colour of the skin on the leg e.g. turning pale, red or blue</p></td><td style="vertical-align:top; width:139.3pt"><p>Deep vein thrombosis</p></td></tr><tr><td style="vertical-align:top; width:293.4pt"><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden unexplained breathlessness or rapid breathing;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden cough without an obvious cause, which may bring up blood;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sharp chest pain which may increase with deep breathing;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe light headedness or dizziness;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeat</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe pain in your stomach;</p><p><u>If you are unsure</u>, talk to a doctor as some of these symptoms such as coughing or being short of breath may be mistaken for a milder condition such as a respiratory tract infection (e.g. a &lsquo;common cold&rsquo;).</p></td><td style="vertical-align:top; width:139.3pt"><p>Pulmonary embolism</p></td></tr><tr><td style="vertical-align:top; width:293.4pt"><p>Symptoms most commonly occur in one eye:</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->immediate loss of vision or</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->painless blurring of vision which can progress to loss of vision</p></td><td style="vertical-align:top; width:139.3pt"><p>Retinal vein thrombosis (blood clot in the eye)</p></td></tr><tr><td style="vertical-align:top; width:293.4pt"><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->chest pain, discomfort, pressure, heaviness</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sensation of squeezing or fullness in the chest, arm or below the breastbone;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fullness, indigestion or choking feeling;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->upper body discomfort radiating to the back, jaw, throat, arm and stomach;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sweating, nausea, vomiting or dizziness;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->extreme weakness, anxiety, or shortness of breath;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeats</p></td><td style="vertical-align:top; width:139.3pt"><p>Heart attack</p></td></tr><tr><td style="vertical-align:top; width:293.4pt"><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden weakness or numbness of the face, arm or leg, especially on one side of the body;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden confusion, trouble speaking or understanding;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble seeing in one or both eyes;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble walking, dizziness, loss of balance or coordination;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden, severe or prolonged headache with no known cause;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->loss of consciousness or fainting with or without seizure.</p><p>&nbsp;</p><p>Sometimes the symptoms of stroke can be brief with an almost immediate and full recovery, but you should still seek urgent medical attention as you may be at risk of another stroke.</p></td><td style="vertical-align:top; width:139.3pt"><p>Stroke</p></td></tr><tr><td style="vertical-align:top; width:293.4pt"><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->swelling and slight blue discolouration of an extremity;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe pain in your stomach (acute abdomen)</p></td><td style="vertical-align:top; width:139.3pt"><p>Blood clots blocking other blood vessels</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong><u>BLOOD CLOTS IN A VEIN</u></strong></p><p><strong>What can happen if a blood clot forms in a vein?</strong></p><p style="margin-left:17.85pt; margin-right:0in; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The use of combined hormonal contraceptives has been connected with an increase in the risk of blood clots in the vein (venous thrombosis).&nbsp; However, these side effects are rare.&nbsp; Most frequently, they occur in the first year of use of a combined hormonal contraceptive.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If a blood clot forms in a vein in the leg or foot it can cause a deep vein thrombosis (DVT).</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If a blood clot travels from the leg and lodges in the lung it can cause a pulmonary embolism.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Very rarely a clot may form in a vein in another organ such as the eye (retinal vein thrombosis).</p><p>&nbsp;</p><p><strong>When is the risk of developing a blood clot in a vein highest?</strong></p><p>The risk of developing a blood clot in a vein is highest during the first year of taking a combined hormonal contraceptive for the first time. The risk may also be higher if you restart taking a combined hormonal contraceptive (the same product or a different product) after a break of 4 weeks or more.</p><p>After the first year, the risk gets smaller but is always slightly higher than if you were not using a combined hormonal contraceptive.</p><p>When you stop Yasmin your risk of a blood clot returns to normal within a few weeks.</p><p><strong>What is the risk of developing a blood clot?</strong></p><p>The risk depends on your natural risk of VTE and the type of combined hormonal contraceptive you are taking.</p><p>The overall risk of a blood clot in the leg or lung (DVT or PE) with Yasmin is small.</p><p style="margin-left:36.05pt; margin-right:0in; text-indent:-21.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Out of 10,000 women who are not using any combined hormonal contraceptive and are not pregnant, about 2 will develop a blood clot in a year.</p><p style="margin-left:35.45pt; margin-right:0in; text-indent:-21.25pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Out of 10,000 women who are using a combined hormonal contraceptive that contains levonorgestrel, norethisterone, or norgestimate about 5&nbsp;‑&nbsp;7 will develop a blood clot in a year.</p><p style="margin-left:36.05pt; margin-right:0in; text-indent:-21.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Out of 10,000 women who are using a combined hormonal contraceptive that contains drospirenone such as Yasmin, between about 9 and 12 women will develop a blood clot in a year.</p><p style="margin-left:.5in; margin-right:0in; text-indent:-21.8pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The risk of having a blood clot will vary according to your personal medical history (see &ldquo;Factors that increase your risk of a blood clot&rdquo; below).</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:266.45pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:159.65pt"><p><strong>Risk of developing a blood clot in a year</strong></p></td></tr><tr><td style="vertical-align:top; width:266.45pt"><p>Women who are <strong>not using</strong> a combined hormonal pill and are not pregnant</p></td><td style="vertical-align:top; width:159.65pt"><p>About 2 out of 10,000 women</p></td></tr><tr><td style="vertical-align:top; width:266.45pt"><p>Women using a combined hormonal contraceptive pill containing <strong>levonorgestrel, norethisterone or norgestimate</strong></p></td><td style="vertical-align:top; width:159.65pt"><p>About 5&nbsp;‑&nbsp;7 out of 10,000 women</p></td></tr><tr><td style="vertical-align:top; width:266.45pt"><p>Women using <strong>Yasmin</strong></p></td><td style="vertical-align:top; width:159.65pt"><p>About 9&nbsp;‑&nbsp;12 out of 10,000 women</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Factors that increase your risk of a blood clot in a vein</strong></p><p>The risk of a blood clot with Yasmin is small but some conditions will increase the risk. Your risk is higher:</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are very overweight (body mass index or BMI over 30kg/m<sup>2</sup>);</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if one of your immediate family has had a blood clot in the leg, lung or other organ at a young age (e.g. below the age of about 50). In this case you could have a hereditary blood clotting disorder;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you need to have an operation, or if you are off your feet for a long time because of an injury or illness, or you have your leg in a cast. The use of Yasmin may need to be stopped several weeks before surgery or while you are less mobile. If you need to stop Yasmin ask your doctor when you can start using it again.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->as you get older (particularly above about 35 years);</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you gave birth less than a few weeks ago.</p><p>The risk of developing a blood clot increases the more conditions you have.</p><p>Air travel (&gt;4 hours) may temporarily increase your risk of a blood clot, particularly if you have some of the other factors listed.</p><p>It is important to tell your doctor if any of these conditions apply to you, even if you are unsure. Your doctor may decide that Yasmin needs to be stopped.</p><p>If any of the above conditions change while you are using Yasmin, for example a close family member experiences a thrombosis for no known reason; or you gain a lot of weight, tell your doctor.</p><p><strong>BLOOD CLOTS IN AN ARTERY</strong></p><p><strong>What can happen if a blood clot forms in an artery?</strong></p><p>Like a blood clot in a vein, a clot in an artery can cause serious problems. For example, it can cause a heart attack or a stroke.</p><p><strong>Factors that increase your risk of a blood clot in an artery</strong></p><p style="margin-left:0in; margin-right:0in">It is important to note that the risk of a heart attack or stroke from using Yasmin is very small but can increase:</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->with increasing age (beyond about 35 years);</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>if you smoke</strong>. When using a combined hormonal contraceptive like Yasmin, you are advised to stop smoking. If you are unable to stop smoking and are older than 35 your doctor may advise you to use a different type of contraceptive;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are overweight;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have high blood pressure;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if a member of your immediate family has had a heart attack or stroke at a young age (less than about 50). In this case you could also have a higher risk of having a heart attack or stroke;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you, or someone in your immediate family, have a high level of fat in the blood (cholesterol or triglycerides);</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you get migraines, especially migraines with aura;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have a problem with your heart (valve disorder, disturbance of the rhythm called atrial fibrillation);</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you have diabetes.</p><p>If you have more than one of these conditions or if any of them are particularly severe the risk of developing a blood clot may be increased even more.</p><p>If any of the above conditions change while you are using Yasmin, for example you start smoking, a close family member experiences a thrombosis for no known reason; or you gain a lot of weight, tell your doctor.</p><p><strong>Yasmin and cancer</strong></p><p>Breast cancer has been observed slightly more often in women using combination pills, but it is not known whether this is caused by the treatment. For example it may be that more tumours are detected in women on combination pills because they are examined by their doctor more often. The occurrence of breast tumours becomes gradually less after stopping the combination hormonal contraceptives. It is important to regularly check your breasts and you should contact your doctor if you feel any lump.</p><p>In rare cases, benign liver tumours, and in even fewer cases malignant liver tumours have been reported in pill users. Contact your doctor if you have unusually severe abdominal pain.</p><p>Psychiatric disorders</p><p>&nbsp;</p><p>Some women using hormonal contraceptives like Yasmin report depression or depressive mood. Depression can be serious and occasionally leads to suicidal thoughts. If you experience mood swings and depressive symptoms, seek medical advice from your doctor as soon as possible.</p><p><strong>Bleeding between periods</strong></p><p>During the first few months that you are taking Yasmin, you may have unexpected bleeding (bleeding outside the gap week). If this bleeding occurs for more than a few months, or if it begins after some months, your doctor must find out what is wrong.</p><p>What to do if no bleeding occurs during the gap week</p><p>If you have taken all the tablets correctly, have not had vomiting or severe diarrhoea and you have not taken any other medicines, it is highly unlikely that you are pregnant.</p><p style="margin-left:0in; margin-right:0in">If the expected bleeding does not happen twice in succession, you may be pregnant. Contact your doctor immediately. Do not start the next strip until you are sure that you are not pregnant.</p><p>Other medicines and Yasmin</p><p>Always tell your doctor which medicines or herbal products you are already using. Also tell any other doctor or dentist who prescribes another medicine (or the pharmacist) that you take Yasmin. They can tell you if you need to take additional contraceptive precautions (for example condoms) and if so, for how long, or, whether the use of another medicine you need must be changed.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Some medicines</p><p style="margin-left:.5in; margin-right:0in; text-indent:-14.7pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->can have an influence on the blood levels of Yasmin</p><p style="margin-left:.5in; margin-right:0in; text-indent:-14.7pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->can make it <strong>less effective in preventing pregnancy</strong></p><p style="margin-left:.5in; margin-right:0in; text-indent:-14.7pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->can cause unexpected bleeding.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">These include:</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->medicines used for the treatment of</p><p style="margin-left:35.45pt; text-indent:0in"><!--[if !supportLists]-->&iexcl;&nbsp;&nbsp; <!--[endif]-->epilepsy (e.g. primidone, phenytoin, barbiturates, carbamazepine, oxcarbazepine)</p><p style="margin-left:35.45pt; text-indent:0in"><!--[if !supportLists]-->&iexcl;&nbsp;&nbsp; <!--[endif]-->tuberculosis (e.g. rifampicin)</p><p style="margin-left:56.7pt; text-indent:-21.25pt"><!--[if !supportLists]-->&iexcl;&nbsp;&nbsp; <!--[endif]-->HIV and Hepatitis C Virus infections (so-called protease inhibitors and non-nucleoside reverse transcriptase inhibitors, such as ritonavir, nevirapine, efavirenz)</p><p style="margin-left:56.7pt; text-indent:-21.25pt"><!--[if !supportLists]-->&iexcl;&nbsp;&nbsp; <!--[endif]-->fungal infections (e.g. griseofulvin, ketoconazole)</p><p style="margin-left:35.45pt; text-indent:0in"><!--[if !supportLists]-->&iexcl;&nbsp;&nbsp; <!--[endif]-->arthritis, arthrosis (etoricoxib)</p><p style="margin-left:35.45pt; text-indent:0in"><!--[if !supportLists]-->&iexcl;&nbsp;&nbsp; <!--[endif]-->high blood pressure in the blood vessels in the lungs (bosentan)</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->the herbal remedy St. John&rsquo;s wort</p><p style="margin-left:0in; margin-right:0in; text-indent:0in">Yasmin may <strong>influence the effect</strong> of other medicines, e.g.</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->medicines containing ciclosporin</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->the anti-epileptic lamotrigine (this could lead to an increased frequency of seizures)</p><p style="margin-left:39.3pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->theophylline (used to treat breathing problems)</p><p style="margin-left:39.3pt; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->tizanidine (used to treat muscle pain and/or muscle cramps).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p>Other drugs may increase potassium. Patients currently on daily, long-term treatment for a chronic condition with any of the medications below, should consult the healthcare provider about whether Yasmin is safe for use, and during the first month of Yasmin use, a blood test to check potassium level should be performed.</p><p>Medications that known to increase potassium level:</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->NSAIDs (such as ibuprofen and others) when taken long-term and for treatment of arthritis or other problems.</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->Potassium-sparing diuretics (such as spironolactone and others).</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->Potassium supplementation.</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->ACE inhibitors (such as Captopril, Lisinopril, and others)</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->Angiotensin-II receptor antagonists (Losartan, Valsartan, and others).</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->&sect;&nbsp; <!--[endif]-->Heparin.</p><p>&nbsp;</p><p>Do not use Yasmin if you have hepatitis C and are taking the medicinal products containing ombitasvir/paritaprevir/ritonavir plus dasabuvir or glecaprevir/pibrentasvir as this may cause increases in liver function blood test results (increase in ALT liver enzyme). Your doctor will prescribe another type of contraceptive prior to start of the treatment with these medicinal products. Yasmin can be restarted approximately 2 weeks after completion of this treatment. See section &ldquo;Do not use Yasmin&rdquo;.</p><p><em>Ask your doctor or pharmacist for advice before taking any medicine.</em></p><p><strong>Yasmin with food and drink</strong></p><p>&nbsp;</p><p>Yasmin may be taken with or without food, if necessary with a small amount of water.</p><p><strong>Laboratory tests </strong></p><p>If you need a blood test, tell your doctor or the laboratory staff that you are taking the pill, because hormone contraceptives can affect the results of some tests.</p><p><strong>Pregnancy</strong></p><p>If you are pregnant, you must not take Yasmin. If you become pregnant while taking Yasmin you must<u> </u>stop immediately and contact your doctor. If you want to become pregnant, you can stop taking Yasmin at any time (see also &quot;If you stop taking Yasmin&quot;).</p><p><em>Ask your doctor or pharmacist for advice before taking any medicine.</em></p><p><strong>Breast-feeding</strong></p><p>Use of Yasmin is generally not advisable when a woman is breast-feeding. If you want to take the pill while you are breast-feeding you should contact your doctor.</p><p><em>Ask your doctor or pharmacist for advice before taking any medicine.</em></p><p><strong>Driving and using machines</strong></p><p>There is no information suggesting that use of Yasmin affects driving or use of machines.</p><p><strong>Yasmin contains lactose</strong></p><p>If you cannot tolerate certain sugars, contact your doctor before you take Yasmin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Take one tablet of Yasmin every day, if necessary with a small amount of water. You may take the tablets with or without food, but you should take the tablets every day around the same time.</p><p>The strip contains 21 film-coated tablets. Next to each tablet is printed the day of the week that it should be taken. If, for example you start on a Wednesday, take a tablet with &ldquo;WED&rdquo; next to it. Follow the direction of the arrow on the strip until all 21 tablets have been taken.</p><p>Then take no tablets for 7 days. In the course of these 7 tablet-free days (otherwise called a stop or gap week) bleeding should begin. This so-called &ldquo;withdrawal bleeding&rdquo; usually starts on the 2nd or 3rd day of the gap week.</p><p>On the 8th day after the last Yasmin tablet (that is, after the 7-day gap week), you should start with the following strip, whether your bleeding has stopped or not. This means that you should start every strip on the same day of the week and that the withdrawal bleed should occur on the same days each month.</p><p>If you use Yasmin in this manner, you are also protected against pregnancy during the 7 days when you are not taking a tablet.</p><p><strong>When can you start with the first strip?</strong></p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>If you have not used a contraceptive with hormones in the previous month</em><br />Begin with Yasmin on the first day of the cycle (that is, the first day of your period). If you start Yasmin on the first day of your period you are immediately protected against pregnancy. You may also begin on day 2-5 of the cycle, but then you must use extra protective measures (for example, a condom) for the first 7 days.</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Changing from a combination hormonal contraceptive, or combination contraceptive vaginal ring or patch</em><br />You can start Yasmin preferably on the day after the last active tablet (the last tablet containing the active substances) of your previous pill, but at the latest on the day after the tablet-free days of your previous pill (or after the last inactive tablet of your previous pill). When changing from a combination contraceptive vaginal ring or patch, follow the advice of your doctor.</p><p style="margin-left:17.85pt; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Changing from a </em><em>progestogen-only-method (</em><em>progestogen-only pill</em><em>, injection, implant or a progestogen-releasing IUD)</em><br />You may switch any day from the progestogen-only pill (from an implant or an IUD on the day of its removal, from an injectable when the next injection would be due) but in all of these cases use extra protective measures (for example, a condom) for the first 7 days of tablet-taking.</p><p style="margin-left:17.85pt; text-indent:-17.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>After a miscarriage</em><br />Follow the advice of your doctor.</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>After having a baby</em><br />You can start Yasmin between 21 and 28 days after having a baby. If you start later than day 28, use a so-called barrier method (for example, a condom) during the first seven days of Yasmin use.</p><p>If, after having a baby you have had sex before starting Yasmin (again), be sure that you are not pregnant or wait until your next period.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>If you are breastfeeding and want to start Yasmin (again) after having a baby</em><br />Read the section on &ldquo;Breast feeding&rdquo;.</p><p><em>Ask your doctor what to do if you are not sure when to start.</em></p><p><strong>If you take more Yasmin than you should</strong></p><p>There are no reports of serious harmful results of taking too many Yasmin tablets.</p><p>If you take several tablets at once then you may feel sick or vomit or you may bleed from the vagina. Even girls who have not yet started to menstruate but have accidentally taken this medicine may &nbsp;experience such bleeding.</p><p>If you have taken too many Yasmin tablets, or you discover that a child has taken some, ask your doctor or pharmacist for advice.</p><p><strong>If you forget to take Yasmin</strong></p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you are <strong>less than 12 hours</strong> late taking a tablet, the protection against pregnancy is not reduced. Take the tablet as soon as you remember and then take the following tablets again at the usual time.</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you are <strong>more than 12 hours</strong> late taking a tablet, the protection against pregnancy may be reduced. The greater the number of tablets that you have forgotten, the greater is the risk of becoming pregnant.</p><p>The risk of incomplete protection against pregnancy is greatest if you forget a tablet at the beginning or at the end of the strip. Therefore, you should keep to the following rules (see the diagram):</p><ul><li><strong>More than </strong><strong>one</strong><strong> tablet forgotten in this strip</strong><strong> </strong><br />Contact your doctor.</li><li><strong>One</strong><strong> tablet forgotten in week 1</strong><strong> </strong></li></ul><p>Take the forgotten tablet as soon as you remember, even if that means that you have to take two tablets at the same time. Continue taking the tablets at the usual time and use <strong>extra precautions</strong> for the next 7 days, for example, a condom. If you have had sex in the week before forgetting the tablet you may be pregnant. In that case, contact your doctor.</p><ul><li><strong>One</strong><strong> tablet forgotten in week 2</strong><strong> </strong></li></ul><p>Take the forgotten tablet as soon as you remember, even if that means that you have to take two tablets at the same time. Continue taking the tablets at the usual time. The protection against pregnancy is not reduced, and you do not need to take extra precautions.<strong> </strong></p><p style="margin-left:.5in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong>One</strong><strong> tablet forgotten in week 3</strong><strong> </strong><br />You can choose between two possibilities:</p><p style="margin-left:.75in; text-indent:-.25in"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Take the forgotten tablet as soon as you remember, even if that means that you have to take two tablets at the same time. Continue taking the tablets at the usual time. Instead of taking the tablet-free period start the next strip.</p><p style="margin-left:.75in">Most likely, you will have a period at the end of the second strip or you may also have light or menstruation-like bleeding during the second strip.</p><p style="margin-left:.75in; text-indent:-.25in">2.&nbsp;&nbsp; You can also stop the strip and go directly to the tablet-free period of 7 days <strong>(record the day on which you forgot your tablet).</strong> If you want to start a new strip on the day you always start, make the tablet-free period <em>less than 7 days.</em></p><p>If you follow one of these two recommendations, you will remain protected against pregnancy.</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If you have forgotten any of the tablets in a strip, and you do not have a bleeding during the first tablet-free period, you may be pregnant. Contact your doctor before you start the next strip.</p><p><strong><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="Word.Picture.8" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1721741690">
 </o:OLEObject>
</xml><![endif]--></strong><strong>&nbsp;</strong><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAnYAAAIICAYAAADjfKNIAAAgAElEQVR4nO2dWbKkKhgGXZcLYj2shs24i/PUDzeC++DAz6RoOSDmF5ER3XUU0bKsLEDp/v7+LAAAAAC8m//++892T1cCAAAAAH7n379/iB0AAABAC/z79892XddZgD08feIC3MXTnzUA+CZHr1mL2BFSml9OOIC3wfWREHJ3EDtyaxA7+BJcHwkhdwexI7cGsYMvwfWREHJ3EDtyaxA7+BJcHwkhdwexI7cGsYMvwfWREHJ3EDtyaxA7+BJcHwkhdwexI7cGsYMvwfWREHJ3EDtyaxA7eDN7nxPF9ZEQcncuFzvdTxdCZbLLGDUt02s7nL2H1lo7aNt3yuZrcDxGdbbXP9R60LZP7rexquvtL0XXGMQO3szeh4EidoSQu3NLi92ge9vlJGXQtu9+lKPsdpXVwzDJ5fliN+7Xet3HOuT+aqzKCO0ou9tit15+fUHs4M3sfeL7LrEzquw6deEP1d8yWN0//2N0aSi47IdxyX62+cOcvCM3iZ22WvfJVrv5b1eInVHzB8tYddGFcNiou6tDtoBMi13ZRXKz/MqC2MGbOTK1T2mMUlapzq50btjxunDND9VfU/pjNJdTfqQadcl3ib+JK6WRkN9zm9iZpFwZq5Tx5GhuBfNbwsZ1tWj52+y+NWopR5lp2/NryzpTi1kXXihzy6f2bUXsvDpktjeJnZ73Z7mqx2IX7XNUfv2RJ9wV8+MB1Mp6xmuhNWp12MqybIVi92uL3Rk/Urd+aJ+TOlomCcml624Tu/hDN/9CW16XrVdTF60ywzJOb1lX/CrLjXEbBiM+fJNQKWNlE7mrj/ygDsG4wPUm9bULiV+HzPaW/XTbdv8W203sc1j+G/LLCQfwNOcL3ZRBW738+AulzV2TlDbWDG6Z5Ydw9OMz8yNy+r+OfkDPy4/L+q1S8Q9rf1NK7K//9/QPdfn6VLfEj9TSH/mpbc3HY28Z+R/7qf0Mvytka2r8vRHtsy1ooCDkQG4VO/+iNVitp39NwhNKkpM2/2LnfYCXD1W01UDsxHY9GRIXzaWYteXDfVv7hZhaN9he0BWbls3cPr/vlyNiB29mS+JSy5fEXSPH6553SfN+1PVWC7GzRuc//96PxvklZbVJ/YC2Nn3dS/ywjrYhxVFcj5I/1K3XKpn9kVr6Iz+qjrgeHygjd/3N72cg4tP7EXXXJva5pIGCkCO5Wez8k1r+MpvFTkqa+5DFYrfd9VggdkZ5v7wuF7vU9naIXbzPiB3AnWyJXGr57YiWn9SP1bmlzRtC0tu+z/2olav2/nrB0Bdrcz+gc9fPuHxXVnzNSm0nEtcd6251Q4fDeo6Ukfqxv7afUsqMno91vEy4z2UNFITsz+1iN//a6VVCZrxfQisXFm8cyjQ2Jd7qpti5D9s9Ypfcnid2svk+IYXRPiN2ADVTJHZLN+zyQvJzPYvAOGa4t1qrgi48d62RQ1+2f0CfI3ap7ZSKXcmP/LX6HCoj82N/bT+X1jzvfSwTO1yOXJHLxc79Es0LjhwXYcSvmPmkT41DcLe05z/kbhn3i8gbk7KMmZh+/XrjSxLLB+Xnxo+k6rB0QUTb849BNL5kY5+98l8QxA6+xO4fvstrQiRkd6tRttd6EZOiLrzwJrCiH9ByzN2WCEkZDMf0JbZjVNSKmJalgh/5a8ftQBnZH/tr+zmt539HJH6Yh/tc1EBByP7c0mJHyBzEDr5E8Q9fKQXLTQ7zD1A9/RAcZULJO+iXH4vrd8mGLUZD4gf0vJz78Vn2BILwB/Te7cgf/LmbJ9Z+5ItCox/ax8vwf+xv7acdtFWpm0OSP8zjfa7x8TXkvUHsyK1B7OBL1HF9HKxW3HVJyFeC2JFbg9jBl6ji+ihuVCOEtB/EjtwaxA6+xJPXRzlWmBDynSB25NYgdvAluD4SQu4OYkduDWIHX4LrIyHk7iB25NYgdvAluD4SQu4OYkduDWIHX4LrIyHk7iB25NYgdvAluD4SQu4OYkduDWIHX4LrIyHk7twmdqmnbr8jcv7WnWuWTPdzQz1qCmIHXwKxI4TcnXvEzqgTBWc980TX4b/vzjylzN79frLOdwSxgy+B2BFC7s4tYudNzHxxjJLz8D3bwnVkv5+u89VB7OBLyLlFAQDu4ug1q0js5CTM84TI8jUnPsaqTlmtezt21w5uguyus3KS5PT61psEWinx7+zkz+M2zbxecpLrsAu0ZB1Xz7zYuf1T2lgzBPU34fHYqEd4LCrNLyccAEDLcH2EpznWYjdo288yNGjbd51VxknOvNyg+2kqnMHqXghNcv3pT4NZlpX/ttZ63cHj2DfjxFEZmxvDNsrg/PpQtE5yv8N49QnrHB+P9XrEx6LWcOECAEjD9RGe5pDYhbLjbjCYWqDcH5Jil1/fBsvG63lNlYuYzdsMBNLVPni9ZJ10XYM/2j5q8ZPlBcdjtR4F26skXLgAAGJ+7UIDOIPDYicnpXZ/S4lM0Cq1uv68Tl7s4tasB8VO7s/S0obYAQB8kTPGRwH8yvGu2C4lX3GLXVJSsuuH/x+irlgnhMaqp1vsjE50E+8Vu7X/1xkuWgAAMYgd1ECZ2CUG98tu0eyNDXNXZeLGgNT6bnPudflvbxuTMC3/V8aVGdwMEb5esk5Yx6TcGW373q+PX8fMDSfejR9y2fqlzlrEDgAg5Kw7GgF+5dqZJ2SLlrXW6Pzdp99M3BX7hnDRAgDwQeygFi4Uu7jbUb+hOerWIHYAAC1w5nPIAH7h4hY7JU7y9wnMtRE3lqw8R6/GcMECAHCc/YBZgF+4VuxIk+GCBQDgQOygJhA7sjtcsAAAHDmx41oJT4DYkd3hYgUAMLImdVwr4QkQO7I7XKwAAEYQO6gNxI7sDhcrAIA0XB/haRA7sjtcuAAA0nB9hKdB7MjucOECAEjD9RGeBrEju8OFCwAgDddHeBrEjuwOFy4AgDRcH+FpEDuyO1y4AADScH2Ep0HsyO5w4QIASMP1EZ4GsSO7w4ULAFpl67l0tfP08YPnQezI7nDxAIBW+fX78MnvU67N8PeH2JED4eIBAK3y5u9Drs3w94fYkQPh4gEArfLm70OuzfD3h9iRA+HiAQCt8ubvQ67N8PeH2JED4eIBAK3y5u9Drs3w9yfEDmAPT5+4AABX0HWIHbybf//+2e7pSgAAANTAL2Knlh+/yhprrR207af/KzX9rdd2WNYYrO7H15U21gzZohE7KAaxAwAAmPipxW4SOWXkS8pqrWyvR2szqlv+bY18vbcasYMTQOwAAAAmfu2KHXQvWuWMVcqMr8nhLLP5zS16Xive8SB28PeH2AEAACz8PsZu7F5VZmqtG0bZk6140RqT+K0tUxLEDv7+EDsAAICFU26eMMofT2eUa6WbWvHGf2rX/Sq6ZY8GsYO/P8QOAABg4ay7Yo3yW+CMCm6ssNZao23fJ14/GMQO/v4QOwAAgIVzxG6wWp0zbm5PEDv4+0PsAAAAFs7qiv11vNyRIHbw94fYAQAALPwidkt36xNWZxE7GEHsAAAAJph5At4OYgcAADCB2MHbQewAAAAmfhG7p6UQsYO/P8QOAABgAbGDt4PYAQAATHhTf72Qp48fPA9iBwAA8CPIFdQCYgcAAPAjiB3UAmIHAADwI4gd1AJiBwAA8COMdYNaQOwAAAB+gJsYoCYQOwAAgB9A7KAmEDsAAIAf4NEjUBOIHQAAwA8gdlATiB2A4OmHi36Bp99jgDPhXIfaQOwABF333gnA3xC+7KA1+CEDtYHYAQgQu2vDFx20BmIHtYHYAQgQu2vDFx20DOc31ABiByBA7K4NX3zQMpzfUAOIHYAAsbs2fPFBy3B+Qw0gdgACxO7a8MUHLcP5DTWA2AEIELtrwxcftAznN9QAYgcgQOyuzRu/+J5+7h8AgGTrmoXYAQi6DrG7MiUXpdrgnCCl4VwhVwexA9gJF+Zrg9iRlsO5Qq4OYgewEy7M1waxI4SQ40HsAHbCl/i1QewIIeR4EDuAnfAlfm0QO0IIOR7EDmAnfIlfG8SOEEKOB7ED2Alf4tcGsSOEkONB7AB2ct6XuLGq660eTiruSAZt+05ZU7CoUZ3tb6gsYkcIIceD2MEn2fswx3DdNjJY3Xe2KxC7Qfe26xC79s8JQsjbg9jBJ/nlqd1tfYkbqwpb7AbdI3YHz4lRoDtPjo0S51yv7faRHazu72jh/bEleUcr8H2poHW8NCXHb9C2Lzpn/Lhz7vxjcWXZBVv/4f0dxOeztvP2WBA7+CS/TM9yXVfsJFlGZb7sjVVTfZQRF6Ne22G+OE3rLBfZoIz4dSd2c6tcTjK+JnZ7WnRLzgmjOquCb409x3R87+qVk0Erq4fyVmCSSsnxm64De8XOqOs+v1eWLTKeY/G/zyrTqM524Yf0hUHs4NXskYAz5+E7I/4XtRA1ZWz2F6j3Sz1owTF6/Le4yHrj4pKvixa7ef1Mvix2W5J3h9jd12J3LEbNdStvBSapFBy/Ay12V35+77o2uHPM//cv8epuFGIH8DS/tLo932IXflHLC3r+S9wJgrG6ny9Kg9V6WnNueeukKOZeHwWy77d/qSJ2+fPiHLFzLbJei83cgpvt5nI/CpQ21sjWB69lRy6nbZ8dMyl/VGy1Isd1VCa/Tq4l2d+2WLfzf4Bo3S/HwC8r/GEUtnz5P5TkZ8GV75bP/eiSxzd8z25tRZ/ETiu5z/kyvc9+4jX/HFw7znGOlz14QxTkOZ/cpjzHlDzfwvc3d/7ltyf3pQGvQ+zg3RyVgL0yF657To6JnTVqvFgZY828zqDt5HXZi1P69emCqNVm186dYnc2V50jkq14Y+oE8zF1x1e893K81aBtnxI7ryW2X2+1Xc4xY3XmvXRSU9iKbK0dBiPO10l2wnWydVpKCbY373N8rDZbn631WqA9UZOtXVP5Tg4Sn7/U8fWq/UArulfv8bgpZ0XJbXmf3+QxcMd/vX6p6uwve9C9kHB5zDL1F+eYf76VnbPZ7S0xVrVgdRaxg5dz9pd26brn5KDYzV+AsiUu/GXrrvLuYpV83W1z63Emb26xu0IW9wpeWVesaB0y4d8z58QsP+IcyLXaThVJtlb4dUh1q26dk+vrrNbJVS7qhhyPgfZez5Ulz2Gj5Q8Vvx7ymKfFMJTrfIvVXMatrehBV6zcp7VtJSUvewxK37NjZbvrkX9e5bcplwvPxYJzNrM9tw+6meEDiB28mjPE7si6ZyTsZjGiW2X7RgYxcHjQVgVXKdc65H9Jhq/LbbqujnQXRdRqclGuELtfz5GzWuxWxc4or9WhWOxEWVIIs40PRtu+X3sfrxO77QaRcrFLljW3cIoW7LB+ruVGlr8idmK5+fjG1b65FX1D7HLbilvL1o5BedfkkbKTLbSr2/xR7DLbm2NMK1qH2MHLeUICzmuxI6m8QeyOnBNbYuf+LrrWvNa1zB2Tsrtu7sbKtdoO2var3VHWln1JHlgnVyf/KCXuFO+tHnKtPXFZRqV+EIUtcClBkNsQY+5Sxze5/ze2ontiFxyzzLai7tLNY7B+nP3qHCs7uW/Zbf7eYndHj0MNQezg1SB27aVWsfvlnCh6jt3SYjp1w4Wtqp3rovUytcCFra1xq62Qj5XuRdlarHe0IkdjCBPr5FqSRSniBpLOrg3gz5aVaMEO6yFboP1e6k68B7MQpI9vmHtb0f0bAcJzItpWdDNK+hjsOs5uY8fKzo2fLDhW46Fx/y46Z1e2lx2/+tIgdvBqELv2UovYcU48ER6V8pkEN4b4YyIb2N6DQezg1SB27QWx+3IQu28kvnEsd5f2O7f3bBA7eDWIXXtB7L6a8DlwpOl4z2e8Qebv3t6DQezg1SB27QWxI4SQ40Hs4NUgdu0FsSOEkONB7ODVIHbtBbEjhJDjQezg1SB27QWxI4SQ40Hs4NUgdu0FsSOEkONB7ODVIHbtBbEjhJDjQezg1SB27QWxI4SQ40Hs4NUgdu3lrWIHAFALW9csxA6qpeQEvmKb5Lo88Z4C3AXnN9QAYgfVgti1F774oGU4v6EGEDuoFsSuvfDFBy3D+Q01gNhBtSB27YUvPmiJM8ZDAZwNYgfV8pTYwbMDfwHeBOc71AZiB9XCRREAagexg9pA7KBauCgCQO0gdVAbiB1UCxdGAHgDiB3UBGIH1cKFEQDeAGIHNYHYQbVwYQSAN4DUQU0gdlAtXBwB4A0gdlATiB1UCxdHAHgLiB3UAmIH1cLFEQDeAlIHtYDYQbVwgQSAt4DYQS0gdlAtXCAB4C0gdlALiB1UCxdIAHgTXLOgBhA7qBYukgBwN8yhDG8HsYNq4WIHAHfTdZ09mqPrcq2DM0HsoFq42AHA3fwidkfDtQ7OBLGDauFiBwB3g9jB20HsoFq42AHA3SB28HYQO6gWLnYAcDeIHbwdxA6qhYsdANwNYgdvB7GDauFiBwB3E4udsapT1hg1Ppqk13YQfx10vzyypNeDPRKudXAmiB1UCxc7ALibUOx0Pz1rTplJ8nq7+NugbT+L3qBt33VWGcQOngWxg2rhYgcAd5NtsRtNzureid2ge6+VzqhjrXZc6+BMEDuoFi52AHA3e8WuE010oeghdvAEiB1UCxc7ALibPWI3dr/O/w/+htjBQyB2UC1c7ADgbkKxM8qNsVtulBA3UMibJ46Mr0Ps4GwQO6gWLnYAcDc87gTeDmIH1cLFDgDuBrGDt4PYQbVwsQOAu0Hs4O0gdlAtXOwA4G4QO3g7iB1UCxc7ALgbxA7eDmIH1cLFDgDuZr7D9W6e3m9oB8QOqoWLHQAAwD4QO6gWxA4A3gTXLKgBxA6qhYskALwJrllQA4gdVAsXSQB4E1yzoAYQO6gWLpIAUDPcFAE1gthBtXBRBIDaQeygNhA7qBYuigBQO4gd1AZiB9XCRREAagepg9pA7KBauDACwBtA7KAmEDuoFi6MAPAGEDuoCcQOqoULIwC8AaQOagKxg2rh4ggAbwCxg5pA7KBauDgCwFtA7KAWEDuoFi6OAPAWkDqoBcQOqoULJNRGyUwDAABns+c6hdhBtew9mQGupus6S0gq8kuYkDOD2EEzIHZQG3xpk7VwfpArgthBMyB2UBt8cZO1cH6QK4LYQTMgdlAbfHGTtXB+kCuC2EEzIHZQG3xxE0LuDmIHzYDYQW3sEbtB99k73Ho9rK1o+05Z8+u3wY/lGDXXt7dr1X1lBm37Xtv0bhmrWtxn8togdtAMiB3Uxj6xU4scDLp3MmfUitgNVved7Q4Kmdvmb+Ws1/Hc+MdJnSZU+bKMVV1nu4zYjUK7LXZn1pWQtSB20AyIHdTG0a5YT+w2Y6w6KGRGSSE5Xs6++v4WWWe//ueVG2W1xW6wut+ux5l1JWQtiB00A2IHtbEudlNLUKK1Jy1K8/Jhy5oTsqU7d5KQpXs0JSVGLV29yohy5tfFOmvleF3I4u/ydbcv4za07qf9nlsK4/1Kri/rrML6p+qZ36f8sUgc50ns9Fy+kvrri13yWEXHmpDrgthBMyB2UBtrYpcWH/e3/GthC5FoaTPavS66R41KbGMwiXJmaRHjxjbKSdZXtnAN2vZdZ5VxEjcvO+h+2l6wT8n1/TpH9Y/qaZw0hvsU1l+WmzrOog5zt7UTNLFc5ljFx5qQ64LYQTMgdlAb57bYWevGwkmxGIWl7/2WpOhmjKipaEUQxd+2y4nrG/7fSU7Q3WtUUuzy68vl4nXieqb3KX1c5d+C4xx0xfr1KzlWZd21hJwRxA6aAbGD2jh1jJ1RXvdlKHZaq6grdL3br1zstroPU2IXSmZS7IRARVKaXH9d7OJ6HhC71HHeIXbpY4XYkfuC2EEzIHZQG2eKnVG5rkAnL15X6dIaNi1zsMVuu5xMV2yXErC4xS7ZMpldPy926XruF7vkcfbELuzSLTlWiB25L4gdNANiB7WxX+yCmwmkRC0D8KduVyFzy7LLMsHfMne7zn8fV3XlZG/CSJUjbgyIWu22bm6Yxq6Vrp+rc1R+4tiE+5Q9Fip1nP33Rdan9FiFdSXkqiB20AyIHdQGM09sRN7sYa01OvdIEUJIaRA7aAbEDmoDsVtL3BWs6ask5OcgdtAMiB3UBmK3EdGNe3jWC0KIF8QOmgGxg9pA7Aghdwexg2ZA7KA2EDtCyN1B7KAZEDuojT1iJ++69KfgWpkW7KyszoV6JPlZHm7PoG1/uJt34zElg7b9Zbe5nveIlJJ5at3dvCds86djXlqf8Bw765w789yV09OddGwLgthBMyB2UBt7W+zcM9RkBqv1laPPpi+fK8Xx5gxaiWfdHR+/N8pF5sv4dBnese39pa3LSu55gjszHvffjnlpfcLjc+7xOinGBI+8uWccKWIHzYDYQW28Q+zs5ZJyd/wWqnC2iz3JtZoNVvdXf0mf/VBjY1XmPc5PYbdzCyrzIOqdKatPahq4ysTOy2C1uuczhthBMyB2UBt754rdFjsxh6k21nitFWutbrJLKPGFO4mdlg87Xl1v/OLWup/qn/q//yUb1zFcJ66PkQ//ne+gDfYxKlfcaTvuxiQZifXlQ5B7v7Lr3WfeDBNhWf7xTW8jX6fctrN13XmswvPLm992Wn6tzsn3Kzru+f3bOlfL67MudvE67lxWRjxwutd2mD9XvbaD17q58j6FDxPfEtlBW3WTdSJ20AyIHdTGmtilvqw2xU50US2tI95rXbKlIz3XqreA7bt4Kq38HK2y3uH/E91iUR1NtI63v33iC3mc2yuaRizc92EwianS5vXFl7ZspZT7L8eHeVObpY6nq8cset57kNxGOD9uUKfUtnN13XOsUvVOvb5R51xLmn/cM8e84Fwtq8+87xmxW3tvFzkLzyW9TCkn5wpOvk9Wzmdc1lLohgdcH8QOmgGxg9o4vcVunoIr0+rkt7Ylyplb+6JpY7cmuQ/XC7vawv/nW0/8L8pcK0dujld/ntx0uWVz4IaSs4hhtO/bYpd+3/LbKKvTdl33HKtUfVKvl9U5ldycwP5+lJyrZfXJi93a8XLv1SiiS1leq/j6fkwF7RC7+7phrUXsoCEQO6iNI2Ps4i9eOZn8mPkLcm5V27wx0yivFaJY7LLr7Re7uI7niF1ShAvFTorFvM9ni11qG0fELl1O+bFK1Tv1elmdUykTu5KbiMvqsy522eNl1NRdbayZ6zlo64axFoqd7Ird/gBGn+Erg9hBMyB2UBu7n2NnVDBWJ/hylnOrzt1a3niv9BeIE48SsXNdTvn19olduo6/i1263DKx87tZxevee5C5wzMcYzfLglePlW3k6pTbdracHcfKFrYsFtU5lcL92zhXy+uz0RWbPV7TcZ22Peg+MXaurMWu+IYTo4qE9qwgdtAMiB3UxpEHFIfdVd4XgtG2XwZsuy9Z98yvzBfvMrC9n9YPl/MHgnvilFgvHAAf/n/Zh9Sg+UwZfnVdS4hczhSUK19Txi8rrJc81qEAZd+D5Xj5xzD33LXUNtbqlNv2Zl03j1Xmrlhx04PXSpar88rd02Hd1/dv61xdr0/2vdx4b8d1xXi34KYGWY5eeZ+WYRHRTR2pXbp3ujzEDpoBsYPaOCJ25CU54SG896X2R4G8MLL13FprdD2PC0LsoBkQO6gNxK7xXDrzxHkpmXmC7EncHa4rOsCIHTQDYge1gdgR0mi85w3W1XKL2EEzIHZQG4gdIeTuIHbQDIgd1AZiRwi5O4gdNANiB7VxvtjVOAi+xjoR8t0gdtAMiB3UxtliF03VVUFqrBMhXw5iB82A2EFt0GJHCLk7iB00A2IHtXGa2Hl34AUTrS935YX/t+Ihqv3yYGOljTXxU2rjdZfXlTXz9uXDaZN1IoQ8HcQOmgGxg9o4Rezkg3DFVEnJOTMnkfPnB1VWayUmQV+b+zSeksrNhemmGsvViRDyfBA7aAbEDmrjDLFbn5TeyZc31VI4b+nccrcyHVSqrL2T1RNCng9iB82A2EFtXCp2Rk1doOFk7+7/3pyY1s2DGU2WkC0LsSPkbUHsoBkQO6iNU7pijRLj3uZWNWWVmgUslDHrxr/NLXRyXkujognLTbastNjl6lTT0/cJ+WoQO2gGxA5q46ybJ8ZHijjGIW9quXGhT4iVkzVrrdHLzRNJAcuUtWxXmaW1b5bFZJ0IIY8HsYNmQOygNp6beWKwWq2NpyOEtBrEDpoBsYPaeEzsjKIFjZCPBrGDZkDsoDbuFjvZdUoI+WYQO2gGxA5q47muWELIV4PYQTMgdlAbiB0h5O4gdtAMiB3Uxh6xW2Z5CBgfTSJmfVjNxnJyxojSHFnncEr3kxCSC2IHzYDYQW3sbbHzHlFirbWDtuo0yyl/3px7sPH5z6gLH5pMCDk3iB00A2IHtfGz2J0e+cDhtXrIVrOydYprkJirlhByXhA7aAbEDmpjXeyMVdNDgWfRCR8q7MtVQrbCGSa85cTcr9pYM6ytJ6ullm7gsS75dZa7cLNz0AZ10Omyte6n4yDrH2x36ZYmhKwFsYNmQOygNtbEbpnJQQiLP5uDL3xdQtjGx5o4GfKWE1OHuVaySSaD9bx6DSaY+zWzjld+RrqCOigjy3b74e+/m7PWe3TLoG3PDBeEbAaxg2ZA7KA2zmuxGxKylZjDVf57EiG/NS23nkzZtqSYZp+dF9Vhrezw73EX8KB7Wu0I2QhiB82A2EFtnDfG7oDYzWtOAuZ1qybL3LetQffFrWeuDogdIVcHsYNmQOygNh4VO9nit3SJnid21ijRSmesSlU8qkOqm3dN7MJlufGCkK0gdtAMiB3UxtHn2IWtUku359SlKacOk38zcjmjbb+UOcpTbr3QlebllFlfx40JzNw1u1IHr+ypPL/8uas6HnNICMkHsYNmQOygNph54pec+5gVQr4SxA6aAbGD2kDsfgliR8iRIHbQDIgd1AZidzTicSfZZ+QRQlL5WexScxsCPPUl+vQXOYCk6xA7Qsi92ftdmBQ7QgnclQ0AACAASURBVGQQO4ARro+EkLuD2JHTg9gBjHB9JITcHcSOnB7EDmCE6yMh5O4gduT0IHYAI0+PdQWAb7LnOoXYkc3sPanO/BJ9+oscAADgTSB2ZDOIHQAAwDtA7MhmEDsAAIB3gNiRzSB2AAAA7wCxI5tB7AAAAN7BcbEzyrtjo9clk8QYq7reFi0aba50G5kM2vbJqWyO1+krQewAAADewSGxG3RvO28yZ2NVgdwZ1dnugESN21svf9Bqpdyxfqk5CkvrtF5+20HsAAAA3sF+sRu07VMilHvdX8jq/ljr2KD7VbEzaqPcbItdWZ02y284iB0AAMA72C12cWvdHNlqZ6zqlDVzd+0iVLNETS1oXefKGrTt5f8T282KnegWViZR9lx+r61W09/U/Bdf7Mz8dymBXvmrh6fJIHYAAADv4JjYZVu+OttrY3Uv5UmOYRMSNYmcFKW17s41sRsGs5Trlgta4rztjXV1/56WM2rZhhzTJ8v/YhA7AACAd3Bii90sdqLFbnk9IXY2lERj1Upz2HpXbNidOixy6Rrm/K7YlADOY/kWMq16XwtiBwAA8A4uGmNXJnay5Wzr5oRisTNquhlCtsrZYrFLuyVi98TJidgBAADs46K7YkvFzrrxa8nuXX+bJWJnVKq71QZil+keNkq00skWRMTuiZPzye1CXZNaAwBAGYefYxd2W8qWLiNuUFiW67U14t++263flCC3lZO7eZtKzTc69Lbv5Q0UrntW1ncI6rTUPehuXsrn5onbeHK75NogdgAA11DBzBOD1Wq9tY48G8SOnB3EDgDgGp4XO6M+2Qr2piB25Oy8Veye7r4GgO9SvdiZ6HlypNbsOaEQO1KSp95bzg1CyBvzCrEj7wliR84OYkcIIeVB7MipQezI2UHsCCGkPIgdOTWIHTk7iB0hhJQHsSOnBrEjZwexI4SQ8iB25NQgduTsIHaEEFIexI6cGsSOnJ0viF0097QgP4uOnaZnTM3HvTM/luMe1t7grDvBFJN+5MxEhNSRW8Tu9R/6Qdu+9FErZ11oXxrEjpydb4idm//amxLRqI3pETsbznyzf5u/lbNex3PjH6f1OcOPlutnnAIzN43l+N22/b12Zl0J2cr1YnfThz784Jz2QQp+ra2X++MFsoEgduTsfEHsZNbnug4j59reF6OkkBwvZ199f4uss1//88qNstpiVzY3+Jl1JWQrl4vdXR/68INzzgdpsLoP54HdKvf4BbKFIHbk7CB21i4tR134w9Fdb7JzWaekxMzzZM9zWk/lzK+LddbK8bqQvR/AqTm7x21o3U+tXP6c3HK/kuvLOquw/ql65vcpfywSx3kSO518UL4vdsljFR1rQq7NpWKX+tBf/oE38f/TF6aCD71R/oc4eTEM67j3QltQj+nCYmR5ieXTxzZ1fDcu+j8EsSNnp02xm68d8Q/FlNi518IWIvFD0mj3uugpMSoepzcMJlHOLC1i3NhGOcn6yhauQdu+66wy7po+LzvoftpesE/J9f06R/WP6mncd0i4T2H9Zbmp4yzqMPfKuK8FsVzmWMXHmpBrc2+L3Q0feGuD/yc/bEPRhz68YEXbSV5s91xoS+oRHh95AQ4uPoljE6+fq8s5Qex+ycMDsYvGh8ofXfe0TLcodvkfYWu9HO7YO7EYz5m+91uSopsxoqaiFUEUf9suJ3GdDP7vrjFBb8byw3nIXFfD9eVy8TpxPdP7lD6u8m/BcY6G48j6lRyrsu5aQs7KrWJ3zwfe2rIP2/aHPr7AppYLL7Z7L7QlF5/cMu7XY/7YhOuXXayPBrF7a8rGh8oxpkad3+KbSotit7fFbuwtcL0ZodhpraLW+/WPdbnYbV0eUmIXXvuS1/noh+3W+utiF9fzgNiljvMOsUsfK8SO3Jvbxe76D7y1ZR+2E8QuebHde6E9T+zSxyZcv+xifTSI3Zuzc3zoTXeAtyl2+aTEzqhcV6B7z7wfc94wEmPVwRa77XIyXbFdSsDiH/DJlsns+nmxS9dzv9glj7MndmGresmxQuzIvbm/K/byD3zw/+yHreBDH46xSwyUjS+2ey+054hd/tikj+/WxfpoELtfIr80tsZeuvGdcjjDuNz0/41B9NnB5la06q62yN1zo9B3xC4YW5wc3zv1BohrzLLsskzwt8x7NP/dG4esTH5scKocMe44arULbhiIzrdpyEjp+rk6R+Unjs3W+byUpVLH2X9fZH1Kj1VYV0KuzLVil/jQ3/GBD/+f+rCVfehTd8WK7SQutmrnhbakHnIZeaxMsPzWsUne6XbyF/PbxM7rkj5Qxpli556JVTYG1G9JCFsw9Prg9+TrmfGhuQzaqhuaIZ4Uu1/Oj7Zacy9IcI4ZfX23PiFfyOUtdodS0wf+4w8c3pu3i93eL/JzPwO5Vux8V45rNR5v7FmGJuhpzcx4yvxg83h8aC53fS5rErs95wdit5a4V0HTV0nIKalQ7Cr8wO+ZeeLjaU3str7InxY7a6axnMZYM68zaDt5XXY8ZX6weTw+NFnTC8dphqlZ7NbOD8RuI6JH58sPdSfk7FQodpYP/Iuz94vwzVQhdvP4H9kSFz4cNTWecmOw+dpjcMIbc6784fX0e/wrhBByd+oUO/La7DmhaLHzI8dY6h0Dv71p7hLj3rYGdJcMxI/Xmbn+br+nzila7AghbwxiR05Ni2K3tT65NrWLHefGRrJzrf7yQO6HH+ZNSMVB7MipaUXs9qxPrk2NYnf2ueFPoehwdyuXSMzGckduBLv15jFkjZAzgtiRU/NmsTu6Prk2tYjd1eeGu8N5yqmPkymbWWTcrPKek3nmOGdv2AAh5JIgduTUvE3sztguuTZPit2d50Ykdqen7IHSRq083PzXGiha5Ai5OogdOTWIHTk7bYpdPFesJ3beszzDLsrcrCRyOTGHtTbWFM1mYr0nEngz6STWyc1o4hLUQafL1rqfjsPKzCtd/i5tQogfxI6cGsSOnJ0WxU4+IFrOAJK629jNSGJtPI+2kyFvOW9mESlL8XpevQaTmI4wsU5uRhOZoA7KmGg6xHj/UzOv2GU2Ih4nSsh27hO7CwfhxhcWObffyjYfm1XinEHCNXZrIHbk7LQodvta7Nbmfs7MmT1Py+i1ppU8G7FsW7kZTfyiwjpszGG9Nn+4DZ+fSAjJ5XKxGwfLnj8I15XfR830coCuUbmuguvqtBX/F3g+2wON67uLDLEjZ6dNsYuTH2N3QOzmNafro9etmixz37b2zDzi6oDYEXJHLhc7vxvgGola/cCvtspdV6f1rM0k4FLWImes2pj+6c4gduTsIHYHxE62+C1doueJXXZGE2+HwjqkunnXxC5ctq4fsYTUmmvFzhuIuzbgN9VtWjDQd8r6L7k1ectvIx4DM9dTPqXfl1Y3CDg1cNmrcXABS+x/MIh5baDy9XfTlQexI2fnC2Inn2MXXsvCmUdMZlYSI5cz2vbBcJTceqnrSXTdSayTm9HEFZSvQ+qa5pcvr4v3zHBCSCu5VOz8gbjpQbhOysJfnukBwsntbLTY5Z8FlRkYLJ+U7g3aTf16jQcBpwcue5XyujTi/Q+O3cZA5Zq6KBA7cna+IHYkzFO9KYS8Pxd3xZZOai5auFyTVeEk6OtiY/RaN2V+/Igsz8lUrk7BRSg5cDl3XHL7Xz5QGbFD7FoOYvfFIHaEHM3zYmeU1315pthtD/BdueNLrOjKLxQ7sZ4va4njkt3/8oHKiB1i13IQu69F9NhUNH6YkLfkcbFz48POFTv/NWN1cuXMNgZte++5Ual9kGPuArFLDlxOH5f8/pcPVGaMHWLXchA7Qggpzw13xXZRN6I3SHa5SaCfBtruG+i7/aDP/MDbtW3IcqU0ubJ72ws58+qXGDScrPPK/stteQONo/K4KxaxazuIHSGElOdysSNXpuyxKXcGsSNnB7EjhJDyIHYvDjNPIHZfCGJHCCHlQezIqfmi2MH1PC1piB0h5C1B7Mip+ZrYAeR4WoYB4LuUXqcQO7KZPSfU2V+iT3+RAwAAvAnEjmwGsQMAAHgHiB3ZDGIHAADwDhA7shnEDgAA4B0gdmQziB0AAMA7QOzIZhA7AACAd4DYkc0gdgAAAO8AsSObQewAAADeAWJHNoPYAQAAvAPEjmwGsQMAAHgHiB3ZDGIHAADwDhA7shnEDgAA4B0gdmQziB0AAMA7QOzIZhA7AACAd4DYkc0gdgAAAO8AsSObQewAAADeAWJHNoPYAQAAvAPEjmwGsQMAAHgHiB3ZDGIHAADwDpJiBxDyxMn51HYBJE9/9gDg2+y9ZkViB1ALR05ogLPpOnoxCCHPBLGDpkDsoAYQO0LIU0HsoCkQO6gBxI4Q8lQQO2gKxA5qALEjhDwVxA6aArGDGkDsCCFPBbGDpkDsoAYQO0LIU0HsoCkQO6gBxI4Q8lQQO2gKxA5qALEjhDwVxA6aArGDGtgrdoPusw8a7fWQW8n2nbLm12+BE8oxaq5vb3PVfW0Gbfte23i3jFWP7O9gdd/gcSanBbGDpkDsoAb2i51avqgH3TuZMyojdoPVfWe7H4Rs3Obv5eTreG7kMUr9/6xy/Rirus52CbEbZXZbsM6q597tku8GsYOmQOygBn7pivXEbjXGqh+EzKhZDn4rp7y+v8XVN/3/s8qNkm2xK2s5O6uee7dLvhvEDpoCsYMaOFfsplajLmxZc0K2dOVOArJ0jSaFxFpr1NLVq8xUzvyaWGerHK8LeVpGvub2Y9yG1v3U2jS3FMb7lVzfq2/8/3Q98/uVPw6J4zyJnZ63oZaaeoKVrENY79L3NFVnURYtdmQtiB00BWIHNbAtdvMXe/wFHYqd+3/YUiNa2ox2r4uuUaPSY/SGwYiyprqMxuTGjRWUE9VXtm4N2vZdZ5VxEjcvN+h+2l6wT8n1w/oG/0/WU4hjuF+Z45A9zqIec7nu3+vHKqz3+nu6Umc5DnLQtkfsyEoQO2gKxA5qYEvs0q1a7m+xRLkvfdfyM37x971sRUrciKFSnaxDIHZzq9Hgic52OX59w7o7yQm6e41Kil1+/VBqS+qZ3q/8ccgc56ArNiVl+TqsdZvm3tP0e+GOC12xZD2IHTQFYgc1cGaL3dgF57ovQ7HTWnlddoPubcbB5FaKxG67nFjsQslMil3UOmU31l8Xu3Q9d4pd7jgXil26Dpntrr6niB35LYgdNAViBzVw5hg7o1LdgNZKCfC6SpfWsGmZgy12ZeUkumI72bWYuUEjdydtdv282OXruU/sssfZEzvZpVtSh/R2S97TWDrl6z/eyUyaDmIHTYHYQQ0cE7vghoL5234ZND91uwqZW5Zblgn+tvLl75Zx5WRvwsiVIwb0e612wQ0D0Y0F07i1VHd0an1ZRlimd/OEqKc8PuF+pY6DUunjHL4v8/ZLj1VY79L3NF9+6mYMQlwQO2gKxA5qgJknNiJv9rDWGp25e5cQsjuIHTQFYgc1gNitJb67VzNgjJDTgthBUyB2UAOI3Ua8Z7IxVoyQM4PYQVMgdlADiB0h5KkgdtAUiB3UAGJHCHkqiB00BWIHNYDYEUKeCmIHTYHYQQ3sFTt/3tTwMSDp6bD8bCwjp6QqzZF1DqdkHwkhJUHsoCkQO6iBIy127qG1UwZt1Smms++BtoNWy4wIZ9/YMJZ9YoGEkCiIHTQFYgc1cIrYnZpwSq+1emRmizijFopWOUKuDmIHTYHYQQ0cmSvWEzvvAb6ym3KSrflxIcmprqz1JpjXxpoht15YLfcYEmXy60QzSUQJt58uW+t+OgZh/YNtB7NTEELyQeygKRA7qIEtsZPTZs3C4k8Z5QufnDDeTTfmZMgtY+eVRLmzOMXrRfUaTDC/a2Idr+yMcEXbl2W7/fD3Xc7BGkyrNk1BxjRahGwHsYOmQOygBs5tsRsC2UpNbB/M5jDPxeq16KXWC7O9LSmlnnx5xYTbXys7Vae4G3jQPa12hBQEsYOmQOygBs4dY3dA7OY1JwlbulWj9fZva9B9ccuZ2/5a2ak6IXaEHA1iB02B2EENPC52ssXPKNtrfZrYWaNEK52xKlXpaPvDStmpOqXG3HHjBSElQeygKRA7OJPwuXJ71tsT+Ry7sFVq6frstdXKdX/K14349+hN2vZLmcqqzHopT/LH+qXXcctk7poNtm9yZU/lxXWau6rjMYeEkPUgdtAUiB2cSeqhwSWix8wTv+b8R60Q8pUgdtAUiB2cyZbY5UQPsfs1iB0hR4PYQVMgdrCHveK2B3I04nEn2efkEUJyQeygKRA7KKXkXKHFjhDytiB20BSIHZRyltjl1iOEkCeC2EFTIHZQyi9iV7Lensi7RZ95VtvaI1DW4+qeWX/Qtm95vFzr+0deF8QOmgKxg1L2it3esvfmlwfwDlr99DiQaEqy8hWzdR7rNI+Xa1V8Wt8/8sYgdtAUiB2UcuW5crfYzfOxHs+xFru1Ors6tX6Ha+v7R94WxA6aArGDUp4Vu3iuWF+SJlkwKrg71N0xqrSxZp4JYmpVVEZ0jXp3lMoH/goJEeuutdjJ+WHnOnpzxoZ3r3p1yu1Lrq7elr2HN7u6Z/YnPG5R17ZbT5nw7tvp/+FDmDfr68Ru6+HPhNwRxA6aArGDUp4Uu5wouam33KwP3nRaoutzbhEbBuNN9+X+nit7WlaODRu07dfGyM2iMmjbd27qs1yLnVenWaZW9yU9tnDQ/bSe36KY3J/ouMX1jfYnNxVbqm7Z+ooWOzmVGiEPBbGDpkDsoJRXtNiNfwlkLGwRcn/3WtGk4CzLuZY9f3v5rthQ3tLCGK21Oefsel2XjSXFLrU/8XFL13/eh3GdUUAXSdRmWSesW76+o6z2fWYfCLk5iB00BWIHpdQ9xi4jdmJZJzS+LCXdwqhJIkcZ2it2Uljker+K3bYHJVrhMvsTH7e4vt76vbaDMdbM6wzaatESGdYtX9+pFVIrumBJFUHsoCkQOyjllWInu/qWrsHB64r1WpKmf7sWKiFCRonxaSt3d3rdtLku0WilTbHL1dVL5q7b5P4sx00Kavh/WT8ni4PufSlL1S1bX7d/uS5lQu4MYgdNgdhBKTWJXfgcu+X/sguw13YweuzyC24amJf3bp5I3iQxdRkKEZHdi7kWNNkN6Xwmd4NCvE/JfbGZuvobHruew+1k9se/qWLrhhDxiJhBW5Xors0d5+Rrs/yt7Q8hNwSxg6ZA7KCUmsSOZBLcjGD0Vlcnjx4hBLGDpkDsoBTErvaE4/6M1ZvdnIgdIYgdNAViB6Ugdi+I95y9LWELn0tHyDeD2EFTIHZQCmJHCGkxiB00BWIHpSB2hJAWg9hBUyB2UEptYjffXdnroeAmgZMiZ594fXKPNiHkW0HsoCkQOyilKrEz7uG20TPVbPBojsLk1nGvrzy77sbs2bcjx4GQrwWxg6ZA7KCU6sROPEQubLGb54XdV2R6Hf/15+8i3bNvR44DIV8LYgdNgdhBKXXNFTv9Pzdf6vJwYPkAXilko6Bp3Y9larlOriy3nplfFy2Fy4N3k3eY7llPzOmqxwcOxw8aTj0cWa5nrIn2KdjnQXbFBvXLPESZkBaD2EFTIHZQypNiJ2dy8KcRi2dLGAbjza8aTSMmBGiZw1Ws4203el0KpRAjMZVXPE1WOH9ryXpzy6D/LLpcPacCRFm9Vcas7vMolG7+WG9+2WkGi+25aQl5fxA7aArEDkqpq8XOZVhaoJZXAvkRLVneHKmyBS9cJ/d6eh5XKZ6eINkf1vPmpt2qp3XTiXktf2vdyLn5ad1xpdWOfCGIHTQFYgel1DbGzncgKW1CWIzyWqWuFLv11q0D603z3Matf+vj5mZZVAaxI6QkiB00BWIHpdQmduGYtJTYOeG7Vuz8mzmMVYUtdtn1Bm17ZRLbXxE7OU+sUbbXqW7kNbELl+XGC/KNIHbQFIgdlFKX2GmrzdT1mOj6nG9IUGq+GaC3vXhUSepGh2WdwMnk68t6yrhu1KmM5W+Ju2b3rTd1HSuT6F7N13Nu4ZNlJesuHxOz/F/eZJLu8iak1SB20BSIHZRSldiRk/P8Y1wIeSqIHTQFYgelIHYtB7Ej3w1iB02B2EEpiF2rEY87ST6Dj5C2g9hBUyB2UApiRwhpMYgdNAViB6UgdoSQFoPYQVMgdlAKYkcIaTGIHTQFYgelIHaEkBaD2EFTIHZQCmJHCGkxiB00BWIHpSB2hJAWg9hBUyB2UApiRwhpMYgdNAViB6UgdoSQFoPYQVMgdlDK1WIHAPAUe69ZiB1Uy5ETGr4J5woAwAhiB9XClzWUwrkCADCC2EG1PPFl/XST+1do4VwBAKgRxA6q5SmxI9cGsQMAuA7EDqoFsWsziB0AwHUgdlAtiF2bQewAAK4DsYNqQezaDGIHAHAdiB1UC2LXZhA7AIDrQOygWhC7NoPYAQBcB2IH1YLYtRnEDgDgOhA7qBbErs0gdgAA14HYQbUgdm0GsQMAuA7EDqoFsWsziB0AwHUgdlAtiF2bQewAAK4DsYNqQezaDGIHAHAdiB1UC2LXZhA7qJWu6x7h6f2GtkDsoFoQuzaD2EGtPPH559yFs0HsoFoQuzaD2EGtIHbQAogdVMv7xc5Y1fVWDycWuTeDtn2nrNlcrJ+6ha6vL2IHtYLYQQsgdlAt7xe7pzNY3Xe22xK7QVs12dyge9upLQ38LYgd1ApiBy2A2EG1/HLBOzo4uS2xs3ZsNdxusXOLK9tf3GSH2EGtIHbQAogdVMuZYlcqedd1xU6CZdRYj17bWJ+MVVMdlZlb2+Zlp/9P6xnVReWkXpNit3S3JrdtrbWD1fra1jprETuoF8QOWgCxg2q5SuzWRO/MC/soWr3Vg5A0Zezq2LtB234Rr8HqXixn9Phv0apmVDf+O/Xa+D/XYjevn8qgbT8dD1rs4KuUfv7dmNT4s6Z1v2usKucunA1iB9Xy1DOlzosUM9klGghbEKM6Ow5zM1b3/fTF4VrT5JfKLIup16bSrOp62/dd0di5QfcrLXrn5Irne/HlCGdQ9PmXP76mH0SyhX3vDyPOXTgbxA6apIYWu6NiZ40a5coYa+b1Bm3nXtJB9zZ0tNRrU2Fj66BWhcJmrLpB7M58H+flnj7n4P2UfP4H3Xvy5lrId45nPfB5ACgBsYMmqWOM3UGxm8fTKdFCJ2XLKL9FTpn0a/O/p+36XbSZvPTmifm9e/q8g3dTKnay9duJHmIHdYDYQZP80qV3VuTNCnq+sUF2m660jA1aOfETjyOZs9woIb5IVl+b5S/4u1dPrwv3uiB2UCvFXbHLGLrcj7fnPw/wXRA7AMG5LXYkFcQOauXIzRPzb6H0XenPfR7guyB2AALE7vogdlArT3z+OW/hbBA7AAFid30QO6gVxA5aALEDECB21wexg1pB7KAFEDsAAWJ3fRA7qBXEDloAsQMQIHbXB7GDWkHsoAUQOwABYnd9EDuoFcQOWgCxAxAgdtcHsYNa2TNjzZk8vd/QFogdgACxuz6IHQDAdSB2AALE7vogdgAA14HYAQgQu+uD2AEAXAdiByBA7K4PYgcAcB2IHYAAsbs+iB0AwHUgdgACxO76IHYAANeB2AEIELvrg9gBAFwHYgcgQOyuD2IHAHAdiB2AALG7PogdAMB1IHYAgqeePP81rnrvnj5/AACeBrEDgCZA7AAAEDsAaATEDgAAsQOARkDsAAAQOwBoBMQOAACxA4BGuFrsnr7hBAC+yd5rFWIHAE1w5AK4t3xCCLkziB0AfBbEjhDSWhA7APgsiB0hpLUgdgDwWRA7QkhrQewA4LMgdoSQ1oLYAcBnQewIIa0FsQOAz4LYEUJaC2IHAJ8FsSOEtBbEDgA+C2JHCGktiB0AfJbaxM6o8anxvR6s0doOF134vQza9p2y5o5tWWNV11tdvGN7lz8zg9X9vO2z6vHk/pCvBLEDgM9SldgZZbt+lLlB98u/5wxanSYErqzB6r6z3Ylid2Y9n8wo2fskbGvfj5RJyN4gdgDwWaoTO+X0KmyxM+o8IfDLMladKHZn1vPZyBa7smzv+/4yCdkbxA4APsuzYmes6mQLzvR/lVAso5bJvec/D7pfXusXU5gkTSzfhxYRlRWsI1oK567hsPVwqsHU2tdZpY01Q75srftpP2VXZEFdw67LQdu+19bM+95rO4T1Lllmbf9Effz3JpTheZlJihPvUVx+2L0blDFo23fntqCS7wWxA4DP8qTY5cUs7q4bBuO39EzysohM11llnGh1zv6mv62U5QmlEBijlnoZlRZE9/dxHb9sVx9ZzrhvZXX1uy7D8mS9Z2EqWSZV/2l5Od5w0Lafth12oQ66n9Z1ZUbHNXn8hvh9DN+fRrqyyXNB7ADgs9TVYucyLC1cyyueEDixmEpSUmT81p5w2bg7UK4jREWIpydgruCxdclrBVsrO/z7eXWdpc9rgVxdJr1//vbDdcP3SbRYmniZ9PGLy/HHUxqrUi22hOwIYgcAn6W2MXZha5X7f0IaxMJOSM4VuxLHmAUmJTe1i13sqoViZ5TX8pgTu/j45QVRGVrryDlB7ADgs9Qmdv5YrLzYyW7C9cdypB6vUShL3s0ciZYkoxPdjnvF7qS6HhC75P4ZJca3yTuG/Xo46c6LXfr4ZW6eyIwBJORIEDsA+Cx1iZ222syD5+Ouz3kgfqor0S0qB+TnH60hy1oG+E9dkVIwlr+lBvMbbfs+/nuybPkYl+X/23XN1kcZr2x5o4QuWCa6OSRRf3lsw3q4GyX66RiM64fvUVh+VE7wntALS84IYgcAn6UqsTsl5z665Nq8qa5XZ7Ba0VpHzgliBwCfBbF7Mm+q68UJxlcS8ksQOwD4LG2JnXiESPVjtd5U1+siu5YJOSuIHQB8lrbEjhBCEDsA+DCIHSGktSB2APBZahK7pWtS8lM3ZerxITsiZ2FoMXv2b9C2P7279Mf356pc8r6XRS89JgAACkVJREFU3a0tKsGcuj8EsQOAz1KT2MXPrpvGYN08/mp8SK58hluL2bF/cvq2o1tLPHg4nKbs6Vz6vhvjlWfUevm1HZu3BbEDgM9Su9idIRV7M8/72v5dqyX7N1jd/34M3DENy65HXu5730se7VLXsXlbEDsA+Cx1zRVb1mIXPvTXu8PUe9huamYHZc3aLAfLg3c7q8z68nE9ZNbqlHrocbCtrgumFnPrKRPeUTv9P3yIcepBxF5dncBkHxzszR6xfgzlA6O9unvHNDxG6bll431PbTN3jFP7O5ahozmIU3XMba/wvdv6ITJoq3LGJurh6pnabuK1ee7i5aHRnVXaWPNBOUTsAOCzPCl28Rd5+EWd6IZdpu4av7x7PYh5Y+Npr0JpdGWmx3cNgwmm/Mosn6hHtG+JOrm5WOOpvrz9nb6k862X4fRdepkGLapXtq6iZUpOjxbshz93bOYYyroFdfePqVe6ez27fn6buWMc769Zygjfp6UmBe972Xu3PW4wOx+uHNsnpsxLbzc+zkvZWu7/N1v9EDsA+CyvaLETrSNSBpcv06VVKey+Kp1nVSacyzW9fLIe3q7l6uT2M54Kze/+86XKHY95Pljdiy98bbL1ytd1lJC+z49jjOuQPibhcr5Abh/r9fW35vIteW+2ulfL3vft926rCzXfDRtL9NZ2p32VLYrj/G9jy92Hn4+I2AHAZ3nFGLvO/9KOHSTR4rW8fp3Yrd/TkamTUZPIhvtaJnbWqPEL2xhr5nUGbbWYPzesV76uU+uSVlkJ2CN2cj/XJcVGr6+vn3sf0sc4vb8niF3Re7cldpN8pWqQO2bZ7bpjMPqc3xI4C+4Xn/2M2AHAZ6ld7MIWO3/M1/QlKbre4vKuEbtkPWQydXItbik5COuaq58TGb/FJn980nV1+5fqTo7LWzkmnoBvtZwmXl9dPy9a23We9/d3sVt/7wrFbm3qNKPEue7uzlXZ7cr1RAud7FbPfjbaDmIHAJ+lJrFLPscu0eKwDIyPBo3746jCGwLk9FXZmwW88teXj+ohk6mTGxw/D3BPDYZff9SF1zKTGIifqtfqa7P8JffFvyt27RjKLtDcexZ1Ixasn91m7hgn9nf9Rpdwncz2Mu9d6Xk1bqPkMSfBuZ89Z/z1nMvq5eaJZdmpjK+03iF2APBZahK7wwkG/htdwdii3XWq+NEqtT6oucb3/ZGUPD7FWiu67FsPYgcAn6XkAhi2oO0t/9rE3Xb68a6nI3WqWOystdfMPPFLanzfH8pa9+6cB54H+WQQOwD4LEfEbo/k3dNiJ5/9VYkc7apT+Fw6UpQa3/cb43WlEy+IHQB8ll/Fbkv0bhE7QggRQewA4LPskba9zOUTQsidQewAAFa4t8Vu+8n9562beqzGBU/qP+HmA3e3ZIMzCWTHf+17P746ywKJg9gBAKxQ/Ri7Kf4UYucvvyfukSTueWSHxe6mZ5HFD7jNTH31Y7l+pse8ZB87s/3+uPIvEnPyuiB2AAAr1H1XrMzWU/9/Xb48fuvRb3e8JmeguCBhi9dZLWCb5WRb7Mren+hYcwPK54PYAQBcxG9dsZMQhU/Wt/JhtlKYZhGYH/YrHyAbzBrRpbo2S7Y9BA9STgibKH+e1zW3H1sPzvXmPU08yDecdkvr3srpp1L1TK4f1jn4f7qe+f1KHwv5EGZx3Cax09Fdnr7YJesQHevgYb3kk0HsAAAuYq/YOQkL5wEV0iWmjMpPNr829ZWcsSIUh/VtuzlN861Jw2ASY/fS+zHXPTullw1a7GTr1jTzgjKuvt6sG6l6JteP6+z9P1nPlfcncyzcfiTq1KWmzUpPHyaPVXys72vhJPUGsQMAuIj9LXZ75uzcv+765PSFE8FviF3pXKdea9zK88hknUNpcZITdPdm6plfP38s8vXcO/fu/H+/hS3sik0JYL4O8XYRO4LYAQBcRHNiF7VUbdVjvS4lXYah2Mntur+F4/jS9cyvvy526XruFDujvBbRvWK3/Z7Hx4t8M4gdAMBFXCF21igxzspYlWy9keuKMXdGifFd4R2rZdveloYysZNdyv5+BKWFXbGdlMxUfVfqmV1/RXKz9dwndk7I18ROdumW1CHeLmPsCGIHAHARe8Vu6XILBtPL18fv+fjmh7Vl+tQg/GDQfdG2p/Fg8c0LfuZteDcerO5H5q5ZcXOA12qXuGHAu7FgpZ6p9cM6Z/dB1HNtv5LHQinxfoRCvf5+rB0rv97cFUsQOwCAy7j3cSc3xGi/dUhXKhFvqeepue7xNeRdQewAAC6iLbGLu1h1lRbxlnqeG2aeIHMQOwCAi2hL7GzwDLzfpgm7NG+pJyEXBLEDALiI5sSOEFJ9EDsAgItA7AghdwexAwC4CMSOEHJ3EDsAgItA7AghdwexAwC4iD1iF00bFT6HTc7z+ta0sA9L0vPDEvJ0EDsAgIvYJ3YqPaepUbbXJpgl4trIuvy6jns9nOnimezZtyPHgZCng9gBAFzE0a7Y9Hyf4Xyo1+XIM9Fy6/iv37cPuezZN54NR94YxA4A4CLWxW6ewzWWh1Wxm5/RJqaOiqbU2lhebGmZzkppY80yWf08TdVcx7ClbSxb636sv5bryCqHr+/dh7J98deV+zROLSZbP5P1TB2LaJ+CfR5kV2xQv5Xp1gi5OogdAMBFrImdHFMXSkBe7LppMnghFWLCe6PmssT8o+HyXpFy3fHvw2CWmRtcPeRsDq7sZf5WsY63H9Hre/ZhKWV9X5Lrzi2D/qwTuXqmjoUyZnWfR5nsrR7C+tllrtpYHgm5PogdAMBFXNJiNy7hyZd3s8ViE+nlgw3ZPmoBC5cVLVmLqIRdqrl5SuPpvfbtw/p687FKrmtUYjzfynyq0bFYq3v497iLOf0eEnJ9EDsAgIu4boydL0XplqECsRPbc+ImljXKa5W6UuzWW7fWxS65rtG271Otf+vj5tyxQOzIO4PYAQBcxB1iZ43yW+n2tNgZnejSdMsaJWXvOrHL78PGejaz7qBtr0xi+ytiFx2LVDfymtiFy3LjBXkmiB0AwEXsFzsxXivoklxuEFDGdT9O3YbL34R4rC3vCh1btXLrKjXfDNBPy43LpG50WNYJnEy+vncfSvbdRutOx3AWvMJ6po5Fsu5TWX495E0m6e51Qu4KYgcAcBHMPPGVPP8YF0LmIHYAABeB2H0liB2pJ4gdAMBFIHZfiOg+Tz6Dj5B7g9gBAFwEYkcIuTuIHQDARSB2hJC7g9gBAFwEYkcIuTuIHQDARSB2hJC7g9gBAFwEYkcIuTuIHQDARSB2hJC7g9gBAFwEYkcIuTuIHQDARSB2hJC7g9gBAFxE580fCgBwD3uvVYgdAAAAQCMgdgAAAACNgNgBAAAANAJiBwAAANAIiB0AAABAIyB2AAAAAI2A2AEAAAA0AmIHAAAA0AiIHQAAAEAjIHYAAAAAjYDYAQAAADQCYgcAAADQCIgdAAAAQCP8+/fPdv/995/99+8fAAAAALyY//77z/4PMFEzPGmq2U0AAAAASUVORK5CYII=" /></p><p><strong>What to do in the case of vomiting or severe diarrhoea</strong></p><p>If you vomit within 3-4 hours after taking a tablet or you have severe diarrhoea, there is a risk that the active substances in the pill will not be fully taken up by your body. The situation is almost the same as forgetting a tablet. After vomiting or diarrhoea, take another tablet from a reserve strip as soon as possible. If possible take it <em>within 12 hours</em> of when you normally take your pill. If that is not possible or 12 hours have passed, you should follow the advice given under &ldquo;If you forget to take Yasmin&rdquo;.</p><p><strong>Delaying your period: what you need to know</strong></p><p>Even though it is not recommended, you can delay your period by going straight to a new strip of Yasmin instead of the tablet-free period and finishing it. You may experience light or menstruation-like bleeding while using this second strip. After the usual tablet-free period of 7 days, <em>start</em> the next strip.</p><p><strong><em>You might ask your doctor for advice</em></strong><strong><em> </em></strong><strong><em>before deciding to delay your menstrual period</em></strong></p><p><strong>Changing the first day of your period: what you need to know </strong></p><p>If you take the tablets according to the instructions, then your period will begin during the tablet-free week. If you have to change this day, reduce the number of tablet-free days (<em><u>but never increase them &ndash; 7 is the maximum!</u></em>). For example, if your tablet-free days normally begin on a Friday, and you want to change this to a Tuesday (3 days earlier) start a new strip 3 days earlier than usual. If you make the tablet-free interval very short (for example, 3 days or less) you may not have any bleeding during these days. You may then experience light or menstruation-like bleeding.</p><p><strong><em>If you are not sure what to do, consult your doctor.</em></strong></p><p><strong>If you stop taking Yasmin</strong></p><p>You can stop taking Yasmin whenever you want. If you do not want to become pregnant, ask your doctor for advice about other reliable methods of birth control. If you want to become pregnant, stop taking Yasmin and wait for a period before trying to become pregnant. You will be able to calculate the expected delivery date more easily.</p><p><em>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in">Like all medicines, this medicine can cause side effects, although not everybody gets them. If you get any side effect, particularly if severe and persistent, or have any change to your health that you think may be due to Yasmin, please talk to your doctor.</p><p style="margin-left:0in; margin-right:0in">An increased risk of blood clots in your veins (venous thromboembolism (VTE)) or blood clots in your arteries (arterial thromboembolism (ATE)) is present for all women taking combined hormonal contraceptives. For more detailed information on the different risks from taking combined hormonal contraceptives please see section 2 &ldquo;What you need to know before you take Yasmin&rdquo;.</p><p style="margin-left:0in; margin-right:0in">The following is a list of the side effects that have been linked with the use of Yasmin:</p><p style="margin-left:0in; margin-right:0in"><strong>Common side effects</strong> (between 1 and 10 in every 100 users may be affected):</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->menstrual disorders, bleeding between periods, breast pain, breast tenderness</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache, depressive mood</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->migraine</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->nausea</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->thick, whitish vaginal discharge and vaginal yeast infection.</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (between 1 and 10 in every 1,000 users may be affected):</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->breast enlargement, changes in interest in sex</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->high blood pressure, low blood pressure</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->vomiting, diarrhoea</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->acne, skin rash, severe itching, hair loss (alopecia)</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->infection of the vagina</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fluid retention and body weight changes.</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (between 1 and 10 in every 10,000 users may be affected):</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->allergic reactions (hypersensitivity), asthma</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->breast secretion</p><p style="margin-left:1.85pt; margin-right:0in; text-indent:-1.85pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->hearing impairment</p><p style="margin-left:21.3pt; margin-right:0in; text-indent:-21.3pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->the skin conditions erythema nodosum (characterized by painful reddish skin nodules) or erythema multiforme (characterized by rash with target-shaped reddening or sores).</p><p style="margin-left:2.0pt; margin-right:0in; text-indent:-2.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->harmful blood clots in a vein or artery for example:</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->in a leg or foot (i.e. DVT)</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->in a lung (i.e. PE)</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->heart attack</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stroke</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->mini-stroke or temporary stroke-like symptoms, known as a transient ischaemic attack (TIA)</p><p style="margin-left:14.2pt; margin-right:0in; text-indent:0in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->blood clots in the liver, stomach/intestine, kidneys or eye.</p><p>The chance of having a blood clot may be higher if you have any other conditions that increase this risk (See section 2 for more information on the conditions that increase risk for blood clots and the symptoms of a blood clot).</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>Other Countries:</strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in">Keep this medicine out of the sight and reach of children.</p><p style="margin-left:0in; margin-right:0in">Do not store above 30 &deg;C. Store in the original package.</p><p style="margin-left:0in; margin-right:0in">Do not use this medicine after the expiry date which is stated on the packaging after &ldquo;Do not use after:&rdquo; or &ldquo;EXP.:&rdquo;. The expiry date refers to the last day of that month.</p><p style="margin-left:0in; margin-right:0in">Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>The active substances are </u>drospirenone and ethinylestradiol.<br />Each tablet contains 3 milligrams drospirenone and 0.030 milligram ethinylestradiol.</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><u>Other ingredients (excipients)</u> are lactose monohydrate, maize starch, pregelatinised maize starch, povidone K25, magnesium stearate, hypromellose, macrogol 6000, talc, titanium dioxide (E 171), iron oxide, yellow (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Each blister of Yasmin contains 21 light yellow, film-coated tablets
•	Yasmin tablets are film-coated tablets; the core of the tablet is coated. The tablets are light yellow, round with convex surfaces, one side is marked with the letters "DO" in a regular hexagon.
•	Yasmin is available in packs of 1, 3, 6 and 13 blisters each with 21 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:0in; margin-right:0in"><strong>Bulk Manufacturer:</strong></p><p>Bayer Weimar GmbH &amp; Co. KG,</p><p>Dobereinerstrasse 20,</p><p>99427 Weimar, Germany.</p><p style="margin-left:0in; margin-right:0in"><strong>Packaging and Final Release</strong></p><p>Bayer AG</p><p>M&uuml;llerstrasse 178</p><p>13353 Berlin, Germany.</p><p style="margin-left:0in; margin-right:0in"><strong>Marketing Authorization Holder:</strong></p><p>Bayer AG</p><p>Kaiser-Wilhelm-Allee 1</p><p>51368 Leverkusen, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2021. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن ياسمين هو حبوب لمنع الحمل.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يحتوي كل قرص مغلف على كمية قليلة من نوعين مختلفين من الهرمونات الأنثوية، وهما دروسبيرينون وإيثينيل إستراديول.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وتُسمى حبوب منع الحمل التي تحتوي على نوعين من الهرمونات &laquo;حبوب منع الحمل المركبة&raquo;.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ملاحظات</strong><strong> </strong><strong>عامة</strong></p><p dir="RTL" style="text-align:right">قبل البدء في تناول ياسمين، يُرجى قراءة المعلومات عن جلطات الدم في القسم 2 . من المهم بصفة خاصة قراءة المعلومات حول أعراض جلطة الدم (انظري القسم 2، &laquo;جلطات الدم&raquo;).</p><p dir="RTL" style="text-align:right">قبل أن تبدأي في تناول ياسمين، سيسألك طبيبك بعض الأسئلة عن تاريخك الصحي وكذلك تاريخ أقاربك المقربين. كما سيقوم الطبيب بقياس ضغط الدم وبناء على وضعك الصحي من الممكن أن يقوم أيضا بعمل بعض الاختبارات الأخرى.</p><p dir="RTL" style="text-align:right">في هذه النشرة يوجد عدة مواقف حيث ينبغي أن تتوقفين عن استخدام ياسمين، أو حيث قد تقل فاعلية ياسمين. في مثل تلك الحالات ينبغي إما عدم ممارسة الجنس أو ينبغي اتخاذ احتياطات إضافية غير هرمونية لمنع الحمل، على سبيل المثال استخدام واقي ذكري أو أي وسيلة مانعة أخرى. لا تستخدمي طريقة الإيقاع أو درجة الحرارة. من الممكن أن تكون هذه الطرق غير موثوق بها، لأن ياسمين يفضي إلى تغير في التغيرات الشهرية لدرجة حرارة الجسم ومخاط عنق الرحم.</p><p dir="RTL" style="text-align:right"><strong>ومثل</strong><strong> </strong><strong>وسائل</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>الحمل</strong><strong> </strong><strong>الهرمونية</strong><strong> </strong><strong>الأخرى،</strong><strong> </strong><strong>فإن</strong><strong> </strong><strong>ياسمين</strong><strong> </strong><strong>لا</strong><strong> </strong><strong>يقي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الإصابة</strong><strong>&nbsp; </strong><strong>بفيروس</strong><strong> </strong><strong>نقص</strong><strong> </strong><strong>المناعة</strong><strong> </strong><strong>البشرية</strong><strong> (</strong><strong>الإيدز</strong><strong>) </strong><strong>أو</strong><strong> </strong><strong>غيره</strong><strong> </strong><strong>من</strong><strong> </strong><strong>الأمراض</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>تنتقل</strong><strong> </strong><strong>جنسيا</strong><strong>.</strong></p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>متى لا ينبغي استخدام ياسمين</strong></p><p dir="RTL" style="text-align:right">ينبغي ألا تستخدمي ياسمين إذا كنت مصابة بأحد الحالات المذكورة أدناه. إذا كنت تعانين من أي من الحالات المذكورة أدناه، ينبغي أن تخبري طبيبك. سيتناقش طبيبك معك عن وسيلة تحديد نسل أخري تكون أكثر ملاءمة.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>لا تتناولي ياسمين:</strong></p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة (أو كنت قد أصبت من قبل) بتجلط دموي في أحد أوردة الساق (تجلط الوريد العميق)، أو في الرئتين (انسداد رئوي) أو في أي عضو آخر؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعرفين&nbsp; أنك تعانين من اضطراب يؤثر على تجلط الدم لديك - على سبيل المثال، نقص البروتين C، أو نقص البروتين S، أو نقص مضاد الثرومبين الثالث، أو العامل الخامس لايدن أو الاجسام المضادة للفوسفوليبيد؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت بحاجة إلى جراحة أو كنت طريحة الفراش لفترة طويلة&nbsp; (انظري قسم &laquo;جلطات الدم&raquo;)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت قد عانيت مسبقا من أزمة قلبية أو سكتة دماغية؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك (أو قد عانيت مسبقا) من ذبحة صدرية (حالة تسبب آلام شديدة في الصدر وربما تكون أول علامة على نوبة قلبية) أو نوبة نقص تروية عابرة (أعراض مؤقتة للسكتة الدماغية)؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بأي من الأمراض التالية والتي قد تزيد من مخاطر حدوث جلطة دم في أحد الشرايين:</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مرض السكري الشديد مع&nbsp; حدوث تلف بالأوعية الدموية</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضغط دم مرتفع جدا</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مستويات مرتفعة جدا من الدهون في الدم (الكوليسترول أو الدهون الثلاثية)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مرض معروف باسم ارتفاع الهوموسيستين في الدم.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعانين (أو قد عانيت من قبل) من نوع من الصداع النصفي يُسمى &laquo;صداع نصفي مسبوقا بأعراض معينة؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعانين (أو قد عانيت من قبل) من مرض في الكبد ووظائف الكبد لديك ما زالت غير طبيعية</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كانت كليتيك لا تعملان بشكل جيد (فشل كلوي)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة (أو قد أُصبت من قبل) بورم في الكبد</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة (أو قد أصبت من قبل) أو إذا كان مشتبها في إصابتك بسرطان الثدي أو سرطان في الأعضاء التناسلية</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك أي نزيف مهبلي غير مبرر</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك حساسية تجاه إثينيل إستراديول أو دروسبيرينون أو أي من المكونات الأخرى لهذا الدواء (المذكورة في قسم 6). وقد يؤدي هذا إلى حدوث حكة، أو طفح جلدي أو تورم.</p><p dir="RTL" style="text-align:right">لا تستخدمي ياسمين إذا كنت مصابة بالتهاب الكبد الوبائي (فيروس C) و تتناولين المنتجات الطبية التي تحتوي على أومبيتاسفير / باريتابريفير / ريتونافير و دسابوفير أو غليكابريفير / بيبرنتاسفير (انظري أيضا قسم &laquo;الأدوية الأخرى و ياسمين&raquo;).</p><p dir="RTL" style="text-align:right">ياسمين مختلف عن الحبوب الأخرى المانعة للحمل لأنها تحتوي على البروجستين دروسبيرينون. يمكن للدروسبيرينون أن يزيد البوتاسيوم. لذلك، المرضى بمرض للكلى، للكبد أو للكظر يجب أن لا يتناولن ياسمين لأنه يمكن أن يسبب مشاكل خطيرة للقلب و للصحة.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>معلومات إضافية عن فئات خاصة</strong></p><p dir="RTL" style="text-align:right"><em>الاستخدام في الأطفال و المراهقات</em></p><p dir="RTL" style="text-align:right">ياسمين ليس مخصص للإناث اللاتي لم يحضن بعد (لم تحدث الدورة الشهرية لهن بعد) .</p><p dir="RTL" style="text-align:right"><em>الاستخدام في السيدات المسنات</em></p><p dir="RTL" style="text-align:right">ياسمين غير مخصص للاستعمال بعد سن اليأس.</p><p dir="RTL" style="text-align:right"><em>سيدات تعاني من ضعف وظائف الكبد</em></p><p dir="RTL" style="text-align:right">لا تأخذي ياسمين إذا كنت تعانين من اضطراب في الكبد. راجعي أيضًا قسم &laquo;متى لاينبغي استخدام ياسمين&raquo; و &laquo;التحذيرات والاحتياطات&raquo;.</p><p dir="RTL" style="text-align:right"><em>سيدات تعاني من ضعف وظائف الكلى</em></p><p dir="RTL" style="text-align:right">لا تأخذي ياسمين إذا كان لديك قصور كلوي أو فشل كلوي حاد. راجعي أيضًا قسم &laquo;متى لاينبغي استخدام ياسمين&raquo; و &laquo;التحذيرات والاحتياطات&raquo;</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL" style="text-align:right"><strong>متى</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>بطبيبك؟</strong></p><p dir="RTL" style="text-align:right"><u>اطلبي المساعدة الطبية فورا</u></p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا لاحظت أي علامات محتملة لتجلط الدم، فقد يعني ذلك إصابتك بجلطة دموية في ساقك (أي تجلط وريدي عميق)، أو جلطة دموية في الرئتين (أي انسداد رئوي)، أو إصابتك بنوبة قلبية أو سكتة دماغية (انظري قسم &laquo;جلطات الدم&raquo; أدناه).</p><p dir="RTL" style="text-align:right">للحصول على وصف لأعراض هذه الآثار الجانبية الخطيرة، انظري قسم &laquo;كيفية التعرف على تجلط الدم&raquo;.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>أخبري طبيبك إذا كان أي من الحالات التالية ينطبق عليك.</strong></p><p dir="RTL" style="text-align:right">تحدثي إلى طبيبك قبل تناول ياسمين ،&nbsp; في بعض الحالات قد تحتاجين إلى عناية خاصة أثناء استخدام ياسمين أو أي حبوب منع حمل مركبة أخرى، وقد يحتاج الطبيب إلى فحصك بانتظام. إذا تطورت الحالة أو ساءت أثناء استخدام ياسمين، يجب أيضا أن تخبري طبيبك.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كانت إحدى قريباتك مصابة أو قد أصيبت في أي وقت مضى بسرطان الثدي</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بمرض في الكبد أو المرارة</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بمرض السكري.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بالاكتئاب</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بمرض كرون أو التهاب القولون التقرحي (مرض التهاب الأمعاء المزمن)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بمتلازمة يوريا الدم الانحلالي (اضطراب في تجلط الدم يسبب فشل الكلى)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة&nbsp; بفقر دم (أنيميا) منجلي (مرض وراثي في خلايا الدم الحمراء)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بمستويات مرتفعة من الدهون في الدم (ارتفاع الدهون الثلاثية بالدم) أو تاريخ عائلي إيجابي لهذه الحالة. ارتبط ارتفاع الدهون الثلاثية بالدم بزيادة مخاطر الإصابة بالتهاب البنكرياس</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت بحاجة إلى جراحة أو كنت طريحة الفراش لفترة طويلة&nbsp; (انظري القسم 2 &laquo;جلطات الدم&raquo;)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت قد وضعت طفلا مؤخرا، فإن مخاطر إصابتك بجلطات الدم تزداد؛ استشيري طبيبك متى يمكنك استخدام ياسمين بعد الولادة.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بالتهاب في الأوردة تحت الجلد (التهاب و تجلط الأوردة السطحية)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بالدوالي</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ذا كنت مصابة بالصرع (انظري &laquo;الأدوية الأخرى وياسمين&raquo;)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بالذئبة الحمامية الجهازية (مرض يصيب الجهاز المناعي الخاص بك)؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بأحد الأمراض التي ظهرت لأول مرة أثناء الحمل أو أثناء استخدام سابق للهرمونات الجنسية (على سبيل المثال، فقدان السمع، أو مرض في الدم يُسمى بورفيريا، أو طفح جلدي مع بثور أثناء الحمل (هربس الحمل)، أو مرض بالأعصاب يسبب حركات مفاجئة للجسم.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة أو قد أصبت في أي وقت مضى بكلف (تغير في لون الجلد خاصة في الوجه أو الرقبة ويُعرف باسم &laquo;كلف الحمل&raquo;). إذا كان الوضع كذلك، تجنبي ضوء الشمس المباشر أو الأشعة فوق البنفسجية.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بوذمة وعائية وراثية، فإن المنتجات المحتوية على الاستروجين قد تسبب أو تفاقم الأعراض. يجب مراجعة طبيبك على الفور إذا أصبت بأعراض الوذمة الوعائية مثل تورم الوجه و/أو اللسان و/ أو الحلق و/ أو صعوبة في البلع أو شرى مع صعوبة في التنفس.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>جلطات الدم</strong></p><p dir="RTL" style="text-align:right">إن استخدام وسيلة منع حمل ذات هرمون مختلط&nbsp; مثل ياسمين، تزيد من خطورة إصابتك بتكون جلطة دموية مقارنة بعدم استخدامك لها.&nbsp; في حالات نادرة من الممكن أن يتسبب تجلط الدم في انسداد الأوعية الدموية وحدوث مشاكل خطيرة.</p><p dir="RTL" style="text-align:right">من الممكن أن تحدث جلطات الدم</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في الأوردة (المعروفة باسم &laquo;التجلط الوريدي&raquo;، أو &laquo;الجلطات الدموية الوريدية&raquo; أو &laquo;VTE&raquo;)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في الشرايين (المعروف باسم &laquo;التجلط الشرياني&raquo;، &laquo;الجلطات الدموية الشريانية&raquo; أو &laquo;ATE&raquo;).</p><p dir="RTL" style="text-align:right">الجلطات الدموية لا تشفى دائما تماما و نادرا ما تؤدي إلى أعراض خطيرة مستمرة، أو قد تؤدي جلطات الدم إلى الوفاة في حالات نادرة جدا.</p><p dir="RTL" style="text-align:right"><strong>من</strong><strong> </strong><strong>المهم</strong><strong> </strong><strong>التذكر</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>الخطر</strong><strong> </strong><strong>الكلي</strong><strong> </strong><strong>لحدوث</strong><strong> </strong><strong>جلطة</strong><strong> </strong><strong>ضارة</strong><strong> </strong><strong>بالدم</strong><strong> </strong><strong>بسبب</strong><strong> </strong><strong>أقراص</strong><strong> </strong><strong>ياسمين</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>خطر</strong><strong> </strong><strong>منخفض</strong><strong>.</strong></p><p dir="RTL" style="text-align:right"><strong>كيف تتعرفين على الجلطة الدموية</strong></p><p dir="RTL" style="text-align:right">اطلبي مساعدة طبية عاجلة إذا لاحظت أي من العلامات أو الأعراض التالية.</p><table cellspacing="0" cellpadding="0" border="1"><thead><tr><td style="height:3.0pt; width:241.25pt"><p dir="RTL" style="text-align:right"><strong>ما</strong><strong> </strong><strong>الذي</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تكوني</strong><strong> </strong><strong>تعانين</strong><strong> </strong><strong>منه؟</strong></p></td><td style="height:3.0pt; width:249.35pt"><p dir="RTL" style="text-align:right"><strong>هل</strong><strong> </strong><strong>تعانين</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>هذه</strong><strong>&nbsp; </strong><strong>الأعراض؟</strong></p></td></tr></thead><tbody><tr><td style="height:3.0pt; vertical-align:top; width:241.25pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تجلط الأوردة العميقة</p></td><td style="height:3.0pt; vertical-align:top; width:249.35pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم في ساق واحدة أو على طول الوريد في الساق أو القدم، خاصة إذا كانت مصحوبة بـ:</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم أو ضعف في الساق، والذي يلاحظ فقط عند الوقوف أو المشي</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->دفء&nbsp; متزايد في الساق المصابة</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تغيرات في لون جلد الساق، على سبيل المثال تتحول إلي اللون الباهت أو الأحمر أو الأزرق</p></td></tr><tr><td style="height:3.0pt; vertical-align:top; width:241.25pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انسداد رئوي</p></td><td style="height:3.0pt; vertical-align:top; width:249.35pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضيق مفاجئ في التنفس أو سرعة تنفس غير مبررة؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سعال مفاجئ بدون سبب واضح والذي قد ينتج عنه دم،</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم طاعن في الصدر ويزداد مع التنفس العميق؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->دوار أو دوخة شديدة؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضربات قلب سريعة أو غير منتظمة؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم شديد في المعدة.</p><p dir="RTL" style="text-align:right">إذا لم تكوني متأكدة، استشيري طبيبك، لأن بعض هذه الأعراض مثل السعال أو ضيق التنفس قد تختلط مع اضطرابات أخف مثل&nbsp; التهاب الشعب الهوائية (على سبيل المثال &laquo;البرد&raquo;)</p></td></tr><tr><td style="height:3.0pt; vertical-align:top; width:241.25pt"><p dir="RTL" style="text-align:right">تجلط في الوريد الشبكي (جلطة دموية في العين)</p></td><td style="height:3.0pt; vertical-align:top; width:249.35pt"><p dir="RTL" style="text-align:right">أعراض تحدث عادة في عين واحدة:</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان فوري للرؤية أو</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدم وضوح الرؤية بدون ألم، والذي قد يتطور إلى فقدان البصر.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td></tr><tr><td style="height:3.0pt; vertical-align:top; width:241.25pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نوبة قلبية</p></td><td style="height:3.0pt; vertical-align:top; width:249.35pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم في الصدر وعدم راحة وضغط وثقل.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->احساس بضغط أو امتلاء في الصدر أو الذراع أو أسفل عظمة الصدر.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انتفاخ أو عسر هضم أو احساس بالاختناق.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عدم راحة في الجزء العلوي من الجسم، يمتد الى الظهر والفك والعنق والذراع والمعدة</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعرق، أو غثيان، أو تقيؤ أو دوار؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف شديد أو قلق أو ضيق في التنفس؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضربات قلب سريعة أو غير منتظمة؛</p></td></tr><tr><td style="height:3.0pt; vertical-align:top; width:241.25pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->السكتة الدماغية</p></td><td style="height:3.0pt; vertical-align:top; width:249.35pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف أو تنميل مفاجئ في الوجه أو الذراع أو الساق، و الذي يظهر بشكل خاص على جانب واحد من الجسم؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ارتباك مفاجئ وصعوبات في التحدث أو الفهم؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اضطرابات مفاجئة في الرؤية في عين واحدة أو في العينين؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مشاكل مفاجئة في المشي أو دوخة أو فقدان الاتزان أو مشاكل في التناسق؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صداع مفاجئ، شديد أو مستمر مجهول المنشأ؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فقدان الوعي أو الإغماء مع أو بدون تشجنات.</p><p dir="RTL" style="text-align:right">في بعض الحالات قد تكون الأعراض قصيرة المدى ومصحوبة بشفاء فوري وكامل تقريبا. ومع ذلك يجب أن تسعين للحصول على علاج طبي عاجل، لأنك قد تتعرضين لسكتة دماغية أخرى.</p></td></tr><tr><td style="height:18.85pt; vertical-align:top; width:241.25pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جلطات دموية تسد أوعية دموية أخرى</p></td><td style="height:18.85pt; vertical-align:top; width:249.35pt"><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورم ولون أزرق بسيط في أحد الأطراف؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم شديد في المعدة (حاد في البطن)</p></td></tr></tbody></table><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong><u>جلطات دموية في الوريد</u></strong></p><p dir="RTL" style="text-align:right"><strong>ما الذي يحدث عند تكون جلطة دموية في أحد الأوردة؟</strong></p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لقد ارتبط استخدام وسائل منع الحمل من الهرمونات المركبة بارتفاع احتمال الإصابة بجلطات دموية في الأوردة (تجلط وريدي).&nbsp; ومع ذلك، فإن هذه الآثار الجانبية نادرة.&nbsp; وعادة ما تحدث أثناء أول عام من استخدام وسائل منع الحمل من الهرمونات المركبة .</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا حدث تجلط دموي في أحد أوردة القدم أو الساق، فإن هذا قد يتسبب في حدوث تجلط وريدي عميق.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا انتقل التجلط الدموي من الساق إلى الرئة وظل عالقا هناك، فقد يتسبب في حدوث انسداد رئوي</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وفي حالات نادرة جدا، من الممكن أن يتكون التجلط الدموي في أحد الأوردة لعضو آخر مثل العين (تجلط الأوردة الشبكية).</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>متى يكون خطر الإصابة بجلطة دموية في الوريد أكبر ما يمكن؟</strong></p><p dir="RTL" style="text-align:right">يكون خطر الإصابة بجلطة دموية في الرئة أكبر ما يكون أثناء العام الأول من استخدام وسائل منع الحمل من الهرمونات المركبة لأول مرة. كما قد يزداد الخطر أيضا إذا بدأت في استخدام وسيلة منع حمل من الهرمونات المركبة مرة أخرى (سواء أكان نفس الدواء أو كان مختلفا) بعد فترة توقف لمدة 4 أسابيع أو أكثر.</p><p dir="RTL" style="text-align:right">بعد العام الأول، يقل الخطر ولكنه يظل دائما أعلى قليلا مما لو لم تكوني تستخدمين أحد وسائل منع الحمل ذات هرمونات مركبة.</p><p dir="RTL" style="text-align:right">عند التوقف عن تناول ياسمين ، فإن مخاطر إصابتك بجلطة دموية تعود إلى الطبيعي في خلال أسابيع قليلة.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>ما هي خطورة تكون جلطة دموية؟</strong></p><p dir="RTL" style="text-align:right">تعتمد المخاطر على الخطر الطبيعي لديك للإصابة بالتجلط الوريدي ونوعية وسيلة منع الحمل من الهرمونات المركبة التي تستخدمينها.</p><p dir="RTL" style="text-align:right">إن المخاطر الكلية للإصابة بتجلط الدم في الساق أو الرئة مع ياسمين منخفضة.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->من بين 10.000 سيدة لا يستخدمن أي وسائل منع حمل هرمونية مركبة ولسن حوامل،&nbsp; فإن حوالي اثنتين من السيدات سيصبن بجلطة في الدم في السنة.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->من بين 10.000 سيدة يستخدمن وسائل منع حمل تحتوي على ليفونورجيستريل، أو نوريثيستيرون أو نورجيستيمات،&nbsp; فإن حوالي 5 -7 سيدات سيصبن بجلطة في الدم في السنة.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->من بين 10.000 سيدة يستخدمن وسائل منع حمل تحتوي على دروسبيرينون، مثل ياسمين، فإن حوالي 9 إلى 12 سيدة سيصبن بجلطة في الدم في السنة.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إن مخاطر الإصابة بخثرة في الدم تختلف بحسب تاريخك الطبي الشخصي (انظري &laquo;العوامل التي تزيد من خطر تجلط الدم&raquo; أدناه).</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="height:3.0pt; width:170.15pt"><p dir="RTL" style="text-align:right"><strong>خطر</strong><strong> </strong><strong>الإصابة</strong><strong> </strong><strong>بجلطة</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الدم</strong><strong> </strong><strong>في</strong><strong> </strong><strong>السنة</strong></p></td><td style="height:3.0pt; width:283.45pt"><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p></td></tr><tr><td style="height:3.0pt; width:170.15pt"><p dir="RTL" style="text-align:right">حوالي 2 من كل 10,000 سيدة</p></td><td style="height:3.0pt; width:283.45pt"><p dir="RTL" style="text-align:right">نساء لا يستخدمن حبوب منع حمل هرمونية مركبة ولسن حوامل</p></td></tr><tr><td style="height:3.0pt; width:170.15pt"><p dir="RTL" style="text-align:right">حوالي 5 - 7 من كل 10,000 سيدة</p></td><td style="height:3.0pt; width:283.45pt"><p dir="RTL" style="text-align:right">نساء يستخدمن حبوب منع حمل هرمونية مركبة تحتوي على <strong>ليفونورجيستريل،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>نوريثيستيرون</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>نورجيستيمات</strong></p></td></tr><tr><td style="height:13.25pt; width:170.15pt"><p dir="RTL" style="text-align:right">حوالي 9 - 12 من كل 10,000 سيدة</p></td><td style="height:13.25pt; width:283.45pt"><p dir="RTL" style="text-align:right">نساء يستخدمن<strong> ياسمين</strong></p></td></tr></tbody></table><p dir="RTL" style="text-align:right"><strong>العوامل التي تزيد من خطر إصابتك بجلطة دموية في الوريد</strong></p><p dir="RTL" style="text-align:right">إن خطر الإصابة بجلطة في الدم مع ياسمين منخفضا ولكن في بعض الحالات قد تزداد المخاطر. يزداد الخطر لديك:</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت شديدة البدانة (مؤشر كتلة الجسم أكثر من 30 كجم / م2)؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان أحد الأشخاص من عائلتك المباشرة قد أصيب بتجلط الدم في الساق أو الرئة أو أي عضو آخر في سن صغير (على سبيل المثال في عمر أقل من 50 سنة). في هذه الحالة قد تكونين مصابة باضطراب وراثي في تجلط الدم؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت بحاجة إلى اجراء جراحة أو كنت طريحة الفراش لفترة طويلة بسبب إصابة أو مرض أو وجود ساقك في الجبس. قد يلزم التوقف عن استخدام ياسمين لعدة أسابيع قبل الجراحة أو أثناء قلة تنقلك (حركتك). إذا احتجت للتوقف عن تناول ياسمين، اسألي طبيبك متى يمكنك البدء في تناوله مرة أخرى</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مع زيادة العمر (خاصة أكبر من نحو 35 سنة)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت قد أنجبت طفلا خلال الأسابيع القليلة السابقة.</p><p dir="RTL" style="text-align:right">إن مخاطر تكون جلطة دموية تزداد مع تزايد الحالات التي تعانين منها.</p><p dir="RTL" style="text-align:right">السفر الجوي (أكثر من 4 ساعات) قد يزيد من مخاطر إصابتك بجلطات الدم مؤقتا، وخاصة إذا كان لديك أي من العوامل الأخرى المذكورة.</p><p dir="RTL" style="text-align:right">من المهم إخبار طبيبك إذا كان أي من تلك الحالات ينطبق عليك، حتى لو لم تكوني متأكدة. وقد يقرر طبيبك أنك بحاجة إلى إيقاف ياسمين.</p><p dir="RTL" style="text-align:right">إذا تغيرت أي من الحالات المذكورة أعلاه أثناء استخدام ياسمين، على سبيل المثال أحد أفراد الأسرة المقربين تعرض لجلطة في الدم من دون سبب معروف، أو اكتسبت الكثير من الوزن، أخبري طبيبك.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>جلطات دموية في أحد الشرايين</strong></p><p dir="RTL" style="text-align:right"><strong>ما الذي يمكن أن يحدث إذا تكونت جلطة دموية في أحد الشرايين؟</strong></p><p dir="RTL" style="text-align:right">تماما مثل الجلطة الدموية في الوريد، فإن الجلطة في الشريان يمكن أن تسبب مشاكل خطيرة. فعلى سبيل المثال من الممكن أن تتسبب في أزمة قلبية أو سكتة دماغية.</p><p dir="RTL" style="text-align:right"><strong>العوامل التي تزيد من خطر إصابتك بجلطة دموية في الشريان</strong></p><p dir="RTL" style="text-align:right">من المهم أن نلحظ أن خطر الإصابة بنوبة قلبية أو سكتة دماغية بسبب استخدام ياسمين منخفض جدا، ولكنه قد يرتفع:</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مع الزيادة في العمر (أكثر من 35 سنة)؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تدخنين، عند استخدام وسيلة منع حمل بهرمونات مركبة مثل ياسمين، يُنصح بالتوقف عن التدخين. إذا كنت لا تستطيعين أن تتوقفي عن التدخين، وكنت أكبر من 35 سنة، فقد ينصحك طبيبك باستخدام نوع مختلف من وسائل منع الحمل؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان وزنك زائدا،</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بارتفاع ضغط الدم؛</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان أحد أفراد عائلتك المباشرة قد أصيب بنوبة قلبية أو سكتة دماغية في سن صغير (أقل من 50 سنة). في هذه الحالة قد تكونين أيضا عرضة لخطر متزايد للإصابة بنوبة قلبية أو سكتة دماغية.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت أنت، أو أي شخص من عائلتك المباشرة، مصاب بمستوى عال من الدهون في الدم (الكولسترول أو الدهون الثلاثية).</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بالصداع النصفي وخاصة الصداع النصفي الذي تسبقه أعراض معينة</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعانين من مشاكل في القلب (مرض في صمام القلب، اضطراب&nbsp; في ضربات القلب ويسمى الرجفان الأذيني).</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت مصابة بمرض السكري.</p><p dir="RTL" style="text-align:right">إذا كنت مصابة بأكثر من واحدة من هذه الحالات أو إذا كان أي منها شديدا بشكل خاص، فإن خطر الإصابة بجلطة في الدم قد تزداد أكثر من ذلك.</p><p dir="RTL" style="text-align:right">إذا تغيرت أي من الحالات المذكورة أعلاه أثناء استخدام ياسمين، على سبيل المثال إذا بدأت في التدخين، أو أصيب أحد أفراد الأسرة المقربين بجلطة بدون سبب معروف، أو اكتسبت الكثير من الوزن، أخبري طبيبك.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>ياسمين والسرطان</strong></p><p dir="RTL" style="text-align:right">لقد لوحظ الإصابة بسرطان الثدي في أحيان أكثر قليلا في النساء اللاتي يستخدمن حبوب منع الحمل المركبة، ولكن ليس معروفا ما إذا كان ذلك بسبب العلاج. فعلى سبيل المثال، من الممكن أن يكون اكتشاف الأورام أكثر في النساء اللاتي يستخدمن الحبوب لأنهن يخضعن للفحص من قبل الطبيب بشكل أكثر تكرارا. ويصبح حدوث أورام الثدي أقل تدريجيا بعد التوقف عن تناول وسائل منع الحمل الهرمونية المركبة، فمن المهم أن تقومي بفحص ثدييك باستمرار وينبغي أن تتصلي بطبيبك إذا شعرت بأي تكتل.</p><p dir="RTL" style="text-align:right">في حالات نادرة، تم الإبلاغ عن وجود أورام حميدة - وفي حالات أكثر ندرة تكون خبيثة - في الكبد في مستخدمي حبوب منع الحمل. اتصلي بطبيبك إذا لاحظت وجود ألم شديد في البطن بشكل غير عادي.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>اضطرابات نفسية </strong></p><p dir="RTL" style="text-align:right">بعض النساء اللآتي تستخدمن موانع الحمل الهرمونية مثل ياسمين تعانين من الاكتئاب أو المزاج الاكتئابي. يمكن أن يكون الاكتئاب خطيرًا ويؤدي أحيانًا إلى أفكار انتحارية. إذا كنت تعاني من تقلبات مزاجية وأعراض اكتئاب، فاطلبي المشورة الطبية من طبيبك في أقرب وقت ممكن.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>النزف بين الدورات الشهرية</strong></p><p dir="RTL" style="text-align:right">خلال الأشهر القليلة الأولى من تناول ياسمين، من الممكن أن تصابي بنزيف غير متوقع (نزيف خارج أسبوع االفجوة (الخالي من الدواء)). إذا استمر النزيف لأكثر من عدة شهور أو إذا بدأ بعد بضع شهور، فيجب أن تخبري طبيبك لمعرفة الخطأ.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>ما الذي ينبغي عليك فعله إذا لم يحدث نزيف أثناء أسبوع الفجوة </strong></p><p dir="RTL" style="text-align:right">إذا كنت قد تناولت جميع الأقراص بطريقة صحيحة، ولم تصابي بقئ أو إسهال شديد ولم تتناولي أي أدوية أخرى، فمن المستبعد جدا أن تكوني حاملا.</p><p dir="RTL" style="text-align:right">إذا لم يحدث النزف المتوقع مرتين متتاليتين، فقد تكونين حاملا. اتصلي بطبيبك على الفور. لا تبدأي في تناول الشريط التالي حتى تتأكدي من أنك لست حاملا</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الأدوية الأخرى وياسمين</strong></p><p dir="RTL" style="text-align:right">أخبري الطبيب دائما عن الأدوية أو المنتجات العشبية التي تستخدمينها بالفعل. وكذلك أخبري أي طبيب آخر أو طبيب الأسنان الذي يقوم بوصف دواء آخر لك (أو الصيدلي) بأنك تستخدمين ياسمين. من الممكن أن يخبروك إذا كنت بحاجة إلى استخدام أي احتياطات منع حمل أخرى (مثل العازل الذكري)، وإذا كان الأمر كذلك، فلكم من الوقت، أو، إذا كان يجب تغيير استخدام دواء آخر تحتاجين له.</p><p dir="RTL" style="text-align:right">بعض الأدوية:</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد يكون لها تأثير على مستويات ياسمين في الدم</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد تجعل ياسمين <strong>أقل</strong><strong> </strong><strong>فعالية</strong><strong> </strong><strong>في</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>الحمل</strong>،</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد تتسبب في حدوث نزيف غير متوقع.</p><p dir="RTL" style="text-align:right">ويتضمن ذلك:</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية التي تُستخدم لعلاج</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الصرع (مثل بريميدون، فينيتوين، باربيتورات، كاربامازيبين، أوكسكاربازيبين)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->السل (مثل ريفامبيسين)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إصابات فيروس نقص المناعة البشرية (الإيدز) والعدوى بفيروس C التهاب الكبد الوبائي&nbsp; (المسماة مثبطات الأنزيم البروتيني و مثبطات إنزيم النسخ العكسي الغير نوكليوزيد ، مثل ريتونافير، نيفيرابين، ايفافيرنز)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الالتهابات الفطرية (على سبيل المثال غريزيوفولفين، الكيتوكونازول)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهاب المفاصل (ايتوريكوكسيب)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ارتفاع ضغط الدم في الأوعية الدموية في الرئتين (بوسينتان)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العلاج العشبي بنبتة سان جون</p><p dir="RTL" style="text-align:right">وقد يؤثر ياسمين على مفعول الأدوية الأخرى، مثل</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية التي تحتوي على سيكلوسبورين</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لاموتريجين المضاد للصرع (وقد يؤدي هذا إلى زيادة تكرار حدوث النوبات)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الثيوفيلين (التي تستخدم لعلاج مشاكل التنفس)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تيزانيدين (التي تستخدم لعلاج آلام العضلات و / أو تقلصات العضلات)</p><p dir="RTL" style="text-align:right">يمكن لأدوية أخرى أن تزيد البوتاسيوم. المرضى اللآتي تتناولن حالياً أي من الأدوية المذكورة بأسفل يومياً لفترة طويلة لعلاج حالة مزمنة، يجب أن تستشرن القائم بالرعاية الصحية عن ما إذا كان تناول ياسمين آمن، و يجب القيام باختبار للدم لفحص مستوى البوتاسيوم خلال الشهر الأول من تناول ياسمين. أدوية معروف عنها أنها تزيد من مستوى البوتاسيوم:</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أدوية مضادة للإلتهاب غير ستيرويدية NSAIDs (مثل إيبوبروفين و آخرين) عندما يتم تناولهم لفترة طويلة و لعلاج التهاب المفاصل و مشاكل أخرى.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مدرات البول الحافظة للبوتاسيوم (مثل سبيرونولاكتون و آخرين)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بوتاسيوم إضافي.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مثبطات الإنزيم المحول للأنجيوتنسين ACE (مثل كابتوبريل، ليزنوبريل و آخرين).</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مناهضات لمستقبلات الأنجيوتنسين II (لوزارتان، فالزرتان، و آخرين).</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->هيبارين.</p><p dir="RTL" style="text-align:right">لا تستخدمي ياسمين إذا كنت مصابة بالتهاب الكبد الوبائي (فيروس C) و تتناولين المنتجات الطبية التي تحتوي على أومبيتاسفير / باريتابريفير / ريتونافير&nbsp; و دسابوفير أو غليكابريفير / بيبرنتاسفير لأن هذا قد يسبب زيادة في نتائج اختبار الدم لوظائف الكبد (زيادة في انزيم الكبد ALT). سوف يصف طبيبك نوع آخر من وسائل منع الحمل قبل بدء العلاج بهذه المنتجات الطبية. يمكن عادة البدء في تناول الياسمين بعد حوالي اسبوعين من انتهاء هذا العلاج. انظري قسم &laquo;لا تتناولي ياسمين&raquo;.</p><p dir="RTL" style="text-align:right">استشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>ياسمين مع الطعام والشراب</strong></p><p dir="RTL" style="text-align:right">من الممكن تناول ياسمين مع أو بدون طعام، وإذا لزم الأمر فمع كمية قليلة من الماء</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الاختبارات المعملية </strong></p><p dir="RTL" style="text-align:right">إذا كنت ستحتاجين لعمل اختبارات دم، أخبري طبيبك أو فني المعمل بأنك تتناولين الحبوب، لأن وسائل منع الحمل الهرمونية قد تؤثر على نتائج بعض الاختبارات</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الحمل</strong></p><p dir="RTL" style="text-align:right">لا يجب استخدام ياسمين أثناء الحمل. إذا حدث حمل أثناء تناولك لياسمين، يجب أن تتوقفي فورا عن تناوله واستشيري طبيبك. إذا كنت ترغبين في الحمل، فيمكنك التوقف عن تناول ياسمين في أي وقت (انظري أيضا &laquo;إذا توقفت عن تناول ياسمين&raquo;).</p><p dir="RTL" style="text-align:right">استشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL" style="text-align:right">لا يُنصح باستخدام ياسمين أثناء قيام المرأة بالإرضاع طبيعيا، إذا كنت ترغبين في تناول الحبوب أثناء الرضاعة الطبيعية، فينبغي أن تتصلي بطبيبك.</p><p dir="RTL" style="text-align:right">استشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL" style="text-align:right">لا يوجد أي معلومات تشير إلى أن استخدام ياسمين يؤثر على القيادة أو استخدام الآلات.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>يحتوي ياسمين على لاكتوز</strong></p><p dir="RTL" style="text-align:right">إذا كان لديك عدم تحمل لبعض السكريات، استشيري طبيبك قبل تناول ياسمين.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">تناولي قرص واحد من ياسمين يوميا، مع قليل من الماء إذا لزم الأمر. من الممكن أن تتناولي الأقراص مع أو بدون طعام، ولكن يجب أن تتناولي الأقراص في نفس الموعد تقريبا كل يوم.</p><p dir="RTL" style="text-align:right">يحتوي الشريط على 21 قرص مغلف. بجانب كل قرص ستجدين يوما من أيام الأسبوع مطبوعا والذي يجب أن تتناولي فيه القرص. على سبيل المثال، إذا بدأت يوم الأربعاء، تناولي القرص المطبوع عليه &laquo;الأربعاء&raquo; &laquo;WED&raquo; بجواره. اتبعي اتجاه الأسهم على الشريط حتى تنتهي من تناول الـ21 قرص.</p><p dir="RTL" style="text-align:right">ثم توقفي عن تناول الأقراص لمدة 7 أيام. وفي أثناء هذه الأيام السبعة الخالية (والتي تسمى أيضا أسبوع التوقف أو الفجوة) يجب أن يبدأ النزيف. وعادة ما يبدأ &laquo;نزيف الانسحاب&raquo; هذا في اليوم الثاني أو الثالث من أسبوع الفجوة.</p><p dir="RTL" style="text-align:right">في اليوم الثامن بعد تناول آخر قرص من ياسمين (أي بعد انتهاء فترة السبعة أيام لأسبوع الفجوة)، يجب أن تبدأي في تناول الشريط التالي، سواء توقف النزيف لديك أم لا. وهذا يعني أنه يجب أن تبدأي كل شريط في نفس اليوم من الأسبوع، وأن نزيف الانسحاب يجب أن يحدث في نفس الأيام كل شهر.</p><p dir="RTL" style="text-align:right">إذا استخدمت ياسمين بهذه الطريقة، فهناك حماية ضد الحمل حتى خلال الـ7 أيام التي لا تتناولين فيها الأقراص.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>متى يمكنك البدء في أول شريط؟</strong></p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>اذا</strong><strong> </strong><strong>لم</strong><strong> </strong><strong>تكوني</strong><strong> </strong><strong>قد</strong><strong> </strong><strong>تناولت</strong><strong> </strong><strong>وسيلة</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>هرمونية</strong><strong> </strong><strong>خلال</strong><strong> </strong><strong>الشهر</strong><strong> </strong><strong>الماضي،</strong></p><p dir="RTL" style="margin-left:0in; margin-right:21.15pt; text-align:right">ابدأي بتناول ياسمين في أول يوم من الدورة (أي أول يوم من دورتك الشهرية). إذا بدأت في تناول ياسمين في أول يوم من دورتك الشهرية، فقد أصبحت محمية من الحمل على الفور. من الممكن أيضا أن تبدأي في اليوم 2 - 5 من بداية الدورة، ولكن في تلك الحالة يجب استخدام وسائل حماية إضافية (على سبيل المثال، الواقي الذكري) للأيام الـ7 الأولى.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>التغيير</strong><strong> </strong><strong>من</strong><strong> </strong><strong>وسيلة</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>حمل</strong><strong> </strong><strong>هرمونية</strong><strong> </strong><strong>مركبة</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>وسيلة</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>حمل</strong><strong> </strong><strong>في</strong><strong> </strong><strong>صورة</strong><strong> </strong><strong>حلقة</strong><strong> </strong><strong>مهبلية</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>لاصق</strong><strong> </strong><strong>هرموني</strong></p><p dir="RTL" style="margin-left:0in; margin-right:21.15pt; text-align:right">من الممكن أن تبدأي في تناول ياسمين في اليوم التالي لآخر قرص فعال (آخر قرص محتوي على المواد الفعالة) من حبوب منع الحمل السابقة، ولكن على أقصى تقدير في اليوم التالي بعد انتهاء الأيام الخالية من الأقراص من حبوب منع الحمل السابقة (أو بعد آخر قرص غير فعال من حبوب منع الحمل السابقة). عند التبديل من حلقة مهبلية أو لاصق هرموني مانع للحمل&nbsp; ، اتبعي نصيحة طبيبك.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>التغيير</strong><strong> </strong><strong>من</strong><strong> </strong><strong>وسيلة</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>بروجيستوجين</strong><strong> </strong><strong>فقط</strong><strong> </strong><strong>(</strong><strong>حبوب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>حقن</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>وسائل</strong><strong> </strong><strong>منع</strong><strong> </strong><strong>الحمل</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>تزرع</strong><strong> </strong><strong>تحت</strong><strong> </strong><strong>الجلد</strong><strong> </strong><strong>و</strong><strong> </strong><strong>تحتوي</strong><strong> </strong><strong>على</strong><strong> </strong><strong>ببروجيستوجين</strong><strong> </strong><strong>فقط</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>لولب</strong><strong> </strong><strong>يفرز</strong><strong> </strong><strong>بروجيستوجين</strong><strong>)</strong></p><p dir="RTL" style="margin-left:0in; margin-right:21.15pt; text-align:right">يمكنك التبديل في أي يوم من الحبوب ذات البروجيستوجين فقط (ومن الوسائل التي تزرع تحت الجلد أو اللولب في اليوم الذي تُزال فيه، وبالنسبة للحقن في موعد الحقنة التالية)، ولكن في جميع تلك الحالات ينبغي استخدام وسائل حماية إضافية (مثل الواقي الذكري) للأيام الـ7 الأولى من تناول الأقراص.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>بعد</strong><strong> </strong><strong>الإجهاض</strong></p><p dir="RTL" style="margin-left:0in; margin-right:21.15pt; text-align:right">اتبعي ارشادات طبيبك</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>بعد</strong><strong> </strong><strong>إنجاب</strong><strong> </strong><strong>طفل</strong></p><p dir="RTL" style="margin-left:0in; margin-right:21.15pt; text-align:right">يمكنك البدء في تناول ياسمين بعد 21 أو 28 يوما من إنجاب الطفل. إذا بدأت بعد أكثر من 28 يوما، يجب أن تستخدمي أيضا ما يُسمى بوسيلة حاجزة (مثل الواقي الذكري) خلال السبعة أيام الأولي من استخدام ياسمين.</p><p dir="RTL" style="margin-left:0in; margin-right:21.15pt; text-align:right">إذا كان قد حدث جماع بعد إنجاب طفلك وقبل البدء في تناول ياسمين (مرة أخرى)، فينبغي أن تتأكدي من أنك لست حاملا أولا أو ينبغي أن تنتظري حتى الموعد التالي لدورتك الشهرية.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>ترضعين</strong><strong> </strong><strong>رضاعة</strong><strong> </strong><strong>طبيعية</strong><strong> </strong><strong>وتريدين</strong><strong> </strong><strong>البدء</strong><strong> </strong><strong>في</strong><strong> </strong><strong>استخدام</strong><strong> </strong><strong>ياسمين</strong><strong> (</strong><strong>مرة</strong><strong> </strong><strong>أخرى</strong><strong>) </strong><strong>بعد</strong><strong> </strong><strong>إنجاب</strong><strong> </strong><strong>طفل</strong></p><p dir="RTL" style="margin-left:0in; margin-right:21.15pt; text-align:right">&nbsp;اقرأي قسم &laquo;الرضاعة الطبيعية&raquo;،</p><p dir="RTL" style="text-align:right">استشيري طبيبك إذا لم تكوني متأكدة متى تبدأين.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>إذا تناولت ياسمين أكثر مما ينبغي</strong></p><p dir="RTL" style="text-align:right">لا توجد تقارير عن نتائج ضارة خطيرة من تناول الكثير من أقراص ياسمين.&nbsp;</p><p dir="RTL" style="text-align:right">إذا تناولتٍ عدة أقراص في آن واحد، قد تعانين من أعراض مثل التوعك، القيء أو النزف المهبلي. حتى الفتيات اللواتي لم تبدأ لديهن فترة الحيض الأولى ولكن قد أخذن عن طريق الخطأ هذا الدواء قد تواجهن مثل هذا النزيف.</p><p dir="RTL" style="text-align:right">إذا تناولت الكثير من أقراص ياسمين، أو اكتشفت أن طفلا قد تناول بعضها، استشيري طبيبك أو الصيدلي.</p><p dir="RTL" style="text-align:right"><strong>إذا نسيت تناول ياسمين</strong></p><p dir="RTL" style="text-align:right">إذا تأخرت في تناول القرص لفترة <strong>أقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>12</strong><strong> </strong><strong>ساعة</strong>، فلن يقل التأثير المانع للحمل. تناولي القرص بمجرد تذكره ثم تناولي الأقراص التالية في الموعد المعتاد.</p><p dir="RTL" style="text-align:right">إذا تأخرت في تناول القرص لفترة <strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>12</strong><strong> </strong><strong>ساعة</strong>، فقد يقل التأثير المانع للحمل. كلما ازداد عدد الأقراص الفائتة، كلما ازداد احتمال الحمل.</p><p dir="RTL" style="text-align:right">وتكون احتمالية الوقاية من الحمل غير كاملة بشكل أكبر إذا نسيت تناول قرص في أول الشريط أو آخره. لذلك، يجب أن تتبعي القواعد التالية (انظري إلى الرسم التوضيحي):</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>قرص</strong><strong> </strong><strong>فائت</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الشريط </strong></p><p dir="RTL" style="margin-left:0in; margin-right:35.3pt; text-align:right">اتصلي بطبيبك.</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>قرص</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>فائت</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الأسبوع</strong><strong> </strong><strong>1</strong><strong> </strong></p><p dir="RTL" style="margin-left:0in; margin-right:35.3pt; text-align:right">تناولي القرص الفائت بمجرد تذكره، حتى لو كان ذلك يعني أن تتناولي قرصين في نفس الوقت. استمري في تناول الأقراص في الأوقات المعتادة واستخدمي<strong> احتياطات</strong><strong> </strong><strong>إضافية</strong> للـ7 أيام التالية، على سبيل المثال، واقي ذكري. إذا كان قد حدث جماع في الأسبوع السابق لنسيان القرص، فقد تكونين حاملا. في تلك الحالة، اتصلي بطبيبك.</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>قرص</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>فائت</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الأسبوع</strong><strong> </strong><strong>2</strong><strong> </strong></p><p dir="RTL" style="margin-left:0in; margin-right:35.3pt; text-align:right">تناولي القرص الفائت بمجرد تذكره، حتى لو كان ذلك يعني أن تتناولي قرصين معا. استمري في تناول الأقراص في الأوقات المعتادة. الوقاية من الحمل لم تنخفض ولا تحتاجين لاستخدام احتياطات إضافية.</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>قرص</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>فائت</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الأسبوع</strong><strong> </strong><strong>3</strong></p><p dir="RTL" style="margin-left:0in; margin-right:35.3pt; text-align:right">يمكنك الاختيار بين احتمالين:</p><p dir="RTL" style="margin-left:0in; margin-right:53.3pt; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->1-&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تناولي القرص الفائت بمجرد تذكره، حتى لو كان ذلك يعني أن تتناولي قرصين معا. استمري في تناول الأقراص في الأوقات المعتادة. بدلا من ترك فترة خالية من الأقراص، ابدأي في الشريط التالي.</p><p dir="RTL" style="margin-left:0in; margin-right:35.3pt; text-align:right">على الأرجح، سيكون لديك دورة في نهاية الشريط الثاني أو قد يأتيك أيضا نزيف خفيف أو شبيه بالحيض خلال الشريط الثاني.</p><p dir="RTL" style="margin-left:0in; margin-right:53.3pt; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->2-&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->كما يمكنك أيضا التوقف عن تناول باقي الشريط والذهاب مباشرة إلى فترة الـ7 أيام الخالية من الأقراص <strong>(</strong><strong>سجلي</strong><strong> </strong><strong>اليوم</strong><strong> </strong><strong>الذي</strong><strong> </strong><strong>نسيت</strong><strong> </strong><strong>فيه</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>القرص</strong><strong>)</strong>. إذا أردت أن تبدأي الشريط الجديد في نفس اليوم الذي تبدأين دائما فيه، اجعلى الفترة الخالية من الأقراص أقل من 7 أيام.</p><p dir="RTL" style="text-align:right">إذا اتبعت إحدى هاتين التوصيتين، ستبقين محمية ضد الحمل.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا نسيت أي من الأقراص في الشريط، ولم يحدث لك نزيف أثناء الأيام الخالية من الأقراص، فإن هذا قد يعني أنك قد تكونين حاملا. استشيري طبيبك قبل البدء في الشريط التالي.</p><p dir="RTL" style="text-align:center"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:294pt;height:535.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/GCHBV/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><!--[if !vml]--><!--[endif]--></p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAYgAAALKCAYAAAAoO8bcAAAgAElEQVR4nOy9dXhUV8Ov3fc732vn+d5znhYPkAQpLW2hrk8NCsWKFYgQIrgGDwGCuxRvgeDuwS0Q3ILFXcZ9Mglxn/v7IyGFJEggyWTC+l3XfXHNZMuazcy6995L9luIiIiIiIiUk7csXQARERERkZqZEkFkZmZiMBpJMpkEAoFA8AZhTDKRkpLybEEYjEaiomOIjYsXCAQCwRtETGwcEpns2YJIMpmIjYsnIVEiEAgEgjeI+IRE5AqFEIRAIBAInkYIQiAQCATlIgQhEAgEgnIRghAIBAJBuQhBCASCGo1Wb8BgTBJUE8YkEyqNlviERCEIgUBQM0mUSEmUSNm7Zy9LFi9h2dJlgupgyVLOnDmLXKEUghAIBDUTiVRGTGwc7X78iZk+PixbskRQDQxyd8fVZQAGY5IQhEAgqJlIpDIiIqNwdnAsU0GJVF2Cg4IY6O6BzmAUghAIBDUTiVRGZFQ0jn37kZKcXK2V5Juca1evMshjoBCEQCCouQhBWCZCEAKBoMYjBGGZCEEIBIIajxCEZSIEIRAIajy1URCFuVmkZ+ZhtnRBnhMhCIFAUOOpdYIoULB/wSymLbtAcqGlC/PsCEEIBIIaT0UFkZWRjEqfWbm1ZWWkMBNl7EOuXfVj8cR57PIPRJ3x8tcQBfmP0Jmyq7CAT+e1BZEokSKRygQCq8DSFZ2gGgSRr+XIMi8mLrtBbmXXmC9IpiaYU/530aYXPPFuDoqH/qyf480Ij9FM9prNtss3uLJnAxu27CT4ZS+I8jScXTufjQFlK+mqSqUIIjomlqjoGIGgxhIdHUuCRGrxik5QDYIoSObkbDd+7LeYyIxKrjFfkCzdfXb67uZmXEpJ24Liui9u7sOZPG0+G3ed4X6UllyyCTq0FMcB07hlfMmNZ4SwpFtPlvjLX7ucGfIgDm87TmxawXOXey1BaPUGfKb70OmXDjj1cxAIaiy/de3K8KHDkCuUJEqEKKyNCgkCUF9aR5/OgzkqyXv2QgU5PEo2kZpjfuYieekmDMmZL9mQnEvo/oUM6NadEUtOoMsHKOTB5pF8/tVvrL1meGLZQkJ3zaZXn3mEPkNi+TnpmEzp5D/eeWY4qxwcWX7h9QWRlyrjot9xbsWZnrvcawlCb0zC1WUAJ48fJzk5WSCosQQHBdG7R0+kMrkQhBVSUUFkhB9kiJMrvs+qfQHSE/DbtIot/uFoZHrSc58+my5MCWaR86989us4TsW8zKWImbwUCYG3r3EnVMvjtueCTAUBWxbi1msyfuEpJcvGHV3FCMeFhD6jqcQUe5EV83cQ9niVrDBWlhJEfvYjUrPyn1ovNzUJpcxIIZCXrEJiTKOwIAudRok+83Gp0rl7ZjtrD0bwvGuI1xKEzmBkkMdAbt648ZxdiIhYPkqlEqd+DkIQVkpFBZGTcJpJY4axJeT5DdVpOgUJoedZ4DqRfQ+eOJsuVHNo1mTGTF2CzyAXhnn7kVROb6P8NA0htyN49MR7YSdWsfaKpsyyUX6rGey5ksvSVADi/FYwpN8CQp7lHnMaiZFRRIYEER4RR1p6NOuc+rPuTmrJIon+a1h6Nv7p9Qx3WTpmOifVgPoMk7z+JEgaz+HVi1hyWley2K110/EYugftc45PpQji2tWrz9mFiIjlI5VKhSCsmAoLQnqL7X+u5Jqu/PPj3GwjUcHyorPnwiSOzRhA9z7ueE2ewjRvbyYO/I229t/gczKIqJPr8B6/gAePym4nI/4cE3/rhOOw8Uyd4s20KePp1/5TPu3kgvcUb6Y9Zup05noP5ac2n+O24hI5gObidqa7LSM8p+x20xKiSTSmAaDz/wMnj6mcjwtjY5/2dOk3rHhfE+nf8TPa/uLA5Cf2NX3CYDp89gFfdx/K9EkefN/qU7o5utO3fTu+be9aVC6vSQzq68bYmedIe85xFIIQeSMiBGHdVFQQybJIbvrfe2blZ5JcZrd/fEnbgi5gPp/Z1+Gdf9aj4TtvY/dNL8aNHUSHdj/yzSc/MHTuAVTlNWfkmzi7uB/1//k2DevWx6Z+Q+ztWtDKtgk29Rs8TYN62DT8kbn7QsnHjPz6MdbOPYGhTANHGrcPnSc4oaj1usB4g4lu3vx5+hKbXH6iRZ13aFi/ATb1G9G8WSs+aGZL45L91KdhfTvafPotX33UhAb17Pjm22/40M4Oezt73rVrjE39BjT85/+h/kedWXXTUOYjPRkhCJE3IkIQ1k1FBVFQkE9e7rNGoBUivebLvBOxxS/TuOo7DU/fs8g1OnQ6LYaUDHJzMlEFHmKKz1w2Xn/yRoyZvOwssrNzydI9ZL2PF1tvJKDT6dA/Fy1aXTJZuWYgF2XcPa4GJ5VTPgW7F+/kemR60cvscNbOWMWha3Iyko0l2zPoNCiVClQaAyaToeR9nU6PMcmEKUmPTqfHZDJh1OufKotOq0WflEL2CwbpCUGIvBERgrBuKiqIF0V7dxduHuP5Y/N2tvwxHQ/3OZyLSX3xigAUkqqN49zmpQx3dWDQ4jO8bE/Vl0sKFxZOZcTIOWzdsYd1PuOZvGYXUaVvcSVHsn/dKlas3UVQFQ3HFoIQeSPyqoJ4/KhLS1eQbzqVLQjyU3h4eiszvaexdPMRIgwVHVKXTeSF3az0PYGsCgZs5yZFcnj1QqZNmcv6XZeQpJTtapthiOHc3j1s3byFywkvK7eKRQjCKlOIPiKUu7djyHrlbeSji7nFxXsycswv18u78lKINvgMO0/dxfScbuoV3qouknuh4ZT3W6+IIBIlUmRyBXKFEplcIQRRA6h0QYi8VIQgrCgFeTnk5JshK4H1owfiufz6a0wlkMbFJQ68/60D66+qKrGUL5MCjBEX2bL1IPdVr664p5PJjbXjcZ20nvhypqp5GUFIZXJUag1yhZLo6BjOnTvHwoWL2Ojri1yhtHgl+SYjBGGZCEFYRcxkKBK4f/Ue8pQ8yIxkkUtPhiy/89xBLi/aZtyxZXT5dQpXtPkvXrxSk07g9uV4Tx7HooMPeaqXX2E2OnUsQYERqHRpvPydVSO7J7vjOGlvufeDnyWIRIkUhVKFVqcnPiGRS5cus379Bhz7OfBei5a0bNacRYsWo1RpLF5JvskIQVgmQhA1PYV55GEm/ug2ls73JVibBRlRLPPoy/A/XkcQoL25jwl9lhKeD+QlEXr1HHfjyutVUV6yibt0hC07LiB9wXwufycHY4oRU7qZTH08gecvci9eTUqSAYMphTyAfCNXj69hvLs3m489IOOlP2A6/vMnMW7KfvTl/LW0IKQyOWqtDpVaQ2DgXXx9fRk7xpMvPv2Mxg0aYmvTmCYNG9HCvhnLli1HpdaWtEcIqh+pTE5UdIwQRDVHCKImpzATybV7aMlDFXaRvbtPEK7Pg5w4/hjYjxEr75Usmm/SEB8aT/rjN8wZKBLCkT4epk8eOmkYcca/a9xH4adZOGAmZx5Gcv/6dQIOr8Fr0lS23HzBbJH5j4i6dRTfP33ZuOUsianlXIEUpiNPiED6ZM8Ls4Jdyxax6qgM0HFo7myOKVJI3LsU7wV7UBY+XlXBZf8L3IkzPNEwl0HI+QCCZKlQaOLutUvc1+WSKbnJiTvxFJDBxfmT8HyBIGRyBUqVmrCICPYfOMio4SPo2rkLdo2bUP/tOtg1bkJzWzta2Nlj36Qp7zZvwapVq0kypaDWaAUWQqvTI5HKcOrnIARRjRGCqMnJk3PQaxZHQxWkpGWQkwMU5pGbHMwi198ZuvQ6WTm55ObkIr2wjamD53E7qeh1ru4BK2aMYom/vOj1o1i2zB/BNL/ootc5uWju7Wd8F3fWnbhDjERLdn461zfOYNCQDcjKazw2m8FsRnPnIBMcJ3Ig/PHVhhn13bNs8T2BJKN4/5pAlvmMZlmAsmR/uVlJnJ07nF4eK4lK1nJkphsO3oe5f2opThMWcVtdtFzeo2AWjp3JX2fiycstXjc3Bf8lI3H22oY8WcbeGSMZOucYoZfW0899I1JzFoGrZjBl6t5ypw6QSaW4ODlz7959Zs6cRYdffqH1u+/x9v/8H2zq1adZU1ta2Nk/RXNbO1rYN+Pbr77mty5d6da5i8CCdGjXnp++/4HMzBd1G8pDGnyJ/X4PSc17nWvsv5Mtvc72faeJMpbzw8g3EXzzPAHhRvIK8lHeP8u1xHKGXb9MCvPJycklvwofImQuzCc7K4usrBwKXtA/RQiiJsesZf/ozrzftDkfffARH3/4IW1af0Cb99/FvkEDmjRpyUetP6BN6w9obdeYhm83oGWrotdtWrWgcb06NLZ7t2SdpvXr0LBpy6LXrT/gg+a2NHy7LvbNW/Np27Z8/MF7tLBtS58xB8uO7jSnEHwvEp0hlbDjc/iyZUvet/+K0euvkAlobm3H5bvWNGv5XvH+m9O4bh0a27Uq2V+b1h/y0bt2NG3QhPdafciHzexp3Mie91s1p2lTW1o9Lvt7LWj8Tn0aP1HWNq0/pHWzptg0asr777emtW1TmjRoSjPb5nw9YAtaCgneuJoVi09S3vyUUqkUZwdHYmLj2Lf/AG4DXPn8k09p1bw5jerVp0mDhiVXDqX56P3WfP7Jp3z+8ScCC/LR+635/tvvyMp6UceGfEL2evPJe71YGyCrjB8i6cqHHNi8ieMPVJS5Xs6KZ8Oo9rR2XMyN4GvMG+DE4vOvuF9TOAe278Q/5hUF8xLJMz5kw8zZzJm1gsvS9OcuKwRRo2NG+/AIU91ccHZyxrW/SzEDGOgxkEFuriXvubsPYviQQXi4FL12cx3IiGHDGebhVrSMixtDBg9lqNuAknXcBrgxaOBABg4ofs+xH/0GjWfTzXJ6NZmC2O9/jfgUMBcauX98FX3bfMPIdcU9qbLjWD+xNz92dSh///1dGODkjMdoT6aM9WSoY38GD57IlEnDce3vyiA3d9xd/v58gzw8GOj6d1ldnZ1xHzQe78mj8HBxYcTIcUwaOwIXp+FsvCIFcypXDxzm2DlpuVMzP3mLSaZQIpXJuXvvPqtXr6a/kzPfff0NDevWo0Gdutg3afrULaalS5ehUKqJT0gUWIhEiZSIyKiXboOQnlmDa9dxXFRXxqm4mQT/PSz2HsnkdWfLmXLDwL4Zo3CafhqDMoAhnVzZGviqQ+dM3Dx+mDP3la9Z5uclg6iAY2zZfpxQtRDEG5ICcp764maj1yc/1Q22ILucWcFeNurLzFy8nsvF39vE68dZOWcTZ2/GY1DE4r9lHmNn7eDvOSyz0OtTqu+JXuY0FCo56pTyK4QnG6kfP11OJleg1miRyGScP+/PrJmzcHJw5P2W71L/7XdoXL8BLZs1Z/nyP9Bo9UhlcoGFkCuUxMTGvbQg9Dd24OXkzZ0sMCdFcGjFSjYdukvFWi8KSE1RkajLoTDTRNTVSwRGJGJMSkIllT8xz9MjziyeySif8zzKDGZ+z2Hsuvv8OY7KTyHau7tw+PxT2g3fTEJ6xeWWq37IzhWr2HE+4pm/PXN6Aps8e/LB565sDyyvxe7vCEHUihQivbyXJYu2E5UOkEfctb1McXVn/NItRD4CMuLYt3IBm6++4uMKc7UcXTUdByd3Ro+fwpI/dnM9RIpJE8Sf4xz51WkKR0If39zJJvrKbrwGuDNh2VYiU5675WrJ88ZBSKQylGoNOoOR8IhIDh48xKwZM/nl53Y0t7Nj8eIlopurlXVzzYw+w8JRw1iy4QinjxzlyNZluHfqy5RNt/i7BSOFOxfPcDHoWZVkLnf2LmPcwmsUALdWzWB1QATaOwfwHjmHGyV3gQq4u2EJXpOOoE0JYl7PIex8FUHkqdi5bAzD5i1hutM4tvgnvqCXYhrRN8Iw5AAUknjDnyOHD7Nv/Tycfh/MqvOJ5a6lu7YKl/HTWOQ1mQnjd/O8iywhiFoRM1kmDYkJclLzAApJT9aRGBFORLyElFygIBONLB6p4dWfwWjO1BF29xY3bwejKel/moUiJpxoxZMWKCDNpCUhIqxo/69x4VJZedmR1HKFEq2u6Goh8O5d9u3bx8lTp5DK5BavJN9kXlYQuRmPMJlMSK5vZ3Sfnnj/dZKQKAXpuWkE+nrh4OLNZWnRQ6RSTLFsnTSeiQsuk5Iaw86FazgfrnziQVNGgvYvoGf7IRyJ1hO0fTyd+s7H//xORo0eyYbbmqLtJBu58ec8Jo/dhuxRDOsch7OrvDPzwgLy8/MoBMwF2aSklHqwlS6KzTP7812HTnT4qAMLDoWXIwgzBXn5mIEC/U1m9B3NFv9Abp09xJ595wmKVZKRZeTs0mmMHnuQZPIJPrCKVYdvo0tOJiU5mdjTS+nW7Vc6fPk9fdz+IPo5l/lCECIVSDoR54+y7+BhrsXWgMuCCqSiczFJpDKUKjUKpcrilaPgZQVRSIzfHH5+14YGdepQ9/++jU1jO95tZk+zJnY0b9KIhu/UwaZRE+waN8GuUV3q1PmW6TsiyEiPYe3gdjRt2BBbm+K/N25KM9smNKnfgCYNmtCssS2N6zekiY0NjerXo1HDxiXb+ec7nzH2rwfkIGf7oNmciy77+8hVSYgIjSSVPALXDeL9ZvZ8+H5r3rOzLdpOkyY0qfs2//i3t/hPm77sCyn7OVMN0Vy7ISkSR4GBE9Mc+b7te9i8XYdGjWx5196eZjYNqVunLR7zr5BNLkG7pvK1fWMaF5fXvlFD6vzX/8Nbb9nQb5Y/ac/pySQEIfLyyTFy5/BfrFyznsO3FS/5nN6aETFZn3XzslcQBcYQNs32YsxITyZNmMjEcWMZ7zmWcZ5jGT9uPJMmTGDC49ejx+Kzci8RxfPcPdw6ga4OAxk7xpNxnmMZN2YM46d4M2/+fGaOGc248bNZvHAmk8aPY+K4CUwcW7SdcSOGMWLGKi5KsjBnBrF5jT+q9NLn/vkkBj/g5g0pkMGdHcsZ268dLW3fo32/YUXb8RzLhPETmew5mikbTiMv05s3H/lDP3bc+fvqRHNlEb/2dsJzzFgmjC3+rCOHM2LaUk7FFt0tyJeewKOHE8NHji763GPHM2mcJ57Tl3A0rAqfSS0EIWItEdN9WzdVMtVGnoHoiHCCHkQRdnkTI4fO5PrLTiTwjBRm6kjUplJQ5r5+NoG7/8Rn5qniwaxpXFw1ip+6TOHW8zsSPVlgQk+vYuLOoKItKu/x59iJrL1VfnvHI3UisRG3WOM5mmnHYl/p8whBiLwREYKwbipdELk6Lu6eS79+TvT+8nva9RzMitOxlDPPYyXFjPLiBhw//YwOvzvi/Fs7PvvsF7x3BFVguhwzqfGXmDVmME5OLoycOJVVW6+iTy87k4E5Pxt14H48f++Jy5Q9yFNfbdpkIQiRNyJCENZNpQvCnEeqSY9CqUQeF0O8wlSBiSFfMflajs/34IumtnzZfyoHLkVQTt3+ghSSYZARERZOvNLAc6v93DRUEjlJOa9+M1gIQuSNiBCEdVNbZnPNTLzB5nVLWL7RH20N6N33oghBiLwREYKwbmqLILIUQRw/eZA9ey4jT6m2YaSvHCEIkTciQhDWTW0RhLVFCELkjYgQhHUjBGGZvLYgBrp7EPTwYbUWWkSkoklOTsbZwVEIwkoRgrBMXksQBmMSLs79mTR+PDu37xBUOdvZuX0HB/btY9+ePSWvBS9myaJFdPm1E3KFUgjCChGCsExeSxBKlZr9+w8wacJEpnhNEVQx3lO88Zrkxe+9euPi3J9p3lOZMtny5bIGJk2YyCbfTcjkCotXdgIhCGvJawkiPiERtVZHUnIKxiSToIpJTnmEVm/A03MsK1euIiMr2+JlshaSTMno9AbiExItXtkJhCCsJa8lCEH1IlcouRhwifdatKRbly5EREaKM2LBG4EQhGUiBGFFKFVqli5diq1NY9p+1IYjR/zQaHUWL5dAUNUIQVgmQhBWglQqIyo6hp7du2NTvwGN6tZjitcUFEoVEqnM4uUTCKoSIQjLRAjCSlCpNZw4eYovPvmUpo1ssKlXn57de3D//gPxzAJBrUcIwjIRgrACEiVSVBotkyZMxKZefZrb2tHc1g67xk3YumUrGq1OdN0U1GoeC8KpnwO5OVYwiVEtyd27gUIQNR2FUsWDoGC6d+1Gw7r1aGFnTws7exrWrceEceOJT0gUj8QU1GokxbdYO3XoyIXz57kbGCioBtatWYOLc3/0xiQhiJqKVqdn+/YdtGrREvsmTUsEYde4Cd9+9TXXb9xEqVJbvJwCQVXx+ArZa9Jk+js64T7ATVANOPTpy+pVq1FrtEIQNZHHVwbjPMdS/+13SuTQws6e5rZ2NGnYiPXrNyATI4QFbwBanR6t3lD0r6DK0ekNqNQa4hMShSBqIiq1hhs3bvLTDz9ia9P4KUG0sLPH1qYxbgNciYuLF7eZBAJBlSEEUcNIlEiRKZSsXLmSuv98m4Z162FTvwEt7Oyxb9KURvXqU+/td2jVogWnTp1GrlBavMwCgaB2IgRRw5DK5MTGxTNv7jza/fgTnTp0pGP7X2hp34w2rT+gy6+d6Nj+Fzp1/JVt27YjkyvEbSaBQFAlCEHUQOITEgkNCyckNIyIyCju3X9A63db0bf37yQkSggNDSMkJJTwiEiLl1UgENRehCBqKBKpDKlMjlKlJiY2jtbvtsKpnwPGJBNSmRypTC5GUwsEgipFCKKGI5MriIyKpvW7rXDs2w+d3mDxMgkEgjcDIYgajhCEQCCwFEIQNRwhCIFAYCmEICxAokSKRCp7KRRKFdExsSVtEAZj0gvXEb2aBAJBZSAEYQESJVLi4hOIio55IXHxCQSHhNLc1o5e3XugUKqeu3xMbJwQhEAgqBSEIKoZtVbHiRMn+eXndjj06YtD337PxbFvP/r93odvv/yKdj/8iJOD43OX7/BzO5YuWYreYLT4ZxUIBNaNEEQ1o9Ub2LhhI2NGjcJkMr0UySYTmZmZpKenY0p6/rI7tm1j1IiRJJmSLf5ZBQKBdSMEUc1o9QZ8fTfhM21amYNeGTl14gRjx3hiTDJZ/LMKBALrRgiimnksiGne3lUiiONHjwpBCASCSkEIopoRghAIBNaCEEQ1IwQhEAisBSGIakYIQiAQWAtCENWMEIRAILAWhCCqGSEIgUBgLQhBVDNCEAKBwFoQgqhmKlMQWUkaEhM0ZAlBCASCKkAIopqpPEGY0T08y5rlu4hILRCCEAgElY4QRDXzaoLIIPzcdmZ5e7No00niH5mL3i7MxmQ0kpYtBCEQCCofIYhq5tmCyEOXEMXd0zvwGurOkAnLCdQVFv1FFcDQL9+ncd2mNP+8P+sCNEWrFGSi1yjRpQtBCASCykcIopopVxCF6dzbOY1fWn2H+4JDPAy+xJoZnuxNKP57tooz6yfyrb0tH/T04ar2sVOiWT5hDPOPJZRsSghCIBBUFkIQ1UxZQZjRB51jxRhvZk8dxHefdGX6cl9WzHBl1NJd+B0+gt9hPw5vnkmHRo34spc3u48cwe/wYQ7vW8ewIeNYdFIqBCEQCCodIYhqpqwg8ok4soFx409iwsStHQtx7/grP3UcwGQfH2ZO92Gmjw+zZs5h0aLFLJ43h1k+PsycPp3pXlNYuPkYcal//8cJQQgEgspCCKKaKSuIQuJPbWaC62YeXwc8UsXyIERf5j/lZSIEIRAIKgshiGqmvDYIxTU/Fo/ei/KVlCAEIRAIqgYhiGqmvDYIkyaaO9elFApBCASCGoQQRDUjptoQCATWghBENSMEIRAIrAUhiGpGCEIgEFgLQhDVjBCEQCCwFoQgqhkhCIFAYC0IQVQzQhACgcBaEIKoZoQgBAKBtSAEUc0IQQgEAmtBCKKa0eoNbNzoy5xZs6pEEAEXLuA5eowQhEAgeG2EIKoZncHI5s1b6NShAzu3b2fn9h0vYDu7duzA7/BhDh04wI5tz19nxJAhjBoxkqTkFIt/VoFAYN0IQVQzcqWK23cC8Znmw5TJXkzxmvJcpk7xxmuyFx9/1Ib2P7djxvQZz11v8sRJHDt2HKVKbfHPKhAIrBshCAsccJlcQZIpGaMpGWOS6bmkPEolLj6Br7/8ioEeA0l+lEpScsozl09KTkGl1hCfkGjxzyoQCKwbIYgajlKlZv36DdjaNOaLzz7n3LnzqDVai5dLIBDUfoQgajCJEilSuYL+zs7Y1G+ATf0GLFiwAK3eYPGyCQSC2o8QRA1GoVRx6coVvvv6Gxo3aEjDOvXo7+REeHgEcoXS4uUTCAS1GyGIGoxOb2Du7DnYNrKhWVNbmjW1pVXzlhw8cBCtTm/x8gkEgtqNEEQNRSZXEB0Ti2PfftR7+x1a2NnT0r4Z9d5+h9mzZiNTKJFIZRYvp0AgqL0IQdRQtDo9hw4foe2HH2HXuAkt7OxpYWePrU1jOrT/hbv37qMQXVkFAkEVIgRRA5FIZShVambNnEXdf75dIocWdvY0a2qLrU1j9u8/gEKlJlEitXh5BQJB7UQIogaiUKm5d/8Bv3XpSpOGjZ4SRAs7e+xsGuM5egwJiRKk4jaTQCCoIoQgahiJEikqtYbdu/fQuEFDmjRshK1NY1rY2dPc1g7bRjY0qluPT9u05fadO8hEbyaBQFBFCEHUMKQyOXHxCczwmcEHrd7j0zZt+bRNW1rY2fNei5Z89vEnfPzhR3z+yads3boNuUIpbjMJBIIqQQiihpEokRIXn8Ct27e5cuUqN27c5MKFi7zf8l16/tade/fuc/XqNa5cucr9+w+EHAQCQZUhBFFDkcrkyBRKVBotsXHxtH63FU79HDAlpyCTK5DJFaKbqxWSKJHWaCx9fAQ1CyGIGo5MriAyKprW77bCsW8/dGKaDatGoVQhlclrJAqlSpx0CJ5CCKKGIwRRO5DK5ERGRePmMoA+vX/HqZ9DjcKxbz+6d+3GhQsXUak1Fj9egpqBEEQNRwiidiCTK0q6LsfFxiKVSmsWEikD3dzYtm27+I4JShCCqOEIQQFUYrMAACAASURBVNQOHguiv6NTmR9bTYm3lxfbtm0X83wJShCCqOEIQdQOHgvC2cGRvLy8aq34XzaTJ05k+/YdQhCCEoQgajhCELUDIQiBNSIEUcMRgqgdCEEIrBEhiBqOEETtQAhCYI1UWBDxCYmoNVqMSSYMxiRBFZOc8giFSk3rd1vh4uRMdk6uxctkLRiTTGj1BuITEi3+QxOCEFgjFRaESq3B13cTA93cGT50mKCKGTFsOEMGDaZZU1s+//gTxowabfEyWQsD3T1YtmQpMrnC4qOEhSAE1kiFBWEwJtHfyZlFCxbgf/68oBo4feoUH3/4EX169uL8uXMWL4+1sG3LVrp26lwjJjSsekHkI71/nl17b5BsfrUtCEEISlNhQegMRgZ5DOT+/Xuv/FUWqXj0Oh1paWmWLoZVxWg04uzgiFQmfwMEAWmyexzZdx5Z5qutLwQhKM0rC+La1auv/EUWEamOSKVSnPo5vBmCKEzl1vpx/PqdI1tuqHmViwghCEFphCBEam3eJEGkR59ijONIJnkOY8wsX6LTK74NIQhBaYQgRGpt3ihBRPgxqMsARrp348dBU7mkqvg2hCAEpRGCEKm1qT2CyMWgDCNYWYA5I5Slg37np+9+pnPH9rT7/gd++v4HfvrmU1q+89/821v/wTdD15OQXfHjJQQhKE3tFURuMtJ4BSk5hZYuicgzYyZDJyNOlkRVNNvWFkGYs1KIvXaBsBzITzzPlMHd+MS+CU1sPuDnDh3p3KEjnX/tQs8eXenccSBrDkW80vEUghCUppYKIh/J8Q14j1tCgDzD0oUReVYKpOyaPZ3pK0+grgJD1BZBFCRHs2/uHM4pi994FMT83h1w9DlLZX67hSAEpamlgsgjZO96lq3eyj1V0bW2OTWO8xfuo03NIdkoIV5d8WvwDPl9TvmdJialnKuSwizUwTEY8ixwxZKXhi45o7jnihltaBjRiTryzdmogmNJesV+8fl6ORKZqlIrocIMDXf9fFm35xyhiaHs+2srp/wD0b7gvyNLryDibgwV6ehbWwRBjpztE3/j+94jmDd7OkN6/sQn3w/GL+4V+7M+I0IQgtLUGEHkZ6WTlpHzSt3zykteagjLB/Siz9jNSAsh+6Evv337Bb9PnMHkiaNZeU1f8TIaoziz7xB3FWWrTMO9vYwYtI6QjNcRRAG5WTnkF1TsKOhvbmRAD1fWXdECKez06stXv01j27Y1jBm7i8SX3VyWhMPrV7Nk3lZCNEouLp/K5MXHMFT4czw75hwTkZf3sW6LH4HxRrTBx1kwZgE3tPnPWSuTm1sXMWSyH6YK7KvWCIJCtIE76PtZA/7xPx/w+7D5HA9SklvBrbwoQhCC0tQAQRSSFHaMqYMcGTptA/fUmeRXiiXyuLN+At980Z5RS3ex948pjBm/EL+zu5jQ1ZnNwRUfdJapCePgn1u4GK4t8zfFueV07LWC0IzXKHyBkiMLV7H3cjwV0Uxm1FEGd/qWf3WfxdnrJ/Ee7MzYTZe5tnMOXQZsQfayGypMJ+bWdc6fv0SUNIyNniMZMv8iWeUubCYrzYgsXo4hOaMC5TWjjfRng+8xYg15GG6sp1vHiVzRPm8LqZxdPoFeY0+Q+ndhycp4REbBs9eqPYIASOPh6S3Mn7mKsyHqV1j/xRGCEJTG4oIoSA5j7bAxrDoXTZoxkUiJkrRCyDbEcC3gLurya6fi5JGcnIQxNR/IJ0WpJ5sC0o1JJCUVXX7nGR8yr3db7Np5clmdB8l3WOQymF1hFesobs7WcvovLxy6/M7AubuJSnn6R666uJru/VY9VxB5j7To0nOBfEymJFLS8jHnmlAlP/6QhaSo4omU6MgzA5gxJQYRcOEe6rTni8dcmMKtbV589dH3eK7wJxVIOLqQ7m5bnymIAlMcAWcvECR7VM5f9ez2msKkpVfLEUQeuYW5JAQeZYbHOFbuv4yx3PrdjDb0On6nrhGflANAri6EjePd6f6bO4v33CDm+m5cei3g7nPnh0jDf9UU+k14QhCpQSxy7YLDnP3Em8o/l65dgnhE0MVj+C5cyeHbEbzOecizIgQhKI3FBZFnDGGj1woCVE9843OSCdy+Dp8x41l3+C5FVb2ZJHki0XHGJ9ZO4sSG1azYFUlBoYRto+dyTangwop5zF0dQA6QKb3M7N4d+JfLQq6rcyA9jPXeo9gZWsGRRCkhrBj7Ow6DPej86wQOhaU89eciQawmvLg2zUtXEiUxkP9ExZlwcgmTd96moFDN9qUr2HgqnoRraxm14kLJvfUcvRx1avEN+dx0Is+sxa1LF7q7TWXr0VtIU551tp5P5LE5dP6qM9M33yUbiDm8gO5u23j835uhTECVUQjkEHn+JDtXr2LSkD706O/DFWXxPnOUnFq7noCEeC4tWsLCxZd4+kjlEH/xJlGaRxTm5/FILSNRYyAjRUfojXCSSs7ozSTFXGX/loU4dBrEol1RRWUIPcqEjn0YOqgX3b1Wcf2KH5N7TcJf8bxKs1gQE08WlyWD6BN7mD+sL9+2bMXPHqu4LS0rudoliKqPEISgNBYXBGRyZd1gfuzqxKhhQxk7aztXAg7g2aknjr//wr++6svac9Hkm7O5vWkxnhP2ojObMZvNmM3ZPNw6C4+RfxBh0nF05gg8N5zixOLp+Mw+ikr1gHkDhrN42ykOrJzHiv13SEmOYsOU4WwPKSWInBRUahXGMo2lxfsqSCc+8Bw7Ns1jyIg1XI97en2l/wo69/qD4PSi5fW31+M6YSPhpvzisprR396Mc++Z3NEZuLbGiyHTN3Hebw0OY3YgKyj6PNdXjMN7+1UyzGbMOVnkZGegiziEc9sm1KvTkvaDfDgZllSqjBnc3z4HzylLOXVyDzNmr+CSJgfpsQV0cd6ExGzGbM7gyrKxTFqygQO7/2TlugNcf6AgMyOWvyYPZPiWoKJyZkvYMqE/M07dJGDhYuYtvFhKEAaOTljO0WuSv9uLClMJPbUWl/YjOS3NLtqO6SELXIaz4epDbmzdxbrVgeSbzRRmaLh35gBb5o1j7PpDPAg8y4xes7imf/peUW6yCbVcVXz1kob/Si/6jDtGqtmM2RjIyiFr8L92lcMLvBnlMpIVh4LLdO18VUEkSqRIZXKkMnml/dBqqyASJVJkcgUyudLilZmg8rG4ILISLzJtoBer9p/l+rWr3LwXgzruElO7fsG7drY0t23F1z91Y4BLf/r82o4fvuuIg4sLri4uuLq4MqBXJ3781w/0cnDFqXt7vvm+HZ17jmXXZTmm8F10/foHergMoP9vw/A9H0v6oxj2zlvKNd3TFVJ2/EOuXLqGuhCkAesZ0r8PPbt0x8Hx8b7cGDp0JKMHD2DY8iPI0p4+j38UtJs+HTvTs68Tri4D6N+jI9989wu9HfoXr++Cu2Nv2n/xPb/1dcG1V0d+/P5nevboQft23XDq74KrizO//fA13/3cFRcXF9wGuOLm4sLgQVPx3X+Bhw/vEvgwHFVyaYtp2DmkO9//qyvuTg54zNxIeHoBybfW0+WnTvR16o+rixO//fA1X3/5Nd9//Q2d+wxg+JBBDHJ3w6H7r/zwSw9cXVxwcXDCZcBULiYmcsF3M5v2R5S6Yskj4eR6hjj0w8nBueizOfWle4cf+frTb+nW2xlXJ0fcR05j5gRPfu/9G906daXbTz3o7+KCm6sHI0aOYJjjMFb73Ucee5nF046ifmonhSjC7hNwOrS40s/jzvbxtP2iI/37u+Darzu/fNuRHr/1pk+3rvQZvpCAmJQyV1YVFYREKkOpUqNUqYmNiycoKJio6JhKufqoPkGYyZTfZPW4uRy+U7G2iooIQiZXoFJrkMrkRERGcebsOaJjYi1+pSaoXCwuiOjj8/HcEVjOXzK5u3sZc5btJEKrQ6NWozUYMCYZ0avVqIvR6o2YTEnoNGp0hiSSDTq0xkfkmIGCbB6lmNBr1Gh0KeTkQ3a6kqDbiWV6gOiu+7F57UF0AGkJ+C0Ywk8dxnAq/O99qdVq1CoNyenZZXtbFeaSlmJEW7ycSqsnSWfAoNeWrKvR6jElJ6HXaIrKnWREr9NjStIXr6dBbzRhMurRlOxThVqle0H3zkKy09NINuhQq7SkpBfd76cgh9RkAxrV39tONiWRlJSEUact3ocGvSEJk0FX/PnUGJIyMOeaiI4KIy6pnFZgcw7JBi1q1eMyatAbjCSnmNBrNahVKjSGR+TkZpJwdQ/zV67i2EPFE8dRhVptJCO7gExNOLfjSvdNyiH4zEE2bHhY/FWQcXiFDwtOhxeVWaMjyWREr9eh1+swpGRSXlv1ywpCrlCi1emRyuQE3r3H3r37cHd1Y5DHQB48DEKueP2z4+oTRDb3d25g0cw/uZJQfp+v3Lxs0jLK9hp7kSAkUhkqtQaNTk9UdAwXLwaw4o8VdOvSla+/+JKQ0LBKOVaCmoPFBSE5v4jfBs8hID655L3ClFiOr1/I4IHT2HnvcZtDHjGXT3L4WGiVjLrNVtxm/axx+Cxdz9b1fzF39hzWnI55xa2lEnhsP76rtnBH+/p91TOk19m+8TiS1Od02alVKUB+ZQ9jncaw4E9fNqxZyuLZu4mr4ICM5wlCIpWhVGvQ6Q2EhUewf99+fKb70LH9L9g1bkKd//tPevfoycOgYCsTBKRE38Nv618cC9IUvZGnJ2DvLk7cSCAzS86+TWvY6F/2R/8sQcjkCrQ6PQqliqvXrrN+/QYGDxrMp20/pknDRjSqV5+2rT8gNCwchVJFokRagqUrOMHrYXFB5CdFs2PGcByc+zNirBfTvJfhu3k982auYO+5CP6+mZJN4u0rXPSP4BUmqnyp6MIvsfmPJaxaf4JwZXk9e14yBSmEBZzlyIEjBMpTXrz8C5KmCuP83rPEpzxvrEAtS2EKD87uYOGcRWw7E4j+FerU0oJ4fL9crdEikUo5e/YcPtN9cOjbj/datKTe2+9ga9OY5rZ2NKxbj36/9yEkNKzkVsrroFSpeRgUXE1tEKn4jenMx9/0Z190OuSFMubXD3i/3x/cu3uYIZ16suBy2a7aTwpCIpWhUKrQaHUEhYSyY8dORg4fQfuf29G4QUMa1q2HfZOmNLe1o2kjGz5r+zHxCYkkmZLR6PRodHq0On3JsROysE4sLggA8pOJuuOP3+HD+B0+x8O4ig9iq5xko1ImEJNgKPeWhYh15SlBSGXExMZx/cZNli//AycHB7758isa1q1Hgzp1sW/SlBZ29iU0qlefPr16c//BQ6RSGXHxCa+FRCIl8O49nB0cKTSbyTOGsmmaJyOmb+KBKqPSBogWJZuYc7uYMciBPoNXcerYBsaPGc+m6/EkxZ5m3AAX1j5ILbPWY0Ho9AbCIyI5fMSPSZMm0bnjr3z4/vvU/efbNG7QkOa2dk8dq+a2drRq3oIe3X7j95696N2jJ7179KRzx1+Z4jVF3HayYmqGIGpIctR3WDHdk+EDV/JAn2Pp4oi8Zh4LQiZXEJ8oYfWq1XRo/wst7Jvxf/73P2jwTp0yld1TlV6Llnz84Ud80qYtn3zU5vVo05Z3m7ega5fumLPi2L1hBWsP3EaiUCONkBX31iokWSlFqkl9ShjmglzyCp5WSH52BqmPiq6v8zMfkZydD+Y80tNSySo+uzHnafGb3Rfb1t1Zfjy+6E1VAF7D3Vh9t+yV7eSJE9m5cxdqjZY//ljBD99+R8tmzfnnP/6/5x6rFnb2tLRvRpvWH9D2gw9LaNP6Az5r+zGftmnLjh070RmMFq/wBEIQrxxzYQG52dlkZeWQX1gFI5FEqjWlbzGFh0dw4uQpZkz3oVOHjnzSpi0N69TFpl59mjW1farCa9bUlo8//IhuXbrSq3sPev7W/bXo1b0Hv/zcnp69+lAgu4DPaDe8N53j/p0bXLp6iyhjJrn6B2yePoaBnou49UT7svTaNjbfKnVLSHOHVdNWcDsDkJ5ixuL9SPRS/P76g7Xni3/QeTqCbh9n44a9nL6RQHYhFCgu4TXSnZWByZTOk7eYoqJjuH79Bn/+9RdO/Rz47qtvaNKwEQ3eqYN94yZPHStbm8Z82qYtD4OCSZRIiYmNIyY2DpVaw57de/hfb73FunV/YjAlW7zCEwhBiIgAZQUhkcqQK5QoVWrCIyLZv/8A4zzH0qlDR5rb2dOwTl3sGjcpaYNw7NuPqOgYjEkmNFrda2EwJhEeGYVLfzfI1XJ8vhON/u0t/u2tt/g3m29Zdi2Kqyu8GDZsDMP7d6bvuIVs8vVlk+8axvb7ke+cJrLB17f4PV82rZhGz399QZfhC9m8yotf2/7I4IleuHZ3ZaJvGGDEb/YoBk78g+1/TMTVZx0PUoCU+yyZPYa1d8u2sZVug5DJFShVaiQyORcDLjF3zlycHB354L33afBOHZo2bFTSBvFpm7ZEREY91V5jTDJx+NBh/vGf/8X69RswJJksXuEJhCBERIDn92KSyuRotDoUShW37wSyadNmRo0YyddffkXTRo2e6sVUumfOqyBXKLn/4CEuLm7k6UPY88d0fJb6sn/fAY6dv4Um1cipWY40/ff/4J069an/P/+bf/zHf/KP//hv3nm7Ho3++T/Fr4v47/96G7tm79PS5n/47/94m/ffb0X9//h36rR15lB0Fij86NaiEf/4f/8X//7Wf/LFkHUk5oBZH8TuNcsI0Lx8N9fH40N0ej0RUVEcOnSY2bNm0eXXTtjUq0+jevVpU9yL6cn2Bp3ewMEDB4UgrBghiEpPIelxASwYOwC3GTuITn695m5zfjapaY949CiTvMe3vQoMXNt3kGuRenLSEgi4eQ9J0ktMl1eQQcK9iwTKKnEC7zwl/kePcuGh+hmTLJrJy8rkUXIK6Vm5ZQazmXOTiboTwAN1ReYmzSbu8iEOXo8hMyeF+xduEaUoe0/9ZcZBPO7uqtZoiYmN4/Kly6z780969eiJQ99+ldvN9UEwAz36ELrPl6VzjxWNuXkiOY8MJIYGsGLSQMZvPk9oSAihoaGEhoYRER5GWEhI0XshIYSEhBEZFUtMVBghwWHExsYQHhxCVKK6qOdfhp7I8FCCg4MJfhiKVFfUrpGmjuH6qTuUbaJ+uYFyMrkCrd6ATKHk7r377Nm9B09PT9r9+BNBwSFCELUMIYhKj5Y9cycydOYubl6+wF35a3SXBXK1N1k+fyreU7cQYiiuRDNCmNf9FxwnbCFg/0Ich8ziRunappzka64xs9dw9ga/RtdbcyaqWCm6lOIOyCkPmdH3F9qP2Ia83IkV84i9eIDZw0ew9MgNkkqduKZHn2Jyr7GcTKxIpwATx6f34TvnmZy9sJsRfcey466xzFIVGUn9uAusUqVGrlASFh7BzVu3K210sEyu4N7DEIa6dubM0kXMXfr04FBzQR6pOinX9q1g7Mi1BJfU4AUk3AngTmLFZx8uL4WFheQ/Y7rkioyklkhlKB6POo9PIPDuvafqiYREIYjagBBEpSeFixsm8MPPA1jrH0vmaz8/KAudVI5KZeDvKlTPkZmDWXYliuhdcxnisYjwcsbj5aYoCboVii67qBD5yotM7jSEfSGvIa1CDceXrmTbuSiK6nolWwdPYdXukGcOYMxPT0IWE0q0OpnSz1PKijrKmF9Hc0ZakSuIXO7snYvTimvoI3bjPGgSfjFlD8DrzMVUNL+QotJ+aI+vIAYN7EfongW4dBrFoSDVE72VUrl7eBUTPedyJOiJbt75JgKPb2XL2XBe4THTFcqrzsUklcnLPVZCENaPEERVJM/A+UXu9Jqx9wWP0swi8tJu5i5ax8XIsr1KHkd//wQr1mziSsLj08pHnFk5ksmnQpGfXs3EScsJK+cEM1cXwb51W7gqL36qnvoS3l2Hsf85gkiXBxOkTAGyiI+JIUGVRV5KLHfijCWVmTkvFb0ptXisiImjEyaybPOt51RgZlINGgxpT0ggS8X9iFjiAo8wqfvYpwSR+0hPTGAkqUCeOpxguYGs1CQk4WHo8gAKCT+6Ehfvs+ikpxg6bjZ+0WWHT9bE2VxdXFzJSwpl/9yR/NauD0M9JzPVey7rNp8kXFdVQ0BfLpU9m6sQhPUjBFFFSYu6xwOJitwnruYLM2QEHLyKOhd4FMWBDZvYuGM7i0c70Ln/bG5oUpGc8+Na1N9nkMmhARzavQHvCUPxPBxX/K6Z27snMfxwMLrrm5g+ZwXPumuUl52GPuo+1+8Go5BcZUb3ERyJKu4/bwrD/07cU/NSyU4vYsjys2QX6tg5by6L94USdXE5A2Ye57FWUqPuEaJ6/MrMzblTWLqh9LTgxX81FyK/eYLlngMZsuwYxa7CLPVjmKsPW/Zuw6uvFxc1f6+TL7/O0pFTuZAEyZeWMnzVEaKDzzN/wiROFD+XWX1pG+4jj2LQXmXMlMUcjih7V70mCsLZwbG4HSaNyBsXOLp/H/v3+eF/NQx9ZmU/I65iEYIQlEYIokqSS+KdW4QqDGSmGIkPiSYdMBtuM6+fC14+c/DxHM+yHae4HRxFzLX9TJk0mb1RWoK2eDFq8W5CoqOJjbnBIuef+OCHTjh1dWDugVvExsQQEx3Oib988DkTifLyRnxmryS01BVEgTaSIFnRtODJtzbgMmImR66exqeTE8v97hEbE8Ot3d60/30KRwMjiY2JITYmhqCTK+jxLw+2X7/PyYXD6O02lc3r59LNZQmXo2KIjQllu2dvnKZvJjgmhtjoSA7Pmc6ag7dLPbvaTKY6lkRlDFsX+zBi+jy8nCey8dgdYmNiiLy+nUHjVnLg6A7G/TKADRfDSsoQ/fAs3q49cF50lvBbm3Fu78byv9YycZQrC46FEBsTzfXDfzJ5pj9JiouMnLoYvyjruIKobdN9Pw8hCOtHCKIqYk7nvt9a1py8RWxUMGcOBxXfr8/k6loPvmvXFcd+zgwaPJRhgzxwcx7MrJWn0AOFsqMM6d0bJycXBrq7MsDREYe+/XB2cGaQuweD3N1xdxnA0BHLuWPIQn7lGHt3+/N0E60Z5YWjBETKi9oFciNZPHo+G45cYI/PGNycXBjo7sFgdzfcBrjh4eZevG0PBnt44ObkjKurB0PcXXF17o+7mztuA1wZWLx/N2cn+jsPYKC7BwNdnHAZs5obpXtGmTOJOnUJSbqeW/tXMszNjT5f/ItO3foxyN0ND5dBzNt7E50ugi2jB+HSf0Dx9j0Y5OGBxwAX+ju7MnjgQNyd+uM6wA0PN1fcXd3xGOCC65AJ7LhvIjfxMmv3HiHcVLbhVQiiYhGCEJRGCKKKE3f5AEvmBhS9SE3kxOpF7C7ndkhWigF1YjBbpo9j5pGQl5ybpwCDRoOmzIyxBdzbsADfs2EAFOqusnDuWs4EP73fgvx8cjOraAJAs44Tc+ZwPKGoaT1fe5XZQ5YSUDwla0FOHoWVsOssnQaNzkh5mxKCqFiEIASlEYKo4qTGX2PRoIG4Dh3N1HlL2Lr3Boac0tV/PobQ40zp04lf3FcTanzde9FmtLd3MN65P0MGj2HS8HEsOXYVzZM9SQt0+PuuYrbXXE7GlO0i+vrJ5uH+eQxxcmPUCC/mzprP6jMPScoDyCP8+A58D10t0+21MiMEUbEIQQhKIwRR5SkgSRZCwDl/bodLnj1VeY6JqPsPidW//vMjijeIIuQOF89e5E5QImml66TCLLTxMYSFhiFLLncAw2unMCeZ6FuX8fe/Tli8/okZcgtJ1UiIk2vJfu1uwM9ObRREQWoEBw9dR1EFU78LQQhKIwQhUmtTGwWhv76abj94sDf42d2iXzVCEILSCEGI1NrURkGYU+4y8beujN/xoJKfISEEISiLEIRIrU1tFAQY2D/md/ovP0dlP7FECEJQGiEIkVqb2imITPwXu9J3+Skqq7XqcYQgBKURghCptamdgsgncMt4Juy4WulzMwlBCEojBCFSa1M7BZFL0IEtnA1Tlpk6/XUjBCEojRCESK1N7RREFpLQRFIyKn/eJiEIQWmEIERqbWqnIKouQhCC0ghBiNTaCEFULEIQgtIIQYjU2ghBVCxCEILSCEGI1NoIQVQsQhCC0ghBiNTaCEFULEIQgtIIQYjU2ghBVCxCEILSCEGI1NoIQVQsQhCC0rySIAa6exAUFFStX14RkYomJSUFZwfHGiOIu/fuM8C5v6UPyzPjM20a27ZtF4IQlFBhQRiMSbg498dz1Ch8N2wUVCkb2Lh+A3t372H/3r0l71m+XNbB3Nmz6fJrJ+QKZY0QxMOgYH747l+sW7PW4semvO9a+59+Yteu3ej0hkr5zEIQ1k+FBaFQqjhy+AjTp05jhs8MQRUy02cGc2fP4b0W79KkkU3RezNmWrxc1sK0qdPYvm07Upnc4j80iVRGbFw8a9esZVpN/O1M92H+vPncv/8AuUJZKZ9ZCML6qbAg4hMSUWt1JJmSMSaZBFVIkimZ9MwsunXuwleff4ExyYQpOcXi5bIWkkzJaPUG4hMSLf5DS0iUkCiRojcmYaypvx1TMjK5otKOlxCE9VNhQQiqj0SJFJVaQ+eOv/LlZ5+TkFh0JmrpcgkEL4MQhPUjBFGDEYIQWDNCENaPEEQNRghCYM0IQVg/QhA1GCEIgTUjBGH9CEHUYIQgBNaMEIT1IwRRgxGCEFgzQhDWjxBEDUQmV5SM/i1PEBKprNL6qgsEVYUQhPUjBFGDSJRIiU9I5Nq160RERqHR6tAbjHT5tRNffvY5coUSrU5PTGwcAZcuExsXb/ERwgLBsxCCsH6EIGoUUqQyOfv276dXjx4sXLCQiwEBdGjXns8+/oRTp06zYsVKev7WnRUrVpIokQpBCGosQhDWjxBEDUOuUHL33n2++PRT7Js05dO2bXmvRUvebdacT9q0pYWdPU0b2XD06DGUao3FyysQPAshCOtHCKKGIZHKSJRImT5tOg3r1qNpIxua29rR3NYOW5vGr7elnQAAIABJREFUNKhTFw83dyIio5DJFRYvr0DwLIQgrB8hiBqISqPl6NFjtLRvRrOmtrSwsy+hcYMGrFy5EqVKLW4vCWo0QhDWjxBEDUShVBEUHELf3/tgU79BiRyaNrLh++/+RUDAJVTi9pKghiMEYf0IQdRAEiVS1BotC+YvoN7b75QIosE7dRk2dChxCYk1YgprgeB5CEFYP0IQNRSNVseJk6f48rPPadrIBvvGTXivRUt8fTdV2hO/BIKqRAjC+hGCqKE8vkIY4Nyfev98G5t69fnl53YE3r2HQqmyePkEghchBGH9CEHUYLR6A8uWLsO+SVNs6jfAc4wnSpXa4uUSCF4GIQjrRwjCwsgVSpQqdbno9AYePAzih+/+Ret3W3Hi1GkMxqRylxVzNAlqGkIQ1o8QhAVJlEi5d+8+586d59w5/zKcP+/PpUuX6dCuPe+/+y5+fke5cOFiqeXOc/nyFaJjYkW3V0GNQgjC+hGCsBCJEikyuYLfe/aiT8//n72zDqsibfiwb3xvbJeurrWrm7q6rrr9bq+1ZSuIgihiYKCC3d0KBqFiYQdKKgKCgQKCSCl5Dt2dJ+/vDxAVMGBlD+M+v73ua2XOnJln4Jy5Z+apAYwxGl0nY0cbozd0GP1//ZWxo41rvW5sZMTnPT/h8OEjpGdm6fy4BII7CEFIHyEIHXFnHKWhg4eQmZFR6w9wb1QqFbm5uQ98ff7cudjY2ApBCJoUQhDSRwhCR9wRxPChw0iu4w9Qn8ydPbuy+asQhKAJIQQhfYQgdMS9gkhKTBSCEDx1CEFIHyEIHSEEIXjaEYKQPkIQOkIIQvC0IwQhfYQgdIQQhOBpRwhC+ghB6AghCMHTjhCE9BGC0BFCEIKnHSEI6SMEoSPqJQitmvLiHAq1QhAC6SAEIX2EIHTEwwWhINrHkRUbjhFfAmjk7Js2kkkb3EgtF4IQSAMhCOkjBKEjHi4IJSH7pvLmM+0w3nGJ7BQfTLt+x/hVp0mrEIIQSAMhCOkjBKEjHvWISVmUQZS3I/OMjBjefyhmmz3IVtaWgxCEoKkiBCF9hCB0xOPWQfhvn0CPD35jV1j+A9cRghA0RYQgpI8QhI54pCCUBUR4OjBnxXZsrZezcJ0bmWohCIF0EIKQPkIQOuJRgtBkXGTqz13p0X8yS+ZNxnDyQVKUdTdjEoIQNEWEIKSPEISOeJQgtGXZRFx25+SRwzgeOo5vbHbdtw9CEIImihCE9BGC0BGio5zgaUcIQvoIQegIIQjB044QhPQRgtARQhCCpx0hCOkjBKEjhCAETztCENJHCEJHCEEInnaEIKSPEISOEIIQPO0IQUgfIQgdIQQheNoRgpA+QhA6QghC8LQjBCF9hCB0hBCE4GlHCEL6CEHoCCEIwdOOEIT0EYLQEUIQgqcdIQjpIwShI+4VRGFhwUMF4OPtjauzywNfX7JoETY2tkIQgiaFEIT0EYLQEfEJMuSJSfzcpy/jxoxhzqxZtbGs5L0OHWnTstXdZfesM9vSki8+/Yx9+/aTnpWt8+MSCO4gBCF9hCB0SIJMjru7B/Z29uy031mLXTt3sW/vPr76/As+6vxh5bJdu+9bx95+Jwf2H+BmWDgyeaLOj0kguIMQhPQRgtAxqWnpZGRmkV4HGVnZFBQW8XOfvnzaoyfpmVlkZufUXi8zC5k8kdi4eJ0fj0BwByEI6SME0YSJT5CRkppG3169+aR7D+LiK+86dF0ugeBxEIKQPkIQTRghCIGUEYKQPkIQTRghCIGUEYKQPkIQTRghCIGUEYKQPkIQTRCZPLG6n0RdgrjTRFbX5RQIHoYQhPQRgmhixMbFcz04hKSU1OoWTncEIZMnkp6RSWp6BiE3QomJjdN5eQWCByEEIX2EIJoQ8QkyEmRy9u3bz5xZs3Fzcyfq1u1qQYSFR+Ds4sosy1lYWVkTExsnHjkJmixCENJHCKKJkZiUjJeXN106deKT7j34uU9fPnz/A95/+x1+7tOXT7r3oPnLr7B37z6SUlKJT5DpvMwCQV0IQUgfIYgmhkyeSExsHJMmTqL5Sy/T8rXmvNW2HR3atadV8xa0fPU1+vTqTdD1YJKSU3ReXoHgQQhBSB8hiCZGfIKMpJRUHBwceLNNWzq0a0/H9m/Ssf2bvP3mW7z20sssW7qMxOQUcfcgaNIIQUgfIYgmSHJqGtcCAunTqzdtW71RLYg327Sl07vvceLESdIzMnVeToHgYQhBSB8hiCZIgkyOTJ7IbMtZNH/5lWpBvP7qa4wyMCAy6pZo5ipo8ghBSB8hiCZKekYmh48c5cMPOtG+dRveatuONi1bsXr1ajLEsN4CCSAEIX2EIJooiUnJhIVHMKj/AFq88iqtX2/Jl599juf586Skpum8fALBoxCCkD5CEE2Y1PQMFsxfQNuWrWj56msYjRyFPClZVE4LJIEQhPQRgmjCJKekcs7zPD0/7s5bbdths8OG1LR0nZdLIHgchCCkT70FERsXjzwxieSUVEEjk5qWTmJSMkMGD+azHj0JC48gLT1D5+WSEolJyTr/kv1VEYKQPvUWRIJMzo3Qm3h6nufcOU9BI3L2nCc+PheYbj6dQQMGcu6cJ56eXjovl5QICrouHsnpCCEI6VNvQWRmZTNpwkT6/PgTxkZGgkZmjNFoxhiNxtiw8t+6Lo+UGPh7f4YOGkyS6FSoE4QgpE+9BZGRlc1oQyP8r1yp9SYRkaaU1NRUhg0eUj18uq6/bH81hCCkT4MEMWa0MRf9/P7M77qISL0jl8vRGzpMCEJHCEFInwYLws/X98/8rouI1DsymUwIQocIQUgfIQiRpzZCELpFCEL6CEGIPLURgtAtQhDSRwhC5KmNEIRuEYKQPkIQIk9FylJCOLRzK8dCMquXCUHoFiEI6SME8YSiVapQazSPXE+jUXF3LRVKtRqNtjFLVjtqtZq7u9RSoVA3aDsatZqHHbFCqUbbyMemKknn2qktjPr+Y1q17YKhzfXq14QgdIsQhPQRgmhw1OTKbhF6K4vSwkgcHc5wK6vsnteV5MhuE5tedM/JWEHUuR3M33qamMwCkj13YecaSOGjvdKgVBSkEXY5iLAYGQWqe8rgc5BVSw5wKyWPxNCTrN57lfJ6b11F7OVjrFywh9DEfLQ1Xku5egIH11BKVXW/+w9HXUjM5WMsGN2Pru3e4I3mr/JS648x2hFYvYoQhG4RgpA+QhANjKIoCtuZM5m7xYtQr40MMF3O5fR7z4Zl3Dxlw/bTIZRWLyvnyjYT3v3KmKOBAViPHcTYDZ6U1d78E0mR/DIbTacwe/UOriSVVp3ElYTss+DTDgPZ5XedAzMG03+J8z1lfNyoiTy6kM/b92XLucQadxJ5nJykx5RN5+rcbklqDJdOH+b4hRDSS+tvx6xbF7FZMI5v3m9DyxataN+mHR3atKJ5+x4Y2wRVrycEoVuEIKSPEMQDo0Lm78Hu9WvZ4x1Gfo0rYUXebY5Z7cQrPIFbnpsYMnEV/hk1VipK4rp/BLn3nANjzmxm8KhdZCgTsTYyZN7Oaygb8SjKc2K5dvEq8Vll1Vf5iW5bMRu5mOCiPE7PHMwom4sN2na6z06mDLfkYm7NV/I5Pc2Q6VbnqwRRwg3nI5zwCacMKEkI5NC6OczffIjrKY+vJmV+LGe2zGXIl51p9VpzWr/Rtnq2vY5CEE0OIQjpIwRRR1SFueSr1OREXeHgljVsPXSB5LIaV7raAm6ec8XZOZBbl7bVFkR5AgcXGvJNryGs9ZRXL046v4sxw3Yg02RwyNSUJXb+VNSncFolRSmh7Fs6GePxK/GKL3nIgaTjvH4C//t8OBuPR3GndBmXdmExfgH+ucV4rTXE0NbvoXUJD0pOoCOzTWZwPg1AS2lBASVKgAJOm98rCCUJl85w8PRlshVaQIuqMJKTx88RlvyQ8tdI1vWDGHRrw/PPvkzrVm3uykEIokkiBCF9hCBqRlNClOtZbitqvpCPv9dp3ELvPhDK8tvFxLHLOHViMwYzthB2z4P8gD2L0dMzZpSJAYvPZ1QvV0S5MHvwSm4WpXJ4wjgW2115hCDKueXqiGtENqAhK8wHJ2dvImSxOK+dgdHUHdwuB015AZn59xc66ug6jIcZMXzoRBbvuXX3BZkLs2da4ibPwXudEaNsGiYI0rxYOH0qx+PVqFN8WT15Egt3+lCsLsFtuhGz7K9Wr6qKO4uDayDVOii7iuWwaey8kPrYu1NXFCO77sIK0/70fLstr7/SgnZt2vO2EESTRAhC+ghB1Iw6kX3jRzNn0z7c3T3w8HDnnOc1EqIvs2LML/w2dRsebu54uLlxbMsCJk1YzNET1hiMMmXjAWfc3dxxP7KRIT/8zpR1DuxcOZ1Fdicql7u5ccR6KRMGL+NmSQHnLKaxdteV2hXEahUledkUawBtDk5LDBk2eyN7rFZgOX8th53cOOd5njN2ixk/3hLvTMjzt8Vo5GwcjrtW7svJBtPv+jB1pS3WGxdjseYAHlVlOGO7kJGT5+CRVMT1vVMYu+tyHYKoIL8gj8IyoCKLoPNncXNxrTr2yu0471zGaDMLnKLicFlsjuVsCyZMNOdYfAo+c40YOX4Fp9zccXdzZ+9SI74fbobdscqf3V3sMftlOnt9kqh3QydlDoFnbJjY/zveb92CFi1aizqIJogQhPQRgqiVYrxWDqP5P5rx92Z/5//+9jf+/Y9WfNHnd/r92J2W//47//zbP/hXs2Y0a9ac/gvOEhdkT993/0OzZs3419//wb/+8S9eeO55mrdqRetnn+e5f/6jcnmzZjRr9gq9Zp+jnGLcFm3mqEc0NRuZluclcvG0L+lVL+QF76TXR+159Z//5Jl//Zv//uOf/PtvzWjW7Fn+N2oHSWooT73E/F5v8+9mzSrL9/f/47lnX6T5K61o3fx5nv2/f1aW4W/NaNbsBfpMciRbAyF7F2PtE13711Caxo2QAGKKIddvLV1e+i///c+zvPiff/Hv6u08w7dj95FdlMCGAR/zXLNm/O3N3qy/FIHXnIG0a9aMvzWrPPb//OtZXn7mv/z3H//gX3//O39v1oxW/RZxPadhTWwBNDnRuNgtYciXnWnz0vO80LobRttFK6amghCE9BGCqCPlObH4nPPAw92dsx5nOevugtPpM3j4+HLxnAce7h6cdXfDxf0CN5NLUBXJuerjjpubO2c9PKrxcHPD/Z6fz7q74XbOm5DUElDKcHHyJSqpdgPTbJk/u60vceeBkULuieXIhew57X7ftlxdvLgemQWApiCULSaz2X7UubJ8Hh6c8/DAw90Nd7fKf995n4uzD6ExeUAR/oeduZVZux6gJPo6nk4epAKKzFt4n9jM8B49+dVkAy7V+/cm5FYuoCXrdjC+x7cycfwEtl1LI+tWEN4uLnjce/z34O7ixqXIJCqeQD+JrNsXsZ9vRI+PPsVkT2j1ciEI3SIEIX2EIHQVTQUlFQrUdTz8L4jxYtWYVbiFxhJ7w5ttcyew8FBo7RWBkswozp0+yKqJI5m22aeeLaJUlBZX1NmZrTjyNHONTbC/JCc3Lx4P65n89O0oDkbUqpxBq1JQWpzF1cNbsJy1m8jGarf7sKgKiA29zq3Mu62ihCB0ixCE9BGCaIrR5HHt4EbGDxmC3vgF7HINJr/O7tZa1MUxOC6ditmC/cSWPsFuy8Wx2Jr3ptWrLWjf9n0+/rwf5ju8ya9jVUVeAu428zExXYJrZF1r6CZCELpFCEL6CEGIPDAFtzxZPmk4Q0ctxy0kidr3Dk07QhC6RQhC+ghBiDw4yiRcd+9gzaJ1uEVn67o09Y4QhG4RgpA+QhAiD46qCPmt20SE3ESW+/gd2ppKhCB0ixCE9BGCEHlqIwShW4QgpI8QhMhTkjISYyKIy7nbbFgIQrcIQUgfIQgRyackJYR9yyby/f++w8wxvHq5EIRuEYKQPk1fEBVp+F+PJq+k4T1u/9RotWi12hrDR2jJDPEnKELegHkXntKo0/C7GkZyzh9oG1WWjNe+1Rj3/YT2r7zAM827YLgtoPplIQjdIgQhfZq4ILREHV7A8Dl2xBX/ydOuNTAVydc5vmMxlmsPExBXULmw8CbLR45h/r6QRh3au/GipaK0iIKCsoYN6ldHUr03M3DUQrzk9RrLtjKqEm5dOMgs/R/58M3WtHrtddq3FmMxNTWEIKRPExcEhO+Zxm+WW4n90xrRKMiS3SI6paBBJ0OtohBZhDcHj7gQHF8101ruFab+MhyLvWFP7AT7Zyf52kmsNp4i8b6xMTQUpicRGXKd26k5KOvh8Aj7afQasZDAvHoUQlVKargvOywN+OS9N2nd4nXatm4rhvtuoghBSJ8mL4goR0sGzdneCIJQkxTsy4m9e3A85sqN5OKq5cUEH7dmveMl8mo81cqKuoiT8xXSH/GcqCh4P9NX2HE9o0oHedeYOcCA2fuaiiBUJASc44xn6H3TnRYnxZKQllNj8EAFGdEh+N8MIyomjdL7XlRy2/MIK6ZNYLGDR+05Mx6SJOflDDVfSVDO45c6L+wYRt3a8uJzr9K2dVs6tBPzQTRlhCCkjzQEMdeGhHufRFRk4n9iM5bmC9ntFFHdw1eZGcmxbctZYXWY8KyHT4ZclujFtO/f4rlmL9Dyne6Mc7g71lFxyg1cz9+8b7rMksRLrBz4JR07fMtcx+t1ThOqLUjAxX4hQ/73Hm0/HIdrXFWhi4KwGDiSOQci7+4jIY64hAzuK2VhNO7nAkgvB0VaJH7eAeSoFcT4nCVQVgBoifHcx+rNx4ktaPgjt4zgE0z//iM6dB7AVh9ZdX1JnNMaRk+zIjjv7oleXZCA1/6VjDMwwHy1PedDU+4vs7qQqPNn8QmM5d6ngBXpNzjjGU4pkB91Dd+rERRVFBB6zpNbhUpSXVcwZGr9BFGcHMrBNVPp9VFH3nitBe3atLsrCSGIJocQhPRpgoLQotbcreSNcrRk0CxrovIVKJVKFPkR2M1ZxDrbvdgvtsB4mA2xCgVKhYKSbDnXzjuzc9UMhvT7iWGWGzjpfpEIeV6tOQeUBSkEHVnMN53f5+PfLTgTnoWiajtRbtsYM3kvCeWV+yxPv86GSfpMs3LlypGlDJ68msDsmpXmZVzbP4s+hjOx276Sod/qsdrpFkqFAmXWZab3H4GlQwgVCgVKRSlXty5h7qIDyMsr96lUKKjIvcaiEaNYeiyUgjhPLAxN2OgRivvmCUw8cIX08EvsXbOUeRbT2egcTFkdjtBqNVV3KVpUKmX1MSkVCpRKBXm3PJg1Up9ljn542kxjyPw9xGRlk1OkoCAtkFVj9Ji63YvcqveUFeSQnibnoq05Hz33Em91+YL+w+dxKjgFpUKBSp2L20JLVu7ypUCprN5XcZwLZv2NsfNPITdgD8ajpuN4KRCHRWOY751EwSUr9GetISCrvp+PCpKuu7N+2lC6vdmWNi1b0a51OyGIJogQhPRpcoJQpgTheUNGWdVlaszxBXz7bis6vNOJrh90olu3rnR66yP0ZltzYvca+r7Rjnc6daZrp8581KUbn/X8jM+6daVL5w/p3vNrBhsu40JiXdf75QTsn8tX77Xktdc78FHXj+hatZ0P2rem+StteP/Odt//gHff/ZCfxm7C/cgaBs9ci6esxnMmTRrH5+jx7fd9GTLoN758/y3at+lIl06d6frBO7Rr0ZJ27d+t2kcn3n3jdVo2b0unqn107dSZrp0/4O02rWjX5m26fvA+b73RmjZt36LjOz2ZcTyQG4cW8dkbbXnnnY58NcORzBqO0hTnEXf9OuloyTi/iZ+/+IjuPT7l825d6dqpM10+6MxH771Hxw96MsxiF64HlzB0gQ2H7OfQ/b33+ahrVzq1bUGL19vR+c6xf9iV7l0/5pOPP+HzT77iq27v0vy5F2nV9p2qcn9Ax9eb80art/jwnmP5qNN7dGjVkjfbv8dH779Lu5atadeuPR27/MCqKzmUB+9h1iY7whs4tp+2Ip8wDwemDfme99q8QatXXubltt0x3iHmg2gqCEFInyYmCC2JZ0/gFZVU3don6dQqRvX9noHDhqM/eCgms9dx8KAdFkY/06NrJz7tPZiRevoY6OljoKeH/uDBjDZfg1d0PhqVEoVCVceMZSrSfPdiZjqbDVZrmDreCIPhelXb0GeUwSiMDUcxSk+fEcOGYTRuGfuO7mOZ8e/0bNeJ/rMPk1ar8Y0WjaqCnPhQfP0vcHLzYiYNG4zecH0M9A0YbWjE6JEGlfvQN8B4zDjGjx2Nob5+9X5HDNdn3IyZWIwZjcHQ0UyePAMz0xGMHLuRoMxy8qM8WGYykgG9P+cb8/2k1GgSlZ8Wg4/bTbRouHXSiimDvuP9Nm3p/OXPGOjpoTdUnwnTN3HokC0Wg3+ka9seTLLx5qaXA8bDhzFiuD6Go4wwHjXyvt+p3uChGE9aj1+qEk1OCNYLJjJ88LDqchuOMmT0SIN73qPPiBEjmTDTghmjDNAbbsIM82mYGI3AdMYeYhRaEr1OcsL5MgV/8BOjKZLjYbOQYV934pXX30NvmxBEU0EIQvo0MUGoCdixiPUnqh4T5EdgNWsxey7Iaq9anMzlC674pzek2jeb4/OXsnJrSD3fl0vASU+CQjPqP01mjVQUZJJdj0rduynn3Lp5LD0SRPl9b9eSeu0EC6Y5kl61RH5+E32+HIrtjdLam1Gk4Od4nkh5UQPK8EejIVOWTHr6k9t3XsxFbNev5UBAWvUyIQjdIgQhfZqYILRkBDoyc4w+o43GYzltHmscLxCX9/AK5/qnnCs75jN81HzO3Eir7NimBXVRFmlZeU9klrOHRZEcyK615ozQm4/TleTHk41WQVKQE2vMRjB8wg7CM2s3pSqJdmXyl5/z86iJTBmrx/c9ejDQ8hhZ0uhC8sQjBKFbhCCkTxMTBICanPibXPa9xPWwJBrQjeqxoiqI5+yeZegNHY7ekCEMHTmJlbvPI8srRd3IJ1RNeQEpibGEBUeRnFXymHcjGkqyZIQGBhOX/YAp2zRFXLGbzufNX6Ld/4awzP4s8gKpzeLw5CIEoVuEIKRPExTEnxkVBTmZpKWmkpaeSW5RxR9+dKTraHJvccp+NUu3nOR2tjT7bT+pCEHoFiEI6fMXF8TTF01uDOec92K9/RSh8fXppvz0RQhCtwhBSB8hCJGnNkIQukUIQvpISBBa1GqpPwBqOtGom8agH40ZIQjdIgQhfSQiCDUptwK4FFmPcRlEHprM2GAuXblF6VPsCSEI3SIEIX0kIYiylIvsd7xARvkfnBNCUUhidBjRGQ8Z+U9bQV72nYH71OQWFFFS9qTmoignI6cEzYNOyqoisgvvtNtSUlyUS9Hj1DNrS8gvLkFZj5O9Rp2Bs81uPIJTHv9N9UxxTgEVOrxTEYLQLUIQ0kfngtCWZXHjgg/hmQ9ouqnO4NSSBdj6xDewhVExty86s2PZHMxMpjNvyWpOReUAKhKD/LgULufehqDqjMssNJ7Kxn2BpKZcYNEyK85GFT9o4w+JmuzbFzly7BQevjEogMSLdpitPk3WA1qelt9ywmLqFNa5RZAW6sL6FRu4mPGo/RRwbf8mrI8HUKwGdXYMl30uEZv/aKmle21mwpzd3CqsvW5Jagz+zkc5cSGYpDpef1TyIp1Zvv4YCTqc6EkIQrcIQUgfnQsCRTYXj+zF5UZ6nS+XxxxlZK+ZnIoorP+2taUEO63DYNQEZs1dxnYHV27E3xnOWkW8zzH2HPUmveLuSUyT5ce0r75j3CZPQk8soffPk3BLakhHPQ1ZoWdYs2YdWx28yVEXctq8P70tHMl5gOkqbp9k6De9mLrHj4sOc+k9YD7BjzzsJGyMRjJjgzcVgDo3itMOezgbkf3oocVTz2PSy5AdF1NrvVSaEoHzjmUs2LAPf1lRveV865glP5ltJ7qOTtx/VoQgdIsQhPTRvSBK43FcM505u3ypa+CFRLdl9B04lwtpdV92q0vzyUjPoURRx+lQk8nhmb3o9NNkvNPqeLk4iRsRcorvPf8ro7ExGIn11TRyzm9k2Li5+D7yKv4BKYhg51JzFh/wp1yrwHvFSIatc+aBk+Pl+TNtyCyOBKcQeWIDxgbriHpkT8FMDk6ewHwrP9SAzNeBMX36YLRoPzGF9+9IU15CUdk9z6yKrrPgl1+wPBRW55YrSvLJzCxApQUUqZw96MCBc7GPNadFzOmF/GZuS4wQxF8WIQjpo2NBVBDisJAhfX/gJ/2p7A+pPbTnrUOz6K2/mGvZtU9LyuJYnLctYZzxMs7G1KUXDaVpQeyePRkj062E5t9/J5BzbSejJ6/nWsY9yzVJHDA3Yr1vIrmXtjHCbB4+dcjl0Snlqu0cBvX5gd5G83COyyVwhynD1ztTDpRlxhMcHE3+vQIoC2XFsFkcvJLA7TPWTNJfQ8QjJ7HOwNFsPPO2+FAGKHJTCPF0wSs0nsJ76y8Kb7Jh4i983d8S76SqjZaEML/fjxhsu1Jrq1plKudPOLDzsC/ywnK0qEiNDODy9ThK7/FOabaM0KBIMgrv//vcLwgt5XnJ3Ai4SnB89uP+Av9whCB0ixCE9NGxINScnz+FeYuXM93YlCnWgbUeZaR6rubn/nPwSrn/UlpdEM/JtWvZ53/38Uh5XiqRN2V1zPucg/O6eUxacZz4vHt7S2fhYD6WabYB96yrwXPDOGY4RZB7xQaDqfPxrv0E5jFShqvFJBYsX8nkURNZ4BjIpX1TGbHFnZL8TC7uXsFYA1OsfOLveU8eB0ymYeceRpTzdqaMXE34A6pm7iaDA5MmsHTn9eoliacdcTx9z0CEmgyOrZnJuPkLmWkwGP2VnpWTIRUGMr/fAJacul1jm1oyrp3jkJ0r8pRA7NftJTSrlMIIT+x3OiG/d+9XDzJdbxgGE5bh6HGdpIISNED8mYX8Pms/d6Z70KQAAaqjAAAgAElEQVRdx3btIqbNX8LarUe5FBxPVk4OhWWN19tbCEK3CEFIn0YVhFpdjPx2GhogN+w89quWsHzlKtasXMmqFStYtWIpkwZ8QdsX/sn/Nf+ceYdv13p8oUx0xbSfBcdv5gNaslPTyckuI/3SVr7/4EuGGluy0zWEQiAv+DDj+/7K+DlLq7a/glUrVrJ69TrWzTLi0269WOsZS07cFXbMnseylauxGNmbLp/8xozFleuvXDqPsUMHsuh8MhXhh5i8dBW+qbWfCSmLU4hOKQOKCXbez6qFS1m9ehWrq/e7GNNfP+GN5/7Jv1r9wLqzMqLcljB1jwchzjaYDNBnwpj+/DTAgHlLq/a93JIR3xizPyCJJN9DLDPZQEQdT9ZKZDHIcwur6lKyOGJuyK99R7O46nc6vu83fPPdMOYurzz+xRP780GHH1hxIoRbPvsZP8SKaIAUD8YMncmJsJo9rtWEH92E/jdGLF41hxGfjuVYeB45kc5M/L0/IybOZ+WKFaxYuJAFlhZMG9OPt159luee68D/Bo9nu2c0t1yX0avfIMwXLGfVipWsWbMea6sNzBzyGc81+y9tOnzGyAU7ufmgGvsnECEI3SIEIX0aVRDlBVGcuyAHivBYYUiHf/+L5559lhefe4FXX3iJV194iZYt29D+9Tfo0mciLvI6ria12TgtssDKIxbUOfj5XSAovoLSzGC2zRtJl/97ni/G7iAJoFyOw/Qfefbfz/BK1fbv8MpLL9G2/SAcb2aSftmevs//h2eee5HXX29Nh9YtafHiS7z6wou88J9nebPrJPzytBQGncLW4QhxtR7zaMkNu8DFFCXkBTN/cDee+cd/ePGZ53jphRer9vkyrVq1pX2LN+j2uwV+OSpij23B0T+SOF87+rV/jeYtWtGm+Wu89mJlGV/6z79p9/MywkuUJF06w/aVHtR+6FbMteMe3Ei4UwldwClLPd765795sfp32pr2rV6n+Ysv8uJ/n6dj976YGBnw6/df8NXXfTGcfooCINl1PTO2nCKlvKYA1UQcX8xHLz7Pc/95lg7fLiSwoHL52RUGtP3bP3jhhZd49cWXaf7yy7z2cmeGm2/B5bw7Z5zPEhCTQaz7Sr5771Wef+b5qt/HC7z47It0+Ho0Nic88HRz4XxQLMWN2MhJCEK3CEFIn0YVRHrgAda5RwOgKckmyHEB337al5VO15HL5VXIkCXISMnIQ/mAyttiuTc2jpfJSQlh/+H9eFaVV50djv2chax3CKBcpaYk6QrWC+aw73IMcpn8nn3IkctkyBNzqNCAuqKQdJkMWc115DJkMhlJKQWo0JIcGkxwYDy12zAV4m+/jfNVM9UVZt7CYdoAvvx+Jh4RslrHlpqZj4oybp69REJmCaCmNDcJr20WmKzYy42YqvUTEkjMKUJDBfJbV/EJzq3jt5HA3tWOBN6Z77osnK3z17L7ZGCNY7l//6Wl+UR6H2Dx1EnsCshGVZrIKbvDXImqu05AUZxLcoIMmSyBhMQMSpQKisJOMWXaLOy9I+/+7mQyZPFJ5NaoTFeX5pKcWPn7rF5PJiM5+yF9UJ5whCB0ixCE9GlUQSR7baTXwKns97zMRff9WPz2NT+a2JNU7w4NatJjb3Aj6iYH1s1nwiJbnM44sWeLNdu2OXMzLopzu9ZgamTApC3ePKlTkOaB5SzAdakBQ8ytuHDlMi67l/Bzz2+Ztu9hExBpq7anoTgzjiBXO6YZzuVIQF1NpLRV/9WVVI7OmoH5HGtOOp1m19p5zN9xlPhHVmbf3TZAVlQoN8KS6qivqR1FVgTOOxYzou8ATNd7UPOBlDYzmCPHzhOf07SGFheC0C1CENKncesgcoJZ2r8HzzT7P1q92YXfjJbiFp75h770JbKr2K9byKy5azl15XaVDAq4fHQrq21cSW2sCSRqJP2qPT93fpV//v0l3u/6I6arDhP9WBMbqckI92THsqXYuITx2Of1e1KWHsLe5XOZOn0+1scDyGvsUb21BQQc2cGq7S4k1VUnknydQw5nCEvVYZvWOiIEoVuEIKRPo7diyo5wZ/lUc5bbOBHbkA7JdUSZn0d6ShJZpbrrpYu2hBtOW5hqtgAH51Ae2dhI5E+PEIRuEYKQPo0uiNKkGxzbMJ+F249wLfEJnEa1BVzes4qZU8xYfvSGDk/MKhICnVk/czG2Tl48oB+fiA4jBKFbhCCkT6MLQqMopygvh5z8Qkrr6u1c72goL8ojJzuL3KLyx+rV2zjRoigrJi8rh/yikgdWsIvoLkIQukUIQvrofqgNEZFGihCEbhGCkD5CECI1oiUn5grOTpdIaUgNehOKEIRuEYKQPkIQIvdHk4vXurnM23CAGxnSrlgRgtAtQhDSRwhCZ9FQlp9DRloauaUPaKeqkHHm4AGcr8nIlkVx4fTV6rGN7os2j4sH9nHa9zbFhfF4+vhwM+XRTW41igz8j3pyK++eWwVtGdFuB7A/7Upo6v1NADS5kXh4ehOZC1BIqO8xnMJq9/V+8A5LCHPZwx6vcApLMvBz8iYiqQHDuD9mhCB0ixCE9BGC0FkURJ6yZ9lcSzafCaPOHgT5wSwc0ptfJm9j/5YF6E89SR5QkZ3A1Wv+XA9LplwLqGRsN+zH76M34XlqCwYjp+Esf3QT4MLgvQzpvxSf1PufJalT/Zg/zpA1fvd34iuNOsrIPsPZdCET1DGsMxrAhJ03Hn+uCE0mRy0H8KXhCs6d283oQeYcCa2HYOoZIQjdIgQhfYQgdBhteSHJoRfxCZHdN4T23SSzx3Q+dkeu4bl7MYMnn6QQKIo8zYypEzGfv4eofA1QhtfaiSxzCSLebRsT9ebgX7O7cx0pCNzFgN+XcSHt/t6F5dFnmNJrODtDalzdl8vYNnowY1a6IQs5xqgfDHGMqk+/9TJ89y1h5LYAcsIdGGYyF/f4xuvZKAShW4QgpI8QRCOlLOES29fY4Sd7SO/A/AjsZpphdUH+gBXyOG1hgdVuT9zslzKs6g4C1JQWFZKfnUV+mQZQ4b/TnImOfsgv7mfO1EVcrnOIJQVR7rtYYe1MogqUN/YyaMDyu4IojMU3MAp5lBfLRxmxM7ig1hZS3dYzbNRkZk0fzZB5x8ip12R7SoKPrGfU3HNkJpxmzLQVuMU1Xu9rIQjdIgQhfYQgGiOlMezbZcvKBYuYteYsWTU7a2hKibnsznHXU2yaqcfY3Xfno0jzP8fFmJzqn/1XzsPKzoUzNkvRm+FSPTRHaXoI52/cXS/6zEJG77lAStBxlsxfUudc1pqMq6ycYcmUsWZYrHHiuq8D+kPXcrXqKY/6liMj9Zdy5rI3a8xHsdKnjmlgVbdZO/J73nm7D9uD6j/5j/zsLsZMcSYrzYvxFutwiXlC3evriBCEbhGCkD5CEI0QTZIHxr0+pMUr7fn8x2XcqPEURpXhz6Jf3qNl974M/+0bvhi2hLOBQQQFXsTKuA/9zbdwMTCIoAB/9i6Yx06nC7jvmM13A1fiFRhIUOBVHBaO4Cv9lXgFBhEUGIDz1nnMOh5IUsBRls1bxpWcmqUqxXeHOaOX7MbvpA0mM5ax3WEzg/pNYpvrZYICA7l62gqDmbb4Bl/Gbq4Ze8PqfnwUccCC38dYcbvWxb+W0uwkbl69RmBgEEE1CbjGmd3rmb3Sl7xEd0znrMc9rvH6wgtB6BYhCOkjBNEYqUji1KYFGP76C7/1Wsb1GrOhqspS8N61numGhpiYmDJxnCkTxpkywXQCZhMnMXnCBCaYmjJ+jBEms+y4kV5KevBRpo4zwdRkXOW6JuMYX/Xv8WPHMGHiWi4mFZF+w5ujDq6k31dHrSHv+hnmTDDGyNiECWPGMW/bGaKjA7FePI0xo8cycfx4Jo4zZ5vbTTLTonCyPsCtB1zca/OjCYzNQlWrG7uGxEtHmTvKCJM7x3QP48cYM27aQk5EFlER48n2467ENl4jJiEIHSMEIX2EIBoxCeesmb34FJn1GG1VqSqjpF7P9e+NloK8LNIzal6VV+C3chl2h67X+a47KS/IIq9ChaI8j6TERjxzA2WZGWTnFtCYwy0KQegWIQjpIwTRCCnNuc2JldMYOmI6p+OKHv2GqiiSLrF57XxmzXck9omO4V3OhcUzWbHJnQed9ivk/tiunMoYk+0Eyp6OsWmFIHSLEIT0EYJohKgrCkmMDCNSlvv4fQQATXk+ibI4YmNSKH4iAxveiQJ/q7XYOV564GRKmvJCUhPjiAqTk9fwW5gmFSEI3SIEIX2EIP4SURIXFEpMQna9hCX1CEHoFiEI6SMEIfLURghCtwhBSB8hCJGnNkIQukUIQvoIQYjoNJnBp9m26RBhuX+kzkVLRpgX9hus8Jbd7ZwhBKFbhCCkjxBEk46GstInM2ueuiyfzLxialY/a7UaFGV3xkPSolCq0NR7h1pKSitQqetTw6EiLy2Cwwtmsdz+OGFpDZt8ojg9Cuets+nV7W3e7NyLbYF3B6ESgtAtQhDSRwiiSScb521rWbPtLOmlf0wThTePM2fWRi6n3j84niIrGKupc9nreYuk8DNsPOBBfUfgLrx9huX2biQXPrqMipx4/I7uw87els2r1rB5/Wa2HdiP5+3a4z49NCXpBDhtY1y/z+nY4nVavfIab3b7BZsgIYimghCE9BGCaNLJ48TU3/n8l8XcyP8jXcrUJPrsx2L4EGbY+JF3z6ZU6X5Y9v6J6XYeeKybyOAp24iv58X8DftJ/Drblkd1nyhP8We1+TQmj5/FJvvjBMbno8gOYJH+QOa5Jz7m3kqIvnyMJeMH0v3NlrR6/Q3eateeN1u2omP3X7EVgmgyCEFIHyGIJh0NgdbTmbHlTHUHt4Y1U9VSkBhDxM0grt6Q398XoiQGh3kTcYjO4OYGc8zm7ie9njcrYXvMGTR/J/IagtBq7y9tkvNC3u3Yk+nH46uXKVO8mdtvGDuu5T7GYeTiaTubrzq05JUXX6FNm/Z0bP8mHdu/KQTRBBGCkD5CEE08EQcXMm/7CeITo3Gznsfg38ay9dxtVFXnXm1BBIcPnyZAVoJaVUGF+t6TsprcDDnR8ZWDKmVFJ1KiUZKXeJsboUkoAMqT2Ld6Agv9ZMiPLsVi7QFS6jnTaG1BKEm6cpBJBgZMWu3JnYdHFfnRHFszgS96/sYqlxi0gDYviDWj9VnvW8fIsbVSQYzvPsb3/YIP2r5B6xataN+2vRBEE0UIQvoIQTTx5PluYfLcOWzZsJcL18Pxd1rLkMEL8EquWqHQj0l607DzjuaaixXLXO//Y8a67mCS5VHy0XBh+Sw2nPTn4t51TLY4QqU2KnDfZcFsz3iSz6zAYv1+kmo8YtKioqy4HO0Dbl9kR2cxbJkjd+aGS3R3YPMuJ676nWLR+BPcP2echqu7ZvDtT0bsupyCojwaq2l6zPd43EdMoC5K5PzeVYz4pgcdWjbn9ddb077lG0IQTQwhCOkjBNGkoiYlxItzV0KJCb/MMdvtzB/1E59+/TMzV21n185d7LFbQv8u36I3aTl2tjbYbJjLiBlbuCDPItbHHlPDGWzeboOdrS12trZYzR/Ld90/Y9zyrawy7cPH/QyZOc6IQV/rscLWFpttG5lnPptdEdkkHFvF0q3HSa/R1Kk8P5Kzl+RoKCf6kht77PZw6MBedlXtY9HIb+naewSrtm5n+05bFpkY03/ABFZsXMG4H01ZZWNbXZ6d9rvYs2Uuvbr2wGCjD4XFMhznTsUx/PHHrLqT4oRr7F5uRq9uHWnx3HO06fqzqKRuQghBSB8hiCYVFYnX3DjjE0RUiDd7N6xlo9V27HZsx3rTRjZt2MCmDVuwsd3B9i2b2LhhAxvXbcXpcjQaoOC2G7MMJrF07To2rt/AxvUb2LzZGlsbG7Zu3MAW6+3YbbPG2morO3ZsZcv69axbvZ6dB/zIRUmEhxt+/nHUfMKUdm0/1r6JoCoh9OxezPp1551Pfmfuqsp9WFnvwH77VrasW8uazbvx8LuCi8My9Af9xMDx89m8fn11eTau38Cm9eux2uVMeFo5ytJ4PPa6klje0EFAlCRcO82K8b/z6Sc/YyOauTYZhCCkjxCExFMsv8rxUyc5dGAn80aZsM49tYFbUlFUXI6yjkFkk3x3YLr2OHFZeeTILrF+jAkLD9x45Bbz0+KQP2JGUbWqjMKiJzA4YGkG4YHXSSy4ewBCELpFCEL6CEFIOJrc25y2mcNvwwbxw7c/MnmNU42Jgp5M1GVyjq+byZAh+pjPW8sR7ygKK5r+sH9CELpFCEL6CEFIOVoNapUKpVKJokLxRHpcPzCaMnLTsyksrWcTJx1GCEK3CEFIHyEIkcdKzu0LbJ5ixtK9riQ2bFSMPz1CELpFCEL6CEGIPFaK06LxO30c1ys3yRaCEDwGQhDSRwhC5KmNEIRuEYKQPkIQIk9thCB0ixCE9GmQIIyNRnMjJOTP/K6LiNQ7+fn5QhA6RAhC+tRbEFnZORiNMkR/6DAWzp8vEDRZJpia8kvffiQlpwhB6AAhCOlTb0HIE5Pw8vJm+7btbN++QyBosmzbug0XF1cSZHKdf9H+ighBSJ96CyI2Lp7k1DQys7LJyMwSCJosmVnZpKal6/xL9lclI1MIQurUWxACgUDwOAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiBQNAoCEFIHyEIgUDQKAhBSB8hCIFA0CgIQUgfIQiB4E9EJk9ElphU+f+mRmIS8QmyJ3asQhDSRwhCIPgTiYq6RXDIjSZJeEQksXHxT+xYhSCkjxCEQPAnIE9MIjwikt9+/oXBAwaiN3RYk2L4kKF889X/cHZxJS0944kcsxCE9Km3IGLj4klLzyAnL5/snFyBoMmSk5tHRmbWE70qbijyxCQCg64zeMBAioqKKC8vb3JMMTPDYbcD6RmZT+SYhSCkT70FkZySyqFDh5lhPh1LC0uBoMkyw3w6drZ2yBOTdP5FuyMI/WHD0Wg0tb5wTSGWM2eyZ8/eJieI9IxM0jOzKv8vaHQyMrNISU0jNi6+/oLIys7BQH8Es2bOxPHAAYGgybJ+7Vr69e5DYlLyE618/aOCUCqVf+Z5/7FjMWNGkxLEnb+Z5UwLRgzXw2ikoeBPYNjgIWzZvIXUtPT6CyIjKxtjo9GEBAf/mZ9dEZF6Jy8vD/1hw5HJE4UgHiNNTRAJMjlRt27T56deeJ49S8C1a4I/ga1WVhjojyAzO6dhghgz2hg/X98/9cMrIlLfyGQy9IYOE4J4zDRFQURG3UJv6DAUFRW6/vX8ZRIQcI0xo43JyMoWghB5eiMEUb80VUEMHzKU/Lw8Xf96/jLx8/UVghB5+iMEUb8IQYiAEITIXyR/NUFoVEqUSnWD3y8EIQJCECJPaUoL8yisuHuC/GsJQkX8NRd27vYmu4GtaIUgREAIQuRpS2k6V45swlhvOAucYqoX/7UEASVJQZxwdCWuuGHvF4IQASGIRoiK9PhUCsoUj1hPS3G2jNiMyhYZ2jw5cRm5VPyp/aY0FGSmkJhcWFmGikzC43LQ1ns7Woqy05An5tf9siqbuOQ8/sATj8dIOdGXT7Jy4gC6vPEqzzT/kFHbAqpf/UsJQpGJ27KRfPJBHza6xtCQPTztglAXJeHreY4bqQpQZpKYmUN51eczP9qf8xcCyXxgYyklGYkJJKYVNWTPJAV44hUUS9mDvmilqYTFJVJQ3oDNPyKawgTOn3Xi+PHLpBc/+gspBPEkoi0g8PhedhwKITXWGcv52wlKv/evW0qk51FOXZWhql5WxtVdU/lWbzZnbsZyccsMLGw8Kaj/2fmxUiQPYPei9dgedSWm8M5OKgg6vJRfvzbj5NXbXD6ylNEr3Kj/RaeSMKc1/PalCQd8ZdzvuFKu2S5i0U4/ShpJEAVxV9i5cCzff9SRVi+/Rts3WtK8fQ+MbYKq1/krCaIk0gnT4RasXjqDSXO3cOMB3n5Ynm5BaEm9ZMMEy1W4BEZx0XYV63b7UlD1wS2+7cN+hxNE5D7ob1OKn81sBgxYgK+85IF7KYq/ynGbNaw/6ENi4Z0Pv4bkS8fYfdSXTFXdX/bsy9vQH72I87In35xXWxLPmSMObNu0j6DER3/ThSAeK1oUpcUU5OZSWK6g5kV+WXYwVjMXsv3ENULc1vC76XIuZ6juWUNDesh5znhHUFa9TEXw3ll83m8BVxNusEp/EJOs/XjUfUdDo8hPwHPPLuz3niAkqbjqLkFD1JEl/PKlKc63b7Nv3C8MXneuAVecWuLPrOW3Tw04FFZU4w4kj+PjhzFl0zlKq/ZZXlRIcZkCLZAXdYndi6Yxy/o4Edn12bOGitwEztotZOA3H/NWi9do2bI1Hdq/Rcc2rZ5qQWi0apQqLaBFUVJMYX4BBQUFFFaREuCI4bf96P/Tp/QcNZcLafXexVMiCBWlRYXk5RRSobr/W5sTdpaDZ6OoqEhmr+kYLNd6Vl8YFSff5MyB04SlP+jkryHU1px+v8zAL131gHVAmR3DBdfDOLqFkFN+Z/9a0kJ9OXHUi6TyugVRLnNlTO/hrHaJfczjrF9Sgn05c8oL2WNcsQlBPCpaDWqtkuhzB1hkMpq5uzxJrXHrpy5LxffIMS6GyYn3tWbwxFX4Z9z/wcmN8mHvruOEZNx9c7zbdvRG7CRVm84eExMW219tgCAqSLwZSFCYnEfdkRYmXGKf/WEC4gqrT+IpnjaYj15EUFEx55aNwNDuYgMeMUHmpT3MGGmBb3bNV/I4bW7IdKvzVYIoxn+fNdYHfcnXaFEXpBDq58TBE+eJTHvw1VjNFMWexbJfD9o3b0Grlm/Qvm17OrZ/s5KnWRDaCtITrhOYpEaTe4XpfT+hQ7t36NrpXd5u154O7drToW1rXn/u/2jW7L98P9mBpAbcpEhfEGpU6nTcd21mlulCTt5IqfF71FZ9znM5MmUCczd6UQpoyxI4uHoKA38aiLmdD3nKur8NcpcNzFluRxJQkRFHgP8Nkgtqy6Iw9TZBAVHklFUKQpF2mVVmoxj4myGrXKOpWy8p7BpjwnKHwAZcrJUiuxlISFRKneeSitRLrJw0koG/j2adR+wD9n83QhAPi1ZLsSyeNKUGdUk20TeuEXA9hlylkuKSfLKqPxClhHscwWrjSQK8tzLMbDVXM+/auSzOlak/96Rd50+YdCiqenma337MhloTp0jD0XQci+38edRNpSo/g+yyqm3nxXPV6zTbl05lUO8RrDoeXnUSrp3y1EssGPwVb7z+FdM2+1d/8HIC9jFrynwuZRZyfvUoDG39at0hPU4KQo8yd9IMzqYAmkz8Tp3EJzIXKOZMlSDu3D0VxV/jnO8NchVVX768a6xfaYfP7cLH3l/ebW9Wjf2Fzm1fp8Wrr/NWuzf/EoLQlOQQ7ulOpArUSZfYstyMfh+/z7vvf4+xmRlTzMyYOnkK082nYDZxKUe8az7ye7xIWRCq4mwifYPJQEtJRhpxUTeJSsunKC2J2NiMypOipoBA96O4B13n8Ewz5m3yogLQJLgyY+xgRpuOpd/gVVzNqvsUmn1pJ/OWr+CokxtHrZYwoldvBlvuJPKex1JFGTI8d6/B9PfhbPetPLFm+2xkxEh9TIxG8fsER+q+uSvEfeZU1u+9+siLvvKCZKKrLqyU6WG4nNjNmmkj+fGrIaxxvk25qpDosEQKq75rGV7r0Rupz1jDkfSfdIjMR2xfCOJhUWfhbWWDX3oNF2sTObBhERtdU6sXFV5zYLyhBfsdNzJqxmZCqy+GM9g1y4xJS2yw3boI26CC6vdU3HZl3uCFBOVncHLKBJbaXXn4B0Kbh+eGWax3CSMvS841bw8uBMZQBmR4bcfUZCH+eVCech1nr8h7tlWI84LJTFtgxeYNW7A6I7+7TbkbMy1mcjI2m4vWJoyy9aNBVQVp3sybORnH20VkXnRk5awZzFq1i1uF+ZydORpL28vVq+ZftWfOjjN3P5yKEBb+NhFrt4T63b0oMrh63JqJ/b+k/WstaN2qDW+1a/9UC0KdH4nD7BkcCq86KaRdZs6vvRi78Wq9tvOoSFkQxYlXsZ1gx30PaDTpnFxuidmM/VTe5BZyau0MTFYdYPesqSy0ulgl0gKunz2I1WoLDMfvJDK3bkGUXN/HtCnjWLHViZuyHEpz/Jkz1IRVx+Kq1sji0KLJTJq+lAWTF3EsNKfqjXLOHbVn+dzpTJrnSt3VQ3m4zFjMntPhdVzhaygqyiG9Sgrx56wwnrkLHz8fjtju5MiF62SXlRKwcwlmZjZEZwazYsQCzkZXXToWJXD2iD3L5pgzaYE7BbW2f3+EIB4WbQr7xvbj6+/6MXzocPSGDmHECAt27t+J+aDPebf7T+gPG47+sKH0/6EXI8y24n12B4O+68n3vwypfK3/D7z/1of0GWmKyS/f0/u3odXv+e2Hnxiotw25shSv2XPZeiCg1h2EpryIxIgIMlUApVy2n8oPA4cwvNdXfPa/Pow0NMJQX49h/X6iv+F8ruZDrr8Ng774ll9+ryrD4N583O59+gwdi5F+P77tNZARVWUY/OM39DNZSVCeklDHmZgfDKh9xakpIEEWS1I+aFIvsnjMKEboG2BkoH93Oz99S1/jZfgnRGKt348fvv2GL3rrYRMajzJmAzEAACAASURBVM+c4XzZ9SsGDxuO/rDh9P/mIzp80INfBlb+rDf0Z779fjqnQ3Mb9GcqSb/FmW0LGPBFJ1q3aEnb15vzarseGO94+gSBMo0j8wfQ9Yu+GOgN5+f/9aTnLxZ4pzzZym4pC0JdJuf4wskMGW7IWOMxmIwZwxj9/nzbvSsfd/8efeMxjB01kqEjzdjmG4b3KjP6fd6bkcZjMBk7nmnTZmBhNoYpNt4U3FeRrCUz3IO1E4zR+/k7PuvxBYOMJjBl4gQmThjDgK++5tvvBlTuc9Rgvu76Nh3e7Mg7737NYANjTIzHMG7cJKZPm86UyZNYfvrWAy6IsvA+5EV4bB2nb00RkTe8ORtSqZaSGDfMPv+Mjz/+mM/+158JZpOZZDIGA31TlttfoUxdylXrGfw+cBijjYwZZzqJGdPMmTzZjJVnoh/5ORCCeGjURDmt4PtunfmwU2c++vBDunXuyXf9+jN0xFD69exKl85d6NbpPd7+4Hss94aRHX2C8b9054P3OtHtwy506/IxX3z2WSXdP+GTrl0rl3d6n/c++obJ+8KBLE6u28f5gLRaH5jCjChcHC/dNX2yOyN6dqNL56588vHHfPxhF7p1/oB3O37B+OXnKAFQJbBD/2vee+c9unbuQrcu3fjss8/54pPP+PLTnnzSraoMnd/nnbe+xnyjH+WouLZzE043U6kZTZaM69euItdAxoUt9PusE21ffoWWLTvQ9c7+O3zBxFU+VKhzOD5nBF++/yatu//KGp8orlqZ0+v9d/mwcxe6fdiF7h9/wlef9KRHly50+/BDPnz7PfrO3ov8DzXrU5Ede5kdFgZ89e4bPN/ifUY8pc1c86NcmNLvQ9q+9S1mS/YQmFzYoHqjh0XKggAoL0wjKuwm4WFhlUREERMXT0JcNJFhYYTfvElUXDIlGlAWZJFwK+LuumFhhIVFkZxX+4GtoiiL+IgwIqKiiY+LIzryzvsiiI6LJTY6qvLn8Ehi42XIZTJkCbHcjgy/u/2bNwmPiiW79EE1AGrKFSrqnCqkIp1zJ23Yc7Pyc6PKDmXXzKU4Bd0iNuZ25bGF3SQ0/DZJOWWoim6zb95ctp7wJezmvfuPI7vsUTUQQhCPFZVKhVKpRKVUoVQqKC8ro0KhQq1SolRWoVJXXXlrUN27/A4KBYqay1SqyvcoUwkKjSa9oPYnIvv2eTYucq088aMi+twOZsw5RnJZze1XUFRQQEFxEQl+u7Ew3U5Ybnn16yqlEqVSgUJx5993UKPRAhQReSmM7JLaJ6yCMC/2bN7FnW5n+WHHMf7yB6baBFFavZ37P9CKOM//Z++8o6K63r+b9/dNMZqmsYGIJTHGVFNMNNYkJrGb2BHsXQFBsffeEHvvHRU7FqyoCNJ7L1PoQ+9lyn7/AEEFFRADY85nrb2WzNy59844c/Yt5zyHxdPncjI4E7VK9dQ2S6KqtBYuk6Dbh5k2fgJrroUXPfo6CQIy8Lx2mFXzLbnoLq10OYD2C+K1jTIRuwNLGT13KzY2ZzmwfRMbjrmXvCGtTsX94i6mGvZm4NyjRFbwBFMIoponJ86dbRNMmTF/OatWLWfOjLkcc4ssZUkVKZEP2bFgMv17GLL5VmiFbk6WllypHRYD/8Bw1mb271nD2B4dadt3Lk6lXBFSZsTidvUAs0aPZdb621TZT1mVR/5jH8BrJQhNOn4ONzi58yBXPULIegWGEIKovsmP9+W45RymTl2O9XUfSu/aoUb+0IbVq3fjFJld6hJliRBEtY8KRZADx7ZuZuuhi3g+7z9bnYzHtTOct6/Y6Nln70I69jsn0/KjN3n3/a8YMGUFFzxjShWQMlOB100bjpy8hewVjAStaF4rQfwLqYggIiRSIiRSIYjXKEIQImVLWihnd61h8bL9T40S145URBAREinyyKhKn8f63xWEmuz0DHLyy3c+WVZBhEdIkMkjiYyKJjxCQlBwCKFh4UIQr0mEIETKllwZlw/sZeMySy76x1b13pQ75RGEVCYnJi4eqUyOm7sH7h4elXrW8e8JQkWS/zWWjprBkXuyct2reJEgJFIZ0bFxREbH4OcfwNWr11i4YCFr1qzF188fiVQmBPEaRAhC5D+RFwkiPEJCZFQ0cfEKAoKCsLE5w4IFC/m7b19Wr16NPDJaCwWRi9uhXaxfc4CH0Y8VllM9UoWGtLQkYhNLDs8sTRCPzhbiFQmER0i4cfMWGzduYpihEV+0/Jx6H9VmyqTJBAWHvJaCUKbL8XjgQVT6K606WYXJIyk+hriU4rNNIQiRKk4uAddOY3PFnYrUxiw1WZE42F3kblhxP/LSBBEhkSKVyYmKjkEqk3Pr9h1WLF/BMCMjvvy8FbXf/4Ameo1Zs2YtkVExWigIyIoK4MKuNey9HlhwXypPzskNq9l+1oOU1CC2r1rEeltpidc9EkRcvAKJVIY8Kpro6BicXVzZuWMn48eNp33bdjSq3wDd+g1oqtcYnXr1mWpiSmhYOPLIKCRSWREJiUmcPnWaWu/UYOfOXSSlpD7x/IuQySMJCAyqUkGEnNnMbIuVXA1+0fAybU0+cYF3OWnnjLywh68QxGsbDSqVshK7j76CaNQkBz1gu/lkluy7SVzOyx6Z5SJ5eIa5Rn/RsuX3jNrjUfTMI0FIZXLkkVHII6OIkEhxc/dgx46dGBoMpX3bdug11KFBnY9p2kiPpnqNadH8E6ysNqBISEIeFf3SRBbi7OJaKIiCvujq/FxycvNfQZfVNGymdOeLL7uxwSEOcj2Y/OcXtBqyHmdHa0b/0YdV9xQlXmUxbRr79x8gJjYObx9fTp48xeQJE/mtcxdaNGtOvdp1aKyjS3P94hpYuvUbYGpsQmBQMBESKaFh4UXExsVjfcKaWu/UYNu27cQnJD7x/IsIj5C8wjOIXPxtD3Dspl+JSgbqvHSiw725cmwXS6dMw8r6Im7ySjuUKVeSfO9wxSmAtKeqwGbHSvFx8C1lVLYGlVJJfr7y+d8rjRplfj7KfDWoFdhusGKPjT8ADnfvCkFUi6R6s3vjEex94sirjFYiL447Nvs5dl9WypO5+F84yqlb7qTmKskJvMXZ6/eJrkB14awoFw4dvkVsGRt3TU4KUeE+3Dl3gt07d7Bly3FOW29gqbUDMSkvHrhTelQkRziya/4Yfv36ExrV+Yj3G37LiG0uRUtIJBIMBg0mJCwch/sPOH78BKamprRt8xOft/gMnXr1adSg4RMN3iNBLFy4CHcPL5weOr80jo5OBAUF4+bugcGgIWhQkSZxYO3kUYww34JDaNILC6iVL0qi3a+za5EpQ40WsG3rcsxmLudKcAKZEdcwH2nEZteSHSVnTrdgx/Yd7Nu3n7/++INPmzajXu06NKxbj6Z6jYvrXj1Gc/0mtPqsJd9/25ofnuLH1t/xzZdf0ayxPl+3+oIfW39XYpnn8eVnLTl48BCjR456BYLIQ+Z4iSMnbhH16MenSsX9ymHmGQxm1MRZbLe+ia+/E3sWTWb2Wf9K3n5Zko/L9kl0+GMYhz0TH3s8kzs7ljBqxvkCQWjySUuIIzkrH5TRXNhlxVzj5VwJLHkQ8Cia9EAOrlrB0gU78MhQIT+zikmzNyNXgfODe4wRgqj6aOJuM75DO7qbHieuEloIVWY8D212senwFUJTn268kzk3ux8//zqOm9JIri0fywCz3RWo+qnkweZxdB27hfAXdmzSkBnjz8nlFgzv34v+A8djeewaXpIkIq5sZtjMjdyrQLmIHEUol/csYcAvrdDX0UFPpxHNGpVei2nYUENcXd2YMH4CrT5ryccffsjHH36Evm6jUhu8R+jr6KJTr36lUOutt9m0cRMhoWEYGg5HleDKdsuV7L0diUajIikipnDQUx7hrve57y59bBCUhvysFFKzn/z/zE1VIJMoUAN5iXLCFBlolJnERMmJLxokkcnN9UNo1PIfttoVVjaV38Bi/HA2Opc89pwxbToHDhzE2cWVpUuX0atHD77/tjU6des9UxLNGuvzQ+vv6PFXN3p26/4EvXv0pEuHjujrNqJDu1/o07NXiWWeR9cuv3LC+iQjh48oEoQmW4GvdzCxaS9XJF+TFcbJjWtZOHsN10IKBvdkex2g64+dMd7vTHZ+PkoNkOPDyj69mXMm6FlrIjslC6XqyR5juYkRON+/wz0XPxTPKPFd6tqU6cQnPhrNrUFqZ0lPsz0EZz6+/gxs106jn9mFgnLlqkRu71zB1kv+KFGjCA3Gw9kRT+nzJgJTkhgeyIO7d/CKzSPLaw8D+ptyLVLDQ+cHQhDVInkBbBhowIqzAS9etgxRKgI5s2YGZks2Yev9dA1uNa4HTOk725pMTRInZoxl1FybCgxqU3LfajRdx28l4oVnH3k4bZ/C518OYq/LkzUkfXeb0bX/nFIH3j0r6uw4XM/vxrxfR5rpNEC3YaOCQn0vqOYqlcnx9vZh3/4DTJ44iT9++x193UY0+LguTRs1fuIMorl+Ez5t2ozePXthPtUcU2OTl2b82HHYXrLF188fo+EjyYuwY8GkQYxZsJWjB/ez9+gZHshSyQi/y475Uxk9aR5XHhsXGWC7njXXJE9+GDEOrJgyj8uxgPQ85hbb8ZEFc3zdElbYFBSPy0sOxvHhXa6cv8DF276k5oM66jazpozE6mHJ//lH9yAUCYlEx8QSFBzC+fMXmDHdgj49e/Fps+bUr10Hfd1GRZ+Zbv0GmJuZI5VHEhevIDomtoi09AzOnT1HzbffYc/efWRk5zzx/IuIjYsnKDiEQf0HFAsi2ZPtq/biICuthnEG7hePcvi6zzMrHBd9lzITCAvyxS8omIioAllmhdkx06AL33ezwC68cA25gWwdPpgVtmGlr0gp49CcFZx2eqwRzZOzd1JPmtXRpcX3fVlmE1rQUOdnERMaQHTWM7of58VwbrMFxpvvFldedtrHoLG7CVFBjtwFa2s7IpJTuLFlDoOmXSy6h6fKSCIyKqH4cplG9YJLl+m4nbTCePIsTnink+t3gIFdxnA2OB8nF0fGCkFUh0RyaNQw1lwMAU0S9w9aMst0LVcDylnALicSF385OSoNaWGePLj9EHlGJtEeroSlFB/mB55bRJ+5J0kjk5tLpzFt7mlKTOXwwihx2DiWPydsK4MgVMT6nMPMqD/jVlg/UXdJcnYx/U1W4FaOt5rgdoRBn9ej5ru1aayn/+TR7AuquUplcmJi44iMiub+fQd27NjJhHHj+fbrb9Br0BB9HV2a6jVGX7cRLZp/wuYtW0nPzCYhMemlSUxKJiY2ruAexJBhoErEbu0I9N98g/974w3e0u/EJocAri6ZwD99BzGoZwd+GzCWGdOnM2O6CQO6tOab3wYxbfr0wsemM9N4OF1af0HbXmOZZWrILy1a03PAYP7sPJCZBwJAJWXn+H50GzCFBVMG0t1kLS7JQKoblkunsr2US0xP92KKkEiJio4hNi4eN3cPDh0+grmZOZ3ad6Cxji56DXWoX+djTKYYExwSilQmJzxCUkS8IoFTJ08V9GLasZOEpOQnnn8REqms1HsQOWkZJMgCcbzl/9hkXNmEuV1iz+4NTB+3mDOOkSUqFKsyonG9bEd40YuyCPWM4PFhqOpEPzaO+Ysf+y3EUZoN6hgOWgxi8jHPZ3wrU7FdMZ5BM62Je9TuZ4ZxcK4RrZu1oEWbPiw4HVHweKIbqyePZK3D0wW31cR4OHL9/Dn2Lp9M78kneHRxKD/wLCMMd+IVFca9c1uZP3c+m2zvcNpqHoYzrxQJIT0hFK+IR7pIwHb1IrZdC3qGJNSEXtrNHGMLVq7dxp2YXHK999J/8DRuRKlxFmcQ1SXZXF82AbOlWzi6+zT2zvc4ttSYv/vP5W5M8X9tqN1BDtwOQokGVb6y5GjmWDtMRy3ndrSKXL+zLJizHjdFNKfMRrP4sSOfRIdt/GNyiBjSuLHEHLO5pyogCHDdNoFuk3fz+MiI1HBXjq0zoX+vsWw88dQZUZYv283GMtPqKvGFk7HILy5jgOlyXBMpc3JTonE6t43xPdrSQrchug10adr4xWcQj/diCo+QEBkdQ2y8gsCgYK7fuIml5Xr+7t2HT5s2Q1+3EfqN9Fi9evUr6MXkjqHRcLKlDuxetYgNx6/j7OyCp18YaTmp3Fw3ntY6DdDXb0zjhjroNdRBr6Eun3zyOV82b1L4tw56DRuiq9uc1j+25+ev9dFt0Jz2HdrRskEDWv42mWuyfJCepd/3n6NXrx71P9Clm8VBopSgivHgxJbNOCaUPIp91jiI8AgJ8sgo4uIVhEdIuH/fgb179jJ61Gg+++RTTI1NXnk317SMVLKjo5DI4gq+P7d2MaG/OZeDFSgUCuRuZzDp04fZNne5vmYOK3ZdI+Wp1lEZ584Gs3FYXgtGoVAQ5WrNhO4mnHSXkaBQkKBIIDktjVjfc4z/7Wd6zz5NfF4y5xeNYvHlp2Z60+SSGBNBWFQSca776dexPxuuBZKgUKCIjSUy+DKTf/6UL36bzo2IOBIUCuJD7rJu5jg2Oj31q1PGcMCiD5+26InZ1DH82tWCK6EF7yvSw4ZZ0w/jdO8kU7v9xE/tfub3yWvZstScvyceJkKhIEERyaXNpvxjcRyJQoEiPoxjsw2YuM+xhCTVymySgq5hOtiQBSe8iwQiu7CasbM3EKEEF3EPomqjzklBHhJAYMA9rMb0ov/kpZyxcyEgXEqE1wUs/u7BjP23CQ4OJiQ4kHPrx9Nt/jmyyOTuzjUsW38cz+BgggsJ8r3K7L9+Z/jqcwQ6nWDUX30ws7Jh/8pRDF51snA9wTidXEnfYbuQkcvD9fOZu8CauJJ7R3Z6NmpAnZ1CZGgggUHF2woODuDkgiF0MVzCbd+C9QbcPcz43hPYZXcf23VLmTx8E06Fy4cEhxAuCcff/hCT/hrAAmtP1EDstVUMmbYS1woYKjc+kHNbZtPrp69p2qA+Og31aF6B+SCkMjnRMbFIZXL8/Py5dMmWGRYz+bVzF6ysrCp/HISbJ6NH/o3L/h1YrrheSj0dDdlxnmybPYUlF3xISEggIUFBfGwciUlJJCYkFD6WQEJCIknJKSQnJ5CgSCQlJYVERQLJaVkFBxB5WSQmJqBQKFDEJ5KRXXDRIj0uAtc7PpRWvKUsI6klUhlR0THII6MIDgnF7voNLl2yJSg4pETJjcoTxGCyc+IIuP+Ae/cKj8ZTfNlq0p2O3QdiMMiAseMXsm7lHIZ0acPnrf5kxVm/UkrPqPC2WUy3zr0xMDDAaOA/9Ozanf4DDDAyGFqIISONhtC3z0hWnfIlT6Xg8tr13Ap/6n9LnczN/fP5+5+BjBg6mL//6kbffwZhZDCUYUONGDnciMG9etK390CGDzPEyMCAIQMMmTr3IIFPF9LKT8LxxDIGd/+dP7p2o2e3XgwcNBSjIUMYMngYy875kpPgw6YpfWnT+ivajLLijLUVA3r/w1ADA4wMDBjYuwfdevzNUIOhDB08GCPDWVzwS37iDEKjyuDhseUM6NuLbn/+zl89TLDxSQUyuLlxM3utvdAADndFN9cqTV7sA+Z1b8k7b7zF+7Xe46P3PqDOhx/yUa33+Oj9D6nz/vt8WLMWH9asxQc1alDzvaYYbH+ImlwCz62g0ye1eeetGsXL1Hqfeg0bovPe+3xYszY6dRtQr/YHfPje+3xU672i9bz7bn16r7NHhRrnrZvZtvlWiXEIamUMDrcCyScPjwPT+aZWDeo11EXnow+Ktvdhrff56L2C9b7/Tk0aNGlFm9Zt6TdpNktMjPiyxtvUfLRszVp8WPM9ar9Xi5rv1qf32tvkA6kP9jB/0z4Cyj6hXIkkB9qzdc4oOrZqSsMP3+dDve8Zuf3JXkxlGUn9aGyETB6JVCbH08ubB45OlT+S2t2LccO6c2XNMuYtf3KaV40ym2h/Bw6usGCC6T5Cii6iZ+J+6ShnnZ+aPvMVpDy1mB5dApLJI4l46syh0gUx0ABlTgS39h1kn3VBfeG8sHvsWbOOq9KC6sVKVcGnmeJ/jXUHz+Me95ge8jJISlAQHXCLlTNmsddNUVhZubAWc2Hl5vzHqxQ/+n9RJRLgXXD59ulo1IUVi5WqwmWVT6zj0Rzwj6oa52alk16mPhma4qrRyifPAUJPWTLZ8gIxuYCmuGKySq0p6rpa8HfJtWZHu3Fw1mruKZSgTiXcLxRFbj5J4S6cvXqP8MLGQIyDqPLkEHTvHJtWrmHDho1s2rCBjVZWbFhvxQYrKzZt2Mimwr83bdjIth1nCUws6OaU53OKGaYTmbNiXcHyhWw/eJBDmzdhtW4L+/YeYPeuTVit38Amqw0Fy1haYmW1F4eINNAkcfvcJa47lewGlyW9xbH7UiCfUIdLbLIYSdsvv6LnmLlF29r4aJ/Xr2f9Gkv2nrmJ64OrWE4dTLsO7RlisZqNj+3bhvVWWFlasnHjfh6EpwJqwm5e4OJVFzJeuntvFgG3jjJ3WFeaNv0So51uRc9UpBbTo4bv6csllSIIV09GjRpC8Nl1GHYeyubL3o8JOgU3272sXrWHe9KM4renSsX3znnOOYS+cGral031reY6mJzcRCRX9jNh0GjM5yxm6dLV7NlrT2IZvj+anGRcTq5h8G/dGLbYtkyveRWJ8brMjj3Xia/Af2RuvD9ndi3EsP9MLntV5MIwZEbcZFV/M65HPf4B5BErDyc8uvicUghCi6JOTSAi8CH29i6437VhzsRJrL3wrC53ZYwmm6S0FNJK+aLG393C0Dm78U8FSMVppyld/jTlRllKMalSCA0PQfHCH6CatKRUMtJfrqviE2tMlXDn0jnuhhZ336yO1VyHDjVCnSHh1t5FDPq9NwOHDGfUSGOWWFrjrah4iebKSPUVxEBSUtNBk4qX/UUOHTzObV95uaoXZ8i8sbtyH0lGZRXEL280pMWF4eEcREoFBtLnp8hwuGbL9Se6QJcv2XIHNo2z4Jr8+X3qhSC0Jhm4WG9g/rQJjBtvzNAhA5lidfnZ3eQqIflSO8Z0+omvv/2ZLh3b0eab35i2+0Gp16yre6qjIAwGDS4c6a4kLjwQD2dnnJ3d8QuKIj2vauv9VGtBJFVsalqR4uSkSLA/a09c/vOP4IQgtCYalHnZZGVlkZWZSVp6Ji/4v62E5OJ3fi09fm5Hn+GzOOUsJbs6l+54TqqrIF6n+SD+NUGIaq4vHU0hL4oQhMhzo0wK5NyGJSzfeRLXCox0ri4RgihfhCAKkpsRS6j0vyskIQiR5yY/OQrP27bY2j8kqCJ31KpJhCDKFyEIUGVGcvP4ZR5GCEEIQYi8OMq8ou6A2pbXWhCaPIKubmd41y50G7OehxWpuvhUhCBUBF/dxKIDTkXFEzXqfLIyM8nKyn3ufO+5iXLcrrmUMq6o7EkJucmR696PdYXVkO5/kakjDBhpbsmDqMrr1PG8CEGIPCca8jJTSUpMQOLvwoWTF3EPT3gFJalffV5rQWSHs2tiZ3Q+bswvU7bgl/LyEv/PCyI7gI1GE9h5v7gQVq7Cjc2zF7Bi9X48k57V+0eF18nVDB57kMhnLPHiqPE7OpOuA5bikvios0IWt1YOo12/xdwLjyG9Uko+vzhCECLPiYpEiS/Ojg44PPRGlpCJWqONenjNBUEyF1bOYOSM81TWVDb/dUEog89g8IcZNn6PfaKaPOKCfLl3057gxOJiYup0CTdPnOa2VxRqwPPQQnqOOkT0S2w/N/gcw7uOZL9z8fgk2dW19Pp7DZ4vqj5YiRGCEPlP5PUWhAqvQ6uYOGYToZU0mcR/XRBpznvo9etkTj0xvF+N/6W9LJhzovjsIDsOu/UzGTd2Nlv22CFLTMbDejl/jzlcLAh1LvHhXgQlq0GThLefhNSMbBKiAvCSPqN8QG4AmwePY+/d4lHz+eFXmdJzPtelL6ytX2kRghD5T+T1FgTIL29issEsHCppiMB/XRA5Pkfp/5sJNv4F49vzUiJwun+Tc9uWMLrPPB4WDntP9T3FlMXHCopVqvPIykrH9dgy/h53/LHil2nYbZvBjNPhkO/BnEmrsXUL4Pz66Yxbebf0UfEaCYdGTOTAveILVfkx91jafw0OMf9eZxEhCJH/RF53Qcgu72DG8CW4VdJsmP91QWgyvFk3ZBy7HOIAJc47pvFL068ZNHY0fdv3YrWtP1KJFKcj8+nYeybn3UOQyeXEJqXy8MA8fuu3jocSCVKJFKkkhMsbptGz10IcwrzYOb4/YxZuZuuy2Yxdfbf00dCqUA5PtuJOSHE1gLwoe9auvIAs89/rKCIEIfKfyOstCCXB18+z3/JmBSZ9Kj3/dUFALl42a1hw0BU1GmQPjmNqNJDevfoyoF9/hgwxZITRMIYbDGbg3/0xMDDEaNBQZm6/jJv9McYbGmA4tGCZEUbDGTnUgMF/D8Bw2AhGGgxgQN+/GTppHqd9S87mB4A6BqfbAaQ8NntgfnwATqHxKP/F24BCECL/ibzegshHoYhEUurMahWLEASoMmVcP3oRF1klnZZpYYQgRP4Teb0FUfkRgihIbloUIdLK6humfRGCEPlPRAiifBGCEAEhCJH/SIQgyhchCBEQghD5j0QIonwRghCBShLE/Xv3/tWdFhEpb2QymRBEOVIdBeHnH8DgAQNRKStpNKDIC+Pq6sLI4SMqLogRw4Zz5/ZtNBqNQFBtCQ8PZ8A//YQgypjqKIiQ0DD++O13Rg0fgfHkyYJ/gd49ejB29BgUCYnlF0S8IgGzqWZ0/fU3DIcMEQiqLb169MDQYCjyyCghiDKkugniEbdu3cba+iQnrU8J/gVOnTyFk9NDJFJZ+QURHiHBPyAQp4fOODo6CQTVF6eH+Pr5V7kchCBeThBR0THExMYRHRMr+BeIiY1DHhlFaFh4+QURFh6BRCpDJo8UCKo9Epm8yuXwSBDOLq4YDjH4Vxv98mTeKQekQQAAIABJREFUnDns27e/2glCUHVUSBACgaB8SGVyPL286dC2HTMtLJg/Z261Yt6cObT76SeOHz9BXLyiUt6zEIT2IwQhEPwLhEdICA0L5/Sp02zbuo0d23dUK7Zv38HBAwfx9vFFIpVVynsWgtB+hCAEgn+R2Lh44hQJxMUrqh+KhKIbk5XxXoUgtB8hCIFA8EoQgtB+hCAEAsErQQhC+xGCEAgErwQhCO1HCEIgELwShCC0HyEIgUDwShCC0H6EIAQCwStBCEL7EYIQCASvBCEI7UcIQiAQvBKEILQfIQiBQPBKEILQfoQgBALBK0EIQvsRghAIBK8EIQjtRwhCIBC8EoQgtB8hCIFA8EoQgtB+hCAEAsErQQhC+xGCEAgErwQhCO1HCEIgELwShCC0HyEIgUDwShCC0H6EIAQCwStBCEL7EYIQCASvBCEI7UcIQiAQvBKEILSfCgkiQipDKpMLBNUeiVRW5T+y/ypCENpPuQURHiEhMCgYV1c3nF1cBYJqi4uLK/4BgVX+I/uvIgSh/ZRbEHGKBKaZmdP1118xGDRYIKi29Oreg2GGRsgjowiPkFT5j+2/hhCE9lMhQQw3GsbNGzdQKpUCQbUlNDSUAf/0QyKVCUFUAUIQ2k+FBDF65Cju37tX4kUiItUpMpmMIQMHCUFUEUIQ2k+FBXHX3v7f/K2LiJQ7EolECKIKEYLQfoQgRF7bCEFULUIQ2o8QhMhrGyGIqkUIQvsRghB5PaJOwd/tAV7RmUUPCUFULUIQ2o8QhIjWJzHYno3mQ2nzXTvGH/AuelwIomoRgtB+hCBeImplLtk5SjSqBJxvuxGZkvPYsxqUuTnkKtWPPaYk2vcm5+6FkpOvJjPwDjc8Q8lUP73mSto/VT7ZGVnk5OVRvAklcl9Hrl71IjNPRUasO2duhaAs99pVxAS5cOWSO6l5T79aQ1aMJ7dcJeSUf8VlTl5iEGc2zaJf+6/Qq/MBtRp8w/CtzkXPC0FULUIQ2o8QRAWjyovkzOrFzNt4hyDnPQwzXo1jbP5jS2TifnorOy/7klv0WDb3t4zi884jOeLkwYmZwxi//ioZmlezj6mhd1g9yoS5Vntxi3u0b7m4HJzBT5/0Z89Nd86vGU+/BedJL/falXifnE/bpj3ZYBvKk45L4+q8cUzbfIPMUt5bfmYKMREhhEUnkF0BgaizFLic38aEnj/RQk8H3foNadpIh3pNfmDUDtei5YQgqhYhCO1HCOKZUZEY7o/TrVu4hMWS89RRfnaCF3sWr+fMA398rqyj38QVPIh7srXLU4Tg4hJKdtEjavxPraD74M2EpwSzxnAI03c6ks+riUaZiczHiVs37hESl8Wjtjr8nCUj/p6FgyKaE5N6Y7D5DhU5iYm8tpVRPY2xi3r61cmcNTZk6sbrZAGQi9zHDa/QWJRAir8922eMZfLKg7jF5JRY7zPfT14qoQ8usHJ8b75sqoduAx2a6OnzSZOmfKInBFHdEILQfoQgSkteNlkqJdJ7Nqw0HsecHZeRZT95KKxRJeJ6+RJ3nIIJv7+F/pNW4viEIDLxOL0eY5OFnPZOLHpUem0nRoN3INPEcWz8eBbvcnzsDKOMyY/l1qHNbNh1CUn28xbMI9BuByYTFmLzILpIAjG3dzFtzHwepmRyc81whu+6WyFBKBwPYTFiGrdin34mhfNmwzHfdKNQEFl42Oxh29HbJCo1oMwiMcqDK1fvExSTVebtJXoex+DLBrxXsw6N9fRp3qRpgRyEIKolQhDajxDE09HkE+PqhqTwsD4/O52UpHTyNdlIwnzxlhY352HX9jN7+jZu2G7GwHQtrsnFq4m8vY0hXTvQumMnppwKKXo82eUk5gMsCcyO5uj4sSx8oSA0JPk74x1X0JDmSB5y/rQNNif3MWvoUCatvETcM1r3eOejjP2zE1+26sbUDcXX5rN8TjLLbA63opO5sWoYw3ZWTBB5wReYZ2rGJRmQ6cfuRQvZahsIZHLRbDjTt9kX3dvIkztxyd6LtEcbSr7H7ImLOOWWWPrKS0lWXAiXdy+mf/uv0K/fAD0dPZrpC0FUV4QgtB8hiKejisJm9lwO3QskMSmZ1LQ00tOzUab5sdF8JMbbHEhMTCQxMYmQq1uZMmYmh49ZMWzKYq4GxBU8F2HPrKHDmb7xJNa7lrLtdkjhaxIJvXMYi37zcU1NxNZ8Cst3O1DaRRa1Kh+lBtAoOLtgNKbbLuF2/wqHDllj7xpIbFoGETe2M2X8DG4rIN33DMvWWOMrTyjYVrQr6w0NmGF5mH27t2J5woOEwn2IcTrEJHMLzoYl47RrEsN33UNVYg80BTWNVABKMpKTSExILHofiYmJxLlZM9V8Ksf9Y/E6uI7lSxYwY+5y7sQquDlzJMYrzxBZuKzXyYUMnb0JZ0nB3wmR9szvbcL2KxGU7xaMmqRQR/YuHkf7Vp+g36ABjXQbC0FUQ4QgtB8hiBJJ4LTpXzSqXRvdBjroNWyAvt7PjDQxY+hf31L3w4/R09GlccP61Hlfn95Tj+F+bzvdvqjDh7Ub0FhHl8YN6lL7/Tp88u0P/NC4EY0a6hY83rA+dT5qzO9jjpFENtfnLGPfaS/yntqD/HQF3neciFYCqAi9vJxO7Vvzeb3afPxxA5rpN6Gprg4NPmhI+8Er8MuGVN9TjGnXEp269Qv3rx51an3MJy2/47svG9Owvk7BPug0oG7NBnQZvZnwHPA6MptF571KNtL5Cfj5exKaDNleB+jWsjnNm7egVfMm6Beup17NerQ32kBIXCCren6PzvvvU+fLnmx4GMjNGX355J2aNCh8743q1uajD+ugW/i3bt3aNOk4jdvS514je3Y0uUidzrJoXF9aN9Oj4Ucf8lHj7xm53aVoESGIqkUIQvsRgigl8d4XWWRhhvlUM6abmzN9qhlmFrNYtGo1K2eaY25mzvSpJkyZupgj96PJjH7A1qXTMDUpXN58OrNmzGDmtGlYTLNgxrRphesxxcRiAfseRINKjs3uczwMSC2x/eQoD6z3ORbf3FbcxfjPAYyeYsaM6dOxMDdnupkpxpPnsfdsQGHjLmfvGEOMxhkzzcyc6ebTmFm4DzOmTS/eBzMTpkxayCHbYFRk47B3Pw4RySX2IU8WiJP9faKBRI+zLLEYQacWn/Jdh4GYPdr+pHnsPReImhzcTmxiwRQj/ug7lHX2YQRe3Msi4ymYmZkz3dwci2kWzLKwKNh3c3PMJpuw0voeSS/bDVaZgOPJDYzv2YYGup9jsE2cQVQXhCC0HyGIqooyBVlcAhml3IBICrjGSpMDSNRAbhRXt85imtXdUleTlxZNUJAvV7bMZKLFKVLKtRPZRIfHkZNf8g5Eqvcl1s5Ywt3CWwSx9/cwuEMf1l5PePba/C6yaPpa7sS/wsEPz9p2tBen9+/hgo+i6DEhiKpFCEL7EYKohlFmSjizeBpG/QYxdKwZi60O4x5fykgFjYrMeDe2mBnSZ9BsrkWUPBupaFQKZ5YYdaR1+14M7t+LX777kR4mu4kopU9uXnIEV3fOw+DvMWy8EFyBQXevJkIQVYsQhPYjBFFNo8xKJCLAj4DQSFKfvknxRPJJjpETlVDBa/nPjIqw61v45+cWtPxmIKsOXScsrfQRGxplDknREsJl8eXvsvsKIwRRtQhBaD9CECLPTm4kVw5tY82KHdyTZ1T13pQ7QhBVixCE9iMEIfLs5MXy4LItNodPcD/82fceqmuEIKoWIQjtRwhC5LWNEETVIgSh/QhBiFRJ8rPSSU3LrtAI7mdFmZdNrrJ4RIcQRNUiBKH9CEGI/PvJj+LMInMWbLpEvKoSStnmp+BzdR9m40az/HJ40cNCEFWLEIT2IwRRlclPIiQ4psRI6oqvL4UgDyc8pKV1d9WQERNJYl5hg5yTRGxiApkla2yUIdnIwmPIUpbz+D8nhXB/T26etGb76kVsvOBOUsV2oDAqIr1usHX2MNo0bcB79b5k2FYxkrq6IASh/QhBVGE0cXeYOsCI6Rtukvgy7eSj5Cfx8NJhDl7zL6W7aSrXlk9mpPFKnGOSCbNZw8w1hwkve7XtwqgJu7qRcTP2E5FdFkHkInM6z+ZFZowZMoypi9ax78wDXG/uZOoWG3zjKlbsPCfam5Prp9Hr51Y0qvNxQekPUYupWiEEof0IQVRlUh4y47dfMVphVymzyuUpgrmwdiamS7dyKyzzqWezuLHGkI4DlxCQFMXRaUP5x/wIinJvV8md1YZ0HrOZiBcOelARdn0/4/sMw2LlJo7b2OEtiSdbBaFHF9LTcD53YstnRk1WHA+sLRnR4xc+bfAxDRo0Kij7LYr1VTuEILQfIYgqjYS9RiPZaCcDIC0qguDgyFJnYXt+VOSq1GiyEvC2O8XRExdxjkhCmZ/3RJVWn5Oz+XvBGXLIwHaBKSbzzpBU7n1W4rBxLH9O2FYGQeThdngarb7qgeXt6CeeCToyk54jFz1RIv1FyZTeYcmgX/lcV4eG9Ruir9dEzAdRjRGC0H6EIKo0cZyaOpL5u6/i5XSH4+tnM7hzX6ZuvIYi55EllCTLQ5ElZT2zLLYq9h5WOy4jz4YM39ucOGpLZH4q9hvXYeNZPJtP2OVV9J1tTTLpXF9ijtnc05R/dMOzBJFBiIsd587fwk+aWrSv6rwEnE4sZ8TQKRxzKa6TJL+4jIFmK3At+3QQJPldZs6AjjRvUJcGdRvSTEwYVK0RgtB+hCCqNHlcXzGWCXPXc+asC8lAfvh5JvYYyn6f4psDAdaLmLDlFtnkIfdwwyv0qcPuHDfm/D2KLY6JEH0Nk2EmHHcN4fzS0Uw54V+8mOdBBozcRQTp2K+cwfR5J1FQ/njtnER34/0Ut+1JXN+3l83r52D0e3+mLi753Yiw3YrZ2BXcDCk4Z5FdWEI/k2W4lEMQAKq0CK7tWYLh79/RqHZd9HQbC0FUU4QgtB8hiCpIXpwXh5aZM3HCCLr/8CXfd+rDlOmzmDHVDAuz8fRp25oufUcw1cSUqcYmGPbpQtcFtuSSwY21U+jxe2/GTzEpeN7EFDOz8fT+rhXf/ToI8ykj6Pz1N7T70wDDAZ1p02NI4XqMGTu4B38ZnyAZNe6bV7By2ZkSglBrMgj1kZEPJHpfZp35JEymFpQqL9ieMUO7/siXP/7JmMmmmJmYYjqyN982/5XVtm64n9jIgO/+YoyJafH+mZgx23w0XVp9zT9rbpAPJN/bzITFG/AopyAeJTHchUPLjOn67Sc0rKdDk4b1qasvBFGdEILQfoQgqiCqrFB2TelO4w8b0KLlF3zV4lOa6+nRpJEeTfSa8nnLVrRq1oQmjRrTpFEjPvm8J5vsIwHI8T3BwF+aU+fjhgXLN9KjSSN9vunYmc6ff4q+zme0a9uRn1p/SvOmn/HlJ81o2kiPJjo66DVpw9wLwUAOd/ce4vgpnxKVV5XpAVy1j0BDFve3m/F93Y+o/cEH1K2rU7itxnz66ed807IFzfX0aFxfl2//NGLG1NF0/70T7du0pqV+k8f2rQB9XT0+/bwDc238UQOxtw+x9dA5Il+qul8WUvfLrBzXh+/06/F+gy8w3Fo8taoQRNUiBKH9CEFUUVR52aQkJZGcnPxcEuIVxMXEkZyehzo3FceDK1iw+STB8U++NjU9nfSUFJKTUkhLSyctNaWU9aWRp9KAOglPTw/85SVb5yS3Iyw97UpB59NcwmzX8mfb7qy46Ff6PiYlk5aVhyo/G8n9kyxbvZzjrtGklPp+CrePCqmHJ37+UZUyklqTl4Druc2MGmzAwgvF838LQVQtQhDajxBEtY6SQLsTbFk1m+kzljDXbDi9hi/gvE/5pgUqT1Jc9tC92zBW7TvNuWObmdS1Lb+O2kFEpY3me3VRZqWT+djkR0IQVYsQhPYjBFGtk4vE1Y7zp45z/Ngxtu/ch513/KvdZFY4uyd05YM3/kd9/W8ZOMWSmwHaV8kVhCCqGiEI7UcIQqREsiId2bpgDit3niG4lInstCVCEFWLEIT2IwQhUiJ5cf5c2LSYJduP80CmBdeWnhEhiKpFCEL7EYIQeUY05GYmEh4URlxKZU9n+u9ECKJqEYLQfoQgRJ6KmrQ4CcGB/rg9sOfShZsERCY/cxR3dY4QRNUiBKH9CEH8W8mN5OqObZx/KKvmja2a9HgZIUGBBIVFVbAc+L8fVVIwl08d5rJ/8cg7IYiqRQhC+/nPCUKt0ZS7gdZo1C/dqMtvHGWp+Uz23ggkr8IrU6NSvQq9aFCWe70a8nIzSU1JJ7dCFbtf/jMFQJmK340DTOnTnibNvmXELveip4QgqhYhCO3nvyMIdTYht09zwUVKfllbJk0OQVcucNU1jEeVkVRZicii4sko80oANGQF3GLPwU1YXfAltwKjw5RJgZw7fpDrweWewOG5UWdHc+v0Xmzcy1nXVZOF151dTDE0Z+PW8wSnPbuYIIA6PQJ7ezdiC29npHicZfOOI7jFPP91z04OUT52rDMZyM8t9NH9uDYf6LZmxDYxYVB1QQhC+/nvCCLXlxX9h7LM2qfso3dzfVk0ZBKLjvoWNWJ5svvs3mONa0x5GmoNWWnx2G+zYOCys8RX4LJN7J1tDOwyApuwik2w86xkB51ldKd+bHUsf1Gk3LQofF2dODJzMH/0X4Dzcyb/SXLYRIfPvmLYmnvkAX77TWj1wXcssQ0rtyDSZJ4ct5xG99bN0W2gg36jxjQXxfqqHUIQ2k/1FERuPA+vnOW6z/MHheUpArl11Q7vuDJ0xVSHsMlgJGtOlk8Qi4dOYclxv+JGLCOYE9v2Y+dX3sFjaZw27kOveScpbULQFyX2znYG/z6as+GVLIjgs4z9dSA7HpZ/ZggAVFJ2LDVn0B8G7HAo+UV6lCzJXdbNHE3334zYbHuFzRYjGWh6kKCksr8fVbqM2wfXMvqPH9CrXw9dncY01xflvqsrQhDaT/UURH4yLhcOccjOj+zHDy81Cq5vnY/5oqOEZoIqNYwrx49yIyDpxUeh6hA2DR31HEFoyFSEYLt1EVOnWnIzIhvUgSwxMmbpcb/CRZK4tWM6P7f4lj7mx4kqw4Q5YXeOMGfSQk65hXNny3iGrLtIRgWuqcTa72BI1zFPCCJf4cvBFaYMn7EJB0lGhS7VZAefY9xvg54tCE0+sYH32D3HGLNFh/B7vMqHJhP3gwsZPHImu05exC0647nb0qhyCL+zlYFt2tN/6l6Cy1moL8HtCEO+bECtmrXRa9S4eC6IShJEhESKVB6JTB5JhERa5T9ObUcIQvupnoIA5B43sb4a+tgjebidWs/kPj3p3K47s44VFJRTZmSQllqGfvrqEDYNHcOGi+FFDykl9px18CMjL4eIB5c5su84Dn6+XNmygOHjN+Ef48vq4VNZfU5a8IJ0FxbNNWHh1m3M7TcVG+/nHXXnE3bjGNuP2+EVFE5MShp3Noxh0NrzpFegJc9w2Y/hnxO4Elf4gEqOzZLprDvpQFCYN/d9oip2szjqGpO6GrDfp/gsTO56AVu/RPJyEnE8c5ijZ+3w8bnHxsljmLLmKkUa0KTic+c822ZNpM8vv9Bn6jouO/gTHZ/Ks3YlReaApekcNu+zJVpVvg8iPzMRvzvHmDHkd75qokvDug1p0rjJSwkiPEKCVCYnKiYWqUyOt48PNjZnuGZ3HYlUVuU/UG1GCEL7qRpB5OeSmZZKDqBKi8TdxQknRyceOj3iNttnjaO30VpuODnx8KETNw8voUenbqy4LkV2fQX/zN5HpFJJoM12Vq05SdTTdauB/NREUvMKn1CHsnnoUMyWHcGxcDsnlozkD4PRzJxhwkjjlZy+bM9DVw9c7A5gMW4yZ5ydsRo7nglLjhXs163jmA3qSPMmn/LNFwM46lWyaF5+bjaZGfmo4u5g+uc/TFy4G8eweHJR4bR9IkOtLpYiCBVZWemkZQGaDMI83XB64PjY5+HElZ1z6Nm+H+vOOvDQyQmHq/uY2qsP8w7cxMfTlQcODwmKKVkXIz8vh/Tkgvmp0+WBuDk+wOmx9d49vY4B7boxd//1gsceXGb5uF70mjgNC+PJmCzczfW7Drh5eHBj93xGjJzCfruC1zo5PsDJ6SGOd48xpd0PfP3Vd/zStgfTNlxBUeI9qol6aM3COZbY3riA1YK1HL4WUc4vTkE0GXJuHVnN0N9+4lOdegXzUpdTEBESKZFR0cTExhEYFMyVK1dZvWo1fXr24ovPWrJmzVoio2Kq/AeqzQhBaD9VIojcWBleju6kkI+LlSE6td6h9ke1qV3jbWr87y1q/O8tar3zLh+8W4Ma/3uTt//fW9Su25K2nbrwe9cRzDQfRq+FJ4nOzSP6phVDpi7kuvzpO7+ZeJ69jE/8o0ZTxvahnajzxhu8VbiNd995lw9qvEutt2vwXo13qfX2O7z75v/4vzfe4tNOc/CNDmbN8La88cYbvPO/t6jx5jt88G4tar75Nk1+X45P2lMXqzTZhPk5Yu+eQl6sIwvGdqPZ/9WgVVcLnNIg/MwSlp5+8ORlM4D8JIJ8HPFKhGzf/XRp/BE1a35A3Q9q8u6jfX37XT587z3ee6vg7xpvvsP7NWvx/ttv8/Ybb/D2218w51zwUytWEx8VwIMHMaCKYuuQNnz0v7f5uPZHvP924XreqsGH771X/Pebb1GrRk0+qFGDWu/U4L0aNaj19tu8++Zb1KxRkw/ffZeabxYv++6b/+PtNxvyq9Fabrl54xsQSkxyaTfw4zlo1I46b7zB2//vDd6o8yuW1+Qv1dU1O9Kdo2vN6fZdC3Q+fJ8PGn3HyOf0Ynp0thAdG4dEIuXuvfust1zPmFGjaf31N+jUq0+jBg1p3qQpa9euIyo6tuh1z6Oqf8TVFSEI7acKBKFC4u3IpXOBAEQ63+Dw8nH8+PmPDJm7lWNHj3Ls6FGOHz3G8cJ/Hzl0lLOXHxLo74L1GmP++Lwby04XTqUZZssKq43cj3uqsVaGcnTLNSLTHokjjK3Gs1m0YjtHC9d77Oixwu0Ub+vY0SMcOngM29thKMnE554th/YfemK/jh45wnk3CSVujefHc//GMU75FzyjTovg+LzJjDY9REx+Ph4nT+EYFFviHkhedDD3zl0iAsiP8ebSCUsMf/6Ojr2ms/fxfT32+H4Wf0ZHDx/i2DE7QhOeuqivSsfP+TxnfXOBFFyvn2fNhN58/d2fzN50uHg9pa736c/l8c/rsceOHOLwkSv4K17UUSAd/+sXOX7gIEcP7ufw5ftI0ytjNgglMldb1pn0o1XL1ozc41H0zCNBSGVyZPJIIqOicXV3Z//+A0wYN57ff/2NRg0a0uDjujRtpMcnTZrSVK8xLZp/gpXVBhISk4mMin4mUdExSGVyQsPCq/yHXB0RgtB+qkQQwRe2M9HQEvfEHJTJoZxYNoouvefjmlW21ytCwoiQJZIqdWazsQlzN98sedkm05u1w2ey93oACQoZ9ocXYbLamqjKaJOeuWsJXNq1FNPNd4hXKPCzv8CmeTu4GZgGqElPzip1oFuO1J5VE8ax+0E0ucpUfC5Y8U+HvljequB8nI+iTuXqjhkYrbIlISePlAgH1gzvQe9p1qS93JqrX7Lj8Lh/B/fI4stsEomEoYOHEBwSis2Zs5iamNK5Q0e++KwlDevWQ7d+A5rrN3niZndz/SZ80rQZP//wI926/smfv3ctlb+6/sHvnbuw3nI9sfGKKv8hV0eEILSfKrnElBFyFbMOrWjW7DO++bY1bTr8w6oz/uW63BDvf5P1k4czevp+/FJKGVigySX46l5MB/TnnyHjWbDlHIGJGZUyg9mzoyYl8AZLTUYycOAYlm21xjUkmRcNe9Bkyzg8uxeNdRrz2Sdf8m3rXxgy/ziyl+7RqiHcbiO/ftKcFp99wffffk+nv4w5+dyb669PpBIJhkMMcHrozIIFC+nUvgPNGutTv3YddOvVp1lj/Sd7Qj3GN198yc8/tuHnH34sQdsf2/DDt6159823mGpsQmJySpX/kKsjQhDaTxX1YsrF78ImRnbtzD8Wm7APqMAkOBo1ynzlC6WiUeaTl5f/isXwZJTZGSTGKUjLK/uIuPTQO6w1G8bQ4Qs5fsOL5Mra4fw4rmyeTrdOvbCwssY3rnJHYlfnPLrEFCGREiGR4ubuwf79Bxg7ZixdOnZCX7cR9WrXoUnh5aXHLzGtW2f5zHsQUdExODo9pOHHdZlmZk5CUnKV/5CrI0IQ2k+VdXNVxrhzeNcqFq06SdDT1861OkpCbx5j9UwTFh9xIKEaTKcQ63GdPSvnsfLEfeJfp4/6BXn8JnWERIpEKiM6JhZZZBT29+5juc6S4UbD+O6bb2lQ52Ma6+iir9uIT5s1Z906S6Jj4ork8jjRMbE4PXQWgngBQhDaT9UJIiUSTw8n7t71JjbldWq11CRLfHC8Y8cdDwnppXS//bf3J1UegqfTHe56hpOcW71ryVZmntXNNTxCQmRUNPGKBAKDgrG1vcyqlav4u09fPtFvQlO9xqxeveaZ3Vwjo6J54OgkBPEChCC0n2o7UE5E5GVTloFyUpmcmLh4ZJFReHp5c8bmDLNnz2HHjp3I5JGlvkYIomwIQWg/QhBalsyYUHxC5GT/mzdVtDTlKbURIZEij4xCHhlFWHjEE9/5pxGCKBtCENqPEIQWRZkcwbk1k5iw/Chh6Voyk08VpqLF+h7da3jW80IQZUMIQvupJoLIJSrEB/cARanP5qdH4BWqQFUtLp8n4uodQnxKJd5cyE1BEuRBeMlKGU8m3oNjOy05fCuMHHXhh5GfSWpGJipAla4gyNG/QtViKyOq9HiCPDyJUQKadII9Q0ktR0+uys6rquYqBFE2hCC0n+ohCGUcp5cO5IuOkzjj/rQkkrm61JSFB51LnehHrcwjJyuTrNx81OUWSD4hNw6xYMEJQrLK9uK4+9sYNGZqTisOAAAgAElEQVQpt6WVd2M93vEQU0aacUlaynUjTRoux7axctVKDt4NJ87vLFPNl3G2sA6U7NIGhg805Zx/NN6nLBkzchuhVXT5KTviBhZ/dGCM1UWcb+5m4tx9hGQ+vjMalHm55Ob/OzsoBFG1CEFoP9VDEJocHLea8cdfM7hbYtKZWA6PGMCMPY4UHLPnkxQVSWxywUxk8W7X2GQxDrMNNgQml/NoVSXHeu1a1m+zwb9M/VE1+Oww4fchC3BJrqzTGTW+1ov5q8csHpa6TjVxXjc4unsPF90jUfieYkSXL/im11K80rJw32fOj3rd2GznwYXV4+g15ijxVXSmpYl3ZK5Rb8yP+xBou4geJtsJfmJ0vBK/y3vZcNqjZD2qVxAhiKpFCEL7qR6CQIXXgZVMGbuZ0BJtfCzHxw9l9j6nwhHJydjv2cDW045kqEGdHkeIx03OXLpPWGJ5B4Fl4Xf7Cpcv3Sf2kZfy05CHxfGs8wPpuSUMMFuFe3I5N/VYlIoA7GzO4xRasJJIux1M6LcQ11LrX6iQ3dqKwS9/MP+QG9maTMK9b7Nz3kTGjzFmovFctl+XoNGocNg1l38mn6b0cdK5RPp6EiAvWYH2UTJkPty5701iRcdupPmxdvZEFlyRE3V7OX3NdhLySBCqLOSBAQT6eeIToXhmOfDKjBBE1SIEof1UE0FA2BlLJg9bjEcmkBnKqe27sPVMABI5MX4oc/Y7F42aTgtzxM7Bn4xHVypibjJv1hbuRmSWc6sqkkJus9p4JfZRBa2iJu4BS8eZcMAltngxdTohznfxScgl6tIyBkxdhVtZq1XkphMfJSVJDaAk0u02p04dZq2pEb0GzONmaCLRd/Ywqd8CXEq7eZDhxbLRUzA2Nmby5Hlce1TXPMmeib90Zvi0fcQUbIh7O+fy96RTlF7BKROP07vZffwKTj5ueEienNxHFe/Gmsm/0bxZW2Zae5YsRFiW5EnYvnQ6M22Ckd5aTl/zXYQVOjtd5sGRpeaMHj6VLYevE6goU+Gtl4oQRNUiBKH9VBtBSC9uYJLhfB4mZxJis5Wlc2cyZ9Vu/JLjOT/FkDkHiss4h9uuxnjTeeIL20pN0j1mdjNm/73o8m844QHzBw1mw3UJ+bl5kJfM/T2zGDLSCt+iBjuJc+umMPm4DzH3rDCYuQbXMs44mhlwmcXmszkfGE2A+x2uXbmFT3Q2kMX5+WOZuf8mgfbHmTl4AS4ZkCO7x8ETd4l9NAdSuhvzB49gpNEg/hxowGbXTFDFcMv2Bs7ublw7ZcN1z3hAjcvBZQyceJJn7poqh5RoT7bMmMSE1fcpus2eEcKeWeMZvfIYdkeW0HfwOjxTK3ITPp6jS2djutWVoNsr+dt8N+GFp2K56Sko5P7sNelB/Y+b0bFbH0ZM34lzZBkme6pghCCqFiEI7afqBJEuxzMgiJjCA0mZ7UamjFyMU6gHi7u347uvWtGqixEH/UK4OKk7XzdtRfv2HencoSM/tWqKbpOWtP2l4O+O7b7nxz/mcVf29FGpkqQoH9xkSsgNZOOkQXRu15luf/zOrx060rlDB35p04bfekzngv1llg/rxI8/d+K3n76lSd3GfNOmPZ07dKRz2zZ82bo9E04Ekea5n+mWO/Ep9UqNBrVaTWpYIAEhUnIBZaIXa8370a5jJ9p+3oLWP3Wm229d6NKxE22/bIvFcUekbtewHLMefxWkeR5lWPs2tPmhLZ06dKRzh5/5Sq8Ob7/xBvodjbmbrCLwsDk/Nf+U9p3a8lWrv5i71xuAANutjFx4hRKdoTKlOHt5I8sAUBFos5ZeLb7g51860Ll9B7r8f/bOOiyqtOHDvluutfVt6u668W69dq+ra6/d3R3Ygd2JiAliYCIGEqKiAiIi3Uh3DN3dMTP39wdYgEHogPv8ruu+LuGcOWfOjDz3OU92bc8v37ZixILDmN+/wtJB27kfVabglmcTGe5DQCLIEq1ZO2YQvXr2YWDf3vTqXvI99Ojclj/+HM1B6wTiLLbTpcWvtO9c8hn27tmLfr360LNvX0Yv38Xxwwc4etmSqMzXN9RcCEKxCEHUfRQmiEwvW8wf2PFoBc2ch/rs3bIP18Q4bu1SYmTPjvzRcxLHHIOxV1/LuF49+affPwzs9w+DBw1l5JDBDPrnHwb260e/v/sy76gpqWXaL+SFWYTa3MUzD2RRlmxZMJx2P37Ht9/8QY9+/zCwX1969xrIfDUL4mIcUVswmL979GXQwMGMHDaUIf1Ljv9Pr36MnbEL28QCYu7rc/W6FeXak+W5eN69xJnbDjhaWGPrEPFoA87nttDt144MGjiIIQMGMLDfPwzo25N+A9dg4p9ItI8FZzQdS+vlE9GZN4xuf/Uoud5/BjBs2FAG9x/HGlULcsnHav8qxvTqxT89/6b3pDVc880CeRE+Zqc4ZBVZ/rP2tsPcwvbxZ10YaMzyv1rSqVc/+vfqw/AJizlyQpMNMwbS/o/f6bvgPFGFz16gLC0WL9sHhMghy1OXBeP70qrZN3z/Qxv69iv5nPp278WEpYfwzoUMl3PMH9ufvr37MfDR9t7/MGOXAVFvaL5AIQjFIgRR91GYIKLvXkDzuH5pdUgGFmcPsefQjcfVIwU+N9i8VgWL2Ko3Z8qyw9DfuY2boaXHyPFDbWJ/xigbVXKsgJz83GJARmxQGFFRFbRQy9JxvH6ec+b23NI6x8VrpetpJ7qgvmUHWndinnNsKWnx/th7SEhITiLA5ChL558gsLJV9NJCkgK9kOSU78mVaKuL+pELRADIE7hxcDOb9lyn3ENQXgIORucw8Y4pN/ttnsSBMztUcSh9PCmMMGdZv74oabi8dDpzRUUIQrEIQdR9FCaIbIk1R5TnMn/hCjauWMfmA+e565eKLC0cCx0VZo2dg+plL6p1s1kcj+76kXQbPo8d2zaxYEwfWv85lcu+lVsuJzPMltN7z+KS9GpjHyLvXWLdlDksXabMipXrUD1lQMhLBsHlJXugtWkewwZOR8tOQk1WvBQmOHFo1TSmzl7KaqUlLNt4AGPfynXDkqV5sG9WP3pPXMHObWuY1K8rHYeswTqx9s75IQShWIQg6j4KbaTOkHhw97ohxiZOxJZOHSHNTSHQ2ZJ7tr7l73ArHTlJD68wpUszGjb+lWEztqDvHE5+JfvgF2TEE+jpT0LOqxbbOYS4WHLdwAhzlzBerRk2D4m7HXYe0a/ljjwz0pt7N69hbOJMbHZVCvUiAu+o0eeXT2nyWQemrT6MeUDSG11no7IRglAsQhB1H4UIIi8jnbSM19d75dnk4H1Xm12bD2HsFlmpVetEyqQogQe6x9m14zjWYdXX9+uOEIRiEYKo+7wxQcgKM4mJjCAqMgg7MxNMLBx56Tr3NZJsvK2M0dp9iKs2nmTW5lve2h5pIjbX9Tipqs5Nj5qtBnsdEYJQLEIQdZ83Joj8OA8Mz5/k5PGTHD90EYeQKLLexHBakX9thCAUixBE3eeNCUKan0VyfDQRoQG42T4kKlPY4W1PYfxDtDXVuRNYuU4BNRUhCMUiBFH3qTUjqd9M5MieqmKSyWXP/Fxu32caLKQUv7EGDDly+dMnkyGV16LWE5mszPurKHL8DfaivP0QZp4JFVZHSWVy5JWfgveVIwShWIQg6j5vXBCZ4W5cPmhI2Kt21SnKJDI0irTcF9R4y/OIDw0lODiImIznd0WVpnlyau9JzN1iSI1yQu+6BeFpzzFEroRbOuocM/EjNSsJJ/3jGPmVb5iV56URGRGEX0A0mXk1VCsvTcPxuib7dB2Jz8gm8JYWFx0ktaPHUFEiZuo6PPBPqLDBvyAjiXA/T3zCY5G43+LEBSPsg0ufIIrS8bO+i70ki8J0d46fu4FX9OsbNScEoViEIOo+b1gQhTieWMGAEQfwf9XlFHKD0dPUxtL3BZMfSZO5d/wwe3ZtQ8s88LkzhRZFmzGnw19M32GI5ZktLJi/H//nDUjL8mXf1G60nq6Os/M15g0ezzGH8gsayZI8uXB8CwsX7+Oud+IrXtRLIk1Ab91Qfh6wjvse1mwZN5KNej41c+xqJs/3EhN7zOCUXUKF21N9rDi9bRnKh/Twi41Eb8so2o7YgUtCMRR7srb9/+i95Dhm5zYxeMxaLKsxEPJlEYJQLEIQdZ83LgiHk6sYOkOb540rLhd5EvdPa3LlQciL76AL4nG5acgD3/jnz0Sa58vhcVM57hpBiM42FigdIqgIyI3Fxeg0B87dwCn8UX15HGfXrGTZIUfSo0yZN2A+hv7ZFR62IDOF2KhI4jNq6m44h/tHNzNpxU0ycz1YP3wa6uYRL3/ZG0ietw7jB69E3+d57QqZuBud5oT2XWKyUnE32MWovv2YvukiDx9eY96weWgY22F/fh2jFuzC/TX2lhWCUCxCEHWfNywIGV5XdzN8pjbRFWwtKigoU89fiI/hPoa3bkHfsbtwTnrO3aY8n3AbHRYPncgxp4qXLQWgOIyzC2eg4RhG4IXtKC0sFURhAg7XNNlx4DQmrtGlTyApGG7exJq9VqQmO7B5iBIGvhUNhy4mxPout0ycSHqq2qy4sIDCl9QJ5Ufbc2j5PCaPGo/SJk1cEh8doADnM6rMX6hPijSEw2PncNQs/DnXFM/di5e4YR1acbfTTH9Or1uG8lGzZ97fK0VWTFqINQeXK7Fkly4RRUCkMdNGr+eqV0Ulu5xk75ss79eB9l1nYeCZAsjJjHPliNIY/m47mG03ggFINN3DuBV7cK14bvIaiRCEYhGCqPu8cUF4XtnJ8BnniQZkBdnkFBQBctJD76Eyfzarj1vy5N40gRMr17N211F2Kc9km0lY+SPmhGO0dyVTBvahXfuuLNQLebJRnoLDJeOnFiHKxXj3XLbf88ZfezuLlh1/IqosH27cvE3AUw5wVt/Nxs03iI61Z/OwBej7lBeELNGFU5d1MbG35Yq2MYEZhRTGunNkrRKLthvw1KoSZAeYYuj85MNOdjdk6V+t+PqTb+k0eTWWT7kt6rYWyrO1kOQEc2T8bDRMnyMIpEhcrTG7Z4aB5j4M/J8egJjI7UObGDd0KD17TEHT9CXtGNJkrC+Z4JtQABQRbGWG0W0r/Hxs2LdkNsuPOpIda8rsketKBVFMdlb2M09s9qf3MXfpEU7snsd8TVNKVujIwcZImz0rdmHiX2KE6Nu7Gbt8Dy5CEG8tQhB1nzcjiLw0oqJiyCiSE256lPFzL5EARN0+yCr1a0TEBKCjtoY1WzYyaeJi9l00xcbaGhurm+yeMYRWzZrxQ6uurDYuKwgpfle3M7RDX9YeOcbaKf/Qd4YqZtbW2Fhbc99Qg7k9R7DtvAk21tZYWxmjumIKG819Cbq0i+mjF6NjXrKvxcXdjB0/mZ0XzUvObW3BiaWLWbf9OrFpPqiPX4xhBU8QyQ7abF63gYu3b7Fv5SzUbj/A8MBu1qzbwtJhM9h9+kbp8R5wesN4+s3bya0HJee0srzPVdW5/O+/LRi2XJ17Vtal+1qhu2c9S+ceJzwvnkszlTh5t7wcKcwnKy21ZL6qXAnnNk1lxPpTWJceR1dlAb26zOCaJB7H/StRVjEkqYwhZPJCMpOzSqb3yPJGdeJUNhw4x3mNPezad447Fg9wcLJHT3UjC2ZdICbRnuVTt2PglwNIOLN9Nat3Xy5935Zc2DGfP5v/yH9/+plhBy0oKkrF7LQqOw9dxuz6SdavvUK0HDIcjjJ9835caqjZpqIIQSgWIYi6zxsRRGH4XXZvVuGmTxoxztos1rCmAEhy1Wb6BFXMXR+wc/BPvPtuQ77+/FM+rv8+9d95l/rvvE/jho1o9P6HfPvHdG5HlG3ZLiLUxpDti+YxfeI4RvfvytcN6/PBf94pef179WnSqBGN3n+P+u+8yzv16vFZ80mYJuURrruFzvXqUe+dd0v3/ZCPGjSk0Xsl+35Qrx71Pu7KnjvRSIv80VpwGOfE8q0b0eaH6PdpPerVq8dnPw3nor0TmvP+5L167/P5F5/zyYcflF7LezSo34iPP6zPh6U/13/3fZo0+pofv/+KTxt+SIN3nzr3ez8xW+MhxSRweek+zLzKl6QZ4X5Y3bJ9PANuzP0DtP64Pu/W+w/v/+dd/u+/HenXpwe9Jy9g6dhxrD9pRtllu3MSH2J891HDvhTvcyv566fP+fDd+jT84AMavPc+9f9Tj3rvNmX0LjuKMhzYsPccdtHFQCb2Wito91E96tUruaaG9RvyccMPaNT4L47YxJARcI1JzT6g3n/e4Z16H/DHqKMlgrA/j6rWZUJf48JyQhCKRQii7vNGBCHNTcD3oQ8RCRlIbA0xCixdrzP5Aas2nsMlKo0Ib2uMdNSYOmoOWw5rY2hggKGBAdcMDDC4asAdcz8yX9BlPi8jlQSJN7evGWCgr4+hgSFG165z88YNbl434pqBAfpX9TE29SELyI7wwvzqFfT0DZ46lyHXSv9tePUKV83skGTJKUp25qLuQyqa4y4vPpAHRlfR1dXj5h03UgsKifN35rbucVaNGs9atTOlxzfEyOg6N42MnpxD3wCjayaY373NNcMn78NQ7yq6xnfxSiyEPF+uXLEjptwKb8WEuN7nykWvx7+Jsb3AnEmbuaCvj76+AabOfoT62HF64xTa9Z3LWcfy7TPxrlc4+uDJGhLJ9ppMXbMTbV39J+9T7ypXr9/BNTafohAr9KydSZACyPC5eoINS3eio2fw+DoN9fUwNHIkLkdKfnII969eRV9fHz19Q+75JwBSQizNsbLxe+7a3zURIQjFIgRR93nj4yDy05KIj08kMdaN86uWsemsNRnFUgoLM3G9spdVe66+eg+nl6Qw3g8bGwcCYqs36ZOsMJuM/Fcd4yCjqCCfEPMTLF53isCnSsCc6CDCUyrZrbM4l4y8QsqPJ5MT+eASa2fu5UFoNIG2emyYPhtVk4o+vVyiklLJruASomy0mLdHF7/YWMLcjNk1c8Vzu7ACSHOzyU2J4KGHHTdO7mbeDGUMvSpbzMvJy84jP//1riQhBKFYhCDqPgoZSZ0RZMmBtYtZtOUKkmwpZARw5cBqJs7ejnlw5ZbyeW5kmXibnkR5mTLbt+sT+YZmlivOjcJMYwszJq3ksvvTg8mycb+mwd4LVqTUULkoy5FwXXUNk4aNZOKiHVy660VWJY8tzQxBd78yY0eNYc7qneg+CKbgpUPGpUisz7Fo4nyOmgQ8d9yJoiMEoViEIOo+Cptq49mpGspOLVHDecPTVMjlsjc7rbis+ueT18AxaluEIBSLEETd5182F5PIvylCEIpFCKLuU2VBODo4vMm/dRGRSicuLk4IQoEIQdR9Ki2IxOQUpk6ego62NiHBwQJBreW+hQXDhwwlIjJKCEIBCEHUfSotiLj4BFT2qDBs8BAmjZ8gENRaRg4bjvLKVURGRQtBKAAhiLpPpQUREhpGZHQMUdExREZFCwS1l+gYomJia/yPRgji1RCCqPtUWhCPCAuXCAR1gpr+oxGCeDWEIOo+VRaEQPBvRQji1RCCqPsIQQgElUQI4tUQgqj7CEEIBJVECOLVEIKo+whBCASVRAji1RCCqPsIQQgElaQ6gnjUA7C2UpON+kIQdR8hCIGgklRHEM7OLlhY3MfivmXtwsISWzt7goKCa0wSQhB1HyEIgaCSVEUQEZFRePv40q9XbyZPmMiMqdNqFdOnTqVrp84YGV0nPiGxRj4nIYi6jxCEQFBJqioIZxdXJowdV+6PrbZk9apVnD17TghC8BghCIGgklRVEC6ubkwaP4Hi4je0OEkls3rVKs6f1xaCEDxGCEIgqCTVFURRUe1cYkkIQlAWIQiBoJIIQbwaQhB1HyEIgaCSCEG8GkIQdR8hCAUSFi4hXBJRLV7HZHSCFyME8WoIQdR9hCAUSFi4hKDgEAICg6pEUHCIEIQCEIJ4NYQg6j5CEAoiITGJrZu30L9vP8aPHVcl+vftx9bNW0hITFL49fybqJ2CkFOYm0V6Rh6yKh5BCEJQFiEIBZGUnML0qdO4bniNlJSUKnHd8BrTp04jKTlF4dfzb6J2CqKYcCdjtE6Zkyit2hGEIARlEYJQEIlJycyZNRs7G9sqFwl2NrbMmTWbxKRkhV/Pv4naKQjIiXBC95wRAZlVe70QhKAsQhAK4pEgrCwfVLU8wMrygRCEAqiVgsiNQm/NaNr83Ivdel7kV+EQQhCCsghBKAghiLpLbRREnp8RcyduQuPAepTWqeGSUvljCEEIyiIEoSCEIOoub14QcoqL88nNlwNS0uNikISGER4ejqQUv/unmfRnN7q3+43WUzZhk1D5/09CEIKyCEEoiFcVRGFSOO4ewaQVycttE4JQDG9cEPJ8YoOdcIyWIku8z5yu/+Wzj7/kh2Zf8flHH/NZKZ82fJ969T5i4MpLxFdhuichCEFZhCAUxKsJIp17p1RZvvo47skF5bYKQSiGNy0IWXYiHreM8ZOCPP4hl07tYFL3trRuP5oNKiqoqqigqrIXNdU97N55AjPnOMrfTrw8QhCCsghBKIhXE0QaFvpXuHzhDiFpQhC1hTcuiHQ/Tq1cyEm7knqj9MA7LO3fnyVaXpU6zssiBCEoixCEgnjVKqaiJBcOzlvOBbuYctuEIBTDG69ikiZxY/d4/mjRgd49etO9Q3t6TNqFU1IVBzw8J0IQgrIIQSiIV26kjrzDtH9mcsI2rtwmIQjFoIheTLkSa7ZP60nrDqPYqnmLkPTCSh/jZRGCEJRFCEJBvEgQxelBmF27g0+qHFIesGjoci46J5XbTwhCMSimm2s2HmaX2LtBlWsuobyOJYeEIARlEYJQEM8ThFyagZuOFrvXbuDIWRtS83zZO3oOx8wjyn1JQhCKQSGCkOcQ8tABU70b2PpFkF+VVuiXRAhCUBYhCAXx3CeIZDtW9+tL765dGTJ1J24xfmiOX80l+9hyX5IQhGKojQPlaiJVFURYuARJRGS53wtB1H2EIBTEcwWRG4zW4lF0/PkH/pq4Cbugh5zZdRn3mNxyX5IQhGKo/YIoICk6lrScyp2nsoKQREQSGxdPVHQM/gGBhISGPbNdCKLuIwShIF7WSB1x/wwbt57ELzIC/4h4ciuodBaCUAy1WxDFxLveYPPkFZy3klRqPMSrCCIsXEJUdAwJSUmEhIVx9645+1T3sXzZcnx8/Z55khCCqPsIQSiI5wmiIC0CG/0DzJmyHPV75b+YpyMEoRhqtyAKeHjxDBrql3BPfPLUKc0rLF0nQkpiYjRhseWfSJ8niEdVSDFx8cTExuHo5MxRTU0WLVxIp/Yd+KRRY1r89jte3j5ERkU/fp0QRN1HCEJBPE8QhZmxuJhdw8jcm5yXFAVCEIqhdgsCClPCuKW5jQN6ziX/hwrCOb11DTvP2ZCU5MWBjcrsNZaUe93TgggLlxARGUVkVDSRUdH4+QdwRfcqi5QW0r9vP3749ju+/Oz/aN7sW75v2ox2rVrjFxBIXHzC49ekpqVjaGAoBFGHEYJQEGKyvrrLI0F89dn/sXb1GnILComLT3ghSckp+Pj6MXnCRIqKpYCcnNRE4hLTqfkRDRkYLRtKi996sONOBOS6snhgK9rM0MDFXpfZ/UegZl9+utenBREUHIK3tw+mpmZs3bqNvr170/p/Lfjmiy/55osv+fG77/m5+Q/83PwHvm/ajLYtW+Hg4Iifnz+eXt54enkTGhrGuTNn+U+9emhoHH0lkQpqF0IQCkIIou7ySBDNvvyKWTNmYmtrh6mp2QsxN7/HlSu6jBszDjlFJPjfY+f8WcxSPoqVb3wNS0JOSogLhprbmT15Fdu3r2PlVg0c43MpjDRHec401F0zyr1q9apVXNC+QGxcPNdv3GD0yFE0/fIrmn31NU2//Irvmzbjp++bPxZDWX76vvkzNG/2La3++B89u//N5ctXiBdL49Y5hCAUxGNBPLCqcjFg9cBKCEIBPBLEH7/8ylf/9zlNGjTk40aNX0zDRnzwn3cZMGAIslRXDu3ZiY5LydJvOTFJlFQ65eBpZsS1ez7kPNW6nJ8RR3zmswrJS47CzzOCQiA/LhB3STLFhRmEBvohSX/Uo6EIuxPT+b7FBE7dL5nHSRZ5D+V50zjinF6hILS1L5CQmIStnR37VPcxacJEOnfoyBefflbuyeERP373Pb//9xemT53GnFmzmT1jJrNnzGTShIns2b2HhMQkwiURCv/eBJVHCEJBJCYlM2vGTBzsHaosCAd7B2bNmCkE8YZ5JIjmTZsxdNBgDh08hMoelReiuleV9WvXM3bcBGTRVuxYOJox8zegsmM72w+cxCwomTQfUzS3rmb+wtXoBz1ZE85dbwdbrvk/893Lo63YOmc5uiEFIDFikdI+HAJ9uLBrE1suBwKQFe3OfQcnHCxMMDRzIakQZHFWrF86i0OOaRUK4lEVkyQi8nFbhImJKTu372DihIn898ef+PrzL/i+aTN+/O57fvq+Od83bUb71m0Il0SQnpFJUnJKCSmpxMUnEBYuUfh3JqgaQhAKIjE5hUVKCxnY7x/mzppdJQb2+4dFSgtJTE5R+PX8m3i6DWLDuvUUyyE5Ne2FZGRmERQcwpTJ00GWhsXhufzSuD6NP6jPp38M4pRzAMYbp9G7e18G9GhPp95DmTR+ApPGj6Z3u1/4b/veTBg/ofR3E5g8ehAdf/uZln8NZcrYAbT9/jf+6tGLTh1HsulyMBQGsHdMHzr3GM2sUT3pNlcF53Qgw53De1ah9TDrhYJ4dK3hkghi4+KJT0zC08sbAwNDtm7ZSt9evR/L4evPv6D1/1qU68UkqPsIQSiIcEkE7g89MDEx5c4dkyphYmKK+0MP8fj+hql6LyZ3pk6bRlagBZq7dnHW3BOJJILouGQKinOwPbGGfq1b0Op//+W/v/xB25ataNuyNV26dOPvTu1Lf25F25YtablZTSoAACAASURBVN2qM337D2dw7/a0atGZYcOH8leLlnQftxGbeClEGDOt71+0+eMP/vdzG6bsMiRRCkUxD9E7dhL3jPIjJF40DiIsXEJkVDRx8QmESyJwc3+I7lU95s+fT/s2bejUrr0QxFuIEIQCP/iIqGhiYuOIjomtEjGxcURERZcbwSp4vVRZEG4ezJk5HHutYxxUtSKv3J8dkOPPyfUrOWgdRVFREUXFheRmZVNQLKW4qKjkd0VFFBUVUyyVIpUWU1RUjFRasl0qKy34ZVIKn9r30a+zk6PwdgqusFH8VUdSh0siiIqOITIqmnBJBHb2Dpw9cxY//wDCxM3KW4UQhEBQSaosCHdP5k0fjJnaDtZtu/dsIV2cTajjTfatmMf8NbpEPW6CSMdO9zjnLIKp2dUfyqeyU22EhUsIl0QQERlFVHSMwr8XQc0jBCEQVJKqVzE9ZOasSYSbajC9x0i2X3hAbF7prX1hMh4W+pw5ewPvpKdWD5RmE+pmhaVH1GsYL1E9QQjefoQgBIJKUp2R1JMnTUFeEI/7DQ3mDBnBqJFjmTB+Nhv2XMYrKb/cH+KbjBCEoCxCEAJBJanuVBvFpQ0CuamJREdEEBERRVxiOgVS2ZuzQQURghCURQhCIKgktX0upqpGCEJQlioLIlwSgSQiUiCo1byOLsBCEIJ/C1UWREhoGL5+/vj4+gkEtRJfP//X0gVYCELwb6HSgng0YGb2jJkMHTSYCWPHCQS1kiEDBzFv9hyiomNqdLoHRQlClumHvu4tfGMKKYx3wNjWBz+Xisc0VCVCEIKyVEkQYeESRg0bjp+fH5mZmQJBrcTLy4vRI0YiiYh8KwSRF3KNGX0Gs3ivNjqHVjB/2S6On3Kg/NI/VYsQhKAsVRbEhLHjiI+Pr6H/miIiNZ/o6Ggmjhv/1giCoihOLR3Ml/Xq8X69/9Doh4EcsU2ssc9LCEJQlmoJIjo6usb+c4qI1HQkEsnbJQikOB1exqSJi9E8f5kbd91JqsHRc0IQgrIIQYi8tXn7BAG+OmuYvucy5Sfrrn6EIARlEYIQeWvzNgrC78ImVh/SI+41dIQSghCURQhC5K3N2yeIQtyv6mBs4cPrmJRDCEJQFiGISicfX/OrXLX2o+DlO4u8qeTF4mBxG9uwJ2stv32CKCA+NonMrOKX71qFCEEIyiIEUcnkBd/j8MZF7LhgS5q0/KIrIm86hUS53mTrjMH88XsHZp/xeLzl7RPE640QhKAsQhClKYpyw9TsLkHlV2IEWRFZKYkkJKWQGmrP1YtnMbCNoOQ+Tk5OtD8ewTEUSbPxcLzLdfu4F59MloS1sS6XTXzJLigzy7+8kEgvC0zdEmrmwl5jinKzSE/P5pn72eJ8MlITiY1PI6/wdU4+JyMj0oWz2+fTr81/afbZxzT+ug0zjrk83kMIonIRghCURQgCgAIcTyozctouPLMr2Jwbg+mRzShvU+GqSxzR1uoMHDKH03bJANjumkaXP2eia36TDVPGs8Yw5MWnywlBU6kHP3RZyt3QMicsDOTYlInsuVXRMeRkxUnwdXfGIyyJAoU+wMiJdbqNpro+YflP3og8xRfdk9tQWn4IM484KnqLBekJBD90wjUgkszCyl9EQUoYZud2M+HvFjT/5hu+/boZPzb7hi+ad2DWCdfH+wlBVC5CEIKyCEEAkI35/hWMm3ucyOfc9Cb73efCiYs4RGYQ63qR+SN70H3EZhzDQ7iwbjZjJu/lrrU+K8eOQcU26eXn27mUmUvOEl12mbBCf9THjUPlTmjJz8UpPLx3D1dJKiAj8oEeqqsXsv7YbSJyFTs9NMUZ+Ht5EZn+9DOElGiPO2id0cVJklmhINICbNDaoMSyvdq4xla48GaFkeUl4m58FuWxPfnpm69o+nUzfvyuOT83/4GfvxWCqG6EIARlqaWCKCbSwxL9a06kV7hdSqj5BXap6uCZUoUGO1kytjoHUV6viUN0HiDHXWsHi+YdI7yiMrcwnps7ptL+525sOu9KPjIyEsK4o7GSEV37MUH5JN7ZQI472xdNZo/1y0a35vFAdS0r1l0irmwJWhjA0YkT2PuUIKx0TqBzz7dkzp2iXNKiXLh+25n4nIoWoZQR43SX63fsSa5gc0GCO2e3K7P5sCHBFSxc/+qRE2V/iWXjprLjoi0Zjz63rDB01o3g9zZ92H47oOJlMmWFZCX7cueODQGxrz5RRLLbRcb//gUNG3zKd99+XyKGRwhBVDtCEIKy1FJBQFqoM4aGd7h//QJX73s8060vzdOIJSOG0ql9D+bsMifjuUcBkBHj9RBnJwkARXH+3NbV556tBae3zGfc4lOE5ObjcXYnSvM0CZeBXCZ9pmCTS0xQmriBI4c2s3DVDqxKmwfSg++yfvxcDl20LpkPJ8mBLUqT2f1SQcjwOLEBpSWaRMghz/8Wm5es56JDDHJZKMcmTWS/RezjvZO87nDd6cmXVOh/mdnT9uEYX/Ew2uxgB67rG2NqpscJY/8nG7J8Ob5yOxqXb2F33wLnkBhyqvgQUiCxYNPUYfTt1JN56y/y6JkpzfYiG2Yqo66+lfHLzhFRWECYuRZL5m7iunfqkwNk2LJ25nouO776VBEFadHYX9NgzsDO/Lfp1zT9qik/iCeIGosQhKAstVIQ0rxs8mVy5PJ8PHXWMWT+dkwfhhAaGkqo6zVWDhzCsuP38bO6wKpJa3iQUP5OuDCvgKIiGZDN/cMbmKd0mHvWNzilfoabFs4ESKKI8DBg2UBlTMKTCdQ7zLqFx5AAkvtarN6ijWtgKKGhoQTaXGBG9250bf0rLceuxDwW8kPucfjgRZzcLDi+VwszjzTI82X/xjnselBBA7O8iNz8QkoWDZPjdXI9SkuO4h8XyrXdm9i5fS3Ku47hFhfC2aljWXfmfsn1hvqjt2cW47Zo4x1a8n4CbC+g1H8DpmE5ZU4io7Awj7wikEtzcb+8gxHDd2DhX/LZ+VtoMbnPQs7bh5AQFYKfTxCJWeUlI5Pmk50nBWRkJsYSGhRMSOm5S/BEe+Nkxq07ioHWCdT3XcYjpGSb+42jzOjRgfbt2vHncDUe2Jtxcts2dm5QYu42TRz9SvYL8bvD+mHL0DKTVFgN9aLkxftxTX0Ngzq24IevvuSbr7/lJyGIakcIQlCW2icIeTbexqb4ppXWTSfZoNT3Dxq9U5+PGzTg4y+b06ZNe3qMn8+m9WtQXriOe2XraaQJ2Fq5Eh5bMlIh1V2PJb1+48tPP+OjDxvxf598ymeNm/BRgwZ823ktblkFhNzU4fBWQ1KBBCcdprRpSuMPG/JJ4yZ82uQjPm34AfXqNab3gnPES9PRndWFT997n08avU+DpsM445QOBWFcPLgBHZ/yLd1Fke7cfxhAaml57K+zjSVrjuHlY87sFk356IP3+L/ui7gZ4InW4JZ88u57fNS4CZ80bsLHjRrxUcPGfNK4CZ80akSjD5vQbsYposqW7QUpeDvexT66pNpNlmTPus4/8NGHDfi49FifNG7Cp42b8HGDD2j81TBOO5SRmVxGhsQJ67ACyPZk0/C2fPzhZ3zf7Cs+b/LoGI1p8mFjvvnqB3798Ts+aVRyzEef1ccNPuC9dz5myJ6beJgcpvunjfj0869o9n+f8Vnpfk0+eJ9veq7BJqbqo0lS/CxRXzudbr815+uPm/Dxt+2ZeVz0YqpqhCAEZal1gpAXBHPluAWJeaV1HzJ/ds2Yz6JV21BT2cO+0/rYOdlwWXUpPTp2ZsQm4/JVTElOaN+5T9CjBowsD1Q2zmL6qj0c3L+fA2pqHNinhtpeFY6bepFPDh6WJly/W1qtk+bJwamzUN69l/1qahxQ28/B/fvYu+ckdxxigXTstE9wQGUvant2oXbpLhG5UJAcyJ1zhkgqqPmJNjfCzNHn8dTM8eanOKB+kfCsFJz0T3Fw/SwGTl/LjYBYHuqf5qCKSum51Tiw/wCHHr/vfaiqHkTfNYKytUOF8SE8uKJH0KMNBcGcnjUOpQ17Hl/HoQMHOKimxv69e9h38jbBaWXacKTZ+N8ywj0byAzB+PJh5g/uSss/BrFqT+n7UVPj4P7S4+xTe/KZPv6s9nNA7STWIakUpARjrKXOruUT+GfcDDbvLtlv324Vzpg9JLPCRorKJAdf8wusn9yH5s1bMOWk2+MttU0Qzi6uTJ4wsboX/Nqyfu1azp49JwQheEytEwQ5nhycvRV911iK8qK4o7aM6WsvU77SppjoiEB84ivoBRP3gC2q6hj7Z1JcFIPZwW0o79bn+aMTCslIi8LbPwA3h/ucWr+AFfutK/3Wi/KzSY6vuOdOwNX97FbXIyqvmPwoR9TWb0PDyKt0sRcpXlcOs0HlKpJqzKFQnOiB1qZVaLslUpwTwXX1Ncxdqc3L+lQ9E2kcBhsXsu+mHwD5sU5sH92fSTvNK10V9CQpGO/ZjIq+V5WP8LJI08K4f8OQB8FPprGrbYLw8vahZ7fuzJs9h0VKSrWLBUp06dgRfX0DIQjBY2qfIGTZuF3ax8yhwxk1aQ6rdp7HNTK13N3yC1OcgZ3ufqaMG834qbPYcFgfz5CMlxZwhfH27Js3gSnLNPHKqMF5lIGCeDdObZzLuBFjmTtnI6fuuBGXLSU30pVz2+Yxdup27gZWNAijEpFm42agyszRwxk7cg6b9p7DRpJVyYI9H8dTC2nbsg1/d+tFz87t6TxkJXfKjtd4pRQT9/Ame5QmMnXVOQLS3mzVSm0SRFi4hJDQMCws7qOvb4CBgWGt4/btO/j5B7yWdbwFdZPaJwgAislKSSIhKZXcqk47IysgIyWRhMRUcl+5GkNKbmYGOVUYvPVKR8/PIjkhgeTUnMfCkxUXkJWWQnp2DQlJXkx2asl151Xxs5OmeHNs6RDathvIyt26eCdVdc0yOdKCXNJTUsl+raOqK05tEsQjYmLjiI2Lr7WESyJeyzregrpJLRWEiGJTRJiDEfs2qHDRwoNqPtcoLLVREAJBXUII4i1JQVI47ra2eMaX7fpalRQSE+iOuYEx1h6BNdCQrJgIQQgE1UMIok6nkCgPG27cuIXZrVuYmN/DLij15S/7l0QIQiCoHkIQdTnyfKK8bbl50xj9UwfRuulAvKLnZ6pFEYIQCKqHEITIWxshCIGgeghBvCUpTgklNDm7ct2B33CkhamE+EdT0tk1m8CwGNJe0+poIAQhEFQXIYi3IUXR6K6fxxZ9j4pnTy0XOTFOZhiZOpJS4QsKCXO/h9buQ1w2dyS5hoYv5IYaM6ffODYdsyHE8zJzl+zlQfjrWF25JEIQAkH1EIJ4G5Jsg1L/EWy/FvDKL8kKsuGqoTmRuRWN+ZCRGumN8bnTXLxpQ3ROzdzlF8feZ3n3wWy77oX3eWX6jd2AY8rrW/VICEIgqB5CEG9D8rxRGTML9dsvWcnuUeT5eOpvZdjoeei4P28ijgJS4iXEVqGPa15qDP4ebri6exL69NQj2V4cmTSNU16pJN3Zzdhle3B7jZ2uhCAEguohBPE2pMCXfWNmceRWcLlNhUl+GF0wxDk88/Hvsnxus236FGbOnsrkHfpE55dtuZCTFeSAzkENdIztkCSVDJXLlrhw9YIxvglPz8CaT1x8Ell5pSIpSOTmznH89vknfN38d/5Zc53Hy3znh3Bm+Uw0nBNINNvLuOV7cE2psU+hXIQgBILqIQTxNkQahMbEOajfCgHkRDo64OYZTX5RBq6XD7Nu4XxWHLpKTGkZnuNpxMYJ01Beo8Q/Q3Zhn1imCkmWyQMjbTRuSEj30GfjgWsESsKxPrePlfPmsuG8BU+G44VycNMhDN0ezalbQLibLksHdKF169Go3A5/6sDp6O+ZzVqzUFKtDjFBeS8ulZpJsHIRghAIqocQRB1OeqATRrp3iSyKw2D+arQto4ACLNUWMWvLeXy8TFnUszsDB/Wla8cO/DNsHBPGjmP8sL60avoR79Z7n/9NOkZ4fvn1NHR3T+CP7kOZNKwHnaYdxMT4JJP/6s7gQb3o1OlPhowsOdaEEf1o2fw3OnQfXPLz+InMmDGJf9r8wndft2DgqPFMGjuOCWPHMnbEYPr2HcMxj0zy3c6wbJ8mHuIJQiCotQhB1OGkeppy9Mh5nKO8uayii7ukpCoox/U0SvtO4ODrzMGp/encpgV//PYrLVq0pX2btnRo15Fuf3Wj+58D2GLwkHKdlKSpmB6ZS/sWLWj1v47MOX6fmAAL1g3tTsfWLfj9199o1arkWO3bdaLn393p1rF9yc9t2tCuVUeGDB/F0H696NK2TenvW9Pq99b0H3uIICnEW+qiY2BO0mvslysEIRBUDyGIuhy5HJlMhixXgoNHMCl5APk4nVdh55nbjwvfmLsnWLH1GO7JUqTSp3l+6SyXyR7v9+T5Qo7fFRWWq11FklV6jMJ8svPyKZbJnzm2rPS9PXs+KTIZgJRo3wBCQ19j/RJCEAJBdRGCeGuSQ9hDKy6qLGXsHBVM/dMoSgrE7KIKs8Yv5cTtsFccI1FR5GREuGN0fCNTxq/DwCn+yaZUT84ePYulX/rzX66gCEEIBNVDCOKtiYz0CA9u6xtgFZAMQGFKGDbXdTG08KnmlN1ysmJ9uat3mVuO4c9UScly43C2tMM3stzCrwqPEIRAUD2EIETe2ghBCATVQwhC5K2NEIRAUD2EIETe2ghBCATVQwhC5O1IThTWptd5EPKksVwIQiCoHkIQdSKvb0K7up98wh0N2TC5P7/+2p5Zpx8+3iIEIRBUj7oliJwwTAwvcd01luzMWJyMTfHJrM0rIDyJrDAZJz1TvOIyX7m4lxclYHX7Pl4Rj+6K5eRnpJKSkV2lLqtZUTacMnQl+4WTs0qJ8jPn7O2AWq4lKalh9pzcOIteLX+i6Wef0OTrNsw45vJ4DyEIgaB61C1BpLiweWwXOiw4gY3peaaO2YNT2tM7SEmNDiMwJJHXtwxN1ZLrc5EJg5W5FpD18p1Lk+97malzldH3e9RJVYrkvh5nrt4jsaiyxXcWd7ZNZcDKiyS+yKnFEWgtHMV4NcvyI6xrSfITg7mttY0xXX/nu6+/4btvmvFjs2/4onkHZp1wfbyfEIRAUD3qliCk4RxeuJjVJ12IdrvEuGG7cSkzPivS3ohjx02Ir0bpVpAUwoPb9wlOf9FBZCQHe2D9wIPUV7idLw7SZ+KIDVwLyHz5zqXJ99Zh8lxl9P2fTI2XE2LJWZ2bBGdU9skpi2urRjNm7y1yX7RbUTDq04cwV8ejksd//ZHlxuNspMXyUd358euvaPpNM378vjk/N/+Bn78VghAIapoaFEQ+IbZGXDL3Ie85f+Dxjgbs2HSYe2Gvfhf9bOLQXrmWrceciHS7zIQRe54IojAFL4tr6Fk4ExqXWa0niMIkf/RPaHHXP/nZDel+XNi1gyM3PCkAUv0ecF7LAL/0l5+tOMiAySM3YvRcQcjJiHDm1PYNbDl+h3gpFPtfZuq81Rg8EkRGEGeUh/Brq55suu5b4TUWxD1Ee89qli5byarly1m5ZCFKK3ai7+iPufoCphy+/dRMrI9elMh94yvoOcUCyVzeNIn5Fx9WcHTFJtntIuN//4KGDT7lu2+/LxHDI4QgBIIapwYFIScpwJrrt0y5ef4K182eXd2sIPQ+m6ZMpHvnroxcpENUleZ9KOTezi3sVLtLkNMVJo1Ww7v0Jl+eEc4Dg6MsHTeYUbNWc+KaHZLYVHILq9JGkYOnpRH3Q55a90Aax839axnUvRtd+izGyCsVkJGTnUl2wcvPURxkwORRW7kT8aRYj3pgiWtwEnJZBi4m+pw9extHu1vsWTqH5Zp2JAZcZYbSBowlJfun215k46zVHNXYzrglWvhnlTlvUQ7hzjdRWzuZls3+jy+bdWX2yk3sPnIR58g4LA/PZeLBUkHIiimWPvoSsrA9t55RS/byIFSC4Y6pFQtClkJweCSp5e4AikmOTuTpxUPjHS6jPG8x+y9bEplRWL49I9+fC6f0cQ4vp6vnpiAjDmfjEygN/Ytfm31N0y+/4YfvxBOEQPC6qCFByMnNyKVYKgdZGub7ljFz/m4sffwJ8A8gwNOEraMHM2WTAYEB99g+YQF6geUrOgpy8ygoKAaKSYsMxt/PD39/fwIe85ALK5aybd8dApx0GTd4NfpOJdv8vL3w8nTDYNdsWn/WnHZ/dmfgsJXc8C2/ZFlxYSG52SXFWW5iJEF+vs+ex82E7YsmsPC4eenvvLiutpgBfZdzNzoC49Xz2HTaAak8mRsnj6JpFFhBo7GMnPQciksnxJMGGzJ52BI0brmUHtOaAzMmMGfhRnZtWMa6AxexdPQgJDwU24v7WDD5OC7uesybPZ8jtx4S4O+P87UjTOvehlatWtJ+wF68sssUu3IoSA9AZ9NK1my9gn9KHsXyJxudzy1lsoYpBUC68yV2aOjgnZpHSngQvvaXmDN+OUdNfbl3cQULL1UgiDgHjh47gI6lL/5+fgSFRpNRIEWaYM3GSSvQvGZfcm0ejljcvozqqum0/7IpLbuNYtPhKzxw9nz8Gft7XGPJACWOmYaXP89LUpgchPHxTQzv0pofv/qSr7/+lp+EIASCGqdmBFEUheltRyKTCgEoCDBkepcvefedD2hSvz4NP/mGlq070G3weJau3cDqmUpcDSgriDz83L0ICc9GmmTJ/FZf88knX/DtF5/xSYOGNGnQkCbv1+Odz3pz5F4c2b7naPvVR9R/rz5NGjTko4YNafxBQ75s3o/1GjdxeOiCq5eE7OKy964y4iMDcHGOh+Io1Md25PMGH9H0qy/5rFHpeRo05KNH5/ywAY0aNKbpz635q1tPRq/czvbpk9h+xYmCohTu7FjOig0XiSv7EFEQirGxC8mlXYbkYbeZ8Fdz3q33/uNzPDp+4/oN+KhREz5t0piPPqzP+x98Qd9lN4gKvsG0Tp9Qr17pNTZqzEcN6vP+Ox/Rd5sxmeVuy4vwMjzMknVa+CcnE52UxZO3JcfryjZ2GbkiBdJ9rzJ7/GYu3TFgRatvqF+vHl/8vRzz0EQczm9Fw1pSvmTO9GPvlA58WO8/fPhefT7/pgUjZy1FWWkmfX7/no8+qE/jDxuUfh+N+OSjL2jVfRQL589iQOsf+fjd92n8Ycl1N3rvXb74YzY3K9EmUzbpQTYc3zyHHv/7ga8/bsLH37Zn5nHRi0kgqClqRBDyaEtOmzoQ96jqIdacNStns2zbYY4eOsjh01excXXlzpmdjOrZmb8XnCeusMwZc0MwtbLEJxFI8cPgxD5m9m1Hq54T2XlYg6PqGhw9uJ/Dl00JyQKSfdA5qYn64SMl29SPcPiABjo33HhhkSPNwNvFBJOAYpDFc//qWdZN6sP/2vRh+a7S86hroKlxFE0NDY6qq3NEXZOr95xwtdRn07S+/NJ9HvreJT2Lwg3PcWS3AQlla3tCTThu7vWkS2n4TRauXMqG3YefnOPoUY4dPfrUuTQ4euQwh45qccs/FXlmKCaXj3HwYOk1amiU7KdxFpugClbayQvlxN417LwXT374LVT3X8I/6dEHnYPjJV2cw0pfV+zDrs2aGFo6Y3zmBIdUD3Hp7kPSCnMItnMhIa+iFo5iIhxNOLV/P+rqRzmueRT1A/tQUz2Ots45Thw/ylF19dLrOIKG5nmsgktuBCLtbnJCbT/q6hoc1TjKMXVNrlh6UYUlr8teNIEPrrBl5gB++rElU7XcH28RghAIqkfNPEFEmLJigyo3vBLJS/BAa9VClhw2Ld8YCmQkhuEdW8Hcoqlu7Ny0BjWzCACSPfSYO2AQy7W9q1F4VJDiZK5rrmXBCXvygYJ4Nw7MGsowZf1Xm/G0IJ6H3v5EZeST5GPCmkUr0bgVQdkHiCx3bWauOYZTbDY5aQHobVyHyiXn1zu2IDsI9Q2zWHrBk+KCTGIiY8l9XM4XkRqfQnJiGnl5MVgc3swyFT0k5VcLIjMlFknCyzsS5KTEv1jG5BEZHE1WBRedFh2Ib3gCua/QfvMqkWdGYHPHGNswMZJaIKgpakYQxSlYnNnOuBEjmDB1DltO3CIo7nl9mZ4TWSL626bTovkf/PnnX/zZugMDpqvhklLTRWox3ga76Przb3Ts1JXuHTvQtc8CdD0rs55BNj53z7BwzDiWapqRVEFvWGluJIaH1jJ65EimzF/OoUs2xKcVlN+xJiMvxFt/N0P/GcdWnfuEhEsID5cQExVHUlpJUZ4jcURrxxImz96HXXh5CRQlunBc/Qw3rYKeaXQul9wIbp1W54xlxHN3SfO/x+Fth3gQ/Wx1ojTejWNqysxadgR7v+TnvLr6EYIQCKpHzfVikheRnZFGWkZ2lbuYFkbasG3GULp1G8kunftEpL2m4W454VzaPouu7XqzdO8F3CMru1qCnOKCXDIzc3jheDVZAZlpqdX6TCodaQ6BFudZtXAmk8ZNZJbSao7dcCLmUdcjWRG5WVnkFFRct5PldYWZ83eiZ+pKwouuTS6jqCCf/KLn1xHJpUXk5+VRKC1zIFkx+fl55OTkUVT8+kbCC0EIBNWjlg2Uy8Xj+lkO7lPlvFXEa62OiXa5w0mVrRy85kp6tevB355I0yR4+kVWc4Gh2hEhCIGgetQuQcjziHC3w9LCjAdesa9xqgcpySFe2FncwtQpiNdd8yOimAhBCATVo3YJQkSkBiMEIRBUj3+VIPKSIwmJTa11E/m9zkgL88jJfuHsS6/x5LnESMJIyFFMHZ4QhEBQPf41gpClB3Fl/zLmH7xJfEHtnsi6JpOfJuH+zXsExr7pejQpsbbaKC9dxln7uHLdgN9EhCAEguqhcEEU58USGJmGrAbLbFlaHFEx8c+Mw5AmOXBE7TDndCyJLTc/k5yMmBgiAhORAfL8LGJ8g8ioubf0BiKjIOtJ12JpbjQuXjHIkBFicYWjZ+6QXCOPTjKSfIKJS8t5yuDRLQAAIABJREFUaSeCwJuH2XP2DoGx2Y/3lRXmkCcHyMQ3KJKUzNf3PCcEIRBUDwULIg1z1dXsuuJWpQVwKk4qt/fvZscJ62cGccnyknC/d5U9C0/ikVp2GHcGt/dvYvHG62QB8mhrto6bzRm319dHv6ZTFGPN5tlLOWFd8p0k22kwoM8o9plHIk+1ZZPSak5Zx1X7PLIEe7ZNXIW2XUyF29MCHdE9tIO9OvcIifLn6jEVtms7lYypyA/m9LL5bLrsQKijNrMWqWApeeFoi2pFCEIgqB4KFkQM56eMZt155xqsgohCc+FCFqhY8XSlirxYSpjJHob334hNQtn+UblYHZpHlyEbcMuE5Puq/N11Ipd8FdnZU0ZeRjoZWfmv9NnkBl5jQstfaNl/OfciM/E8uYgurQZxxDYJiOf4nCnMVzGtdvfVLHctRvScy0X3tAq3FySHcv/KMTR1zAhNiub61sE0+3UgardCkOa5sLhlG4as0MToyDIGTdyIY+rrq+4TghAIqoeCBRHHpbmT2HjBpVwhWJgSiqO1O5Lkl4/ITgv346FPVGnjcyynVixnqZp1uZHAkaZ7GTxcBZf08kVuToAeUwdM4YiFN7d2TGXonDNEP6dkluWlEOwXTmqFN79ykgNduHvHjvC0sk8qz0aal0psWu5zqmpycNM7zTFtC5JfwRByWS4xHlacU1nH7NmLmTN1LToWoaVPZinoLRvP8OXaxFf2Ua0oGQ9rK5z8E0rOE3KNqSPXoeddcQWcPC+UCysnMHbmAbxTCsiN88Lw2DYWzFzMlo1rmLf5CqF5BUQa72Tcsj24lZ9st8YiBCEQVI/aIQgd12cKyewIW1RnDqdlh+GomJR/c09HnuHL2fVTGTNhMRqWkUAiZ1auYKmaTckThDybEH8v/GPzSHU8yYgxarhUNDJOnsDFtfOYPn0uU/pM4IDF889bnObDuQPHuGHlTrC/P4/nw5PnEeZ+g51rlVm+aCfnrrmSVvD8OvY0j0ssXXwAp9inRJKXhI+jNwm5MgozonD3DSbtsYgKifb2JiA8+flPFYnObBvcjt47DEl8/MtUDJaPoc+Ck0S9cHCJjLSoRLILS76NjFAvLK5fQk15LoOGK3HhYRKy6FtMH7WOq14VTU1SgLvuYWaOn4vS9JnsufawdCxLPrdUF9Dtl2Fc9C2p+Iu+VSII1wrmHKypCEEIBNWjFghiMlt1n5qQL9sP9SUr2XTYCHsfb0JTXnQXXoCX0SlUT5oQEmiF6hZVHEP9OKeszMojTo8OyK3921h/wJ4It3OMGrUP5+cMnU6xOcbwNk35ecAuvF6ypGdBVhKh1tosXbCYi0GP9k1Ae88iFl8KBqAoIYVcadnnAzmFRQUUFgM5EVxcNZe5and5PCuSNJQTC+ZzyjWZotgHqKzbh2ngk6cot+NbWKuiS3wF3pFmxOJ4ywR7FxsML+th459U+gQRj7bSVJR2337x5Ho5fqgv2spVh3ASwr2wuGmBk39Ju4XL2e3MXaJPfOx9Fo7diJ53FpCCg8Vd7B6vsy3H+bwKE0YvZsW8QQzfe4M85MQFu2Fq4YqnzW10jT3IARIt1Bi/ei8uSS/8mKsVIQiBoHooWBAJXJrWjw6t/2TY0OGMHDacob078fvPw9F48PxJ4B4lV3KP5X3a06JDf8aPHs6AXuO54uzNlc1T+eWXLgwfNpyRQ/vz5+99WKZmT2LYTWYs1MIr4zn1LAV+qEwcwgKNZ9svnk52sC8+wREl2/ND0Vwzljad+zJi2HBGDvmHLq1/p2XnPowaOpRhoyay7pxDuSVY4xx1WdK3L0NHjGFI91Z890Nr/hlScv3DB/ele+dBaNinIM2KQGflRHp17cmQIcMYOWwovdu0Z+pOfRLL+asQN+2VdGzVjv5jxjK4fV+26j8sEUSuB9sWr2S/cUj5qry8OLxcIygEKIxDd+VkRg0eQp8uHejSfSATxo9jzIjh9P+rHxOVDEhNd0Z56QFuB+cBkZxbPYmubXuUfNbDhjOoWxuaffgO773fHKVLnuQnurFzZGfad+3P6GH96D30AEFyyHE5xfJ9mnjWwiqmR//Hn7ddCELwb0HBgkjFZNMc+rVtTccOnejSrj1/Dp7IrPFDGDh+KYb+FTepZoZacf7SLa5rKdOlXUe6/9mZDq3aM3CCBiEZydw9oUyX1m3p0rETXdq1o8foFdwIyKXAz4CtFyyfVAmVSxH+pnfxCE96TrtALm4mFtg5RZZul+OgpUzrb/5Lx46d6NKxM393+5teXf+kS7u2tOvUhzV63uUK5Xh7HWa1a0Xb9h3p9tff9Pm7G107dqJLx050bt+FYYtPE1zaR9dXeyN9W/5G27Yd6dqhLZ36zuO8XWwF7y8DiyPz6N6lE13atabzXwsx8Cipv0l2ucpOVS08K2gQTgu+i47l/7d3nmFRXlsb5sTk8yQ5J92osaAx50tOPpMcC/YaDcoxmqYmGk00KmJBBUGwBStWLGDBrtilKESlSUekKCC9M0PvvQ7M3N8PEA0MKg7W7Oe67h/jvI0Z5332u/ZeayU1HC/fexsj+n9B774DGTKgPwP6atC/1xd8PuhrTBwkyNPd2XLqMnH1Dw0pV835/rOP+Ow/fenfV4NBA4cwcvgQRo42wCWxhKLoP1g8TAONvn3o1WsAP29zoRwFqa5nOWn9cPMrj6qWGkRSsoTUtHTS0jOIT0hsdjthEIK/Ck89D0KZ5FW5RAeFIilRNtJXkHr9LKY797Fu3VyMryY3fyCFAllZMSUVldQApbEhhGcWqLCktoArFpYct6sLIdVm+LFFfwW7HFreNlOp5DLKKkooyMwit6SQ9Ns26P6gh5VvJqBAVl1KQXElimYW/iiUvCErTcfd+hJugelK95F47me5dWT9+fNw270KozMBlDfzIVWnRBEeE4mkqJjCjFAOGa1g16kwms09VChQNElyqSU1MobExMe7jPhhDUIiTSEjMwtJSir+AYEcPHAQOzs7kiUpSrcXBiH4q/BMGgRUEOZ8joNWvjTftiabk1u00bOLb/4wikL8LmxFx2gLNs4x3H9N0cNIRvzFvej88Cv6K1ehN38RKzZbEfPg3joPp9JoTm0yZfnc2Wjrz+KH4WNZsP1y/XxDBSEOh1k+ZwVH3YIpeciRd2V+BonRKc2GzAqjL6O3cDFLV65m3drlLDOwJEhJn4g/qbqQoKuWzBs/jl9WHCSyJa00nqCaM4jEpGSSkiWkpKaRnpnJ7fAIzp07j6GBIVpjxqLeqTMbN24kNS1D6Y9GGITgr8IzahBVpMeGcSs4uUn8vkE1OdjtW8b80+HNH0ZejjTqBvZOXoRHZbROdVh5IeHuDpw4dJyL3jFKu+Y98qGrcgn38MHTw41rrpe54hRIdoOrVZERFYKnvTP+cSlUtFpoporUYFdOHD7C+au+pD5kn6fy9Ns42rsRm/c0img8nO41iKRkCckSKdKUVFJS04iLT8DRyYk1a9Yw4evxfNHzMzq89x7t332Pj7p/iJnZDrJz8pCmpjUhOyeXwKCbwiAELzzPqEE8hKpLiPa6jHtKa96ihV4k3TEIaUoq0npT8PbxZe/efUz8YSK9Pv+C7l3U6fBeO7p+0Ike6t3o1rkL//qwB2vXriM8PJKbt4KbEB4egaOTszAIwQvP82sQCgWtWsBJ6IVTcnIyU378icioaA4dOszMGTP5v48/oYd6N7p0/IAuHTrSvUtXeqh3a0K3zl3o+kGnZlHv1Jn33nwLw6UGwiAELyzPr0EICT1AkuRkfv5pCoGBQaxasZJxY7X49/9+zLtvvEmn9h34sKt6E2P4sKs6H3XrjpbmGObN1UF79pwmzJurwy/TptPurbdZqqcvDELwwiIMQuiFVUOIKTWNrOwcwiMiOXfuPMuNlzPmK026de5Cp/fbo96pM927dOXDruoNISZzcwtKSsvJyctvQklpGaFh4bz56mvozl9AXkHhU/8hCwSPg+fGIKrypYTciG1+0lpIqJEar2KSSFPIzM5BmprGDf8ArKxOskh3ERp9+vBhl650/aATH7zfnh7durN167ZmVzElJUuIio7h3LnzeHp6IZEqXw4rEDzvPB8GIcvF+4I115MKH2/jGYWMyntKWNTWVFLVohPWUlH1dLqnta5qKC2/u+artqrqqTT8UVXNLXNtnBB33e8G+y0PMOmHifzfJ//mow97sGFD88tc7/wOsnJySU1Lv29SnUDwPPMcGIQcqbslRntdKW6tu1RVAVHhN3Dzvk1m/t1nElmSC5tNN2F1Q0phkg8nLC3xzb7Pce5VbQH+F49w2kf1ngtPVfIirltbsNn6zvLhIrz2rGfzEXskJbXU5CUREp5IgQpd+SqyJURGxlP0mHu/PihRLjEpmWSJlJTUNKQpqSQkJOLs7MLates4fsIKSUrqU/+BCgRPk2ffIGTJ7J81hbUXbj+wg9lDq0yC3bF1zJm3DhuveGT1xlMZZc2kIYP4xcIZ35O/o/XNMvwetlZQaQhbxn/LFhepypdXkRWHl6Mf6ZVPaJWWvIKs5CQyi2Qgi2CD1nBmHL1V/2Ye55d+TT8tPXxyZVQnurJz53H80x492Fcc443VkXOE5z9eh2hJqY07yXPSlFTS0jPqDOMZ+IEKBE+TZ98g0l2YrTmN3a6q33j/pJoCIq97ExCTRc2d+3CBH4snGXA6IIVI261Mm7KZyIdteFZ2mx2TfmS76/3Lkz+MKrPCOL//JH6S+9ZebSXJkERc45BtIDklMpBFseU7TWYfD65/vxa/I4uYuNa+vgVrLaUFBZTJHt28qlN8Md9qxh8RypsOtZYeVzVXgeCvwjNvEDVR55k06jcO3Wgm1tOQC6GgvEiKl5Up076dxQ6HsPvMH1QT4WDG5GEafG1ygYw72cqVoaybbMgJnyTiru5lwU+mhDUzUM6LdWf/LhsS7uTpld/GrLFBKGqbpGrUyqqorKgbOcurKiivkQNyqqoquHvPLSfMx54zLonNPjUlOOxh9m8mXAxJb6gtVV2US05+6Z/2qa2uorJSWQ65nMLcQqprK4i7dphF2ju5kVKCQhbD1u/vNQgFoRdW8e1qG/IAZMlYrTJk9QEPCmtbbhLyMgkXTKbRv7cGE9edR1r+/HWUEwj+KjzzBqGQXmHGV9OxcG98LgVptzw4e8yHcqA6IwYnaweCJJkk+R7m14lLsQ7JR15TTm5m9p+6y5VHObD41zksmPcz08zsuDuOzefELD0OXA4n+so+FkzZyO3yZi6sPA2/a96ExkrJzStAVhbBrslT2XPj7qg/I+AsVjcy/7xfVhD7TCwIrACkV1m30xZJjhT7IxYc9ruzrxyP3UbMXFx/U26s4mD2G5lz5vQRNplsxSmyFJlMwrlN+szQMcVJevemWx7hzO71h4hqbHTyZM6fcycxSw7l6STn33HTVHZP0mLehbs1rvJ89vH9vKMk119botsepmpqcyHsEYow5fpj9st8LA6Z8fOUldiEP75CTsIgBALVeOYNgsoYzH6egqldXcXR0oJCigorgVriHHYx42ttdh7chbGuAdsPnMHO7iL2lw6gO0aHA84SqvP8MZ03jYXbTmBrbY2NtRWrfv2WkdPWYbV3LYarTTl+zhoba2tsLhxAX+s3DrnHI/E6w+8zNhGqJMRUnZNOdlld+bs0p13MX7oZP2kklpPHMWv1vrpjWZ/C5DdNRsxYzRnr+uNbW2NzbDNTRg7kW/092B5fx/g+o9H93RT9qZOZMHMTF6ytsb1whm1LlqCrb0eTKRBFCd77ljBh1krOXjrN2um6rDe/xnU7U2brLWPxb9P4bv62hvMd36zHtJ8W4pTWaKReHY7pnPks+X0/trZ2XLp4ETsbG2zO7Oa3Yf0Zt3h7/WdyAcu185kw/wypZTnc8rDn3CkL9LUWKL25lxcXkZ9TCtSQGuiK3fnz2FjbNFyP9bHtzBz+bzq1e5tOvRZwNb45B1ZdwiAEAtV49g2CGkJOLGfOPi9qawrx9/UmMKauT4SiKIxd03rz5mv/5J9t/85rr7xC2zYv84qaGq9/NpsridUgy+Pi2ql8oKZGm5fa0Pall3n91X/wXvt2dHynHe+1bUvbNm1o+1IbXlZT400NPW4UVJHu54D5SmuymkRAKgm95EhQQl0rtPL4i8yYrIelizu7tHryhpoar7zUhrZtXuGfr7/Fe6+/yt9fqjt+25fa8D9tXqfDB91Rb/d3Xnnpdbp370a711/nn6//g7dfa0vbl9rwipoaf3tfg9+vNp13KY+3Y3q/zryq9jJt1dRQe284267F4L9vFt3/8TJvvPEO7d94te58f1NDTe1tRs4/Smrjcq6KIpw2TafzK2r8Ta0Nbdu8XLdPm7a89ebbvPNq3bX8j5oabV7tju6leCriL/Hzp6+gpqbGRz+Yk9SkRGw1iTEhBIUUQvltjIf04LW/vcKbr73Kq/WfcduX2/LWm2/xdts3GLjwIMnNlZltBQmDEAhU4zkwCKjODePobmvik25xwd4az7T6N0pjObRzGcaHruDt5dWAl7sbXmGJdSWxZdlY71/P0m0X8LxnG28PDzw9PPD6037u+EalUkUVybc9cfBQ1kMhlXMWdgQn3Bn5JmO5chennKORhgbgXX9MH29vfHx8uO57nes+3nfP4enDDf+bBAX44OnpQ9DNm/j5+DS6fne8A26TUd54EqWGEMs1LNXdwCUPL7zd3fAIiiCrEuQlqQQHXGXr0gXMMTpSdw1ennj6BhGTpnyUXlOYwk0/Lzw8PP90/j9di6cn3t43SS+robY0k/DrHri5exKYnNc0N6IqA0/X8zjEKYAyYoLc2K6tRa+RMzly5d7jeuLh5kOkNE+F3hwPljAIgUA1nguDAChKDMf/6hV2797I2uMehIX7c2bz7xgYWdXHxhupLI0Qd2vMjHSZobOLkIddjQSAHFlNFcpz3rKwMVrGis3nuHU7hKsHTFi8cR83Mxs9atRk4ev4B5ddgpqGiR5ZMnxNV7Bxq2Oj/g61lBfnEe1xEmM9ExwT66+lJJFr9k74BERR+JhzDgCoTuPEhvn8vM6WpLR0wpwP8dtXo5lt7v/gfR+DhEEIBKrx3BgEgLymluzQy5jozmTqdG02WrmQnKe8y4NCXk6ozU7mL9yEa3xrdfSpU2HMNbYunMXUybNYvu4oN5KzmjQjKk4N5Nimjfy+eg12rdZRp5bgPcYY/n6C1HvNS1ZImMsRFmovYe/V6IaRfU7kNcwX/87249ZEFT2JnAoZ0Zc2M6RTO959pyOffjaQH+buxD+zVTpxtFjCIAQC1XiuDEJITvQfVpy09qTwWa3oUZ3Jlf2rmDZxNrts/chVvY3fI0sYhECgGsIgnivJKcwppLT0Kd51H6haEj1s2LNxJZsvBFH0FI1MGIRAoBrCIIRaWXJKslJJjI0kWppL5VOs8icMQiBQDWEQz5DKsyXESbOofh5Lpz51ySnMySCn7O58hzAIgUA1hEE8I6opTMZuyzx0TE+TXPasTjA8m5IXSXA+vI7JEyZgaB3d8O/CIAQC1XgxDKJUSmh0KmUKoCqP5IQo0p+VzkLVRaQkRiAtfcB2mQEc37uNk+6JVN4p4FRTQVllJXKgtiSPxFux3H89lowsSTQR8c0UwaspJTFCQmnts9DLu5DbUUnkqFTzu5gQx2MYTfuKj99/i9fa9WT6noCGd4VBCASq8YQNoppkv7Os32bBybM3aK2Vl6UhJ5j6zTgWHPcl2sUS3QUmeOe0zrFVVbafFYu1DbmaouSPVRQScHY/W7dv47RfEmmh1ugZmeESW+cmEoddzP7VGMe4TELPmzF39gGS7veZ1WRjt2kKn4/QxS646QeQ6LqbOatPk6akEqtCXkuNrBpZrfyRyqqXJvmwf+12XBMebklxjv9BftbegHtyixJU6qUgK8wFs8WTGfCJOh3eeY+uH3SgnXofZu4PathKGIRAoBpP2CDklKQFY3/hPBcdA8iqaB2HqE1yYMpXU9nueBvvA8vQ+tH04ct0P1bJuX16NZrjlxNUpOz9GtICr3Dc8iD2N9PIDj3Nj4M+oc/E7cRUVnFzvy7/6aiJucstbDfMYrz2WXLvdzpFFf57F/PlqCW4pTVd6RRstRhN/WOk1dSduzgni7ziShRATrAze5bpoL/bjpiCloa4qok4t5u1m/fgEp7zUAYTfmARoyatwD+/Bf8HFDJK0iKw2b6ErzQ+pev77figY2c+VO9Gj84dhUEIBK3Mkw8xyavIiokju6LlM7Gy4gzCbnjj4eFJYHTa3RUy+ddZ8t0yLoSmEWltxtzp24luJjerPD+FiDAJzZWIkxckE+QfRtYjNuupzYvD64oLISl1I2nJFQu0J60jWGmIqZYU931MHzGejRfCqZQXERVwhR1LZzF/gQG6i1ewxzGBmtpqPPYY8YOuHfdPuZMTbrWZBbN3E68kchN6dhnjDU+QVgtQiOehHVhY+1Eqh9qidCIDHLG+5EV8bkvdVUFeuAe2lx0Jzajft6aUjJQ8mkuRk1xcy8TFG7nZgjTz4mgHFgz7lA5vt6NTx05069qNHur1CIMQCFqdJ24QBbHX2LHNkguOvkRJ6pop5Ee5YHnElrCce0a9NaVkZaaQd2cuQVHFrZMGaHzwFu07dOST77cTeacXQ1UYmyYv46xfEhHWZuhM20ZUM6kC+XHuWJgdxzsomMjYJErv9alKKceXTuHj7n2Za+FLmfJD3FVVGXlZ6RQqAGpJC/HG5vxR1mtPZtxPa/GVFJLqegCdSWu5pSzyUhzC+t90mKutjc6CtXhm119Mlgszew9kusExsuouDPc9Rny/0JYHtdhJvLiTBb+s4WYpQBkhl05xzimCaiDi3DLGL7Mivf4BoSjBD2ffSErumEmWO2tW7ccnqeUVVqtyY7HeZsxun7r6VYpsPzbo6HHy1j19POSlJAXfILqgivTLG5i4aCNBSuuZK1dRgg+7l/xInx6daP9ue7p1VRcGIRA8Rp6sQShKuXHalAMhGUjdj2Cy8yxRyQnYmG1Ff64u682u0TDQLghih+lqTobfrTqUG+fNjnnj+aLbUBbuv37PDTydI78u4KBzJFH2e9H7dSsRzVYJlVNWnMOt0yZMW7KJgIbQTx4u2wyYudCcC6e3M+vrpVzLuH9CWmnEH6wz/J2rCTnEhfni6niNsIxqoBQb41kYW3kS7XYSg6lruFUOFVI/zl4KoCGCUxrE8smz0Jk9Da2fprH/VjnIs/Fy9iAwKBAn64t4RuYBNVw/bMLkBTYPrOuUcmU386Yux78QCmIdMF2zisXG27CJyiP24gq+MT7TEKZKcTFDb8/luz0ninxZprWAIw3VEFuiPE6t/oXJm1wpVwC1RfgcMmLqbHNiGr6oYi7vXMTCs2FkeO9kisEmAls6VyQv5LbjMQynjuKj9h3qniS6qAuDEAgeA0/4CSKDk9qj6D9wGKP6fI6W3i6cLu5Eq/9ARg7sT+//7cWXmmPQ0hyD1vB+/KubOj37j6x7rTmWCRO+YUy/nnR+uysaQ79i/Ji6bceOHoxGr1nYx+WT4naGTfP3Eq8kgpV905/IzLogTU2GB7o/jqJ3v5GM1dRES3MYX3T9iC/nbOKy+x/s0JnF0ZCmw/7ixFhiE1OpBmRZAazX/Zbho8cw/POeDBiuxQ9fj+O/Y8cyss8Qlp27QXLAZbbN2UGUAgoCj/LTwAEMHTaKsZpj0NIcTq+u79JWTQ31EYvwLqgh+uRSBn3SE02tUfT5YgImxyMACLtkzkwTR5pEqsrSCYuJJaN+0J96dTfzp60isLCEa6u+o7dGX3r11GTZ0WDCLq+g3+efMezLr9DSHMPw//yLLj0+Y8Sou5/jwNErcEtq/OxUS2FmJMFSGVTHY7l0JlqjxvLdhK8ZV/99jRk5kmFjv8fQ4ghbdMYxfKQW44b3o0f77mgMrTuf1qgR9NYYwqxTkRSFHEV/6z5CH7GSYVWBBLcTm5k6shfqHTrSud27vNO1DzP3CYMQCFqLJ2wQuVw2+Y3RA3rT94sxmBzzJyPeBb3vxzKkdy/+8++eDBg0mGGDBjNsaJ0xaA4bUvd60CAGDxjCN99NZurE7xg9ZDBD67cdrNEXrWUnSauVEedpz2HLAJpG0XNxPelMdGpxw+tDCybR88PPGNxPg4Fjp7LGbAdGs76l9797MnTieoILG7tMOUGOblz3v9OnoZbrB43o1/1zRgwfzsihddc6dKAGg0cs5nJUNtJQFw5b+NXF4hVpHJ2hSe9efRkycDDDBg9l9OhRjBwyniUbXSinHNd189Dq34/BGr3p/90SbCJKQFFNiOMBzNylTSaAS8N9cXX35U4x2bIQazau2EhAkYzo8yZ8Paofn6oPZ6m5L9E++5n23yEM6j+QYYMGM2L4KMZ8OZIRg+s+30F9BvDzNntyGs1fKKrLSPR1IbgM5KnuGM8Yw6edO9KxXQ80Bt3d95tfNuN1053NM7+kd58BDB82kjGjR/HlkPrvT2Mg/524HLeMSjLcz3Pa1o08ldYpKChJC+bEGm1Gf6bOG+9/zJQ9gQ3vCoMQCFTjGcmDqMX3sCmrtzrcDaEoaqiubGnNoSoypFGES5UlQSRy2NgC54i6MXjOzVMs1NmMU0yjp4SKLLz/OIGFc5yS1TgFXLE4zNk/JHUv826xx2QdB+68VvJ35aWH4xMsJa8gnzjXfSyZs4+o0hZO0NdWkhkZTIKSBLo011Pss7StDxOV4XPKAlMzG7LunKIqCvOVq9ijpPnQw0pRloTdxnVckdSfvzwas6maTFh4hpZFiGqoKJcBCtKj40hObq1C6DKk/raY6Otj7n73uxAGIRCoxlM2iBpy4vw4sXohk39bxaXYuzfrqlQ/Du3ag3P8A6eKH1Il+Oxaxa+TZ2O4wpiFsxaz/YwXBS26V1cT/8dRDKfpYLhsFcscyZiWAAAFFUlEQVQMjNmw7yyNPaaxyrJuYrlCm2+0prPPK6lVm+SUJnqwY+lsFugZs9ZoJSs3HcAhNAdkBUR4XsB49nTmrTuJRJXOnjUZnDH6luETF7F9qyl6P4/hc40fORryoCnzRtcq8ePYtmPczHlca5AVfzJ1YRACgWo8ZYOopSg9Gjdbe7zCM//8TkkawYGBxGS1Xkq0vCID/8vWWJ2yxSsy+8E7KJOiiAivy5w+cRoH39i67O0H7lNKzHVXrgVIeBx9e/LiA7h02opzNp4kF9Q/ddWUIg33wfbSNWJzVT2rguwgKyb1bk/bv3dH80cDTnjF0KTh3QNUUZBGeEAoaSVPpj+EMAiBQDWekRCT0LOvMm47HmXtyh38EfTo4aonKWEQAoFqCIMQekiVcdvjEnvXbOWM5y2Kn4OKs8IgBALVEAYh9MJKGIRAoBrCIIReWAmDEAhUQxiE0GOQAvlD5zc8vtLjwiAEAtUQBiH0ACmoLEgnLiGJ1Owy5bdzeQ5O+/Zy1uk2WQlBODq6kahs6a+8hJvnLbC4FEhuYQpOpy4Tknz/8oOqSBiEQKAawiCEHiA56X4nMFhuwu6j3hQoWzErS8RiuhYTtbdxarsJC2ZbkCgHWX4SPvZX8QiIIF8GKHI4b/Q9g2ZswtXpINO+XcTZ20rroLeKhEEIBKohDELoIVSJJO4WntfjKFaawlCK69b5bL5yg8DDpsybvQcJUJV+g53z5qO3YT8BmdWADO+T6/hlbxD5Ecf4UXsFjknNVlVUWcIgBALVEAYh9GCVRLNv9UIMToQ3s0E1voeWsOiUM9cPbWTBnD0k1i+Dra0qp7i4mJIKGVBDyPntTDdyIlviwKwlG7mSoEqK9/0lDEIgUA1hEEL3USWx3vacOXEe89WLmWJ4paEBUGaUKzbed8uCxzqYoHP8Cl6WG9Cdd6i+jwWUSSLxcI1u2C7V9SizdR3ISb+GtsEWHOIe1Kz70SUMQiBQDWEQQk1UXZjG7cBIMjNC2PjLAN5/vy/jvhpBn8GzOHLVBVeXq5gt+oa+367E1sUFF2cnTm42Zo29H76HTJg0cjbHnFxwdXFkv8EMRg7V5riTC65OTpw0X4/xFh8KpVeZu8IMp8TWK6XSWMIgBALVEAYh1EQlSTc4YX6OWymZxLhZsWHlUgyWLmOFkSGGevoY6C1l+fIVrF5uhKGePvqLFrHM2JKQnAoKo9zZrb+YJUv0MdDTx3CpIcaGhhjo6aO/SBf9lVu4mlBBVew1jti7kNxatRiVSBiEQKAawiCEHkmVxaVUlD16EcDKvDyKSsp4nBU7hEEIBKohDEKoxZLlh3F0hTEr1+/CJ/PxrUJSVcIgBALVeGSD+GnSZIqLi5vsKPTXkLyygorqJ1O2+1GVn5/PlMk/CoMQCB6RRzKIZImUMaO/Yq/FHmysrQV/MWxtbLl0yR6HS5e4aPP0r6c5zHft5r+aY5CmpAqDEAgegRYbREJiEskSKbt27mK+znwW6S4SCJ5J5uvMw3y3ORJpylP/oQkEzyOPZBDxCYlkZeeQl19Abl6+QPBMkpdfQFZ2DvEJiU/9hyYQPI88kkEIBAKB4MVHGIRAIBAIlCIMQiAQCARKEQYhEAgEAqUIgxAIBAKBUh5oELl5eUTFxBIXnyAQCASCvxCxcfEkSyTNG0RJSQlp6elkZGYJBAKB4C9EekYmOTk5zRuEkJCQkJDQvRIGISQkJCSkVMIghISEhISU6v8BPnrlphs1eQIAAAAASUVORK5CYII=" /></p><p dir="RTL" style="text-align:right"><strong>ما الذي يجب فعله في حالة القئ أو الإسهال الشديد</strong></p><p dir="RTL" style="text-align:right">إذا تقيأت في خلال 3 - 4 ساعات من تناول القرص أو أُصبت بإسهال شديد، فهناك احتمالية من عدم امتصاص المواد الفعالة في القرص كاملة من الجسم. هذه الحالة شبيهة جدا بنسيان القرص. بعد التقيؤ أو الإسهال، يجب تناول قرص آخر من شريط احتياطي في أسرع وقت ممكن. إذا كان ممكنا، تناوليه في خلال 12 ساعة من الوقت المعتاد الذي تتناولين فيه القرص. إذا لم يكن هذا ممكنا أو مر أكثر من 12 ساعة، ففي مثل تلك الحالات اتبعي التعليمات المذكورة تحت &laquo;إذا نسيت تناول ياسمين&raquo;،</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>تأخير الدورة الشهرية: ما الذي يجب أن تعرفيه</strong></p><p dir="RTL" style="text-align:right">على الرغم من أنه لا ينصح بذلك، يمكنك تأخير الدورة الشهرية عن طريق البدء مباشرة في شريط جديد من ياسمين بدلا من ترك فترة خالية من الأقراص والانتهاء منه. من الممكن أن تصابي بنزيف خفيف أو شبيه بالحيض أثناء استخدام هذا الشريط الثاني. بعد فترة الـ7 أيام المعتادة الخالية من الأقراص، ابدأي في الشريط التالي.</p><p dir="RTL" style="text-align:right"><strong>من</strong><strong> </strong><strong>الأفضل</strong><strong> </strong><strong>أن</strong><strong> </strong><strong>تستشيري</strong><strong> </strong><strong>طيبك</strong><strong> </strong><strong>قبل</strong><strong> </strong><strong>اتخاذ</strong><strong> </strong><strong>القرار</strong><strong> </strong><strong>بتأخير</strong><strong> </strong><strong>الدورة</strong><strong> </strong><strong>الشهرية</strong><strong>.</strong></p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>تغيير أول يوم من الدورة الشهرية: ماذا يجب أن تعرفيه </strong></p><p dir="RTL" style="text-align:right">إذا تناولت الأقراص حسب التوجيهات، فستبدأ الدورة الشهرية أثناء الأسبوع الخالي من الأقراص. إذا أردت تغيير هذا اليوم، قللي عدد الأيام الخالية من الأقراص (ولكن لا تزيديها أبدا &ndash;&nbsp; 7 أيام هي الحد الأقصى!) على سبيل المثال، إذا كانت فترة الأيام الخالية من الأقراص تبدأ عادة يوم الجمعة، وتريدين تغييريها إلى يوم الثلاثاء (3 أيام مبكرا)، فابدأي الشريط الجديد قبل الميعاد الطبيعي ب3 أيام. إذا جعلت الفترة الخالية من الأقراص قصيرة جدا (على سبيل المثال 3 أيام أو أقل) فقد لا يأتيك نزيف خلال تلك الأيام. من الممكن أن تصابي بنزيف خفيف أو شبيه بالحيض أثناء استخدام هذا الشريط الثاني.</p><p dir="RTL" style="text-align:right"><strong>إذا</strong><strong> </strong><strong>لم</strong><strong> </strong><strong>تكوني</strong><strong> </strong><strong>متأكدة</strong><strong> </strong><strong>مما</strong><strong> </strong><strong>يجب</strong><strong> </strong><strong>فعله،</strong><strong> </strong><strong>استشيري</strong><strong> </strong><strong>طبيبك</strong></p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>إذا توقفت عن تناول ياسمين</strong></p><p dir="RTL" style="text-align:right">يمكنك التوقف عن تناول ياسمين متى تشائين. إذا لم تكوني ترغبين في الحمل، استشيري طبيبك عن طرق أخرى موثوقة لتحديد النسل. إذا كنت ترغبين في الحمل، توقفي عن تناول ياسمين، وانتظري لأول دورة حيض قبل محاولة الحمل. سيمكنك حساب تاريخ الولادة المتوقع بسهولة أكبر.</p><p dir="RTL" style="text-align:right">إذا كان لديك المزيد من الأسئلة، اسألي طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">مثل جميع الأدوية، من الممكن أن يتسبب هذا الدواء في آثار جانبية، وإن لم تكن تصيب الجميع. إذا أُصبت بأي آثار جانبية، خاصة لو كانت شديدة ومستمرة، أو كان هناك أي تغير في صحتك والذي تعتقدين أنه قد يكون نتيجة لتناول ياسمين، فضلا تحدثي مع طبيبك.</p><p dir="RTL" style="text-align:right">زيادة مخاطر جلطات الدم في الأوردة (الجلطات الدموية الوريدية (VTE)) أو جلطات الدم في الشرايين (الجلطات الدموية الشريانية (ATE)) موجودة لدى جميع النساء اللاتي يتناولن موانع الحمل الهرمونية المختلطة. للمزيد من التفاصيل عن المخاطر المختلفة من تناول وسائل منع الحمل الهرمونية المختلطة يُرجى مراجعة القسم 2 &laquo;ما الذي يجب أن تعرفينه قبل تناول ياسمين&raquo;.</p><p dir="RTL" style="text-align:right">فيما يلي قائمة بالآثار الجانبية التي ارتبطت بتناول ياسمين:</p><p dir="RTL" style="text-align:right"><strong>آثار</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong> (قد تصيب بين 1 إلى 10 من كل 100 سيدة تستخدم ياسمين):</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اضطرابات الدورة الشهرية، ونزيف بين الدورات، ألم افي لثدي، شد في الثدي</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صداع، حالة اكتئابية</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->صداع نصفي</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->غثيان</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إفرازات مهبلية بيضاء كثيفة وإصابات فطرية مهبلية</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>آثار جانبية غير شائعة</strong>&nbsp; (قد تصيب بين 1 إلى 10 من كل 1,000 سيدة تستخدم ياسمين):</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تضخم في الثدى، تغيرات في الرغبة الجنسية</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ارتفاع ضغط الدم، انخفاض ضغط الدم</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قئ، إسهال</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حب الشباب، طفح جلدي، حكة شديدة، فقدان الشعر (صلع)</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهاب في المهبل</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->احتباس السوائل و تغيرات في وزن الجسم.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>آثار جانبية نادرة</strong> (قد تصيب بين 1 إلى 10 من كل 10,000 سيدة تستخدم ياسمين):</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعلات حساسية (فرط الحساسية)،</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ربو</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إفرازات الثدي</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضعف السمع</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حالات جلدية تعرف بحمامي عقدية (تتميز بعقد حمراء ومؤلمة في الجلد) أو حمامي متعددة الأشكال (تتميز بطفح جلدي مع احمرار أو تقرحات).</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جلطات دم ضارة في الوريد أو الشريان، على سبيل المثال:</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في الساق أو القدم (أي تجلط الأوردة العميقة)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في الرئة (أي انسداد رئوي)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->نوبة قلبية</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سكتة دماغية</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->سكتة دماغية مصغرة أو أعراض مؤقتة مماثلة للسكتة الدماغية، وتسمى نوبة نقص تروية عابرة&nbsp; (TIA)</p><p dir="RTL" style="margin-left:0in; margin-right:.5in; text-align:right; text-indent:-.25in"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->جلطات دموية في الكبد أو المعدة/ الأمعاء أو الكلى أو العين.</p><p dir="RTL" style="text-align:right">قد تزداد احتمالات حدوث تجلط الدم إذا كنت تعانين من أمراض أخرى تزيد من هذه المخاطر (لمزيد من المعلومات عن الحالات التي تزيد من خطر تجلط الدم وأعراض تجلط الدم، انظري قسم 2).</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL" style="text-align:right">إذا أصبت بأي أعراض جانبية، تحدثي مع طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة وغير مذكورة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك أن تساعدي في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>للإبلاغ عن الأعراض الجانبية</strong><strong>:</strong></p><p dir="RTL" style="text-align:right"><strong>السعودية:</strong></p><p dir="RTL" style="text-align:right">المركز الوطني للتيقظ الدوائي</p><p dir="RTL" style="text-align:right">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL" style="text-align:right">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL" style="text-align:right">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL" style="text-align:right"><strong>بلدان أخرى</strong><strong>:</strong></p><p dir="RTL" style="text-align:right">يرجى الاتصال بالسلطة المختصة ذات الصلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">احفظي هذا الدواء بعيدا عن متناول ورؤية الأطفال.</p><p dir="RTL" style="text-align:right">لا يُحفظ في درجة حرارة أعلى من 30 درجة مئوية ويُحفظ في عبوته الأصلية.</p><p dir="RTL" style="text-align:right">لا تستخدمي هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد &laquo;لا يُستخدم بعد:&raquo; أو &laquo;EXP&raquo;. تاريخ الانتهاء يشير إلى آخر يوم من الشهر المذكور.</p><p dir="RTL" style="text-align:right">لا تتخلصي من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي عن كيفية التخلص من الأدوية التي لم تعودي تستخدمينها. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong><u>المواد</u></strong><strong><u> </u></strong><strong><u>الفعالة</u></strong> هي دروسبيرينون وإيثينيل إستراديول. يحتوي كل قرص على 3 مجم دروسبيرينون&nbsp; و 0.03 مجم إيثينيل إستراديول</p><p dir="RTL" style="text-align:right"><strong>المكونات</strong><strong> </strong><strong>الأخرى</strong> هي: مونوهيدرات اللاكتوز، نشا الذرة، نشا الذرة ما قبل التهلم، بوفيدون K25، ستيرات المغنيسيوم، هايبروميللوز، ماكروغول 6000، تلك، ثاني أكسيد التيتانيوم (E 171)، أكسيد الحديد، الأصفر (E 172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يحتوي كل شريط من ياسمين على 21 قرص مغلف لونها أصفر فاتح</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->أقراص ياسمين هي أقراص مغلفة، (قلب القرص مغلف) القرص ذو لون أصفر فاتح، وهو مستدير بأسطح محدبة؛ وعلى أحد الجانبين مميزة بأحرف &laquo;DO&raquo; في شكل مسدس منتظم.</p><p dir="RTL" style="margin-left:0in; margin-right:20.05pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يتوفر ياسمين في عبوات ذات 1، 3، 6 و 13 شريط؛ كل منهم به 21 قرص.</p><p dir="RTL" style="text-align:right">ليس من الضروري أن يتم تسويق جميع الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>مصنع البلك:</strong></p><p dir="RTL" style="text-align:right">باير فايمر جي أم بي اتش أند كو. كي جي</p><p dir="RTL" style="text-align:right">دوبراينرشتراس 20،</p><p dir="RTL" style="text-align:right">٩٩٤٢٧ فايمر، ألمانيا</p><p dir="RTL" style="text-align:right"><strong>التعبئة و الإفراج النهائي:</strong></p><p dir="RTL" style="text-align:right">باير ايه جى</p><p dir="RTL" style="text-align:right">مولر شتراس 178</p><p dir="RTL" style="text-align:right">13353 برلين، ألمانيا.</p><p dir="RTL" style="text-align:right"><strong>حامل تصريح التسويق</strong></p><p dir="RTL" style="text-align:right">باير ايه جي</p><p dir="RTL" style="text-align:right">قيصر-ويلهلم - آلي 1</p><p dir="RTL" style="text-align:right">51368 ليفركوزن، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو 2021.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Yasmin 0.03 mg / 3 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 0.030 mg ethinylestradiol and 3 mg drospirenone
Excipient with known effect: lactose 46 mg (as lactose monohydrate 48.17 mg)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets
Light yellow, round tablets with convex faces, one side marked with the letters "DO" in a regular hexagon
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral contraception</p><p>The decision to prescribe Yasmin should take into consideration the individual woman&rsquo;s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Yasmin compares with other combined hormonal contraceptives (CHCs), see sections 4.3 and 4.4.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Method of administration</em></strong></p><p>Oral use</p><p><strong><em>Posology</em></strong></p><p><strong>How to take Yasmin</strong></p><p>The tablets must be taken every day at about the same time, if necessary with a little liquid, in the order shown on the blister pack. One tablet is to be taken daily for 21 consecutive days. Each subsequent pack is started after a 7-day tablet-free interval, during which time a withdrawal bleed usually occurs. This usually starts on day 2-3 after the last tablet and may not have finished before the next pack is started.</p><p><strong>How to start Yasmin</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->No preceding hormonal contraceptive use (in the past month)</p><p>Tablet-taking has to start on day 1 of the woman&rsquo;s natural cycle (i.e. the first day of her menstrual bleeding).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Changing from a combined hormonal contraceptive (combined oral contraceptive (COC), vaginal ring, or transdermal patch)</p><p>The woman should start with Yasmin preferably on the day after the last active tablet (the last tablet containing the active substances) of her previous COC, but at the latest on the day following the usual tablet-free or hormone-free tablet interval of her previous COC. In case a vaginal ring or transdermal patch has been used, the woman should start using Yasmin preferably on the day of removal, but at the latest when the next application would have been due.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Changing from a progestogen-only-method (progestogen-only pill, injection, implant) or from a progestogen-releasing intrauterine system (IUS)</p><p>The woman may switch any day from the progestogen-only pill (from an implant or the IUS on the day of its removal, from an injectable when the next injection would be due) but should in all of these cases be advised to additionally use a barrier method for the first 7 days of tablet-taking.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Following first-trimester abortion</p><p style="margin-left:0in; text-indent:0in">The woman may start immediately. When doing so, she need not take additional contraceptive measures.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Following delivery or second-trimester abortion</p><p>Women should be advised to start at day 21 to 28 after delivery or second-trimester abortion. When starting later, the woman should be advised to additionally use a barrier method for the first 7 days. However, if intercourse has already occurred, pregnancy should be excluded before the actual start of COC use or the woman has to wait for her first menstrual period.</p><p>For breastfeeding women see section 4.6.</p><p><strong>Management of missed tablets</strong></p><p>If the user is <strong>less than 12 hours</strong> late in taking any tablet, contraceptive protection is not reduced. The woman should take the tablet as soon as she remembers and should take further tablets at the usual time.</p><p>If she is <strong>more than 12 hours</strong> late in taking any tablet, contraceptive protection may be reduced. The management of missed tablets can be guided by the following two basic rules:</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp; <!--[endif]-->tablet-taking must never be discontinued for longer than 7 days</p><p style="margin-left:14.15pt; text-indent:-14.15pt"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp; <!--[endif]-->7 days of uninterrupted tablet-taking are required to attain adequate suppression of the hypothalamic-pituitary-ovarian-axis.</p><p>Accordingly the following advice can be given in daily practice:</p><p style="margin-left:0in; text-indent:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Week 1</p><p>The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. In addition, a barrier method such as a condom should be used for the next 7 days. If intercourse took place in the preceding 7 days, the possibility of a pregnancy should be considered. The more tablets are missed and the closer they are to the regular tablet-free interval, the higher the risk of a pregnancy.</p><p style="margin-left:0in; text-indent:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Week 2</p><p>The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. Provided that the woman has taken her tablets correctly in the 7 days preceding the first missed tablet, there is no need to use extra contraceptive precautions. However, if she has missed more than 1 tablet, the woman should be advised to use extra precautions for 7 days.</p><p style="margin-left:0in; text-indent:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Week 3</p><p>The risk of reduced reliability is imminent because of the forthcoming 7-day tablet-free interval. However, by adjusting the tablet-intake schedule, reduced contraceptive protection can still be prevented. By adhering to either of the following two options, there is therefore no need to use extra contraceptive precautions, provided that in the 7 days preceding the first missed tablet the woman has taken all tablets correctly. If this is not the case, she should follow the first of these two options and use extra precautions for the next 7 days as well.</p><p style="margin-left:14.2pt; text-indent:-14.2pt"><!--[if !supportLists]-->1.&nbsp;&nbsp;&nbsp; <!--[endif]-->The user should take the last missed tablet as soon as she remembers, even if this means taking two tablets at the same time. She then continues to take tablets at her usual time. The next blister pack must be started as soon as the current blister pack is finished, i.e., no gap should be left between packs. The user is unlikely to have a withdrawal bleed until the end of the second pack, but she may experience spotting or breakthrough bleeding on tablet-taking days.</p><p style="margin-left:14.2pt; text-indent:-14.2pt"><!--[if !supportLists]-->2.&nbsp;&nbsp;&nbsp; <!--[endif]-->The woman may also be advised to discontinue tablet-taking from the current blister pack. She should then have a tablet-free interval of up to 7 days, including the days she missed tablets, and subsequently continue with the next blister pack.</p><p>If the woman missed tablets and subsequently has no withdrawal bleed in the first normal tablet-free interval, the possibility of a pregnancy should be considered.</p><p><strong>Advice in case of gastro-intestinal disturbances</strong></p><p>In case of severe gastro-intestinal disturbances (e.g., vomiting or diarrhoea), absorption may not be complete and additional contraceptive measures should be taken. If vomiting occurs within 3-4 hours after tablet-taking, a new (replacement) tablet should be taken as soon as possible. The new tablet should be taken within 12 hours of the usual time of tablet-taking if possible. If more than 12 hours elapse, the advice concerning missed tablets, as given in section 4.2 &ldquo;Management of missed tablets&rdquo;, is applicable. If the woman does not want to change her normal tablet-taking schedule, she has to take the extra tablet(s) from another blister pack.</p><p><strong>How to postpone a withdrawal bleed</strong></p><p>To delay a period the woman should continue with another blister pack of Yasmin without a tablet-free interval. The extension can be carried on for as long as wished until the end of the second pack. During the extension the woman may experience breakthrough-bleeding or spotting. Regular intake of Yasmin is then resumed after the usual 7-day tablet-free interval.</p><p>To shift her periods to another day of the week than the woman is used to with her current scheme, she can be advised to shorten her forthcoming tablet-free interval by as many days as she likes. The shorter the interval, the higher the risk that she does not have a withdrawal bleed and will experience breakthrough-bleeding and spotting during the subsequent pack (just as when delaying a period).</p><p><strong><em>Additional information on special populations</em></strong></p><p><em>Paediatric patients</em></p><p>Yasmin is only indicated after menarche. Based on epidemiological data collected on more than 2000 adolescent women aged below 18 years, there are no data indicating that safety and efficacy in this young age group is different from that known in women aged above 18 years.</p><p><em>Elderly patients</em></p><p>Yasmin is not indicated after the menopause.</p><p><em>Patients with impaired hepatic function</em></p><p>Yasmin is contraindicated in women with severe hepatic disorders. See also sections&nbsp;4.3 and 5.2.</p><p><em>Patients with impaired renal function</em></p><p>Yasmin is contraindicated in women with severe renal insufficiency or acute renal failure. See also sections&nbsp;4.3 and 5.2</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Combined hormonal contraceptives (CHCs) should not be used in the following conditions. Should any of the conditions appear for the first time during CHC use, the product should be stopped immediately.
•	Presence or risk of venous thromboembolism (VTE)
o	Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE])
o	Known hereditary or acquired predisposition for venous thromboembolism, such as APC resistance, (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency
o	Major surgery with prolonged immobilisation (see section 4.4)
o	A high risk of venous thromboembolism due to the presence of multiple risk factors (see section 4.4)
•	Presence or risk of arterial thromboembolism (ATE)
o	Arterial thromboembolism – current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris)
o	Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g. transient ischaemic attack, TIA)
o	Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant)
o	History of migraine with focal neurological symptoms
o	A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as:
•	diabetes mellitus with vascular symptoms
•	severe hypertension
•	severe dyslipoproteinaemia
•	Presence or history of severe hepatic disease as long as liver function values have not returned to normal
•	Severe renal insufficiency or acute renal failure
•	Presence or history of liver tumours (benign or malignant)
•	Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts)
•	Undiagnosed vaginal bleeding
•	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Yasmin is contraindicated for concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir or glecaprevir/pibrentasvir (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Warnings</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->If any of the conditions or risk factors mentioned below is present, the suitability of Yasmin should be discussed with the woman.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In the event of aggravation, or first appearance of any of these conditions or risk factors, the woman should be advised to contact her doctor to determine whether the use of Yasmin should be discontinued.</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In case of suspected or confirmed VTE or ATE, CHC use should be discontinued. In case anti-coagulant therapy is started, adequate alternative contraception should be initiated because of the teratogenicity of anticoagulant therapy (coumarins).</p><p style="margin-left:0in; text-indent:0in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Circulatory Disorders</p><p style="margin-left:0in; text-indent:0in"><strong>Risk of venous thromboembolism (VTE)</strong></p><p style="margin-left:0in; margin-right:0in">The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with no use<strong>. Products that contain levonorgestrel, norgestimate or norethisterone are associated with the lowest risk of VTE. Other products such as Yasmin may have up to twice this level of risk. The decision to use any product other than one with the lowest VTE risk should be taken only after a discussion with the woman to ensure she understands that:</strong></p><ul><li><strong>the risk of VTE with Yasmin, </strong></li><li><strong>how her current risk factors influence this risk, and </strong></li><li><strong>that her VTE risk is highest in the first ever year of use. </strong></li></ul><p>There is also some evidence that the risk is increased when a CHC is re-started after a break in use of 4 weeks or more.</p><p>In women who do not use a CHC and are not pregnant, about 2 out of 10,000 will develop a VTE over the period of one year. However, in any individual woman the risk may be far higher, depending on her underlying risk factors (see below).</p><p>It is estimated<sup><!--[if !supportFootnotes]--><sup>[1]</sup><!--[endif]--></sup> that out of 10,000 women who use a CHC containing drospirenone between 9 and 12 women will develop a VTE in one year; this compares with about 6<!--[if !supportFootnotes]-->[2]<!--[endif]--> &nbsp;in women who use a levonorgestrel-containing CHC.</p><p>In both cases, the number of VTEs per year is fewer than the number expected during pregnancy or in the postpartum period.</p><p>VTE may be fatal in 1&nbsp;‑&nbsp;2% of the cases.</p><p><strong>Number of VTE events per 10,000 women in one year</strong></p><p><img src="data:image/png;base64,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" /></p><p style="text-align:center">&nbsp;</p><p>Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal or retinal veins and arteries.</p><p><strong>Risk factors for VTE</strong></p><p>The risk for venous thromboembolic complications in CHC users may increase substantially in a woman with additional risk factors, particularly if there are multiple risk factors (see table).</p><p>Yasmin is contraindicated if a woman has multiple risk factors that put her at high risk of venous thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors &ndash; in this case her total risk of VTE should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p><strong>Table: Risk factors for VTE</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:185.4pt"><p><strong>Risk factor </strong></p></td><td style="vertical-align:top; width:258.85pt"><p><strong>Comment</strong></p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Obesity (body mass index over 30 kg/m&sup2;)</p></td><td style="vertical-align:top; width:258.85pt"><p>Risk increases substantially as BMI rises.</p><p>Particularly important to consider if other risk factors also present.</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Prolonged immobilisation, major surgery, any surgery to the legs or pelvis, neurosurgery, or major trauma</p><p>Note:&nbsp; temporary immobilisation including air travel &gt;4 hours can also be a risk factor for VTE, particularly in women with other risk factors</p></td><td style="vertical-align:top; width:258.85pt"><p>In these situations it is advisable to discontinue use of the pill (in the case of elective surgery at least four weeks in advance) and not resume until two weeks after complete remobilisation. Another method of contraception should be used to avoid unintentional pregnancy.</p><p>Antithrombotic treatment should be considered if Yasmin has not been discontinued in advance.</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Positive family history (venous thromboembolism ever in a sibling or parent especially at a relatively early age e.g. before 50).</p></td><td style="vertical-align:top; width:258.85pt"><p>If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Other medical conditions associated with VTE</p></td><td style="vertical-align:top; width:258.85pt"><p>Cancer, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (Crohn&rsquo;s disease or ulcerative colitis) and sickle cell disease</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Increasing age</p></td><td style="vertical-align:top; width:258.85pt"><p>Particularly above 35 years</p></td></tr></tbody></table><p>There is no consensus about the possible role of varicose veins and superficial thrombophlebitis in the onset or progression of venous thrombosis.</p><p>The increased risk of thromboembolism in pregnancy, and particularly the 6-week period of the puerperium, must be considered (for information on &ldquo;Pregnancy and lactation&rdquo; see section 4.6).</p><p><strong>Symptoms of VTE (deep vein thrombosis and pulmonary embolism)</strong></p><p>In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p>Symptoms of deep vein thrombosis (DVT) can include:</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->unilateral swelling of the leg and/or foot or along a vein in the leg;</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain or tenderness in the leg which may be felt only when standing or walking,</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increased warmth in the affected leg; red or discoloured skin on the leg.</p><p>&nbsp;</p><p>Symptoms of pulmonary embolism (PE) can include:</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden onset of unexplained shortness of breath or rapid breathing;</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden coughing which may be associated with haemoptysis;</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sharp chest pain;</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe light headedness or dizziness;</p><p style="margin-left:.25in; text-indent:-.25in"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeat.</p><p>Some of these symptoms (e.g. &ldquo;shortness of breath&rdquo;, &ldquo;coughing&rdquo;) are non-specific and might be misinterpreted as more common or less severe events (e.g. respiratory tract infections).</p><p>Other signs of vascular occlusion can include: sudden pain, swelling and slight blue discoloration of an extremity.</p><p>If the occlusion occurs in the eye symptoms can range from painless blurring of vision which can progress to loss of vision. Sometimes loss of vision can occur almost immediately.</p><p>&nbsp;</p><p><strong>Risk of arterial thromboembolism (ATE)</strong></p><p>Epidemiological studies have associated the use of CHCs with an increased risk for arterial thromboembolism (myocardial infarction) or for cerebrovascular accident (e.g. transient ischaemic attack, stroke). Arterial thromboembolic events may be fatal.</p><p><strong><u>Risk factors for ATE</u></strong></p><p>The risk of arterial thromboembolic complications or of a cerebrovascular accident in CHC users increases in women with risk factors (see table). Yasmin is contraindicated if a woman has one serious or multiple risk factors for ATE that puts her at high risk of arterial thrombosis (see section 4.3). If a woman has more than one risk factor, it is possible that the increase in risk is greater than the sum of the individual factors - in this case her total risk should be considered. If the balance of benefits and risks is considered to be negative a CHC should not be prescribed (see section 4.3).</p><p><strong><u>Table: Risk factors for ATE</u></strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:185.4pt"><p><strong><u>Risk factor</u></strong></p></td><td style="vertical-align:top; width:258.85pt"><p><strong><u>Comment</u></strong></p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Increasing age</p></td><td style="vertical-align:top; width:258.85pt"><p>Particularly above 35 years</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Smoking</p></td><td style="vertical-align:top; width:258.85pt"><p>Women should be advised not to smoke if they wish to use a CHC. Women over 35 who continue to smoke should be strongly advised to use a different method of contraception.</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Hypertension</p></td><td style="vertical-align:top; width:258.85pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Obesity (body mass index over 30 kg/m<sup>2</sup>)</p></td><td style="vertical-align:top; width:258.85pt"><p>Risk increases substantially as BMI increases.</p><p>Particularly important in women with additional risk factors</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Positive family history (arterial thromboembolism ever in a sibling or parent especially at relatively early age e.g. below 50).</p></td><td style="vertical-align:top; width:258.85pt"><p>If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any CHC use</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Migraine</p></td><td style="vertical-align:top; width:258.85pt"><p>An increase in frequency or severity of migraine during CHC use (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation</p></td></tr><tr><td style="vertical-align:top; width:185.4pt"><p>Other medical conditions associated with adverse vascular events</p></td><td style="vertical-align:top; width:258.85pt"><p>Diabetes mellitus, hyperhomocysteinaemia, valvular heart disease and atrial fibrillation, dyslipoproteinaemia and systemic lupus erythematosus.</p></td></tr></tbody></table><p><strong><u>Symptoms of ATE</u></strong></p><p>In the event of symptoms women should be advised to seek urgent medical attention and to inform the healthcare professional that she is taking a CHC.</p><p style="margin-left:0in; margin-right:0in">Symptoms of a cerebrovascular accident can include:</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden numbness or weakness of the face, arm or leg, especially on one side of the body;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble walking, dizziness, loss of balance or coordination;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden confusion, trouble speaking or understanding;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden trouble seeing in one or both eyes;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sudden, severe or prolonged headache with no known cause;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->loss of consciousness or fainting with or without seizure.</p><p>Temporary symptoms suggest the event is a transient ischaemic attack (TIA).</p><p style="margin-left:0in; margin-right:0in">Symptoms of myocardial infarction (MI) can include:</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->pain, discomfort, pressure, heaviness, sensation of squeezing or fullness in the chest, arm, or below the breastbone;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->discomfort radiating to the back, jaw, throat, arm, stomach;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->feeling of being full, having indigestion or choking;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sweating, nausea, vomiting or dizziness;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->extreme weakness, anxiety, or shortness of breath;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->rapid or irregular heartbeats.</p><p style="margin-left:0in; margin-right:0in; text-indent:0in"><u>Tumours</u></p><p>An increased risk of cervical cancer in long-term users of COCs (&gt; 5 years) has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the confounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).</p><p>A meta-analysis from 54 epidemiological studies reported that there is a slightly increased relative risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using COCs. The excess risk gradually disappears during the course of the 10 years after cessation of COC use. Because breast cancer is rare in women under 40 years of age, the excess number of breast cancer diagnoses in current and recent COC users is small in relation to the overall risk of breast cancer. These studies do not provide evidence for causation. The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The breast cancers diagnosed in ever-users tend to be less advanced clinically than the cancers diagnosed in never-users.</p><p>In rare cases, benign liver tumours, and even more rarely, malignant liver tumours have been reported in users of COCs. In isolated cases, these tumours have led to life-threatening intra-abdominal haemorrhages. A hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, liver enlargement or signs of intra-abdominal haemorrhage occur in women taking COCs.</p><p>With the use of the higher-dosed COCs (50&nbsp;&micro;g ethinylestradiol) the risk of endometrial and ovarian cancer is reduced. Whether this also applies to lower-dosed COCs remains to be confirmed.</p><p style="margin-left:0in; text-indent:0in"><u>Other conditions</u></p><p>The progestin component in Yasmin is an aldosterone antagonist with potassium sparing properties. In most cases, no increase of potassium levels is to be expected. In a clinical study, however in some patients with mild or moderate renal impairment and concomitant use of potassium-sparing medicinal products serum potassium levels slightly, but not significantly, increased during drospirenone intake. Therefore, it is recommended to check serum potassium during the first treatment cycle in patients presenting with renal insufficiency and a pretreatment serum potassium in the upper reference range, and particularly during concomitant use of potassium sparing medicinal products. See also section 4.5.</p><p>Women with hypertriglyceridemia, or a family history thereof, may be at an increased risk of pancreatitis when using COCs.</p><p>Although small increases in blood pressure have been reported in many women taking COCs, clinically relevant increases are rare. Only in these rare cases an immediate discontinuation of COC use is justified. If, during the use of a COC in preexisting hypertension, constantly elevated blood pressure values or a significant increase in blood pressure do not respond adequately to antihypertensive treatment, the COC must be withdrawn. Where considered appropriate, COC use may be resumed if normotensive values can be achieved with antihypertensive therapy.</p><p>The following conditions have been reported to occur or deteriorate with both pregnancy and COC use, but the evidence of an association with COC use is inconclusive: jaundice and/or pruritus related to cholestasis; gallstones; porphyria; systemic lupus erythematosus; haemolytic uremic syndrome; Sydenham&rsquo;s chorea; herpes gestationis; otosclerosis-related hearing loss.</p><p>In women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema.</p><p>Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal. Recurrence of cholestatic jaundice and/or cholestasis-related pruritus which previously occurred during pregnancy or during previous use of sex steroids necessitates the discontinuation of COCs.</p><p>Although COCs may have an effect on peripheral insulin resistance and glucose tolerance, there is no evidence for a need to alter the therapeutic regimen in diabetics using low-dose COCs (containing &lt; 0.05 mg ethinylestradiol). However, diabetic women should be carefully observed, particularly in the early stage of COC use.</p><p>Worsening of epilepsy, of Crohn&rsquo;s disease and of ulcerative colitis has been reported during COC use.</p><p>Depressive mood and depression are generally known undesirable effects with the use of hormonal contraceptives (see section&nbsp;4.8). Depression can be serious and is a generally known risk factor for suicidal behaviour and suicide. Women should be advised to contact their doctor in the event of mood swings and depressive symptoms, even if these occur shortly after initiation of treatment.</p><p>Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum. Women with a tendency to chloasma should avoid exposure to the sun or ultraviolet radiation whilst taking COCs.</p><p>This medicinal product contains 46 mg lactose per tablet. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption who are on a lactose-free diet should take this amount into consideration.</p><p style="margin-left:0in; margin-right:0in"><u>ALT elevations</u></p><p>During clinical trials with patients treated for hepatitis C virus infections (HCV) with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin, transaminase (ALT) elevations higher than 5 times the upper limit of normal (ULN) occurred significantly more frequent in women using ethinylestradiol-containing medications such as combined hormonal contraceptives (CHCs). ALT elevations have also been observed in women treated with glecaprevir/pibrentasvir and taking ethinylestradiol-containing medicinal products such as CHCs (see sections&nbsp;4.3 and 4.5).</p><p style="margin-left:0in; margin-right:0in">&nbsp;(see sections 4.3 and 4.5).</p><p>Medical examination/consultation</p><p>Prior to the initiation or reinstitution of Yasmin a complete medical history (including family history) should be taken and pregnancy must be ruled out. Blood pressure should be measured and a physical examination should be performed, guided by the contra-indications (see section 4.3) and warnings (see section 4.4). It is important to draw a woman&rsquo;s attention to the information on venous and arterial thrombosis, including the risk of Yasmin compared with other CHCs, the symptoms of VTE and ATE, the known risk factors and what to do in the event of a suspected thrombosis.</p><p>The woman should also be instructed to carefully read the user leaflet and to adhere to the advice given. The frequency and nature of examinations should be based on established practice guidelines and be adapted to the individual woman.</p><p>Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmitted diseases.</p><p><strong>Reduced efficacy</strong></p><p>The efficacy of COCs may be reduced in the event of e.g. missed tablets (see section 4.2), gastro-intestinal disturbances (see section 4.2) or concomitant medication (see section 4.5).</p><p><strong>Reduced cycle control</strong></p><p>With all COCs, irregular bleeding (spotting or breakthrough bleeding) may occur, especially during the first months of use. Therefore, the evaluation of any irregular bleeding is only meaningful after an adaptation interval of about three cycles.</p><p>If bleeding irregularities persist or occur after previously regular cycles, then non-hormonal causes should be considered and adequate diagnostic measures are indicated to exclude malignancy or pregnancy. These may include curettage.</p><p>In some women withdrawal bleeding may not occur during the tablet-free interval. If the COC has been taken according to the directions described in section 4.2, it is unlikely that the woman is pregnant. However, if the COC has not been taken according to these directions prior to the first missed withdrawal bleed or if two withdrawal bleeds are missed, pregnancy must be ruled out before COC use is continued.</p><p><!--[if !supportFootnotes]--></p><p>&nbsp;</p><p><!--[endif]--></p><p><!--[if !supportFootnotes]-->[1]<!--[endif]--> These incidences were estimated from the totality of the epidemiological study data, using relative risks for the different products compared with levonorgestrel-containing CHCs.</p><p><!--[if !supportFootnotes]-->[2]<!--[endif]--> Mid-point of range of 5&nbsp;‑&nbsp;7 per 10,000 WY, based on a relative risk for CHCs containing levonorgestrel versus non-use of approximately 2.3 to 3.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.</p><p style="margin-left:17.0pt; text-indent:-14.15pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Effects of other medicinal products on Yasmin</p><p>Interactions can occur with drugs that induce microsomal enzymes which can result in increased clearance of sex hormones and which may lead to breakthrough bleeding and/or contraceptive failure.</p><p>Management</p><p>Enzyme induction can already be observed after a few days of treatment. Maximal enzyme induction is generally seen within a few weeks. After the cessation of drug therapy enzyme induction may be sustained for about 4 weeks.</p><p>Short-term treatment</p><p>Women on treatment with enzyme-inducing drugs should temporarily use a barrier method or another method of contraception in addition to the COC. The barrier method must be used during the whole time of the concomitant drug therapy and for 28 days after its discontinuation. If the drug therapy runs beyond the end of the tablets in the COC pack, the next COC pack should be started right after the previous one without the usual tablet-free interval.</p><p>Long-term treatment</p><p>In women on long-term treatment with hepatic enzyme-inducing active substances, another reliable, non-hormonal, method of contraception is recommended.</p><p>The following interactions have been reported in the literature.</p><p><em>Substances increasing the clearance of COCs (diminished efficacy of COCs by enzyme-induction), e.g.:</em></p><p>Barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, and HIV medication ritonavir, nevirapine and efavirenz and possibly also felbamate, griseofulvin, oxcarbazepine, topiramate and products containing the herbal remedy St. John&#39;s Wort (hypericum perforatum).</p><p style="margin-left:0in; margin-right:0in"><em>Substances with variable effects on the clearance of COCs:</em></p><p style="margin-left:0in; margin-right:0in">When co-administered with COCs many combinations of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors, including combinations with HCV inhibitors can increase or decrease plasma concentrations of estrogen or progestins. The net effect of these changes may be clinically relevant in some cases.</p><p style="margin-left:0in; margin-right:0in">Therefore, the prescribing information of concomitant HIV/HCV medications should be consulted to identify potential interactions and any related recommendations. In case of any doubt, an additional barrier contraceptive method should be used by women on protease inhibitor or non-nucleoside reverse transcriptase inhibitor therapy.</p><p style="margin-left:0in; margin-right:0in"><em>Substances decreasing the clearance of COCs (enzyme inhibitors):</em></p><p style="margin-left:0in; margin-right:0in">The clinical relevance of potential interactions with enzyme inhibitors remains unknown.</p><p style="margin-left:0in; margin-right:0in">Concomitant administration of strong CYP3A4 inhibitors can increase plasma concentrations of the estrogen or the progestin or both.</p><p style="margin-left:0in; margin-right:0in">In a multiple dose study with a drospirenone (3 mg/day) / ethinylestradiol (0.02 mg/day) combination, co-administration of the strong CYP3A4 inhibitor ketoconazole for 10 days increased the AUC(0&nbsp;‑&nbsp;24h) of drospirenone and ethinylestradiol 2.7-fold and 1.4-fold, respectively.</p><p style="margin-left:0in; margin-right:0in">Etoricoxib doses of 60 to 120 mg/day have been shown to increase plasma concentrations of ethinylestradiol 1.4 to 1.6-fold, respectively when taken concomitantly with a combined hormonal contraceptive containing 0.035 mg ethinylestradiol.</p><p style="margin-left:0in; text-indent:0in"><u>Effects of Yasmin on other medicinal products</u></p><p>COCs may affect the metabolism of certain other active substances. Accordingly, plasma and tissue concentrations may either increase (e.g. ciclosporin) or decrease (e.g. lamotrigine).<u> </u></p><p>Based on in vivo interaction studies in female volunteers using omeprazole, simvastatin or midazolam as marker substrate, a clinically relevant interaction of drospirenone at doses of 3&nbsp;mg with the cytochrome P450 mediated metabolism of other active substances is unlikely.</p><p>Clinical data suggests that ethinylestradiol is inhibiting the clearance of CYP1A2 substrates leading to a weak (e.g. theophylline) or moderate (e.g. tizanidine) increase in their plasma concentration.</p><p style="margin-left:0in; text-indent:0in"><u>Pharmacodynamic interactions</u></p><p>Concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin or glecaprevir/pibrentasvir, may increase the risk of ALT elevations (see sections 4.3 and 4.4).</p><p>Therefore, Yasmin-users must switch to an alternative method of contraception (e.g., progestagen-only contraception or non-hormonal methods) prior to starting therapy with this combination drug regimen. Yasmin can be restarted 2 weeks following completion of treatment with this combination drug regimen.</p><p>In patients without renal insufficiency, the concomitant use of drospirenone and ACE-inhibitors or NSAIDs did not show a significant effect on serum potassium. Nevertheless, concomitant use of Yasmin with aldosterone antagonists or potassium-sparing diuretics has not been studied. In this case, serum potassium should be tested during the first treatment cycle. See also section 4.4.</p><p><u>Other forms of interaction</u></p><p><em>Laboratory tests</em></p><p>The use of contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins, e.g. corticosteroid-binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range. Drospirenone causes an increase in plasma renin activity and plasma aldosterone induced by its mild antimineralocorticoid activity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Yasmin is not indicated during pregnancy.</p><p>If pregnancy occurs during use of Yasmin, the preparation should be withdrawn immediately. Extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used COCs prior to pregnancy, nor a teratogenic effect when COCs were taken inadvertently during pregnancy.</p><p>Animal studies have shown undesirable effects during pregnancy and lactation (see section 5.3). Based on these animal data, undesirable effects due to hormonal action of the active compounds cannot be excluded. However, general experience with COCs during pregnancy did not provide evidence for an actual undesirable effect in humans.</p><p>The available data regarding the use of Yasmin during pregnancy are too limited to permit conclusions concerning negative effects of Yasmin on pregnancy, health of the foetus or neonate. To date, no relevant epidemiological data are available.</p><p>The increased risk of VTE during the postpartum period should be considered when re-starting Yasmin (see section 4.2 and 4.4).</p><p><u>Breastfeeding</u></p><p>Lactation may be influenced by COCs as they may reduce the quantity and change the composition of breast milk. Therefore, the use of COCs should generally not be recommended until the breast-feeding mother has completely weaned her child. Small amounts of the contraceptive steroids and/or their metabolites may be excreted with the milk during COC use. These amounts may affect the child.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. No effects on ability to drive and use machines have been observed in users of COCs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For serious undesirable effects in COC users see also section 4.4.</p><p>The following adverse drug reactions have been reported during use of Yasmin:</p><table cellspacing="0" cellpadding="0" border="1" style="width:619px"><tbody><tr><td style="vertical-align:top; width:124.0pt"><p><strong>System Organ Class (MedDRA)</strong></p></td><td colspan="3" style="vertical-align:top; width:340.2pt"><p style="text-align:center"><strong>Frequency of adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:127.6pt"><p style="text-align:center"><strong>Common</strong></p></td><td style="vertical-align:top; width:106.3pt"><p style="text-align:center"><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:106.3pt"><p style="text-align:center"><strong>Rare</strong></p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:127.6pt"><p><strong>&ge; 1/100 to &lt;&nbsp;1/10</strong></p></td><td style="vertical-align:top; width:106.3pt"><p><strong>&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100</strong></p></td><td style="vertical-align:top; width:106.3pt"><p><strong>&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000</strong></p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Immune system disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:106.3pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:106.3pt"><p>Hypersensitivity, Asthma</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>Depressive mood</p></td><td style="vertical-align:top; width:106.3pt"><p>Libido increased, Libido decreased</p></td><td style="vertical-align:top; width:106.3pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>Headache</p></td><td style="vertical-align:top; width:106.3pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:106.3pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:106.3pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:106.3pt"><p>Hypoacusis</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Vascular disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>Migraine</p></td><td style="vertical-align:top; width:106.3pt"><p>Hypertension, Hypotension</p></td><td style="vertical-align:top; width:106.3pt"><p>Venous thromboembolism (VTE)</p><p>Arterial thromboembolism (ATE)</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>Nausea</p></td><td style="vertical-align:top; width:106.3pt"><p>Vomiting,<br />Diarrhoea</p></td><td style="vertical-align:top; width:106.3pt"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Skin and<br />subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:106.3pt"><p>Acne,<br />Eczema,<br />Pruritus,<br />Alopecia</p></td><td style="vertical-align:top; width:106.3pt"><p>Erythema nodosum, Erythema multiforme</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:127.6pt"><p>Menstrual disorders, Intermenstrual bleeding, Breast pain,<br />Breast tenderness,<br />Vaginal discharge,<br />Vulvovaginal candidiasis</p></td><td style="vertical-align:top; width:106.3pt"><p>Breast enlargement,<br />Vaginal infection</p></td><td style="vertical-align:top; width:106.3pt"><p>Breast discharge</p></td></tr><tr><td style="vertical-align:top; width:124.0pt"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:127.6pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:106.3pt"><p>Fluid retention,<br />Weight increased,<br />Weight decreased</p></td><td style="vertical-align:top; width:106.3pt"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Description of selected adverse reactions</p><p>An increased risk of arterial and venous thrombotic and thrombo-embolic events, including myocardial infarction, stroke, transient ischemic attacks, venous thrombosis and pulmonary embolism has been observed in women using CHCs, which are discussed in more detail in section 4.4.</p><p>The following serious adverse events have been reported in women using COCs, which are discussed in section 4.4 Special warnings and precautions for use:</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Venous thromboembolic disorders;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Arterial thromboembolic disorders;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Hypertension;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Liver tumours;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Occurrence or deterioration of conditions for which association with COC use is not conclusive: Crohn&rsquo;s disease, ulcerative colitis, epilepsy, uterine myoma, porphyria, systemic lupus erythematosus, herpes gestationis, Sydenham&#39;s chorea, haemolytic uremic syndrome, cholestatic jaundice;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Chloasma;</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Acute or chronic disturbances of liver function may necessitate the discontinuation of COC use until markers of liver function return to normal.</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->In women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema.</p><p>&nbsp;</p><p>The frequency of diagnosis of breast cancer is very slightly increased among COC users. As breast cancer is rare in women under 40 years of age the excess number is small in relation to the overall risk of breast cancer. Causation with COC use is unknown. For further information, see sections 4.3 and 4.4.</p><p>&nbsp;</p><p><u>Interactions</u></p><p>Breakthrough bleeding and/or contraceptive failure may result from interactions of other drugs (enzyme inducers) with oral contraceptives (see section 4.5).</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via</p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p style="margin-left:0in; margin-right:0in"><strong>Other Countries:</strong></p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There has not yet been any experience of overdose with Yasmin. On the basis of general experience with combined oral contraceptives, symptoms that may possibly occur in this case are: nausea, vomiting and withdrawal bleeding. Withdrawal bleeding may even occur in girls before their menarche, if they accidentally take the medicinal product. There are no antidotes and further treatment should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group (ATC): Progestogens and estrogens, fixed combinations<br />ATC Code: G03AA 12</p><p>Pearl Index for method failure: 0.09 (upper two-sided 95 % confidence limit: 0.32).<br />Overall Pearl Index (method failure + patient failure): 0.57 (upper two-sided 95 % confidence limit: 0.90).</p><p>The contraceptive effect of Yasmin is based on the interaction of various factors, the most important of which are seen as the inhibition of ovulation and the changes in the endometrium.</p><p>Yasmin is a combined oral contraceptive with ethinylestradiol and the progestogen drospirenone. In a therapeutic dosage, drospirenone also possesses antiandrogenic and mild antimineralocorticoid properties. It has no estrogenic, glucocorticoid and antiglucocorticoid activity. This gives drospirenone a pharmacological profile closely resembling the natural hormone progesterone.</p><p>There are indications from clinical studies that the mild antimineralocorticoid properties of Yasmin result in a mild antimineralocorticoid effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; text-indent:35.4pt">Drospirenone</p><p><u>Absorption</u></p><p>Orally administered drospirenone is rapidly and almost completely absorbed. Maximum concentrations of the active substance in serum of about 38 ng/ml are reached at about 1&nbsp;‑&nbsp;2 h after single ingestion. Bioavailability is between 76 and 85 %. Concomitant ingestion of food has no influence on the bioavailability of drospirenone.</p><p><u>Distribution</u></p><p>After oral administration, serum drospirenone levels decrease with a terminal half-life of 31 h. Drospirenone is bound to serum albumin and does not bind to sex hormone binding globulin (SHBG) or corticoid binding globulin (CBG). Only 3 - 5 % of the total serum concentrations of the active substance are present as free steroid. The ethinylestradiol-induced increase in SHBG does not influence the serum protein binding of drospirenone. The mean apparent volume of distribution of drospirenone is 3.7 &plusmn; 1.2 l/kg.</p><p><u>Biotransformation</u></p><p>Drospirenone is extensively metabolized after oral administration. The major metabolites in plasma are the acid form of drospirenone, generated by opening of the lactone ring, and the 4,5-dihydro-drospirenone-3-sulfate, formed by reduction and subsequent sulfatation.<s> </s>Drospirenone is also subject to oxidative metabolism catalyzed by CYP3A4.</p><p>In vitro, drospirenone is capable to inhibit weakly to moderately the cytochrome P450 enzymes CYP1A1, CYP2C9, CYP2C19 and CYP3A4.</p><p><u>Elimination</u></p><p>The metabolic clearance rate of drospirenone in serum is 1.5 &plusmn; 0.2 ml/min/kg. Drospirenone is excreted only in trace amounts in unchanged form. The metabolites of drospirenone are excreted with the feces and urine at an excretion ratio of about 1.2 to 1.4. The half-life of metabolite excretion with the urine and feces is about 40 h.</p><p><u>Steady-State Conditions</u></p><p>During a treatment cycle, maximum steady-state concentrations of drospirenone in serum of about 70 ng/ml are reached after about 8 days of treatment. Serum drospirenone levels accumulated by a factor of about 3 as a consequence of the ratio of terminal half-life and dosing interval.</p><p><u>Special Populations</u></p><p><em>Effect of renal impairment</em></p><p>Steady-state serum drospirenone levels in women with mild renal impairment (creatinine clearance CLcr, 50-80 mL/min) were comparable to those of women with normal renal function. The serum drospirenone levels were on average 37 % higher in women with moderate renal impairment (CLcr, 30 - 50 mL/min) compared to those in women with normal renal function. Drospirenone treatment was also well tolerated by women with mild and moderate renal impairment. Drospirenone treatment did not show any clinically significant effect on serum potassium concentration.</p><p><em>Effect of hepatic impairment</em></p><p>In a single dose study, oral clearance (CL/F) was decreased approximately 50 % in volunteers with moderate hepatic impairment as compared to those with normal liver function.The observed decline in drospirenone clearance in volunteers with moderate hepatic impairment did not translate into any apparent difference in terms of serum potassium concentrations. Even in the presence of diabetes and concomitant treatment with spironolactone (two factors that can predispose a patient to hyperkalemia) an increase in serum potassium concentrations above the upper limit of the normal range was not observed. It can be concluded that drospirenone is well tolerated in patients with mild or moderate hepatic impairment (Child-Pugh B).</p><p><em>&nbsp;</em></p><p><em>Ethnic groups</em></p><p>No clinically relevant differences in the pharmacokinetics of drospirenone or ethinylestradiol between Japanese and Caucasian women have been observed.</p><p style="margin-left:0in; text-indent:35.4pt">Ethinylestradiol</p><p><u>Absorption</u></p><p>Ethinylestradiol is rapidly and completely absorbed after ingestion. After administration of 30&nbsp;&micro;g, peak plasma concentrations of 100 pg/ml are reached 1-2 hours after ingestion. Ethinylestradiol undergoes an extensive first-pass effect, which displays great inter-individual variation. The absolute bioavailability is approx. 45 %.</p><p><u>Distribution</u></p><p>Ethinylestradiol has an apparent volume of distribution of 5 l/kg and binding to plasma proteins is approx. 98 %. Ethinylestradiol induces the hepatic synthesis of SHBG and CBG. During treatment with 30&nbsp;&micro;g ethinylestradiol the plasma concentration of SHBG increases from 70 to about 350&nbsp;nmol/l.<br />Ethinylestradiol passes in small amounts into breast milk (0.02 % of the dose).</p><p><u>Biotransformation</u></p><p>Ethinylestradiol is subject to significant gut and hepatic first-pass metabolism. Ethinylestradiol is primarily metabolized by aromatic hydroxylation but a wide variety of hydroxylated and methylated metabolites are formed, and these are present as free metabolites and as conjugates with glucuronides and sulfate. The metabolic clearance rate of ethinyl&shy;estradiol is about 5&nbsp;ml/min/kg.</p><p>In vitro, ethinylestradiol is a reversible inhibitor of CYP2C19, CYP1A1 and CYP1A2 as well as a mechanism based inhibitor of CYP3A4/5, CYP2C8, and CYP2J2.</p><p><u>Elimination</u></p><p>Ethinylestradiol is not excreted in unchanged form to any significant extent. The metabolites of ethinylestradiol are excreted at a urinary to biliary ratio of 4:6. The half-life of metabolite excretion is about 1 day. The elimination half-life is 20 hours.</p><p><u>Steady-state conditions</u></p><p>Steady-state conditions are reached during the second half of a treatment cycle and serum levels of ethinylestradiol accumulate by a factor of about 1.4 to 2.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In laboratory animals, the effects of drospirenone and ethinylestradiol were confined to those associated with the recognised pharmacological action. In particular, reproduction toxicity studies revealed embryotoxic and fetotoxic effects in animals which are considered as species specific. At exposures exceeding those in users of Yasmin, effects on sexual differentiation were observed in rat fetuses but not in monkeys. Environmental risk assessment studies have shown that ethinylestradiol and drospirenone have the potential of posing a risk to the aquatic environment (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core:</u></p><p>Lactose monohydrate<br />Maize starch<br />Pregelatinised maize starch</p><p>Povidone K25<br />Magnesium stearate</p><p>Tablet coating:</p><p>Hypromellose<br />Macrogol 6000<br />Talc<br />Titanium dioxide (E 171)<br />Iron oxide pigment, yellow (E 172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0in; margin-right:0in">Do not store above 30 &deg;C</p><p style="margin-left:0in; margin-right:0in">Store in the original package</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aluminium blister pack.</p><p>Pack sizes:</p><p style="margin-right:368.55pt">21 tablets<br />3x21 tablets<br />6x21 tablets<br /><!--[if !supportLineBreakNewLine]--></p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product may pose a risk to the environment (see section 5.3). Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG
Kaiser-Wilhelm-Allee 1
51368 Leverkusen, Germany.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>